



UNIL | Université de Lausanne

Unicentre

CH-1015 Lausanne

<http://serval.unil.ch>

Year : 2017

FUNCTIONAL AND STRUCTURAL TOPOGRAPHY WITHIN CORTICO- SUBCORTICAL LOOPS IN PARKINSON'S DISEASE USING MAGNETIC RESONANCE IMAGING

Marquis Renaud

Marquis Renaud, 2017, FUNCTIONAL AND STRUCTURAL TOPOGRAPHY WITHIN CORTICO-
SUBCORTICAL LOOPS IN PARKINSON'S DISEASE USING MAGNETIC RESONANCE
IMAGING

Originally published at : Thesis, University of Lausanne

Posted at the University of Lausanne Open Archive <http://serval.unil.ch>

Document URN : urn:nbn:ch:serval-BIB_D13C3F095E784

Droits d'auteur

L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir le consentement préalable de l'auteur et/ou de l'éditeur avant toute utilisation d'une oeuvre ou d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière.

Copyright

The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose offenders to the sanctions laid down by this law. We accept no liability in this respect.

Département des Neurosciences Cliniques

**FUNCTIONAL AND STRUCTURAL TOPOGRAPHY WITHIN CORTICO-
SUBCORTICAL LOOPS IN PARKINSON'S DISEASE USING MAGNETIC
RESONANCE IMAGING**

Thèse de doctorat en Neurosciences

présentée à la

Faculté de Biologie et de Médecine
de l'Université de Lausanne

par

Renaud MARQUIS

Neuroscientifique diplômé de l'Université de Genève, Suisse

Jury

Prof. Kim Do Cuénod, Président
Prof. Bogdan Draganski, Directeur
Dr. Ferath Kherif, Co-Directeur
Prof. Stéphane Lehéricy, Expert
Dr. Thilo Van Eimeren, Expert

Thèse n° 208

Lausanne 2017

*Programme doctoral interuniversitaire en Neurosciences
des Universités de Lausanne et Genève*

Imprimatur

Vu le rapport présenté par le jury d'examen, composé de

Président·e	Madame Prof. Kim Do Cuénod
Directeur·trice de thèse	Monsieur Prof. Bogdan Draganski
Co-directeur·trice de thèse	Monsieur Dr Ferath Kherif
Expert·e·s	Monsieur Prof. Stéphane Lehéricy Monsieur Dr Thilo Van Eimeren

le Conseil de Faculté autorise l'impression de la thèse de

Monsieur Renaud Marquis

Master interdisciplinaire en Neurosciences, Genève


intitulée

**FUNCTIONAL AND STRUCTURAL TOPOGRAPHY WITHIN
CORTICO-SUBCORTICAL LOOPS IN PARKINSON'S DISEASE
USING MAGNETIC RESONANCE IMAGING**

Lausanne, le 3 juillet 2017

pour Le Doyen
de la Faculté de Biologie et de Médecine

Prof. Kim Do Cuénod



KNOW THYSELF.

AMERICAN PHRENOLOGICAL JOURNAL.

HOME TRUTHS FOR HOME CONSUMPTION.

1848.

VOL. X. MARCH. NO. 3.

O. S. FOWLER, EDITOR.

PHRENOLOGY, PHYSIOLOGY, PHYSIOGNOMY, MAGNETISM.

NEW YORK:
FOWLERS & WELLS,
 PHRENOLOGICAL CABINET, 131 NASSAU-STREET.

Terms \$1 a Year, invariably in advance. Ten cts. a Number.

Source: <https://en.wikipedia.org/wiki/File:Phrenology-journal.jpg>

De ces prémisses incontrouvables il déduisit que la Bibliothèque est totale, et que ses étagères consignent toutes les combinaisons possibles des vingt et quelques symboles orthographiques (nombre, quoique très vaste, non infini), c'est-à-dire tout ce qu'il est possible d'exprimer, dans toutes les langues. Tout: l'histoire minutieuse de l'avenir, les autobiographies des archanges, le catalogue fidèle de la Bibliothèque, des milliers et des milliers de catalogues mensongers, la démonstration de la fausseté de ces catalogues, la démonstration de la fausseté du catalogue véritable, l'évangile gnostique de Basilide, le commentaire de cet évangile, le commentaire du commentaire de cet évangile, le récit véridique de ta mort, la traduction de chaque livre en toutes les langues, les interpolations de chaque livre dans tous les livres; le traité que Beda ne put écrire (et n'écrivit pas) sur la mythologie des Saxons, ainsi que les livres perdus de Tacite.

Jorge Luis Borges, *La Bibliothèque de Babel* (1941).

Œuvres complètes, tome 1 (1993) pour la traduction française.

À mon épouse Eléonore et mon fils Caleb, qui ont toujours été présents, dans mon cœur et mon esprit, et m'ont aidé à traverser ce labyrinthe, même dans les plus sombres recoins.

Acknowledgments

I would like to thank my thesis director, Prof. Bogdan Draganski, and my thesis supervisor, Dr. Ferath Kherif, for their continuous support and guidance throughout this thesis work. I learned a lot during my PhD thanks to your amazing mentoring and suggestions.

I would like also to sincerely thank the external experts of my thesis committee, Prof. Stéphane Lehericy and Dr. Thilo Van Eimeren, as well as the jury president, Prof. Kim Do Cuénod.

I am also very grateful to the medical doctors and colleagues in the Clinique des Mouvements Anormaux at CHUV for their generous help for the recruitment of patients and her constructive suggestions, especially Dr. Deepa Pothalil for her help with motor examinations and for her professionalism.

I would like to thank Kay Corday and coworkers from the Atelier CES-Brico at Cery, who made the wood part of the custom device we used in this study.

I am very grateful to the Swiss National Science Foundation, Foundation Parkinson Switzerland, Foundation Synapsis, Roger De Spoelberch and Partridge Foundations as well as the European Union Seventh Framework Programme for their generous financial support. I want also to express my gratitude to the Clinical Neuroscience Department at CHUV for providing the research infrastructure.

I want to give special thanks to all my colleagues and friends at LREN. I want to thank Estelle Dupuis for her support with scanning, Rémi Castella for his help building the custom device, and Dr. Sara Lorio for the fruitful collaboration and support for writing. I want to thank also Dr. Antoine Lutti, who helped me a lot for improving my writing and understanding of MRI physics. I want to thank also Dr. Sandrine Muller and David Slater for the passionate exchanges we had and their support for performing analyses with cutting-edge tools. Many thanks also to Dr. Elisabeth Roggenhofer for her help with motor examinations and sharing insights in Parkinson's disease from a neuroscientific and clinical perspective. I will miss all the fascinating discussions I had with you, Dr. Anne Ruef and Dr. Lester Mélie Garcia in particular.

I especially want to express my immense gratitude to my family for her continuous support and help during these exhausting years. In particular, I want to thank Charlotte for having reviewed the writing of this thesis, Sylviane and Daniel for having taken care of Caleb so that I could finish it. I want to thank all of you for your encouragement.

I want also to thank my son, Caleb, who helped me to take a step back when I was too much involved. Last but not least, I will never thank my wife enough. Eléonore, you endured it

with me, you supported me, you encouraged me, you helped me, you took care of Caleb without me so many times, you had to do everything I should have normally do, so that I could finally finish this thesis. Thanks for reminding me of childhood memories where everything was as fresh as the bright blue sky.

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative disorder due to loss of dopamine producing cells in the substantia nigra. Given the fact that clinical symptoms emerge after a long preclinical period with gradual decline in dopamine production, there is pressing need to advance our understanding about the progression of motor and non-motor symptoms in symptomatic phase of PD. Recent theoretical work and animal models suggest a link between dopamine-dependent loss of neuronal specificity (LOS) in the basal ganglia (BG) and a broad range of symptoms in movement disorders. The overall goal of my thesis project was to test and validate this hypothesis *in vivo* using non-invasive magnetic resonance imaging (MRI). In a preparatory study for my main experiment, I evaluate how the spatial resolution of different MRI protocols impacts BGs motor somatotopy mapping. The second study tests the LOS hypothesis in PD patients and how functional segregation of motor somatotopy is affected by dopamine substitution. In a following study I expand the LOS hypothesis on the insular cortex, which shares major connections with the BG. My last experiment extends these findings to structural connectivity patterns of projections between thalamus, BG and cortex. I am truly convinced that my thesis project will contribute to advance our understanding of PD pathophysiology that helps monitoring and predicting clinical outcome.

Résumé

La maladie de Parkinson (MP) est une maladie neurodégénérative débiliteuse résultant de la perte des cellules dopaminergiques dans la substance noire. Etant donné l'émergence de symptômes cliniques après une longue période préclinique caractérisée par un déclin progressif de la production de dopamine, il est urgent de faire avancer notre compréhension de la progression des symptômes moteurs et non-moteurs dans la phase symptomatique de la MP. De récents travaux théoriques et modèles animaux suggèrent un lien entre une perte de la spécificité neuronale (PDS) dans les ganglions de la base (GB) dépendant de la dopamine et un large éventail de symptômes dans les troubles du mouvement. L'objectif général de mon projet de thèse était de tester et valider cette hypothèse *in vivo* en utilisant l'imagerie par résonance magnétique (IRM) non-invasive. Dans une étude préliminaire, j'ai évalué l'impact de la résolution spatiale de différents protocoles IRM sur la cartographie de la somatotopie motrice dans les GB. La deuxième étude teste l'hypothèse de la PDS chez des patients atteints de la MP et comment la ségrégation fonctionnelle de la somatotopie motrice est affectée par la substitution de dopamine. Dans l'étude suivante j'étends l'hypothèse de la PDS au cortex insulaire, qui partage d'importantes connexions avec les GB. Ma dernière expérience étend ces découvertes aux patterns de connectivité structurelle entre le thalamus, les GB et le cortex. Je suis sincèrement convaincu que mon projet de thèse contribuera à l'avancée de notre compréhension de la pathophysiologie de la MP qui aide au suivi et à la prédiction de l'issue clinique.

Table of Contents

ACKNOWLEDGMENTS	3
ABSTRACT	5
RÉSUMÉ	6
LIST OF COMMON ABBREVIATIONS	9
1. THEORETICAL FRAMEWORK	11
1.1. PARKINSON'S DISEASE	11
1.1.1. A brief history.....	11
1.1.2. Definition and symptoms.....	12
1.1.3. Epidemiology.....	14
1.1.4. Risk- and protective factors.....	15
1.1.5. Pathophysiology.....	18
1.1.6. Etiology.....	20
1.1.7. Treatment.....	23
1.2. SEGREGATION AND INTEGRATION OF INFORMATION IN CORTICO-SUBCORTICAL LOOPS.....	29
1.2.1. Structural and functional architecture of cortico-basal ganglia-thalamic circuitry	29
1.2.2. Theoretical models of basal ganglia function and dysfunction.....	38
1.3. BRAIN IMAGING	46
1.3.1. Functional MRI of the brain	48
1.3.2. Diffusion MRI.....	52
1.3.3. Quantitative MRI.....	53
1.4. RESEARCH QUESTIONS AND HYPOTHESES	55
2. EXPERIMENTAL WORK.....	58
2.1. OPTIMAL MAPPING OF MOTOR SOMATOTOPY IN HEALTHY SUBJECTS	58
2.1.1. Study 1	58
2.2. FUNCTIONAL SEGREGATION IN PARKINSON'S DISEASE	81
2.2.1. Study 2	82
2.2.2. Study 3	126
2.3. STRUCTURAL SEGREGATION IN PARKINSON'S DISEASE.....	142
2.3.1. Study 4	143
3. GENERAL DISCUSSION	177
3.1. INTERPRETATIONS AND LIMITATIONS.....	178
3.2. FUTURE DIRECTIONS	183

The topography of cortico-subcortical loops in Parkinson's disease

LIST OF FIGURES AND TABLES..... 185
REFERENCES..... 186

List of common abbreviations

AADC: amino acid decarboxylase	GDNF: glial cell line-derived neurotrophic factor
ACh: acetylcholine	GLM: general linear model
AD: Alzheimer's disease	GMV: grey matter volume
ADC: apparent diffusion coefficient	GPe: globus pallidus pars externa
ADHD: attention deficit hyperactivity disorder	GPI: globus pallidus pars interna
BG: basal ganglia	GTP: guanosine triphosphate
BOLD: blood-oxygen-level dependent	GTS: Gilles de la Tourette's syndrome
CBD: corticobasal degeneration	IoS: index of specificity
CSF: cerebrospinal fluid	HC: healthy control
DA: dopamine	HD: Huntington's disease
DBS: deep brain stimulation	LB: Lewy bodies
DMS: dorsomedial striatum	LIDs: levodopa-induced dyskinesias
DLPFC: dorsolateral prefrontal cortex	LOS: loss of specificity
DLS: dorsolateral striatum	LTD: long-term depression
DTI: diffusion tensor imaging	LTP: long-term potentiation
DWI: diffusion-weighted imaging	LTS: low-threshold spiking
ECT: electroconvulsive therapy	M1: primary motor cortex
EEG: electroencephalography	MAO: monoamine oxidase
EMG: electromyography	MD: mean diffusivity
EPI: echo planar imaging	MNI: Montreal Neurologic Institute
ET: essential tremor	MRI: magnetic resonance imaging
FA: fractional anisotropy	MS: multiple sclerosis
FDR: false discovery rate	MSA: multiple system atrophy
fMRI: functional MRI	MSNs: medium spiny neuron
FOG: freezing of gait	MT: magnetization transfer
FSI: fast-spiking interneurons	MVB: multivariate Bayes
FTD: frontotemporal dementia	NAcc: nucleus accumbens
FWER: family-wise error rate	NMDA: N-methyl-D-aspartate
GABA: γ -aminobutyric acid	NMS: non-motor symptoms

The topography of cortico-subcortical loops in Parkinson's disease

NPY: neuropeptide Y	RSA: representational similarity analysis
OCD: obsessive compulsive disorders	rTMS: repetitive transcranial magnetic stimulation
PANs: phasically active neurons	SMA: supplementary motor area
PCA: principal component analysis	SN: substantia nigra
PCM: pattern component model	SNc: substantia nigra pars compacta
PD: Parkinson's disease	SNr: substantia nigra pars reticulata
PET: positron emission tomography	SPECT: single-photon emission computed tomography
PFC: prefrontal cortex	SPNs: spiny projection neurons
PNS: peripheral nervous system	STN: subthalamic nucleus
PPN: pedunculopontine nucleus	T2*WI: T2*-weighted magnitude imaging
PSP: progressive supranuclear palsy	TANs: tonically active neurons
RBD: rapid eye movement sleep behaviour disorder	TMS: transcranial magnetic stimulation
RD: radial diffusivity	VBM: voxel-based morphometry
RL: reinforcement learning	VEGF: vascular endothelial growth factor
RLS: restless legs syndrome	VTA: ventral tegmental area
ROI: region of interest	

1 **1. Theoretical framework**

2 In this introductory section, I define the core features of Parkinson's disease (PD) from a
3 clinical and pathophysiological perspective by providing the current view on its
4 pathogenesis from the perspective of structural and functional characteristics of cortico-
5 subcortical loops. I also review the existing models explaining basal ganglia (BG)
6 dysfunction in PD and other brain disorders. Finally, I emphasize on several different *in*
7 *vivo* imaging approaches aiming to characterize its complex manifestations, monitoring its
8 progression, providing clues into its pathophysiology and highlighting potential new
9 venues for therapeutic strategies. Given the fact that I used functional MRI throughout the
10 entire project, I focus on its methodological description. Research questions and general
11 hypotheses are formulated for the experimental work section. Specific hypotheses and
12 methodological procedures regarding data acquisition and analysis are demonstrated
13 separately for each study in section 2.


14 **1.1. Parkinson's disease**

15 In the following section I review current knowledge of PD accumulated over the last
16 decades. After a very brief history of research on PD, the latter is defined from the clinical
17 point of view, in terms of symptoms and in regard to other neurological diseases. Following
18 subsections provide an overview of PD epidemiology, risk and protective factors, as well as
19 insights into its pathophysiology and etiology. The last subsection attempts to summarize
20 treatment options available for patients, from conventional medical practices to
21 experimental treatments undergoing pre-clinical studies.

22 **1.1.1. A brief history**

23 200 years after the publication of James Parkinson's essay (1817), there is still no cure for
24 PD, the second most common neurodegenerative disorder after Alzheimer's disease (AD)
25 (Dauer and Przedborski, 2003; De Virgilio et al., 2016), despite considerable progress
26 achieved in the past decades. In the late 1950's, the main neurotransmitter lost in PD was
27 localized in the brain and the first pharmacological model of PD was developed (Goetz,
28 2011). Later, Langston and colleagues (1983) observed that a self-administered narcotic
29 derivative, 1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine (MPTP), induced symptoms
30 strikingly similar to that of PD. One of the most influential animal models of PD was born
31 (Dauer and Przedborski, 2003). The discovery of this neurotoxin triggered an exponential
32 increase of studies on PD (**Figure 1**). Nevertheless, the causes of PD remain unknown. The
33 discrepancy between research investments and the puzzle of PD pathogenesis has recently
34 led some researchers to question the existence of the disease entity itself and propose the
35 usage of the term "syndrome" rather than "disease" (Titova et al., 2017).

The topography of cortico-subcortical loops in Parkinson's disease



36

37 **Figure 1:** Number of publications referenced in the U.S. National Library of Medicine MEDLINE. A query was
38 performed at <http://dan.corlan.net/medline-trend.html> using the keywords “Parkinson’s disease”.

39 **1.1.2. Definition and symptoms**

40 PD is a debilitating progressive neurodegenerative disease characterized by the following
41 cardinal symptoms: generalized slowing of movements in the absence of weakness
42 (bradykinesia), increased muscle tone (rigidity), postural instability and rest tremor,
43 whose typical frequency lies between 4 and 6 Hz (Jankovic, 2008; Mazzoni et al., 2012). The
44 terms “akinesia” and “hypokinesia” refer to specific aspects of motor symptoms, though
45 their usage may vary: the former denotes the delayed initiation and the poverty or paucity
46 of movements, whereas the latter designates the reduction of movement amplitude, force,
47 or both (Dauer and Przedborski, 2003; Mazzoni et al., 2012). Other clinical signs resulting
48 from the cardinal features include hypomimia, dysarthria, hypophonia, sialorrhoea,
49 dysphagia, decreased arm swing, shuffling gait, festination, difficulty arising from a chair or
50 turning in a bed, micrographia, striatal position of fingers and toes, glabellar tap reflex,
51 blepharospasm, dystonia, scoliosis and camptocormia (Dauer and Przedborski, 2003;
52 Jankovic, 2008; Moustafa et al., 2016).

53 According to the UK Parkinson’s Disease Society Brain Bank’s clinical criteria, a diagnosis of
54 probable PD can be made when bradykinesia and at least one of the other three cardinal
55 symptoms are present (Hughes et al., 1992). While the National Institute of Neurological
56 Disorders and Stroke proposes slightly different diagnosis criteria (Gelb et al., 1999), a
57 unilateral disease onset with later persistent asymmetry, a progressive disorder course

58 lasting 10 years or more, and an excellent response to dopamine (DA) replacement therapy
59 leading to severe dyskinesias are all supportive criteria (Jankovic, 2008). It has to be noted
60 however that tremor is a peculiar symptom: it does not progress at the same rate as other
61 cardinal symptoms, responds less well to DAergic treatment, can occur on the body side
62 contralateral to the one most affected by other symptoms, is absent in up to one out of four
63 patients, and its severity does not correlate with other symptoms (Helmich et al., 2012;
64 Lang and Lozano, 1998a).

65 In addition, non-motor symptoms (NMS) are frequent in PD and gained recently more
66 attention because they may precede classical motor abnormalities and the hallmark of the
67 neurodegenerative process (De Virgilio et al., 2016; Miller and O'Callaghan, 2015). NMS
68 comprise bradyphrenia, cognitive impairment, depression, apathy, anhedonia, fatigue,
69 hyposmia, ageusia, deafness, pain, paraesthesias, weight loss, hallucinations, delusion,
70 psychiatric symptoms such as psychosis and paranoia, disturbance of sleep and
71 wakefulness such as excessive daytime sleepiness or rapid eye movement sleep behaviour
72 disorder (RBD), and disorders of the autonomic nervous system such as constipation,
73 hypotension, urinary frequency, impotence and sweating (Bosboom et al., 2004; Burn,
74 2002a, 2002b; Chaudhuri et al., 2006; Davie, 2008; De Virgilio et al., 2016; Jankovic, 2008;
75 Kaji and Hirata, 2011; Kalia and Lang, 2015; Kirsch-Darrow et al., 2011; Lang and Lozano,
76 1998a; Mizuno et al., 2008; Postuma and Berg, 2016; Robbins and Cools, 2014; Sharma et
77 al., 2013). NMS in PD are not negligible: cognitive impairment leads to dementia in 83% of
78 patients with a disease duration of 20 year, depression affects 25% to 50% of patients and
79 psychosis can occur in up to 30% of patients. Although neuro-behavioural measures may
80 be confounded, interesting analogies between NMS and motor symptoms can be made, for
81 example between apathy and akinesia, bradyphrenia and bradykinesia, difficulties in
82 movement sequences and shifting set in learning situations (Mandir and Vaughan, 2000).

83 Objective tests can measure various symptomatic aspects of PD. For example, tremor can
84 be quantified using muscle action potentials, hyposmia can be measured with the
85 University of Pennsylvania's Smell Identification Test (UPSIT) and polysomnography can
86 detect RBD (De Virgilio et al., 2016; Kalia and Lang, 2015; Sharma et al., 2013). Most
87 importantly, PD diagnosis mostly relies on the clinical picture. Disease severity is typically
88 assessed by the Unified Parkinson's Disease Rating Scale (UPDRS; Fahn et al., 1987). The
89 latter has been recently revised by the Movement Disorder Society (Goetz et al., 2008) and
90 comprises different subscales that aim at capturing cognitive, behavioural, motivational
91 and psychiatric symptoms (UPDRS I), the impairment during activities of daily living
92 (UPDRS II), motor symptoms (UPDRS III) and complications (UPDRS IV). Other scales of
93 disease progression or disability, such as the Hoehn and Yahr staging (Hoehn and Yahr,
94 1967) or the Schwab and England activities of daily living scale (Schwab and England,
95 1969), are sometimes referred to as UPDRS V and VI respectively. While the premotor
96 phase can last 12 to 14 years, NMS, motor complications due to DAergic therapy and

97 treatment-resistant motor symptoms such as choking, freezing of gait (FOG) and falls
98 prevail in late-stage PD (Baas, 2000; Bargiotas and Konitsiotis, 2013; De Virgilio et al.,
99 2016; Tinazzi, 2006). Besides a decreased quality of life, mortality increases considerably
100 with PD, reported as being 1.5 to 2.7 times as high as age-matched healthy individuals, up
101 to a hazard ratio of 5 (Lang and Lozano, 1998a; de Lau and Breteler, 2006). However PD is
102 marked by heterogeneity (Obeso et al., 2010), in terms of age of onset, rate of disease
103 progression and clinical symptoms (Kempster et al., 2010; Lotharius and Brundin, 2002).
104 These factors will vary noticeably as a function of the precise form of parkinsonian
105 syndrome (Williams and Litvan, 2013).

106 Indeed, the diagnosis of PD is a clinical one that besides resembling essential tremor (ET)
107 due to the presence of tremor (Deuschl and Bergman, 2002; Jankovic, 2008), is sometimes
108 difficult to differentiate from other disorders with distinct pathophysiology - multiple
109 system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal
110 degeneration (CBD). Additionally, there are a number of other differential diagnoses
111 including vascular parkinsonism, dystonia, frontotemporal dementia (FTD), Niemann-Pick
112 disease type C, and prion disease (Williams and Litvan, 2013). Another terminology
113 frequently used to avoid misdiagnosis refers to “atypical” or “secondary” parkinsonism
114 (Martí and Tolosa, 2013).

115 Most PD cases are sporadic – i.e. not linked to a known genetic factor, hence called also
116 “idiopathic” PD. The genetic forms of PD account for only 5-10% of the cases (Cali et al.,
117 2011; Dauer and Przedborski, 2003; Lill, 2016; Pan and Yue, 2013; Spatola and Wider,
118 2013; Thenganatt and Jankovic, 2014; Winklhofer and Haass, 2010; Wood-Kaczmar et al.,
119 2006). Additionally, recent studies suggested that several subtypes can be identified in PD
120 patients (Marras and Chaudhuri, 2016; Moustafa and Poletti, 2013; Thenganatt and
121 Jankovic, 2014). This heterogeneity poses important issues for the diagnosis of PD:
122 underdiagnosis is not rare, and misdiagnosis has been reported in 24% of the cases (Lang
123 and Lozano, 1998a). As a consequence, an *in vivo* biomarker of PD onset, progression and
124 prognosis is urgently needed, as its definitive diagnosis still relies on neuropathological
125 examination at autopsy (Lang and Lozano, 1998a; Miller and O’Callaghan, 2015).
126 Supportive diagnostic criteria do not suffice: asymmetric onset may be seen in CBD and
127 hemiparkinsonism-hemiatrophy, and the response to DAergic therapy can be initially
128 encouraging in patients with MSA (Lang and Lozano, 1998a).

129 **1.1.3. Epidemiology**

130 With an incidence of 8 to 18 per 100'000 person-years, PD affects 0.3% of the entire
131 population (de Lau and Breteler, 2006; Sveinbjornsdottir, 2016), in all ethnic groups, with
132 only a little predominance among males (Lang and Lozano, 1998a; de Lau and Breteler,
133 2006). Other surveys consider gender as an established factor and report a male-to-female
134 ratio of 3:2 (De Virgilio et al., 2016). This general prevalence increases exponentially with

135 age, with 1-2% of the population over 65 years old and 3-5% after 85 years old (Alves et al.,
136 2008; Lang and Lozano, 1998a; de Lau and Breteler, 2006). Although estimates might vary
137 depending on the methodology (de Lau and Breteler, 2006), it is believed that the number
138 of people with PD will increase by more than 50% by 2030 (De Virgilio et al., 2016) and
139 that PD could surpass cancer by becoming the second most common cause of death in
140 elderly by the year 2040 (Lilienfeld and Perl, 1994).

141 **1.1.4. Risk- and protective factors**

142 Age represents the biggest risk factor for PD (De Virgilio et al., 2016; Reeve et al., 2014).
143 The links between age and PD is so strong that Rodriguez et al. (2015) suggested that there
144 might be a common aetiology for ageing and PD, and that PD can be interpreted in the
145 context of accelerated ageing triggered by insufficient mitochondrial homeostasis and
146 compensatory mechanisms. Several environmental risk factors, such as the use of beta-
147 blocker and prior head injury, have been proposed (De Virgilio et al., 2016; Kalia and Lang,
148 2015). Although subject to controversy and despite the lack of data implicating a specific
149 toxin in PD, living in a rural environment, agricultural occupation, drinking from a water
150 well and exposure to pesticides, herbicides, plant-derived toxins, organic solvents, carbon
151 monoxide, carbon disulfide, bacterial and viral infection have been generally considered to
152 increase the risk of developing PD (Dauer and Przedborski, 2003; De Virgilio et al., 2016;
153 Kalia and Lang, 2015; Lang and Lozano, 1998a; Schapira and Jenner, 2011). Nevertheless,
154 the fact that the proportion of patients with PD exposed to pesticides has been estimated to
155 only 10% spreads doubts on the importance of rural environment as a risk factor, and even
156 if an important causative role of exogenous toxins might be inferred from the fact that the
157 first formal description of the disease occurred during the Industrial Revolution,
158 descriptions of akinetic and tremulous symptoms strikingly similar to PD were found
159 between 4500 and 1000 B.C. (Lang and Lozano, 1998a). Other factors such as alcohol
160 consumption, cancer and dietary habits – including fat, fatty acids, iron and nutriment
161 influencing homocysteine concentration – led to inconclusive results but drinking coffee
162 had protective effects, and smoking has been shown to drastically reduce the risk of PD by
163 half (Lang and Lozano, 1998a; de Lau and Breteler, 2006).

164 More recently, vagotomy, the use of anti-inflammatory drugs, antihypertensives,
165 antilipidaemics and physical activity were associated with a decreased risk of developing
166 PD, whereas olfactory disturbances, risk-avoiding personality type, depression and anxiety
167 were linked to a higher risk of future PD (De Virgilio et al., 2016; de Lau and Breteler, 2006;
168 Petzinger et al., 2013; Schapira and Jenner, 2011; Svensson et al., 2015). Although the
169 significance of antioxidants has been the matter of controversy (Filograna et al., 2016; de
170 Lau and Breteler, 2006), latest studies also suggest that these may have protective effects
171 in relation to the possible role of reactive oxygen species in PD pathogenesis (Ataie et al.,
172 2016; Magalingam et al., 2015). Coenzyme Q10, mitochondrial ubiquinone-NADH

The topography of cortico-subcortical loops in Parkinson's disease

173 oxidoreductase, melatonin, metallothioneins, N-acetyl-aspartate, and superoxide dismutase
 174 may also have neuroprotective effects (Sharma et al., 2013).

Gene	OMIM ¹ entry	Function
<i>PTEN-induced putative kinase 1 (PINK1; PARK6)</i>	608309	Mitochondrial function and mitophagy
<i>DJ-1 (PARK7)</i>	602533	
<i>Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 (CHCHD2)</i>	616244	
<i>POLG1</i>	174763	
<i>Sterol regulatory element-binding transcription factor 1 (SREBF1)</i>	184756	
<i>Parkin (PRKN, PARK2)</i>	602544	Mitochondrial function and mitophagy, UPS
<i>F-box only protein 7 (FBXO7; PARK15)</i>	605648	Ubiquitin–proteasome system (UPS)
<i>Ataxin 3 (ATXN3)</i>	607047	
<i>RAB39B</i>	300774	Regulation of protein membrane and trafficking
<i>Cyclin G-associated kinase (GAK)</i>	602052	
<i>RAB7L1</i>	603949	
<i>Vacuolar protein sorting-associated protein 35 (VPS35; PARK17)</i>	601501	Regulation of protein membrane and trafficking, lysosome autophagy pathway
<i>DNAJC13</i>	614334	
<i>Leucine-rich repeat kinase 2 (LRRK2; PARK8)</i>	609007	Regulation of protein membrane and trafficking, lysosome autophagy pathway, neurite structure, synaptic function and DA neurotransmission
<i>Synuclein α (SNCA; PARK1; PARK4)</i>	163890	Protein aggregation, synaptic vesicle formation, prion-like transmission, synaptic function and DA neurotransmission
<i>Microtubule-associated protein tau (MAPT)</i>	157140	Protein aggregation, synaptic vesicle formation, neurite structure
<i>ATP13A2 (PARK9)</i>	610513	Lysosome autophagy pathway
<i>Glucosylceramidase beta (GBA)</i>	606463	
<i>SCARB2</i>	602257	
<i>Synaptojanin-1 (SYNJ1; PARK20)</i>	604297	Synaptic function and DA neurotransmission
<i>Syntaxin-1B (STX1B)</i>	601485	
<i>guanosine triphosphate (GTP) cyclohydrolase 1 (GCH1)</i>	600225	

175 **Table 1:** Genes involved in PD.

¹ Online Mendelian Inheritance in Man (OMIM®); www.omim.org

176 Alternatively, neurodegeneration in PD might be triggered by a combination of inherited
 177 and environmental factors (Dauer and Przedborski, 2003; De Virgilio et al., 2016; Kalia and
 178 Lang, 2015; Lill, 2016; Schapira, 2006; Thomas and Beal, 2007). Genetic factors provided
 179 an important contribution to the understanding of PD, though as mentioned above
 180 inheritance accounts for only 5-10% of PD cases, at utmost 15% (Mochizuki, 2009; Wider
 181 et al., 2010). More specifically, genetic influence seems determinant in 2-3% of the late-
 182 onset forms and ~50% of early-onset cases (Obeso et al., 2010). Genes identified as playing
 183 a role in PD (**Table 1**) influence various molecular pathways (Abou-Sleiman et al., 2006;
 184 Feany, 2004; Haelterman et al., 2014; Kalia and Lang, 2015; de Lau and Breteler, 2006;
 185 Moore et al., 2005; Pan and Yue, 2013; Thenganatt and Jankovic, 2014; Valadas et al., 2014),
 186 which will be discussed in detail in section 1.1.6.

187 Mutations in *ATP13A2*, *FBXO7*, *POLG1*, *ATXN3* and *SYNJ1* are usually found in atypical forms
 188 of parkinsonism with juvenile onset and presenting pyramidal signs, gait disturbance,
 189 ophthalmologic abnormalities and cognitive impairments (Kalia and Lang, 2015). While
 190 *SNCA*, *LRRK2*, *VPS35*, *EIF4G1*, *DNAJC13* and *CHCHD2* are associated with autosomal
 191 dominant forms of PD, *PRKN*, *PINK1* and *DJ-1* seem to mediate autosomal recessive forms
 192 with early age of onset and slow disease course (Abou-Sleiman et al., 2006; Bonifati, 2013;
 193 Gandhi, 2005; Kalia and Lang, 2015; Mizuno et al., 2008; Schapira, 2006; Steece-Collier et
 194 al., 2002; Surmeier et al., 2011a; Winklhofer and Haass, 2010; Wood-Kaczmar et al., 2006).
 195 Other genes possibly involved in PD include *eukaryotic translation initiation factor 4*
 196 *gamma 1* (*EIF4G1*; *PARK18*; OMIM 600495), *chromosome 9 open reading frame 72*
 197 (*C9ORF72*; OMIM 614260), *phospholipase A2 group VI* (*PLA2G6*; *PARK14*; OMIM 603604),
 198 *ubiquitin carboxy-terminal hydrolase L1* (*UCH-L1*; *PARK5*; OMIM 191342), *fibroblast growth*
 199 *factor 20* (*FGF20*; OMIM 605558), *HtrA serine peptidase 2* (*HTRA2*; *OMI*; *PARK13*; OMIM
 200 606441), *nuclear receptor subfamily 4 group A member 2* (*NURR1*; *NR4A2*; OMIM 601828),
 201 *GRB10 interacting GYF protein 2* (*GIGYF2*; *PARK11*; OMIM 612003), *granulin precursor*
 202 (*GRN*; OMIM 138945), *dynactin 1* (*DCTN1*; OMIM 601143), *FBXO2* (OMIM 607112), *DNAJC6*
 203 (OMIM 608375), *ataxin 2* (*ATXN2*; OMIM 601517), *spatacsin* (*SPG11*; OMIM 610844) and
 204 *RAB39B* (OMIM 300774) (Bose and Beal, 2016; Hardy, 2010; Kalia and Lang, 2015; Lill,
 205 2016; Moore et al., 2005; Obeso et al., 2010; Schapira, 2006; Thenganatt and Jankovic,
 206 2014; Wider et al., 2010). Several genes linked to PD are also involved in other disease
 207 phenotypes. Variants of *SNCA* have been associated to MSA (Stefanis, 2012). Mutations to
 208 *ATXN2* and *ATXN3* cause spinocerebellar ataxia (SCA). *GBA* is notably known for its role in
 209 Gaucher's disease (Obeso et al., 2010). FTD and CBD are linked to mutations in *GRN* and
 210 *MAPT*. While *UCH-L1*, *HTRA2* and *GIGYF2* would be involved in autosomal dominant PD,
 211 *ATP13A2*, *PLA2G6*, *DNAJC6* and *FBXO7* would be implicated in autosomal recessive forms
 212 (Spatola and Wider, 2013; Thenganatt and Jankovic, 2014). Common genetic models used
 213 in mammals manipulate *SNCA*, *LRRK2*, *PRKN*, *DJ-1*, *PINK1* (Dawson et al., 2010; Jagmag et

214 al., 2016). Unfortunately, none of the animal models provide insights into selective SNc
215 cells vulnerability (Dawson et al., 2010).

216 **1.1.5. Pathophysiology**

217 Between 5 and 15 years before the onset of clinical symptoms, neuromelanin containing
218 DAergic neurons in the substantia nigra pars compacta (SNc) begin to die and α -synuclein,
219 a small and flexible monomeric 140 amino acid protein characterized by a lack of
220 secondary structure, starts to abnormally accumulate (Braak et al., 2004; Fearnley and
221 Lees, 1991; Forno, 1996; Golbe, 1999; Miller and O'Callaghan, 2015; Postuma and Berg,
222 2016; Ross and Pickart, 2004; Stefanis, 2012). When the first motor symptoms appear,
223 60% of DAergic cells have been lost and about 80% of DA in the putamen is depleted
224 (Dauer and Przedborski, 2003; Miller and O'Callaghan, 2015).

225 Together with the severe loss of DA in the striatum, the presence of eosinophilic
226 intracytoplasmatic proteinaceous inclusions termed Lewy bodies (LB), and dystrophic
227 Lewy neurites in surviving neurons has been reported primarily in the SNc, but also in
228 regions thought to be involved in NMS, including the locus coeruleus, pedunculo-pontine
229 nucleus, raphe nucleus, dorsal motor nucleus of the vagal nerve, hypothalamus, olfactory
230 bulb, substantia innominata, parasympathetic and sympathetic post-ganglionic neurons,
231 Meynert nucleus, amygdala and cerebral cortex – particularly the cingulate and entorhinal
232 cortex (Dauer and Przedborski, 2003; Lang and Lozano, 1998a; Mizuno et al., 2008;
233 Thomas and Beal, 2007). However LB are especially abundant in late-onset disease forms
234 and their role in cell death remains unclear (Obeso et al., 2010). Furthermore, LB are not
235 only found in PD but also in AD and in elderly people, in which they are even found at a
236 greater frequency (Dauer and Przedborski, 2003).

237 Other neuronal systems comprising catecholaminergic – notably norepinephrine – and
238 serotonergic nuclei, as well as mesolimbic DAergic neurons in the ventral tegmental area
239 (VTA), are considered less affected (Dauer and Przedborski, 2003; Lang and Lozano, 1998a;
240 Lotharius and Brundin, 2002). This might explain the lesser DA depletion in the caudate,
241 site of VTA neurons projection, as well as the greater dependence of synaptic DA clearance
242 in the striatum on DA active transporter as compared to the prefrontal cortex (PFC),
243 another critical projection site of VTA neurons where DA is modulated by other
244 monoaminergic transporters and the synaptic enzyme catechol-O-methyltransferase
245 (Dauer and Przedborski, 2003). It has to be noted that VTA neurons also project to the
246 hippocampus and amygdala (Broussard et al., 2013; Shohamy and Adcock, 2010), the latter
247 projecting further to the ventromedial striatum (Fudge et al., 2002), thereby increasing the
248 complexity of DA circuitry. Therefore, patients with PD exhibit progressive, nonlinear loss
249 of serotonergic function, which starts in the caudate, thalamus, hypothalamus and anterior

250 cingulate cortex and expands into other areas in the basal ganglia, limbic system and cortex
251 with disease progression.

252 The levels of decline between the serotonergic and DAergic systems are similar in the
253 caudate (reduction of 30–40%), but there is attenuated serotonergic loss (20–30%)
254 compared with profound DAergic dysfunction (70–80%) in the putamen (Politis, 2014).
255 Some evidence suggest that tremor might be related to serotonergic rather than DAergic
256 dysfunction (Politis, 2014). Serotonergic function is mainly affected in the raphe nuclei and
257 several other brain regions involved in the regulation of sleep, arousal, satiety and emotion
258 (Politis, 2014).

259 Falls in PD are related to decreased cholinergic innervation in the thalamus (Politis, 2014).
260 FOG is associated with cortical grey matter loss and with decreased activity signal in
261 striatal and extra-striatal regions (Politis, 2014). Limbic noradrenergic and DAergic
262 function are reduced in patients with PD experiencing depression compared with those
263 without depression. These decreases correlate with the severity of anxiety and apathy.
264 Studies also showed a reduced striatal and thalamic serotonergic function and reduced DA
265 capacity in the caudate of patients with PD who experience fatigue compared with those
266 who do not (Politis, 2014). Patients with hallucinations show increased serotonin
267 availability in the ventral visual pathway and other cortical regions, as well as increased
268 glucose metabolism in the frontal cortex in those with psychosis (Politis, 2014). Patients
269 with ICDs exhibit an abnormal increase in DA release in the ventral release (Stoessl et al.,
270 2014). Similarly, increased activity in brain networks controlling reward and decreased
271 activity in areas associated with behavioural inhibition is seen in patients with
272 hypersexuality (Politis, 2014).

273 Cognitive dysfunctions are induced by a greater medial nigral cell loss, involving
274 projections to the caudate (Lang and Lozano, 1998a). Dementia, gait dysfunction and falls
275 in late-stage PD are thought to reflect the degeneration of hippocampal structures and
276 cholinergic cortical inputs (Dauer and Przedborski, 2003; Kalia and Lang, 2015). However,
277 degeneration in the Meynert nucleus, locus cœruleus, and cerebral cortex might also
278 contribute to cognitive symptoms (Lang and Lozano, 1998a), although serotonergic and
279 noradrenergic systems are not as well documented as those related to DA system (Dauer
280 and Przedborski, 2003). Similarly, hyposmia, depression and dysautonomia are frequently
281 linked to neurodegeneration in the olfactory bulb, brainstem serotonergic and
282 noradrenergic nuclei, and intermediolateral nucleus of the spinal cord as well as
283 sympathetic and parasympathetic ganglia respectively (Lang and Lozano, 1998a). The
284 amygdala might be involved in both behavioural and autonomic nervous system
285 dysfunctions (Lang and Lozano, 1998a). More generally, dysfunctions in DAergic,
286 cholinergic, glutamatergic, noradrenergic and serotonergic systems are thought to
287 contribute to symptoms in PD, and recent accounts suggest that the different motor and
288 non-motor manifestations of the PD, which typically have a poor response to DAergic

289 medication in late-stage PD, might be linked to different patterns of neurodegeneration
290 (Kalia and Lang, 2015; Lima et al., 2012; Tremblay et al., 2015).

291 Most importantly, the DA depletion follows a specific topology, different from the one
292 observed in normal ageing: whereas the cell loss affects the ventrolateral tier and caudal
293 aspects of the SNc in PD, it concentrates on the dorsomedial portion in healthy ageing
294 (Dauer and Przedborski, 2003; Lang and Lozano, 1998a). The process underlying the death
295 of DA neurons in PD is therefore different from the ones observed in striato-nigral
296 degeneration, PSP and ageing, despite age being the most important risk factor for
297 developing PD (Dauer and Przedborski, 2003; Lang and Lozano, 1998a). It results in a
298 regionally specific pattern of striatal DA loss, starting in the dorsal putamen and considered
299 to be responsible of akinesia and rigidity (Cools, 2006; Lang and Lozano, 1998a;
300 Vaillancourt et al., 2013). Surprisingly, the majority of DAergic cells in the substantia nigra
301 (SN) resides in the neuropil, a calbindin-rich area, while neurons most susceptible to PD
302 seem to be found in calbindin-poor regions of the SNc (Dauer and Przedborski, 2003).
303 Interestingly, the loss of striatal synaptic terminals seems more remarkable than SNc DA
304 cell death. The protection of terminals in MPTP-treated mice prevents cell death in the SNc,
305 indicating that abnormal neurite function and integrity in the striatum possibly precede
306 somatic cell death in the SNc – i.e. a “dying back” process (Dauer and Przedborski, 2003),
307 which as been considered as possibly resulting from alterations in structural functions of
308 neurofilaments in axonal connections from the SNc to the striatum by LB (Lang and Lozano,
309 1998a).

310 Neurotoxin based models of PD attempt to mimic the pathophysiology and symptoms of PD
311 using chemical compounds such as MPTP, a precursor of 1-methyl-4-phenylpyridinium
312 (MPP+), 6-hydroxydopamine (6-OHDA), rotenone, N,N'dimethyl-4,4'-bipyridinium
313 dichloride (Paraquat) and methamphetamine (Beal, 2001; Jagmag et al., 2016). While these
314 models greatly improved our understanding of PD, most of them do not reproduce all
315 features of PD or lack a detailed understanding of the causal chains of chemical events. The
316 exception might be rotenone, which imitates successfully almost all features of PD, but has
317 a low reproducibility due to high mortality in rats (Jagmag et al., 2016). Similarly, studies
318 using actacystin, epoxomicin, or PSI (Z-Ile-Glu(OtBu)-Ala-Leu-al) raised hope for realistic
319 models of PD. However, not only the neurotoxic effects are not as remarkable as initially
320 reported, but also the reproducibility of these models is low (Schapira and Jenner, 2011).

321 **1.1.6. Etiology**

322 The common view on PD is that it results from a multi-factorial pathogenic process that
323 explains the heterogeneity of PD clinical manifestations (Vila et al., 2008) and underlines
324 the need for multiple biomarkers (De Virgilio et al., 2016; Kalia and Lang, 2015; Miller and
325 O'Callaghan, 2015). The causes underlying PD pathophysiology are debated though several

326 potential culprits have been considered, such as mitochondrial dysfunction (Amano et al.,
327 2014; Schapira and Gegg, 2011), Ca²⁺ dyshomeostasis (Calì et al., 2011; Surmeier et al.,
328 2011a), neuroinflammation (Dias et al., 2013), α -synuclein aggregation (Brundin et al.,
329 2016; Mizuno et al., 2008; Sidhu et al., 2004; Spillantini et al., 1997), iron dysregulation
330 (Mochizuki and Yasuda, 2012), oxidative and nitrosative stress induced by DA toxicity
331 (Hare and Double, 2016), as well as altered protein handling, accumulation and
332 phosphorylation (Eriksen et al., 2005). Other factors could be implicated in PD, including
333 lipid peroxidation, decrease in glutathione, increase in hydroxynonenal-modified proteins,
334 increase in 8-hydroxy-deoxy guanine, abnormalities in the endolysosomal compartment,
335 chaperone-mediated autophagy, excitotoxicity and autoimmune-mediated mechanisms. τ
336 proteins, as well as β -amyloid plaques, are rather associated to cognitive impairments in
337 PD (Halliday et al., 2014; Irwin et al., 2013). The possible interactions between these
338 mechanisms raised the view of PD etiology as a network rather than a cascade of events
339 (Haelterman et al., 2014; Schapira, 2006; Sulzer, 2007).

340 Based on the aforementioned agents, several biomarkers of PD were proposed. While
341 pathological markers such as confirm the diagnosis after death, other markers only support
342 the clinical diagnosis and are non-specific to PD (Sharma et al., 2013). Pathological markers
343 include death of DAergic neurons in the SNc, α -synuclein index, the presence of LB and
344 Charnol bodies, which are formed following mitochondrial dysfunction, as well as iron
345 accumulation. Pyridoxal kinase and lysosomal ATPase have been identified as potential
346 additional markers of PD. Other biomarkers use samples in the cerebrospinal fluid (CSF),
347 blood, serum, plasma, and urine. They include quantification of α -synuclein, DJ-1, tau (τ)
348 proteins, β -amyloid, β -glucocerebrosidase, glutathione-SH, neuromelanin antibody, platelet
349 complex I activity, urinary 8-OH-2dG, parkin, ubiquitin, brain-derived neuronal factor
350 (BDNF), cytokines, monoamines, endogenously synthesized tetrahydroisoquinolines,
351 salsolinol, and plasma homocysteine, monoamine oxidase-B (MAO-B) and osteopontin
352 (Chahine and Stern, 2011; Chahine et al., 2013; De Virgilio et al., 2016; Kalia and Lang,
353 2015; Sharma et al., 2013). Additionally, epidermal growth factor might be characteristic of
354 dementia in PD, and interleukin-8 might discriminate β -glucocerebrosidase mutation
355 carriers. Furthermore, ApoA1 could be linked to motor disease severity and age at disease
356 onset (Chahine et al., 2013).

357 Nonetheless, recent meta-analyses considering cross-sectional and longitudinal studies
358 including biomarkers provided by electrophysiology, transcranial duplex ultrasound,
359 cardiac 123I-MIBG scintigraphy, brain MRI, magnetic resonance spectroscopy (MRS),
360 positron emission tomography (PET) and single-photon emission computed tomography
361 (SPECT), as well as other biomarkers found mainly in the CSF, serum, urine, plasma and
362 blood, revealed the lack of sufficient evidences to recommend the use of any biomarker to
363 measure motor or non-motor disease progression in PD clinical trials (McGhee et al., 2013).

364 Further, several inconsistencies were raised concerning most of the proposed causal
365 mechanisms leading to nigral cell death in PD.

366 Abnormal iron levels are more generally associated with other disorders, such as AD,
367 Huntington's disease (HD), multiple sclerosis (MS), MSA, PSP, CBD, restless legs syndrome
368 (RLS), neurodegeneration with brain iron accumulation (NBIA) and other diseases (Dušek
369 et al., 2012; Ke and Ming Qian, 2003; Rouault, 2013; Sian-Hülsmann et al., 2011; Zecca et al.,
370 2004). Despite the existing comorbidity between PD and RLS (Rijsman et al., 2013; Tan et
371 al., 2002), iron levels in the SN seem reduced in the latter whereas they appear to be
372 increased in the former. This raises questions regarding the specific role of iron in PD
373 pathogenesis. Furthermore, even if iron chelation and overexpression of iron-sequestering
374 ferritin are advanced as potential neuroprotective strategies (Benarroch, 2009; Zecca et al.,
375 2004), reports about the stage at which iron deposition reaches an abnormal level in the
376 parkinsonian SN are conflicting, especially concerning the prodromal phase (Sian-
377 Hülsmann et al., 2011). The role of mitochondrial dysfunction in PD etiopathogenesis poses
378 the issue of the selective vulnerability of the SNc, as mitochondria and endoplasmic
379 reticulum are not different across neuronal cell types (Surmeier et al., 2011a). Despite the
380 links between the pathogenic processes suggested for PD and the free radical theory of
381 ageing (Wickens, 2001), ventrolateral SNc cells do not specifically exhibit a regionally
382 different DA metabolism that could lead to an increased toxicity, and their vulnerability is
383 unrelated to the amount of neuromelanin within each cell (Obeso et al., 2010). Moreover,
384 although SNc neurons show diminished calcium buffering capacity and greater dependence
385 on L-type Ca²⁺ channels in SNc neurons, they do not exhibit pacemaking activity and are
386 associated with levels of DA way below the toxicity threshold (Obeso et al., 2010), yet
387 opinions on the later statement are divergent (Surmeier et al., 2005). Furthermore, DAergic
388 therapy does not seem to accelerate disease progression (Surmeier et al., 2011a). The
389 amount of LB does not correlate with clinical severity, disease duration, nigral cell loss and
390 α -synuclein deposition (Jellinger, 2009). Moreover, LB are found in other
391 neurodegenerative diseases (Lang and Lozano, 1998a; Schapira and Jenner, 2011).

392 The neuropathologist Heiko Braak contested the brain-centred view by claiming that the
393 PD pathology affects primarily the olfactory bulb, the anterior olfactory nucleus, autonomic
394 neurons of the peripheral nervous system (PNS), and the dorsal motor nuclei of vagal and
395 glossopharyngeal nerves in the medulla of the brainstem. The neurodegenerative process
396 further propagates through the brain, affecting the spinal cord grey matter and pons –
397 including the locus coeruleus, magnocellular portions of the reticular formation and the
398 posterior raphe nuclei –, leading to stage 2. In stage 3, the pedunculopontine nucleus, SNc,
399 central subnucleus of amygdala and magnocellular nuclei in the basal forebrain such as the
400 nucleus basalis of Meynert would be reached. In stage 4, the interstitial nucleus of stria
401 terminalis, ventral claustrum, intralaminar thalamic nuclei, anteromedial temporal

402 mesocortex, CA2 hippocampal subfield, as well as accessory cortical and basolateral nuclei
403 of the amygdala would be affected. In final stages 5 and 6, neurodegeneration would harm
404 multiple cortical regions, including insular, associative and primary cortices (Goedert et al.,
405 2012; Jellinger, 2011; Kalia and Lang, 2015). Braak and colleagues (2003) used α -synuclein
406 immunohistochemistry and suggested that PD was the consequence of infectious agents
407 likely entering in the body through the guts (Braak et al., 2003b; Del Tredici and Braak,
408 2008; Hawkes et al., 2009). Although supported by recent findings (Sampson et al., 2017;
409 Svensson et al., 2015), the Braak staging hypothesis does not explain the asymmetry of
410 clinical symptoms and has been criticized (Burke et al., 2008). It has to be noted that
411 subjects without clinical manifestations have shown widespread α -synuclein aggregates
412 (Stefanis, 2012) and that the latter fail to reproduce entirely clinical and neuropathological
413 features of PD (Corti et al., 2005).

414 **1.1.7. Treatment**

415 The currently available treatment for PD are symptomatic – meaning that they alleviate
416 some of the symptoms rather than curing the disease (Dauer and Przedborski, 2003; De
417 Virgilio et al., 2016). The main therapeutic strategy includes DA substitution (Kalia and
418 Lang, 2015; Lang and Lozano, 1998b), deep brain stimulation (DBS) (Bittar et al., 2005;
419 Hickey and Stacy, 2016; Lozano et al., 2002; Perlmutter and Mink, 2006) and surgical
420 ablation (Davie, 2008). DA replacement therapy consists of the administration of various
421 pharmaceutical compounds, including levodopa, ergoline and non-ergoline DA agonists,
422 monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT)
423 inhibitors, amantadine, clozapine and anticholinergics, the latter comprising notably
424 benztropine, ethopropazine and trixyphenidyl (Blandini and Armentero, 2014; Davie,
425 2008; Fernandez and Chen, 2007; Hauser, 2009; Kaakkola, 2010; Kalia and Lang, 2015;
426 Lang and Lozano, 1998b; LeWitt and Fahn, 2016; Tomlinson et al., 2010). Levodopa is often
427 used in combination with inhibitors of dopa decarboxylase (or amino acid decarboxylase
428 (AADC) inhibitors) such as carbidopa or benserazide. Each drug class targets the treatment
429 of motor symptoms and acts on a particular component of DA synthesis and metabolism
430 (Bainbridge et al., 2008; Hauser, 2009; Kalia and Lang, 2015; Koller and Rueda, 1998;
431 Youdim et al., 2006).

432 DA agonists work by stimulating post-synaptic DA receptors. Ergot-derived DA agonists
433 comprise bromocriptine, cabergoline, pergolide and lisuride. Non-ergot-derived DA
434 agonists include apomorphine, piribedil, pramipexole, ropinirole and rotigotine. MAO-B
435 inhibitors such as rasagiline and selegiline prolong DA activity by preventing its metabolic
436 break down and disinhibiting its neuronal uptake. Besides the prescription of pramipexole
437 and clozapine for depression and psychosis respectively, other drugs can counteract NMS
438 such as cognitive impairment, depression, psychosis, RBD, constipation, gastrointestinal
439 motility, urinary dysfunction, orthostatic hypotension, sialorrhoea and fatigue, although

440 treatment options and responses are more limited than in the case of motor symptoms
441 (Chaudhuri et al., 2006; Kalia and Lang, 2015; Rascol et al., 2003).

442 For example, cholinesterase inhibitors rivastigmine and donepezil appear to partially
443 alleviate cognitive, gait and balance dysfunction (Kalia and Lang, 2015). DA substitution is
444 considered as the most common and effective symptomatic treatment for motor
445 dysfunction in PD (Lang and Lozano, 1998b). Given the lack of evidence for both neurotoxic
446 and neuroprotective effects of DAergic drugs (Davie, 2008; Kalia and Lang, 2015; Lang and
447 Lozano, 1998b; Surmeier et al., 2011a), it is generally considered that treatment should not
448 be delayed and rather be oriented towards preserving independence, safety, function and
449 quality of life of patients (De Virgilio et al., 2016; Lang and Lozano, 1998b; Magrinelli et al.,
450 2016). However, symptoms such as tremor, abnormal posture, FOG, postural instability
451 and dysarthria frequently do not improve with DA replacement therapy (De Virgilio et al.,
452 2016; Helmich et al., 2012; Lang and Lozano, 1998b; Rascol et al., 2003). These treatment-
453 resistant symptoms are considered to be due to neurodegeneration in non-DAergic
454 structures (Kalia and Lang, 2015; Nonnekes et al., 2016).

455 Additionally, *de novo* patients typically experience at first the so-called “honeymoon”
456 period and develop later motor complications (Dauer and Przedborski, 2003; Davie, 2008;
457 Müller, 2002; Rascol et al., 2003; Stocchi et al., 2010; Valadas et al., 2014). During the
458 “honeymoon” period, DAergic therapy abolishes most motor symptoms without severe side
459 effects. This phase lasts 5 years for half of the patients, up to 10 years at utmost in general
460 and only 6 in young patients. On one hand, late-stage PD patients suffer from motor
461 fluctuations such as the “wearing-off phenomenon” – consisting of a gradual shortening of
462 the effect individual levodopa doses – and the “on-off phenomenon” – characterized by
463 abrupt and unpredictable phases of motor inability and stiffness dissociated from levodopa
464 supply –, resulting in periods of good (“on-time”) and bad (“off-time”) control of motor
465 symptoms (Davie, 2008; Kalia and Lang, 2015; Lees, 1989). Likewise, fluctuations can occur
466 in NMS (Kalia and Lang, 2015). Pre- and postsynaptic changes occurring in the DAergic
467 nigrostriatal system and glutamatergic striatopallidal projections were advanced as
468 contributing to the shortening of levodopa effects (Lang and Lozano, 1998b). On the other
469 hand, long-term levodopa intake induces dyskinesias – i.e. choreiform dystonic involuntary
470 movements – at a rate of 10% per year after starting the treatment (Davie, 2008; Kalia and
471 Lang, 2015).

472 Levodopa-induced dyskinesias (LIDs) typically include “off” period dystonia, “peak dose”
473 dyskinesias and “diphasic” dyskinesias (Davie, 2008; Voon et al., 2009). While motor
474 fluctuations are mostly associated with quantity of levodopa and disease duration,
475 dyskinesias are strongly linked to the duration of treatment (Davie, 2008). With a half-life
476 of 60-90 minutes, current recommendations tend towards using frequent and small doses
477 of levodopa, as both oscillating levels of levodopa and PD progression are thought to
478 contribute to the appearance of motor complications (Davie, 2008; Lees, 1989). Despite

479 strategies to ameliorate motor fluctuations and the potential efficacy of amantadine and
480 clozapine to alleviate LIDs, the treatment of motor complications – especially of “wearing-
481 off phenomenon” and LIDs – remains unsatisfying (Davie, 2008; Kalia and Lang, 2015;
482 Müller, 2015).

483 The pathophysiology of motor complications remains poorly understood but may involve
484 fluctuating stimulation of DAergic receptors subtype D1 – inducing an increase in
485 dynorphine/substance P –, glutamatergic overactivity, as well as interactions between D1-
486 and D2-mediated striato-pallidal pathways and colocalization of neuropeptides, N-methyl-
487 D-aspartate (NMDA) receptors and γ -aminobutyric acid (GABA) receptors (Baas, 2000;
488 Bargiotas and Konitsiotis, 2013). Similarly to PD pathogenesis, the multifactorial aspect of
489 LIDs pathogenesis inspired novel therapeutic approaches based on drugs interfering with
490 glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission
491 (Bargiotas and Konitsiotis, 2013), as well as technical advances aiming at delivering drugs
492 in a continuous fashion such as continuous delivery of subcutaneous apomorphine,
493 transdermal rotigotine administration, intraduodenal or intrajejunal levodopa infusion, but
494 also DBS, which will be covered later in the text (Davie, 2008; Nyholm, 2012; Timpka et al.,
495 2016; Voon et al., 2009). Nonetheless, motor complications are less frequent with DA
496 agonists, which commonly have a selective affinity for D2 receptors, albeit the latter are
497 associated with a lower efficacy and higher risk of side effects as compared to levodopa
498 (Baas, 2000; Davie, 2008; Kalia and Lang, 2015). Indeed, LIDs and motor fluctuations are
499 not the only disadvantages of DAergic medication. If nausea, vomiting, anorexia, vivid
500 dreams, nightmares and sleep disorders have been reported (Hauser, 2009; Lang and
501 Lozano, 1998b; LeWitt and Fahn, 2016), DA agonists are particularly renowned for being
502 associated with such side effects but also with psychotic symptoms such as illusions,
503 delusions and paranoia, as well as presence or passage hallucinations, well-formed visual
504 hallucinations, and less frequently auditory, tactile or olfactory hallucinations (Calabresi et
505 al., 2015; Kalia and Lang, 2015).

506 Psychiatric symptoms were regarded as possibly related to the stimulation of DA receptors
507 in the mesolimbic and mesocortical systems (Lang and Lozano, 1998b). Moreover, impulse
508 control disorders (ICDs) – which occur in 13.6% of patients and include pathological
509 gambling, hypersexuality, mania, punding (hobbyism), compulsive shopping, eating and
510 medication use –, are associated with the use of DA agonists and high doses of levodopa but
511 not with DA agonists dose (Davie, 2008; Voon et al., 2009, 2011).

512 Other risk factors for ICDs are known, such as younger age, being unmarried and a family
513 history of gambling problems (Voon et al., 2009), and the DA overdose hypothesis states
514 that ICDs in PD might result, apart from genetic factors, from the mismatch between the
515 selective and progressive caudorostral pattern of striatal denervation and the lack of
516 spatial selectivity of DAergic treatment, which leads to a DA overdose in striatal regions
517 initially spared by the disease, such as the ventral striatum (Cools, 2006; Vaillancourt et al.,

518 2013). In any event, ICDs and psychotic symptoms contraindicate the use of DA agonists in
519 patients with history of addiction, obsessive-compulsive disorder and impulsive
520 personality, as well as in elderly patients, especially those with cognitive impairment (Kalia
521 and Lang, 2015). MAO-B inhibitors can be effective in addition to levodopa in advanced PD
522 or as monotherapy in early disease stage by hampering DA enzymatic metabolism,
523 although their potential neuroprotective and neurotoxic effects are a matter of controversy
524 and their mechanisms of action leading to alleviate clinical symptoms in PD remain to be
525 elucidated (Bargiotas and Konitsiotis, 2013; Davie, 2008; Fernandez and Chen, 2007;
526 Youdim et al., 2006). In combination with AADC inhibitors, COMT inhibitors – which
527 include entacapone, tolcapone and nebicapone – prevent a set of enzymes to metabolize
528 DA, increasing thereby the availability and the steadiness of the latter in the plasma and the
529 brain (Davie, 2008). However, despite probable neuroprotective effects through reduced
530 production of free radicals via DA deamination (Müller, 2015), the efficacy of this drug
531 class could be improved as COMT inhibition with current pharmaceutical compounds does
532 not reach 90% (Kaakkola, 2010).

533 The widespread acknowledgment of LIDs and DAergic therapy shortfalls encouraged
534 clinicians and surgeons to reconsider ablative surgery, introduced back in the early 1950s,
535 as a therapeutic alternative for PD (Davie, 2008; Wagle Shukla and Okun, 2013). Current
536 irreversible procedures include pallidotomy and thalamotomy (Mandir and Vaughan,
537 2000). With the introduction of stimulators, a new therapeutic approach, termed deep
538 brain stimulation (DBS), emerged (Davie, 2008). DBS consists of implanting electrodes of
539 varying technical complexity (Hickey and Stacy, 2016) via surgery in predefined deep brain
540 nuclei to induce electrical stimulation via a implantable pulse generator similar to a
541 pacemaker (Bittar et al., 2005; Hickey and Stacy, 2016; Lozano et al., 2002). Notable
542 advantages of DBS over surgical ablation are its reversibility, programmability and safety
543 of bilateral surgery (Davie, 2008; Lang and Lozano, 1998b; Wagle Shukla and Okun, 2013).
544 Despite its effectiveness, precise mechanisms of action of DBS remain largely unclear
545 (Hickey and Stacy, 2016; Kalia and Lang, 2015; Lang and Lozano, 1998b; Lozano et al.,
546 2002; Perlmutter and Mink, 2006) and are apparently more complex than the original
547 suggestion of long-term inhibition within the defective motor circuit via depolarization
548 blockade of aberrant neuronal firing, as DBS seems to inhibit soma while concurrently
549 activating axons, change neurotransmitter release, and could improve PD symptoms by
550 normalization of global functional networks or selective stimulation of white matter tracts
551 (Hickey and Stacy, 2016; Lang and Lozano, 1998b; Lozano et al., 2002; Perlmutter and
552 Mink, 2006). The specific pathology leading to indication for DBS defines the precise
553 nucleus to be targeted as well as the settings of the implantable pulse generator, including
554 amplitude, pulse width and frequency of stimulation, based also on the type of electrode
555 implanted (Bittar et al., 2005; Hickey and Stacy, 2016).

556 Similarly to early ablative procedures, common target nuclei include the subthalamic
557 nucleus (STN) and internal part of the globus pallidus (GPi) for the global treatment of
558 motor symptoms in PD, as well as the motor thalamus – notably the Vim nucleus – for the
559 specific treatment of tremor in PD (Bittar et al., 2005; Lang and Lozano, 1998b; Lozano et
560 al., 2002; Perlmutter and Mink, 2006). While STN DBS allows the diminution of DAergic
561 medication, GPi DBS can reduce LIDs (Perlmutter and Mink, 2006). Beyond this difference,
562 both targets are comparable in terms of motor symptoms improvement (Perlmutter and
563 Mink, 2006; Wagle Shukla and Okun, 2013). DBS can also improve NMS such as sleep
564 disorders and behavioural abnormalities, although further studies are needed to
565 disentangle the effects specific to DBS and the reduction of DAergic medication that
566 accompanies it (Kalia and Lang, 2015).

567 Notwithstanding the average delay of 10-13 years between PD diagnosis and DBS surgery,
568 recent findings suggest that early DBS intervention might better improve quality of life of
569 patients as compared to any other therapy (Kalia and Lang, 2015). DBS targets currently
570 under investigation are the spinal cord, to treat chronic pain, and the pedunculopontine
571 nucleus (PPN), for axial symptoms such as balance and gait dysfunction (Rowland et al.,
572 2016). Other DBS targets such as the zona incerta (ZI), periventricular gray matter (PVG),
573 fornix, subcallosal cingulate, lateral habenula, ventral capsule, ventral striatum, nucleus
574 accumbens, inferior thalamic peduncle, centromedian-parafascicular thalamic complex,
575 external part of the globus pallidus (GPe), medial forebrain bundle, ventralis oralis
576 posterior (Vop), ventroposterior lateral (VPL) and medial (VPM) thalamic nuclei are
577 currently used or studied to treat AD, dystonia, ET, pain – including neuropathic, phantom-
578 limb, failed low back, and cluster-headache pain –, depression, anorexia, obsessive
579 compulsive disorders (OCD), addiction, Gilles de la Tourette's syndrome (GTS), rubral,
580 proximal and MS tremor (Bittar et al., 2005; Cleary et al., 2015; Lipsman et al., 2013;
581 Perlmutter and Mink, 2006; Rowland et al., 2016). However one cannot exclude the
582 possibility that structures adjacent to the targeted nuclei are additionally stimulated (Bittar
583 et al., 2005).

584 Nowadays, computed tomography (CT) and magnetic resonance imaging (MRI) are
585 fundamental to improve the accuracy of DBS electrodes placement, as well as in the use of
586 focused ultrasound and gamma knife radiosurgery (Bittar et al., 2005; Higuchi et al., 2016;
587 Rowland et al., 2016). However, despite considerable technical progresses and the possible
588 postoperative adjustment of electrical stimulation settings, risks of irreversible
589 complications exist (Lang and Lozano, 1998b). Some of the latter are related to surgery
590 itself or device failures: cable discomfort, buzzing sound, lead fracture, dislocation of
591 device, headache, mental status change, confusional state, paresthesia, pain, delirium,
592 impaired wound healing, infection, infraclavicular hematoma, air embolus, intracerebral
593 abscess, cerebral hemorrhage, stroke and death (Wagle Shukla and Okun, 2013). Yet
594 adverse effects can also be induced by electrical stimulation and affect worsening of

595 mobility, gait and balance disturbance, falls, speech disorders, visual field defect, emotional
596 lability, anxiety, depression, impulse control disorder, obsessive-compulsive disorder,
597 mania, changes in personality, cognitive symptoms, psychiatric disturbance, psychosis,
598 hallucinations, suicide (Cyron, 2016; Davie, 2008; Wagle Shukla and Okun, 2013).

599 There is evidence suggesting that DBS might impair spatial delayed recall and response
600 inhibition (Cavanagh et al., 2011; Frank et al., 2007; Perlmutter and Mink, 2006). DBS is
601 therefore limited to PD patients presenting no contraindications such as depression,
602 cognitive impairment or other comorbid neuropsychological and neuropsychiatric factors.
603 DBS further requires careful screening of the surgical candidates depending on age, disease
604 duration and levodopa responsiveness, with apparently 30% of DBS failures being due to
605 surgical candidacy issues (Davie, 2008; Rowland et al., 2016; Wagle Shukla and Okun,
606 2013). Some of these complications may cumulate over time (Perlmutter and Mink, 2006).
607 While benefits from surgery appear to last for at least 4 years, patients often experience a
608 “second honeymoon” during which symptoms improvements are lost (di Biase and Fasano,
609 2016; Perlmutter and Mink, 2006). This shortcoming, together with the suboptimal efficacy
610 of DBS for the treatment of axial symptoms, incited trials of low-frequency DBS, typically
611 around 60-80 Hz, as an alternative to high-frequency DBS, which is generally above 100 Hz
612 (di Biase and Fasano, 2016). Apart from detrimental effects of very-low-frequency DBS,
613 these studies suggest notably that the different cardinal symptoms of PD might respond
614 differently to each stimulation frequency, although further investigations are needed,
615 experimental designs being largely variable and inconsistent across studies (di Biase and
616 Fasano, 2016). Future technical developments for DBS might include closed-loop
617 stimulation systems, which would deliver electrical stimulation pulses based on the
618 detection of physiological signals (Rowland et al., 2016). However, the development of such
619 adaptive DBS systems would require a deeper understanding of the links between PD
620 pathophysiology and symptomatology.

621 Other stimulation techniques, such as repetitive transcranial magnetic stimulation (rTMS)
622 and electroconvulsive therapy (ECT), are commonly used for the treatment of depression
623 in patients without PD (Kalia and Lang, 2015). In PD, psychotherapy and electroconvulsive
624 therapy (ECT) are therapeutic alternatives to medication for the treatment of depression
625 (Veazey et al., 2005) and recent reports suggest that repetitive transcranial magnetic
626 stimulation (rTMS) alleviates symptoms on lower limb and improve gait (Chung and Mak,
627 2016).

628 Rehabilitation strategies might be considered as motor relearning methods, possibly acting
629 at the basal ganglia (BG) level (Magrinelli et al., 2016). These comprise nonspecific
630 physiotherapy, occupational therapy, dance, martial arts therapy, treadmill and robotic
631 training, speech and cognitive therapy, motor imagery, action observation therapy, virtual
632 reality and telerehabilitation. Studies on the effects of rehabilitation procedures have

633 shown significant improvement in PD symptoms, especially gait and balance, though PD
634 neurodegenerative processes are not blocked by such approaches.

635 Other approaches in the experimental phase such as neural transplantation for DA
636 transmission restoration, gene therapy, immunomodulatory therapy using for instance
637 minocycline, anti-inflammatory treatments, as well as recent local and systemic drug
638 delivery systems for administration of DA, levodopa, agonists, neuroprotectors,
639 antioxidants, protein inhibitors, peptides and neurotrophic factors using micro- and
640 nanoparticles are currently under study and may hold promising future therapeutic
641 applications for patients with PD. Some gene therapy approaches combine tricistronic
642 vector encoding tyrosine hydroxylase, AADC and GTP cyclohydrolase hydroxylase, while
643 others aim at delivering neurturin, AADC or glutamic acid decarboxylase (GAD) through
644 adeno-associated viral vector serotype 2 (AAV2). To date, none of the recent gene therapy
645 approaches demonstrate a clinical efficacy leading to a consistent improvement in PD
646 symptoms in clinical trials (Bartus et al., 2013; Feng and Maguire-Zeiss, 2010).

647 Anti-inflammatory treatments include fibrates, rosiglitazone, metformin, pyrroloquinoline
648 quinone, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) and resveratrol (Sirt1).
649 Neuroprotectors comprise anti-apoptotic agents (TCH346, CEP-1347), glutamate
650 antagonists, promitochondrial drugs (coenzyme Q10, creatine) or calcium channel blockers
651 (isradipine). Typical neurotrophic factors are glial cell line-derived neurotrophic factor
652 (GDNF) and vascular endothelial growth factor (VEGF). Still, further knowledge of the
653 relationships between PD etiopathogenesis and pathophysiology are necessary, as most of
654 these approaches still do not surpass the benefits of DAergic medication or DBS (De Virgilio
655 et al., 2016; Garbayo et al., 2013; Lang and Lozano, 1998b; Miller and O'Callaghan, 2015;
656 Obeso et al., 2010; Rodríguez-Nogales et al., 2015; Rowland et al., 2016).

657 **1.2. Segregation and integration of information in cortico-subcortical loops**

658 The pathogenesis of PD is multifactorial and remains unclear. Cortico-subcortical loops
659 represent a key element in PD pathophysiology. In this section I focus on cortico-
660 subcortical circuits: what are their constituents and organization in terms of structure and
661 function, as well as theoretical models attempting to explain their role in disease, notably in
662 PD.

663 **1.2.1. Structural and functional architecture of cortico-basal ganglia-thalamic** 664 **circuitry**

665 The BG are a phylogenetically ancestral set of interconnected subcortical structures (**Figure**
666 **2; Figure 3**) that receive connections from essentially the whole cortex and contribute to
667 multiple behavioural functions (Alexander et al., 1989; DeLong and Wichmann, 2009;

668 Grillner and Robertson, 2016; Haber, 2003; Utter and Basso, 2008). The main input nucleus
669 of the BG is the striatum, the other being the STN. The two major output stations of the BG
670 are the substantia nigra pars reticulata (SNr) and the GPi, whose activity pathologically
671 increases in PD (Lang and Lozano, 1998b). The dorsal striatum, which comprises the
672 putamen and caudate nucleus, as well as the ventral striatum, project to the dorsal
673 pallidum, which includes the GPi and GPe, as well as the ventral pallidum. The term
674 “ventral striatum” encompasses the nucleus accumbens (NAcc) – wherein two regions, the
675 shell and the core, can be identified – and striatal cells of the olfactory tubercle (Afifi,
676 1994a; Haber, 2003; van der Meer and Redish, 2011). Features of the shell are similar to
677 those of the limbic structures, whereas the core resembles more to regions in the dorsal
678 striatum (Clarke and Adermark, 2015). Another frequent terminology divides the dorsal
679 striatum into dorsolateral striatum (DLS), implicated in stimulus-response learning, and
680 dorsomedial striatum (DMS), involved in goal-directed learning (Clarke and Adermark,
681 2015; Devan et al., 2011).

682 The ventral pallidum lies in the sub-commissural part of the substantia innominata
683 (Lanciego et al., 2012; Root et al., 2015). While the GPi sends back information to the cortex
684 via the thalamus and projects to brainstem nuclei and the habenula, the GPe projects to all
685 BG nuclei but principally to GPi, SNr and STN, as well as SNc (Chan et al., 2006; Parent et al.,
686 1999, 2001). The STN projects back to GPe and sends further connections to the
687 pedunculo-pontine nucleus (PPN), GPi and SNr (Joel and Weiner, 1997; Lenglet et al., 2012;
688 Martinez-Gonzalez et al., 2011; Nakano, 2000). Apart from excitatory inputs from the STN,
689 cerebral cortex and thalamus (Kita, 2007), most afferent to the GPe are inhibitory inputs
690 from the striatum. However there are also feedback projections from the STN and thalamus
691 to the striatum, from the thalamus to the striatum, as well as from the GPi to GPe (Afifi,
692 1994a; Haber and Calzavara, 2009; Joel and Weiner, 1997; Smith et al., 2004).

693 The SNc is reciprocally connected to the striatum, modulating cortico-striatal inputs
694 through long-term potentiation and depression by means of phasic and tonic DA signals of
695 various intensities, and sends also projections to the GPi and STN (Calabresi et al., 2007;
696 Goto et al., 2007; Lenglet et al., 2012; Redgrave et al., 2011). Striatal DA elevates in regions
697 innervated by nigrostriatal projections that are activated, while it reduces in adjacent
698 zones, as evidenced by DA reinforcement of specific sets of corticostriatal connections and
699 concurrent inhibition of other inputs (Lanciego et al., 2012). Studies show that
700 striato/pallidal neurons receive greater input from pyramidal tract (PT) cortical neurons,
701 whereas striatonigral neurons preferentially receive input from intratelencephalic (IT)
702 cortical neurons (Lei, 2004).


703 The thalamus, a complex including several nuclei and situated in the diencephalon, receives
704 inputs from the GPi/SNr and projects back to the cerebral cortex (Herrero et al., 2002). The
705 main type of neurons found in the thalamus are relay cells, whose morphology is
706 exceptionally constant, and intrinsic interneurons (Sherman, 2004). Despite being often

707 seen as a simple relay nucleus, the thalamus receives also direct inputs from the cortex, as
708 well as inputs from the cerebellum, and projects back to the striatum and cerebral cortex
709 by integrating these various excitatory and inhibitory inputs (Goldberg et al., 2013;
710 Graybiel, 2008; Guillery and Sherman, 2002; Haber, 2003; Haber and Calzavara, 2009;
711 Haber et al., 2000; Pelzer et al., 2016; Smith et al., 2004).

712 The cerebellum can also modulate motor commands sent through the spinal cord notably
713 via the red nucleus, the latter being possibly involved in ET (Ramnani, 2006; Sharifi et al.,
714 2010; Telford and Vattoth, 2014) conversely to neighbouring retrorubral area A8 which
715 may be implicated in PD resting tremor according to the dimmer-switch model (Helmich et
716 al., 2012). Although the role of the cortico-cerebellar network has been recently proposed to
717 underlie pathophysiological changes in PD (Martinu and Monchi, 2013), the latter circuit is
718 largely viewed as playing a compensatory role that occasionally favour cortico-BG
719 dysfunction.

720 Both the SNr and SNc project to the PPN, but in addition the SNr sends connections to the
721 reticular formation and superior colliculus, which projects back to thalamic nuclei (Lenglet
722 et al., 2012; McHaffie et al., 2005; Tykocki et al., 2011). Afferent and efferent connections as
723 well as neurotransmitter types in the PPN are topographically organized (Martinez-
724 Gonzalez et al., 2011; Mena-Segovia et al., 2008). The striatum principally receives afferent
725 connections from VTA and SNc, the loss of the latter being considered as the pathological
726 hallmark of PD as discussed in section 1.1.5. Despite asymmetry in DAergic nigrostriatal
727 projections in PD, the latter pathway is generally symmetrical in healthy subjects, while the
728 meso-striatal projections from the VTA to the striatum are asymmetrical at baseline
729 (Molochnikov and Cohen, 2014). A third pathway, termed "meso-cortical", sends DAergic
730 projection from the VTA to the PFC (Seamans and Yang, 2004). Nigro-cortical projections
731 are more diffuse (Haber and Knutson, 2009).

The topography of cortico-subcortical loops in Parkinson's disease



732

733 **Figure 2:** Anatomy of basal ganglia, thalamus and midbrain nuclei rendered on a canonical T1-weighted
734 image . The thalamus (light green) is rendered in a semi-transparent fashion to make apparent the STN, SN
735 and RN. The Harvard-Oxford atlas provided with FSL (<https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases>) is used
736 to represent the putamen, caudate, NAcc and thalamus. The GPe, GPi, STN, SN and RN are rendered using the
737 ATAG atlas (Keuken et al., 2014).

738 Striatal neuronal cells predominantly consist of inhibitory GABAergic medium spiny
739 neurons (MSNs), which are also named spiny projections neurons (SPNs) and likely
740 correspond to phasically active neurons (PANs) (Kreitzer, 2009; Smith et al., 2014). The
741 latter have massive dendritic arborisation to integrate inputs from virtually the whole
742 cortex, hippocampus and amygdala while sending axons collaterals to neighbouring MSNs
743 (Parent et al., 2000; Surmeier et al., 2010). Electrophysiologically, MSNs have a bimodal
744 distribution of membrane potentials, hence the terms “up” and “down” characterizing these
745 two states (Nicola et al., 2000). Consistent with the hypothesis that striatal MSNs receive
746 converging cortical inputs firing in a correlated but not entirely synchronous fashion, the
747 up states correlate among MSNs (Kreitzer, 2009). The “up” and “down” states in MSNs

748 become bistable with DA innervation (Gruber, 2003) and long-term potentiation is
749 consolidated via a 3-factor learning rule, which uses a reward-predicting signals from DA
750 neurons (Houk et al., 1995). Besides astrocytes, other striatal cells comprise interneurons
751 (Clarke and Adermark, 2015). Large interneurons likely correspond to tonically active
752 neurons (TANs) and are cholinergic (Lim et al., 2014). They spread dense connections
753 throughout the striatum despite representing only 1-2% of striatal cells (Lim et al., 2014).
754 It is worth mentioning that striatal levels of ACh are outstanding compared to other brain
755 regions. Some neurotransmitters used by small aspiny neurons are GABA, somatostatin,
756 neuropeptide Y (NPY), neurotensin and thyrotropin-releasing hormone (Tepper and
757 Bolam, 2004). GABAergic interneurons have been further subdivided into low-threshold-
758 spiking (LTS) and fast-spiking interneurons (FSIs). The latter, also designated as GABAergic
759 interneurons, are parvalbumin-positive and interconnected by dendritic gap junctions
760 (Berke, 2011; Kreitzer, 2009), which may cause synchronous activity in the striatum
761 (Hjorth et al., 2009). Furthermore, FSIs project preferentially to MSNs, can be depolarized
762 directly by cholinergic interneurons via nicotinic receptors and might be play a particularly
763 important role in the DLS, as they are distributed along a postero-ventro-median to antero-
764 dorsolateral gradient of increasing density (Clarke and Adermark, 2015). LTS interneurons
765 express NPY, somatostatin and nitric oxide synthetase (Clarke and Adermark, 2015). Other
766 GABAergic interneurons express tyrosine hydroxylase (TH) or the calcium binding protein
767 calretinin. Striatal cholinergic interneurons can reduce glutamatergic input to striatal
768 neurons by activating muscarinic receptors and modulate FSIs by releasing both glutamate
769 and ACh. Further, when synchronously activated, they enhance GABA co-release at DA
770 terminals and mediate thereby considerable inhibitory signals in MSNs by acting on
771 nicotinic receptors (Clarke and Adermark, 2015; Nelson et al., 2014).

772 It has been reported that neuropeptides such as substance P, enkephalin, and dynorphin
773 are differentially involved in each efferent striatal connection (Afifi, 1994a; Calabresi et al.,
774 2000; Haber, 2003). Additionally, muscarinic and opioid receptors in striatal interneurons
775 regulate DA release (Rice et al., 2011). GABAergic interneurons in general have been
776 considered to influence spike timing of MSNs, whereas cholinergic interneurons are
777 thought to modulate sub- and supra-threshold MSNs responses (Tepper and Bolam, 2004).
778 Besides neurotransmitters modulating striatal function via afferent connections, striatal
779 output is therefore modulated by its local microcircuitry via several mechanisms. Other
780 intra-striatal mechanisms include “feedback inhibition”, which is supported by a weak
781 lateral inhibitory network between competing MSNs at pre- and postsynaptic levels (Houk
782 et al., 2007; Plenz, 2003), and a forceful control over striatal excitability allowing “feed-
783 forward inhibition” by GABAergic and cholinergic interneurons, both of which are involved
784 in the induction of synaptic plasticity (Clarke and Adermark, 2015). Intra-striatal circuitry is
785 therefore strongly influenced by GABAergic and cholinergic interneurons, as well as
786 DAergic input, in terms of spiking activity as well as synaptic plasticity (Calabresi et al.,

787 2014; Reynolds and Wickens, 2002; Shen et al., 2008; Surmeier et al., 2007). Furthermore,
788 DA alters both voltage-dependent conductance and synaptic transmission in the striatum
789 (Nicola et al., 2000). Recent studies showed that the apparently antagonistic behaviour of
790 DA and ACh might be revised because synchronous activation of cholinergic interneurons
791 seems to promote striatal DA release via activation of presynaptic nicotinic ACh receptors
792 (Surmeier and Graybiel, 2012).

793 Concerning DA receptors, two major types were reported in the striatum: D₁ and D₂ (Afifi,
794 1994a; Missale et al., 1998; Surmeier et al., 2010). Though striatal subregions
795 cytoarchitectonics appear similar, each of these is associated with different cellular
796 morphologies, receptor localization, as well as afferent and efferent circuitry (Clarke and
797 Adermark, 2015). While PD neurodegeneration seems to affect D₁ rather than D₂ receptors,
798 the former are preferentially found in striosomes, or “patch” striatal compartment,
799 whereas the latter are more frequently detected in matrisomes, also termed “matrix”
800 compartment of the striatum (Afifi, 1994a; Graybiel, 1990; Lanciego et al., 2012). An
801 imbalance between these two intermingled compartments has been argued to play a role in
802 basal ganglia disorders (Crittenden and Graybiel, 2011; Graybiel, 2008). Cholinergic
803 modulation takes place mostly in the extra-striosomal compartment (Clarke and Adermark,
804 2015; Nakano et al., 2000). While the ventral tier of the SNc and ventral SNr are
805 preferentially connected to striosomes, the VTA and dorsal SNc neurons project to
806 matrisomes. In thalamo-striatal circuits, the centromedian and parafascicular thalamic
807 nuclei – considered as more susceptible to PD neurodegeneration – are interconnected
808 with the striatal matrix, while the rest of the thalamus shows no clear preference for any
809 compartment (Smith et al., 2014). Furthermore, MSNs expressing D₁ receptors mostly
810 forward cortical inputs to GPi, forming the so-called “direct” pathway (Gerfen and
811 Surmeier, 2011; Parent and Hazrati, 1995a; Smith et al., 1998; Surmeier et al., 2011b). On
812 the contrary, D₂-expressing MSNs convey cortical signals to GPi by passing through GPe
813 and STN. The term “indirect” pathway designates this detour.


814 However, it has to be noted that further distinction can be made between “short” and
815 “long” indirect pathways. The first connects the striatum to GPi via GPe, whereas in the
816 second striatal output goes through the GPe and STN before ending in the GPi (Schroll and
817 Hamker, 2013). However some projections terminate in both pallidal segments and there
818 are MSNs co-expressing D₁ and D₂ receptors, suggesting that the separation between direct
819 and indirect pathways may not be complete (Bergman and Deuschl, 2002; Calabresi et al.,
820 2007; Wichmann and Dostrovsky, 2011). Thalamostriatal projections seem to innervate
821 preferentially striatal neurons of the direct pathway (Smith et al., 2004). However recent
822 studies suggest that they may equally project to both pathways, like specific cortical layers
823 (Wall et al., 2013). On the contrary, motor cortex would have a higher affinity for the
824 indirect pathway and sensory cortex as well as limbic structures were reported to project
825 mainly to the direct pathway (Wall et al., 2013). A third pathway is referred to as the

826 “hyperdirect” pathway, across which the cortex reaches the GPi/SNr via the STN, without
827 transiting through the striatum (Nambu et al., 2002). Nevertheless, there exist other
828 cortico-subcortical loops (Afifi, 1994b; Parent and Hazrati, 1995b).

829 Other DA receptors include D₃ and D₄ in the D₂-like family as well as D₅ in the D₁-like
830 family. D₁ is the most prevalent receptor and is mainly expressed in the dorsal and ventral
831 striatum, limbic system, hypothalamus and thalamus (Missale et al., 1998). D₅ is weakly
832 expressed compared to D₁ and has been found in the hippocampus, lateral mammillary
833 nucleus, diagonal band area, substantia nigra, striatum as well as in parafascicular, medial
834 and lateral nuclei of the thalamus. D₁ and D₅ receptors are also expressed in prefrontal,
835 premotor, cingulate and entorhinal cortex, as well as in the dentate gyrus. D₂ is principally
836 found in the dorsal and ventral striatum, but also in the amygdala, hypothalamus, SNc, VTA
837 and granule cells of the hippocampal formation, as well as in prefrontal, cingulate, temporal
838 and entorhinal cortices. D₃ is especially found in limbic areas, such as the ventromedial
839 shell of the NAcc, the olfactory tubercle and the islands of Calleja, but also in the
840 hippocampus, cerebellum and medial temporal lobe. It is rarely found in the dorsal
841 striatum, SNc and VTA. Levels of D₄ are low in the pallidum, SNr and reticular thalamic
842 nucleus, but high in the frontal cortex, amygdala, hippocampus, hypothalamus and
843 mesencephalon. It is worth mentioning that DA receptors are also found in blood vessels,
844 adrenal gland, kidney, sympathetic ganglia and heart. While the role of D₃ and D₄ receptors
845 was less studied, D₁, D₂, D₃ and D₅ receptors are likely to play a role in motor activity,
846 learning and memory (Missale et al., 1998).

847 Apart from the rostro-medial tegmental area (RMTg) in the tail of the VTA, which contains
848 GABAergic interneurons and seems involved in aversion, DAergic neurons in the VTA are
849 more heterogeneous than initially thought and participate differently to rewarding and
850 aversive stimuli (Russo and Nestler, 2013). Following DA depletion, the number of striatal
851 D₁ and D₂ receptors increases and a shift from long-term depression (LTD) to long-term
852 potentiation (LTP) is observed in the indirect pathway (Kreitzer and Malenka, 2008). Both
853 the firing and membrane resistance of MSNs of the indirect pathway increase as well, while
854 the latter cells lose dendritic spines. Additionally, DA depletion might increase the
855 propensity of oscillatory activity in cortex and thalamus. The recurrent GPe-STN circuit
856 may then further amplify synchronous activity in striatal outputs to GPe. Therefore,
857 although GABA remains the prominent neurotransmitter within the BG, signals within the
858 latter are notably modulated by DAergic and serotonin inputs mainly from the midbrain
859 and hindbrain, cholinergic striatal interneurons and excitatory glutamatergic
860 neurotransmission from the cortex, thalamus and STN (Conn et al., 2005). GABA allows
861 striato-pallidal pathways exerting tonic inhibitory control over the thalamus, using
862 henceforth disinhibition as one of its main physiological mechanism (Chevalier and Deniau,
863 1990).

The topography of cortico-subcortical loops in Parkinson's disease



864

865 **Figure 3:** Simplified schematic of BG circuitry based on the reviewed literature, focusing on main BG intrinsic
 866 connections, as well as its afferents from and efferents to the thalamus, cortex, midbrain and hindbrain.
 867 DAergic, GABAergic, glutamatergic and cholinergic projections are shown in green, red, blue and black
 868 respectively. Neurotransmitter in play for connections in grey is unknown. Some projections may involve
 869 multiple neurotransmitters, which are not thoroughly shown. Reciprocal connections are shown with double-
 870 headed arrows. Additional references to original research articles supporting some of the depicted
 871 connections are available at <http://www.frontiersin.org/files/cognitiveconsilience/index.html> (Solari and
 872 Rich Stoner, 2014). For an alternative schematic including raphe nuclei, locus cœruleus and nucleus basalis of
 873 Meynert, see Weingarten and colleagues (2015).

874 Functionally, BG nuclei are organized topographically into several open and closed loops
 875 subserving different brain functions (**Figure 4**). This topographical organization mirrors to
 876 a certain extent the one found in the cerebral cortex (Accolla et al., 2014; Afifi, 1994b;
 877 Alexander and Crutcher, 1990; Alexander et al., 1986, 1989; Draganski et al., 2008; Galvan
 878 et al., 2015; Graybiel, 2008; Haber, 2016; Haber et al., 2000; Haegelen et al., 2009;
 879 Iwamuro, 2011; Joel and Weiner, 1997, 2000; Lambert et al., 2012; Nakano et al., 2000;
 880 Nambu, 2008, 2011, Obeso et al., 2008, 2014, Redgrave et al., 2010, 2011; Romanelli et al.,
 881 2005; Seger and Spiering, 2011). While major functional territories are the limbic,
 882 associative and sensorimotor subdivisions, experimental evidences support the notion of
 883 further detailed topographical organization within the BG such as somatotopy (Alexander
 884 and Crutcher, 1990; Iwamuro, 2011; Nambu, 2011; Obeso et al., 2008; Romanelli et al.,
 885 2005). Segregation at the level of cerebellothalamic, pallidothalamic and nigrothalamic
 886 projections to the cortex, between oculomotor and skeletomotor functions, but also
 887 between various cognitive functions (Middleton and Strick, 2000) has been advanced, as
 888 well as the existence of distinct visual, parietal, premotor and cingulate corticostriatal loops


889 (Seger, 2013; Seger and Peterson, 2013; Takada et al., 1998, 2001; Utter and Basso, 2008).
890 Retinotopic and tonotopic organization might also be partially preserved across
891 corticostriatal projections (Updyke, 1993; Xiong et al., 2015). The putamen, STN, GPe, GPi,
892 SNr as well as oral parts of the ventrolateral and ventro-postero-lateral nuclei of the
893 thalamus are thought to embed somatotopically-organized representations, yet the SNr is
894 often considered to play a role in eye movements (Basso and Sommer, 2011).
895 Somatotopically organized representations found in the primary motor cortex (M1) and
896 the supplementary motor area (SMA) are both preserved at the BG level, although M1 and
897 SMA representations of the same body part are more difficult to distinguish, especially in
898 the pallidum and STN (Iwamuro, 2011). Somatotopy in the SNc is regarded as weaker and
899 its existence is unclear (Nambu, 2011; Rommelfanger, 2010), although topographic
900 arrangement is observed in the SN and VTA (Haber, 2016; Haber et al., 2000). A fractured
901 somatotopy is found in the cerebellum, which is apparently involved not only in motor
902 function but also in emotional and executive functions (Apps and Hawkes, 2009; Bernard
903 and Mittal, 2014; Bostan et al., 2013; Manni and Petrosini, 2004; Ramnani, 2006; Stoodley
904 and Schmahmann, 2009, 2010; Stoodley et al., 2012).

905 The insula, which shares massive connections with the striatum, is a distinctive part of the
906 cerebral cortex as it intrinsically embeds a topographic gradient from social-emotional to
907 sensorimotor functions (Christopher et al., 2014; Kurth et al., 2010). There are also reports
908 of somatotopic organization in the insular cortex, at least for somatosensory function but
909 possibly also for pure motor function (Baumgartner et al., 2010; Brooks et al., 2005; Fink et
910 al., 1997; Henderson et al., 2007, 2010). DA neurons in the SNc and VTA also integrate
911 sensory, motor and cognitive information from multiple afferents to modulate BG
912 signalling, notably through their intimate link with the striatum (Haber et al., 2000;
913 Morikawa and Paladini, 2011). Interestingly, spinal neurons preserve the topography of
914 muscle effectors found in the motor cortex to a certain extent, although the representation
915 is probably best described as “musculotopic” instead of somatotopic (Levine et al., 2012).

916 Functional topography does not solely concern striato-pallido-thalamic but also thalamo-
917 striatal and thalamo-cortical projections (Herrero et al., 2002; Smith et al., 2004, 2009).
918 Thus, the previous concept of serial processing across BG has been mostly replaced by the
919 one of parallel channels (Afifi, 1994a), which converge across nuclei to a certain degree
920 (Haber, 2003; Utter and Basso, 2008). While earlier debates on BG functional organization
921 focused on two opposite views (Bergman et al., 1998a; Nambu, 2011; Parent and Hazrati,
922 1995a), namely the parallel (or segregated) processing (Alexander et al., 1986; Hoover and
923 Strick, 1993) hypothesis and the information convergence (or funnelling) hypothesis
924 (Bolam et al., 1993; Kolomiets et al., 2001, 2003; Percheron and Filion, 1991), it is
925 nowadays generally accepted that parallel circuits subject to relative overlap form
926 topographical gradients along different spatial axes depending on the brain structure
927 considered (**Figure 4**). Borders between functional territories are not strict, and

928 interactions between cortico-subcortical loops are promoted by striato-nigro-striatal,
 929 thalamo-cortical and striato-pallidal pathways (Seger, 2008).

930 Alternatively, in regard to the organization of the striatum into patch and matrix
 931 compartments, a pattern of divergence-reconvergence across cortico-striato-pallidal
 932 pathways has been proposed (Graybiel et al., 1994). While the notion of topographical
 933 organization mirroring – at least partially – the organization of the cerebral cortex in the
 934 BG, thalamus and related nuclei is now widely accepted, the very existence of maps
 935 parallelizing high granularity topographies found in the cortex (Badre and D'Esposito,
 936 2009; Conant et al., 2014; Grill-Spector and Malach, 2004; Kanold et al., 2014) remains
 937 uncertain. Furthermore, the extent to which topographic maps found in BG might be
 938 modified through experience-dependent plasticity as shown in the cortex (Ejaz et al., 2015;
 939 Stoeckel et al., 2009; Wiestler and Diedrichsen, 2013) remains unknown at present.



940
 941 **Figure 4:** Functional topography in cortico-BG-thalamo-cerebellar circuits following the concept of parallel
 942 channels. Legend on the upper left shows the colour codes for the different functional territories. Symbols of
 943 hand and foot designate the presence of somatotopy. For the simplicity of the schematic, multiple nuclei are
 944 grouped into single entities and the presence of somatotopy is not mentioned for each nucleus separately but
 945 rather for the whole entity.

946 **1.2.2. Theoretical models of basal ganglia function and dysfunction**

947 The classical “box and arrow” model (Albin et al., 1989; DeLong, 1990; Wichmann and
 948 DeLong, 1996; Wichmann and Dostrovsky, 2011) is probably the most influential model of
 949 BG function and dysfunction. It postulates that an imbalance between the direct and
 950 indirect pathways is at the origin of movement disorders such as PD and possibly later
 951 motor complications following DA replacement therapy (Zhuang et al., 2013). This model
 952 focuses on neuronal firing rates and is based on the presumed different contributions of D₁
 953 and D₂ striatal MSNs to locomotion and hypoactivity respectively (Kreitzer and Berke,

954 2011; Lang and Lozano, 1998b). According to this model, DA depletion in PD leads to
955 hypoactivity in D₁-mediated direct pathway and hyperactivity in D₂-mediated indirect
956 pathway. The increased inhibition of the GPe leads to a disinhibition of the STN, which
957 further accentuates activity in the GPi and suppresses activity in thalamus and motor centres
958 in the brainstem, causing PD (Obeso et al., 2014). This view greatly contributed to our
959 understanding of BG function and dysfunction by generating a wealth of studies (DeLong
960 and Wichmann, 2009).

961 Although recent evidence found support for the “box and arrow” model (Macpherson et al.,
962 2014) it has a number of limitations that have been extensively discussed in the literature
963 (Nambu, 2008; Nelson and Kreitzer, 2014; Obeso et al., 2000). First, studies using MPTP
964 reported loss of recurrent lateral connections between striatal MSNs and selective
965 eradication of glutamatergic synapses on MSNs of the indirect pathway instead of
966 hyperactivity in the GPi (Nambu, 2008). Even if the ratio between GPi neurons increasing
967 and decreasing activity during movements elevates after MPTP treatment, the simplistic
968 view stating that the direct and indirect pathways are involved in movement facilitation
969 and inhibition can be regarded as reductionist, as both pathways are activated during
970 movement execution (Calabresi et al., 2014) and several BG circuits are involved in
971 inhibitory control (Jahanshahi et al., 2015). Furthermore, this model is incomplete, as it
972 does not account for thalamo-striatal connections, projections from GPe to striatum, GPi
973 and reticular nucleus of the thalamus, but also from the cortex to the STN, as well as the
974 role of DA outside of the striatum (Bergman and Deuschl, 2002; Lang and Lozano, 1998b).
975 Also, this model does not account for information processing within each “box” (Bronfeld
976 and Bar-Gad, 2011). Similarly, the increased firing rate of the GPe was questioned by
977 physiological and metabolic studies (Bergman and Deuschl, 2002). Its predictions
978 regarding therapeutic interventions are problematic: thalamotomy should worsen PD and
979 pallidotomy should produce hemiballism, but the first alleviates efficiently tremor and the
980 second eliminates levodopa-induced dyskinesias (Lang and Lozano, 1998b).

981 There is also a lack of consensus on reports about the decreased GPi activity in dystonia
982 and hemiballism (Bergman and Deuschl, 2002; Nambu, 2008). GPi lesions have been shown
983 to improve symptoms in dystonia, chorea and LIDs, while the “box and arrow” model
984 predict that the latter should aggravate (Ellens and Leventhal, 2013). The fact that this
985 model only accounts for firing rates and not firing patterns might partly explain these
986 inaccurate predictions. For example, intraoperative microelectrode recordings of STN
987 neurons showed that neuronal spiking activity parameters, including oscillatory activity
988 around beta and gamma frequencies, intra-burst rate and ratio of interspike intervals
989 below/above 10ms, could explain more than 60% of variance in motor scores in late-stage
990 PD patients (Sharott et al., 2014). However, this recent study did not find any activity
991 parameter correlated with tremor. The “box and arrow” model has been extended to
992 incorporate the idea of temporal scaling to explain the convergence of the direct and

993 indirect pathways on the same pallidal neurons (Darbin et al., 2006, 2013a, 2013b).
994 Contrasting with the classical association with direct and indirect pathways, recent models
995 emphasized the crucial role of intra-striatal connections (Calabresi et al., 2014) or
996 proposed that D₁- and D₂-expressing striatal pathways “prepare” and “select” actions
997 respectively (Keeler et al., 2014).

998 Each of the subsequent models highlights particular functional contributions of the BG
999 (Gillies and Arbuthnott, 2000; Joel et al., 2002; Schroll and Hamker, 2013; Seo et al., 2012).
1000 The first category comprises models focusing on serial processing and motor sequencing.
1001 These models are based on the idea that each single response of a motor sequence is a
1002 stimulus for the following one and that the BG link the different elements of a sequence in a
1003 stimulus-response fashion, leading ultimately to the formation of habits (Berns and
1004 Sejnowski, 1998; Marsden and Obeso, 1994; Matsumoto et al., 1999). While some of these
1005 views underlined the role of BG in the execution of well-learned and automatized motor
1006 plans (Marsden, 1982), others emphasized their importance in motor learning (Doyon,
1007 2008; Doyon et al., 2009) or the formation of habits (Graybiel, 2008).

1008 The thalamus is considered as a gate in the “vector integration” model (Gillies and
1009 Arbuthnott, 2000). Perspectives similar to motor sequencing models focus on the
1010 modulation of response “vigor” according to motivational factors (Dudman and Krakauer,
1011 2016; Mazzoni et al., 2007; Turner and Desmurget, 2010; Wang et al., 2013). One of the
1012 mechanisms accounted for in models of serial processing is “chunking”, a mechanism by
1013 which sequences of motor commands are concatenated into “chunks” (Graybiel, 1998;
1014 Wymbs et al., 2012). These perspectives attempts to explain the impairment of motor
1015 sequence learning, more specifically of chunking, in PD (Doyon, 2008; Tremblay et al.,
1016 2010), as well as the impairment of PD patients in procedural learning and the appearance
1017 of stereotypies in some cases (Graybiel, 2008). However these models do not account for
1018 other motor and non-motor symptoms observed in PD.

1019 The next group of models considers the BG as pivotal for action selection and represents
1020 one of the most widely accepted current views on the topic (Gurney et al., 2001a, 2001b;
1021 Humphries et al., 2006; Redgrave et al., 1999). The action selection hypothesis has been
1022 originally proposed by Denny-Brown and Yanagisawa Denny-Brown and Yanagisawa
1023 (1976). These models include occasionally also the cerebellum (Houk, 2005; Houk et al.,
1024 2007) and the hyperdirect pathway (Nambu, 2004, 2005; Nambu et al., 2002). In a typical
1025 action selection model, the presumed “surround inhibition” mechanism, often represented
1026 as a two-dimensional response function having the form of a “Mexican hat”, is considered
1027 to underlie the selection of appropriate responses based on the environmental context
1028 (Mink, 1996, 2003). This concept, originally borrowed from sensory physiology to explain
1029 enhanced contrast for visual stimuli, refers initially to reduced corticospinal excitability of
1030 non-active neighbouring muscles. While intra-cortical and intra-striatal mechanisms of
1031 inhibition – notably lateral inhibition between MSNs – have been proposed to subserve

1032 motor surround inhibition, the neuronal correlates of surround inhibition remain unknown
1033 (Beck and Hallett, 2011; Bronfeld and Bar-Gad, 2011; Kassavetis et al., 2014).

1034 However, surround inhibition is not systematically observed and does not correlate with
1035 electromyography (EMG) at adjacent muscles (Kassavetis et al., 2014). While reduced
1036 surround inhibition has been proposed to contribute to pathophysiology of dystonia,
1037 counter-intuitive observations show that it is reduced in musicians (Shin et al., 2012). If the
1038 latter finding may potentially explain why musicians develop dystonic symptoms in rare
1039 cases, this type of activity usually requires dexterous individuated fingers movements.
1040 Nevertheless, action selection models generally assume that the striatum generates focused
1041 inhibition in a subset of GPi neurons through the direct pathway and that diffuse GPi
1042 excitation is induced by projections from the STN and GPe through the hyperdirect and
1043 indirect pathways. The combination of signals from these pathways produces the “Mexican
1044 hat” activation pattern, wherein focused centre of GPi inhibition is surrounded by diffused
1045 excitation (Schroll and Hamker, 2013). While action selection models originally apply to
1046 motor function, an extension to any kind of cortical input has been proposed (Trapp et al.,
1047 2012). Further, action selection has been also thought to extend to stimulus-response-
1048 outcome associations (Redgrave and Gurney, 2006).

1049 The “competition between verbal and implicit system” (COVIS) model emphasises on
1050 bringing together both motor and cognitive impairment resulting from BG dysfunction
1051 (Ashby et al., 1998; Hélie et al., 2011). Experimental evidence invalidated some of the
1052 predictions made by action selection models. In action selection models, PD would be due
1053 to an inability to disinhibit the desired motor program and, most importantly, to inhibit
1054 competing motor programs (Mink, 1996). Instead, the potential for cortical disinhibition
1055 seems preserved in PD, as GPi neurons still exhibit a combination of firing rate increases
1056 and decreases comparable to that of the normal state (Bronfeld and Bar-Gad, 2011). Action
1057 selection models predict that motor tics are caused by aberrant inhibition of a limited
1058 number of GPi neurons. Instead, localized motor tics were associated with inhibition of the
1059 majority of GPi neurons, which would normally lead to simultaneous activation of multiple
1060 motor programs (Bronfeld and Bar-Gad, 2011).

1061 The third category emphasizes the role of BG in reinforcement learning (RL), which is
1062 assumed in many models of BG function (Schroll and Hamker, 2013). In this framework, BG
1063 adapt behaviour by promoting actions, emotions and cognitive processes that maximize
1064 reinforcements (Amemori et al., 2011; Belin et al., 2009; Dayan and Daw, 2008; Doya, 2000;
1065 Frank, 2005; Gläscher et al., 2010; Guthrie et al., 2009; Hikosaka et al., 2014; Kamali
1066 Sarvestani et al., 2011; Mannella et al., 2013; Parush et al., 2011; Wolpert and Landy, 2012).
1067 Unexpected rewards (Ashby et al., 2007; Brown et al., 2004; Suri et al., 2001; Vitay and
1068 Hamker, 2010), punishments (Bromberg-Martin et al., 2010; Frank, 2004; Palminteri et al.,
1069 2012) and more generally any unexpected sensory event (Redgrave and Gurney, 2006) are
1070 thought to induce learning in BG. This is not only supported by the role of DA in modulating

1071 synaptic plasticity at the BG level, but also by phasic DA signals from possibly distinct
1072 neuronal systems encoding reward prediction (Hollerman and Schultz, 1998), salient
1073 unexpected events (Horvitz et al., 1997), earlier learning-induced BG activity in the BG as
1074 compared to PFC (Antzoulatos and Miller, 2011; Pasupathy and Miller, 2005), differential
1075 recruitment of brain regions in instrumental conditioning and in the prediction of
1076 immediate and future rewards (O'Doherty, 2004; O'Doherty et al., 2006; Tanaka et al.,
1077 2004) and the pharmacological modulation of striatal response to reward prediction error
1078 (Pessiglione et al., 2006).

1079 RL is compatible with any model of BG function and dysfunction, as it does not attribute a
1080 particular function to BG but rather specify the path of the latter to the function (Schroll
1081 and Hamker, 2013). The actor-critic framework is a recent development in RL theory.
1082 According to these RL models, the "actor" is a sub-network performing actions in order to
1083 maximize the weighted sum of future rewards (Barto, 1995). Another sub-network, the
1084 "critic", computes the latter at every time step and learns to predict it based on the actor's
1085 policy and the current sensory input (Barto, 1995). The critic is therefore adaptive and
1086 performs an iterative process of comparison between its predictions and the actual
1087 rewards obtained by the acting agent (Barto, 1995). The adaptive critic's weights are
1088 updated using the temporal difference error between two adjacent predictions, i.e. a
1089 temporal difference learning rule (Sutton, 1988).

1090 Among the models using this framework, some postulate that the actor is implemented by
1091 the dorsal striatum and the critic is attributed to the ventral striatum, while others assume
1092 that these are fulfilled by the striatal matrix and striosomal compartments respectively
1093 (Brown et al., 1999; Contreras-Vidal and Schultz, 1999; Gillies and Arbuthnott, 2000; Houk
1094 et al., 1995; Joel et al., 2002; Seger, 2008; Suri and Schultz, 1998, 1999; Suri et al., 2001).
1095 Some of these address issues related to timing is omitted rewards, MSNs states, LTP in
1096 corticostriatal transmission, DA response to novelty, generalization and discrimination of
1097 appetitive and aversive stimuli (Joel et al., 2002).

1098 Contrasting with conventional models that use monosynaptic Hebbian learning, another RL
1099 model formalized heterosynaptic Hebbian learning and allowed for neuromodulation of
1100 synaptic plasticity to evolve neuronal learning rules of a neural network model of decision-
1101 making in foraging bumble-bees using evolutionary computation techniques (Joel et al.,
1102 2002; Niv et al., 2002). While neuromodulation of synaptic plasticity states that the activity
1103 of a neuron can modify connections between other neurons heterosynaptic, Hebbian
1104 learning rules allow for synaptic plasticity even when only the pre-, only the post-, or none
1105 of the synaptic component has been active, both of which having been shown in neural
1106 tissue (Joel et al., 2002). Some other RL models of BG consider that PD is due to random
1107 learning (Parush et al., 2011) or deficient information integration (Ashby et al., 2007),
1108 explaining impairments in set-shifting and value reversal tasks (Hikosaka et al., 2014).
1109 Most of the implementations of the actor-critic framework at the neuronal level are based

1110 on assumptions that are inconsistent with neuroanatomical knowledge regarding their
1111 underlying neural substrates (Joel et al., 2002).

1112 The prefrontal cortex and basal ganglia (PBWM) model, alternatively designated as the
1113 Basal Ganglia Go/NoGo (BG-GNG) model, is a distinctive computational account that puts
1114 an emphasis on the cognitive domain and the role of BG in working memory gating and
1115 maintenance (Frank et al., 2001; Hazy et al., 2007; Maia and Frank, 2011; O'Reilly and
1116 Frank, 2006; O'Reilly et al., 2007). This model is based on grounds like those of the "box
1117 and arrow" model and attributes to the BG the process of updating working memory
1118 representations maintained by the PFC. According to this model, DAergic signals
1119 implement a Primary Value and Learned Value (PVLV) Pavlovian learning algorithm that
1120 modulates BG function to learn selectively updating working memory representations
1121 when needed. In the PBWM model, the indirect - or "no-go" - pathway, associated with D₂
1122 receptors, mediates learning from positive and negative outcome via DA bursts and dips
1123 respectively and produces LTD and LTP respectively. On the contrary, the direct - or "go" -
1124 pathway, associated with D₁ receptors, promotes learning from positive and negative
1125 outcome via DA bursts and dips respectively and induces LTP and LTD respectively, the
1126 latter effect being caused indirectly via the effect on D₂. Increase and decrease in tonic DA
1127 produces "go" and "no-go" biases respectively through both direct and indirect pathways.

1128 Cumulating empirical evidence validated the predictions of this model (Cavanagh et al.,
1129 2011; D'Ardenne et al., 2012; Frank, 2004; Frank et al., 2007; Moustafa et al., 2013, 2014;
1130 Shohamy et al., 2008). Here, DA depletion results in an amplified "no-go" bias via
1131 hyperexcitability of the indirect pathway, which induces increased resistance to distractors
1132 and deficits in working memory updating. On one hand, DA replacement therapy reverse
1133 this bias towards an exaggerated "go" bias (Frank, 2004). On the other hand, as predicted
1134 by the key role played by the STN within this computational model, STN DBS leads to
1135 impulsivity during high-conflict choices (Cavanagh et al., 2011; Frank et al., 2007). Based
1136 on the assumptions of the PBWM model, the basal ganglia acetylcholine-based entropy
1137 (BABE) model tries to account for the role of striatal cholinergic interneurons and to
1138 explain some dynamics aspects of decision-making as well as skill acquisition such as the
1139 generation of exploratory actions (Stocco, 2012). Another computational model attempts to
1140 reconcile cognitive action planning with habitual and goal-directed control (Daw et al.,
1141 2005) in the form of a trade-off between automatically executed and attention demanding
1142 cognitive actions (Norman and Shallice, 1986).

1143 The reinforcement-driven dimensionality reduction (RDDR) model aims at unifying hypo-
1144 and hyperkinetic movement disorders and postulates that movement disorders, including
1145 PD, dystonia, GTS and chorea as seen in HD, LIDs and hemiballism, as well as behavioural
1146 disorders such as OCD and ADHD, are characterized by a loss of specificity (LOS) in
1147 neuronal activity at the BG level (Bar-Gad and Bergman, 2001; Bar-Gad et al., 2000, 2003a;

1148 Bergman and Deuschl, 2002; Bergman et al., 1998a, 1998b; Bronfeld and Bar-Gad, 2011).
1149 This hypothesis states that in these neurological conditions, multiple behavioural events
1150 are equally encoded at the neuronal level. Regarding the debate between hypotheses on
1151 information funnelling and parallel processing, the LOS hypothesis might be translated as
1152 an increased funnelling of information – or a loss of functional segregation – across cortico-
1153 BG-thalamic loops, i.e. an inability of keeping parallel channels independent in movement
1154 disorders. The identity of functional territories affected by LOS and the extent of the latter
1155 might underlie these different disorders. In normal conditions, the BG, notably the
1156 striatum, are thought to perform a dimensionality reduction of the massive cortical input,
1157 similarly to principal component analysis (PCA). Decorrelation, or desynchronisation, of
1158 activity from multiple cortical sources is considered as necessary, given the remarkable
1159 reduction in the number of processing units (i.e. neurons) throughout cortico-BG-thalamic
1160 loops, especially in cortico-striatal and cortico-pallidal projections (Bar-Gad et al., 2003a).

1161 Although the whole cerebral cortex projects to BG, it has been estimated that cortical
1162 afferents do not project on neighbouring striatal neurons, each of the latter receiving
1163 inputs from at most 0.01% of the corticostriatal projections neurons, and that in the case of
1164 convergence, corticostriatal input is likely coming from adjacent cortical neurons (Bar-Gad
1165 et al., 2003a; Kincaid et al., 1998; Zheng and Wilson, 2002). An additional funnelling of
1166 information operates from striatum to pallidum (Oorschot, 1996). The RDDR model is
1167 therefore based on the funnelling structure of BG and the lack of electrophysiological
1168 evidence for mutual inhibition between striatal neurons despite extensive lateral
1169 connectivity between MSNs. In the RDDR model, the weights of the dimensionality
1170 reduction performed by the BG are modulated by DA input. Therefore, the dimensionality
1171 of cortical signals should not be reduced based solely on statistical properties of the input
1172 but also and mostly regarding their behavioural significance, i.e. the novelty, salience and
1173 predictive ability of the input patterns. Stronger reinforcement signals result in more
1174 discriminative information extraction and better reconstruction of the input signals, while
1175 novel inputs induce correlated activity between output neurons, which produces transient
1176 changes in lateral inhibitory synapses and feed-forward connections that lead to efficient
1177 active decorrelation and compression of information.

1178 A subtle and key difference between RDDR and action selection models lies therefore in the
1179 transient nature of lateral connectivity within BG nuclei. Correlation between pallidal
1180 neurons, which is initially weak, was increased when a primate learned associations
1181 between cues and key presses (Bar-Gad et al., 2000, 2003b). This experimental validation
1182 cannot be explained by the sparsity of BG connectivity – it rather represents a proof-of-
1183 concept of the assumption of the PCA-like role of the BG.

1184 The method used to calculate correlation between neuronal activity can greatly influence
1185 the resulting estimate of response similarity between neuronal pairs (Cohen and Kohn,
1186 2011; Nevet et al., 2007). Because the number of events and the magnitude of the event-

1187 related rate modulations can influence correlation estimates, a lack of correlation does not
1188 necessarily imply a lack of LOS (Leblois et al., 2007; Levy et al., 2002). Conversely,
1189 correlated neuronal activity can be elicited in the absence of LOS by global brain activation
1190 states or population wide oscillatory activity patterns (Nini et al., 1995; Urbain et al., 2000).
1191 Various neural mechanisms might underlie LOS. Intra-nuclei mechanisms such as lateral
1192 connections between MSNs or striatal interneurons, as well as inter-nuclei mechanisms
1193 such as DA innervation and STN input, may implement neuronal specificity (Bronfeld and
1194 Bar-Gad, 2011). Both DAergic and cholinergic neurotransmission might play a role in
1195 dimensionality reduction in the BG (Bergman et al., 1998a; Morris et al., 2003, 2004).

1196 While a combination of multiple mechanisms might be in play, the sources of LOS remain to
1197 be elucidated. LOS might explain multiple facets of PD symptoms, such as tremor,
1198 bradykinesia and rigidity (Bar-Gad and Bergman, 2001; Bar-Gad et al., 2003a; Bergman and
1199 Deuschl, 2002; Bergman et al., 1998a; Bronfeld and Bar-Gad, 2011; Helmich et al., 2012). In
1200 this view, a persistent state of negative reinforcement, inefficient dimensionality reduction,
1201 and abnormally synchronized BG activity characterize PD. There are indeed several reports
1202 of synchronized oscillatory BG activity in PD (Belluscio et al., 2013; Ellens and Leventhal,
1203 2013; Levy et al., 2000; Nambu and Tachibana, 2014), after DA depletion (Dejean et al.,
1204 2008, 2012; Jaidar et al., 2010). This oscillatory neuronal activity was found within and
1205 between BG nuclei (Moran et al., 2012) and typically affects beta frequency bands (Brown,
1206 2007; Stein and Bar-Gad, 2013). Evidence also suggests that DA substitution does not fully
1207 abolish synchronous activity (Heimer et al., 2006).

1208 Although somatotopy is still preserved to a certain extent in the parkinsonian state, at least
1209 in the GPi and STN (Baker et al., 2010; Rodriguez-Oroz et al., 2001; Theodosopoulos et al.,
1210 2003), several studies also showed a larger relative number of pallidal neurons exhibiting
1211 movement-related activity (Baker et al., 2010; Erez et al., 2011; Fillion et al., 1988; Williams
1212 et al., 2005), as well as a substantial proportion of neurons modulating their activity in
1213 response to more than a single body part (Baker et al., 2010; Boraud et al., 2000; Fillion et
1214 al., 1988; Levy et al., 2001; Taha et al., 1996a). Although not explicitly predicted by the
1215 RDDR model, one study found increased synchronous activity in M1 (Goldberg et al., 2002).
1216 The RDDR model is therefore supported by multiple experimental observations made in
1217 non-human primates and in patients undergoing surgery using intracranial recordings
1218 (Bronfeld and Bar-Gad, 2011). Moreover, LOS has been confirmed in humans with dystonia
1219 (Delmaire et al., 2005; Nelson et al., 2009; Quartarone et al., 2008; Tamburin et al., 2002),
1220 and indirectly in patients with GTS (Ganos et al., 2015; Yael et al., 2015). Furthermore, its
1221 relevance to the study of PD pathophysiology is attested by studies using MPTP in
1222 primates, which found evidences of LOS in the GPi (Leblois et al., 2006) and BG-recipient
1223 thalamus (Pessiglione et al., 2005). Although the RDDR model builds on motor function and
1224 dysfunction, it may also apply to associative and limbic functions, both which being
1225 differentially affected along PD progression and according to symptomatic treatments

1226 (Cools, 2006; Tremblay et al., 2015). Although a recent fMRI study interpreted cortical
1227 activity changes in PD as supporting the LOS hypothesis, it provided only weak evidence
1228 for minor changes in the BG (Disbrow et al., 2013). In summary, in PD patients the
1229 relationship between LOS, disease progression and their modulation by DA substitution
1230 remain under-investigated and largely unknown.

1231 **1.3. Brain imaging**

1232 In humans, the striatal loss of DA innervation is particularly evident when investigated
1233 with PET and SPECT imaging (Brooks and Pavese, 2011; Stoessl, 2011a). PET imaging is
1234 more expensive, but usually provides imaging at higher resolution as compared to the
1235 latter (Weingarten et al., 2015). These non-invasive methods quantify the density of
1236 presynaptic terminals within the striatum or striatal DA receptors and are commonly used
1237 to differentiate PD from other neurological diseases without loss of DA neurons such as ET,
1238 vascular parkinsonism, psychogenic movement disorder, dystonic tremor, normal pressure
1239 hydrocephalus, dopa-responsive dystonia and AD (Kalia and Lang, 2015).

1240 Nowadays, MRI, PET and SPECT are part of the medical procedure that assist differential
1241 diagnosis in PD (Brooks, 2010). PET and SPECT imaging measures include activity of
1242 aromatic aminoacid decarboxylase with ^{18}F -dopa PET, availability of presynaptic DA
1243 transporters with ^{123}I -2 β -carbomethoxy-3 β -(4-iodophenyl)tropane (^{123}I -CIT) or ^{123}I -2 β -
1244 carbomethoxy-3 β -(4-iodophenyl)-N-(3-fluoropropyl)nortropane (^{123}I -FP-CIT) SPECT and
1245 amount of vesicular monoamine transporter (VMAT2) with ^{11}C -dihydrotetrabenazine (^{11}C -
1246 DTBZ) or ^{18}F -dihydrotetrabenazine (^{18}F -DTBZ) PET, as well as less common radio ligands
1247 such as ^{11}C -PK11195 (Algarni and Stoessl, 2016; Brooks and Pavese, 2011; Pavese and
1248 Brooks, 2009; Politis, 2014; Weingarten et al., 2015). Asymmetric loss of putaminal fluoro-
1249 dopa or DA transporter, typically following a rostro-caudal gradient, further confirms PD
1250 diagnosis (Obeso et al., 2010; Schapira, 2006). The posterior-to-anterior gradient is
1251 preserved but the initial side-to-side asymmetry later vanishes with disease progression
1252 (Politis, 2014). Additionally, DA imaging techniques revealed that loss of DA innervation is
1253 faster early in disease course.

1254 The discovery of patients diagnosed with early PD but presenting scans without evidence
1255 of DAergic deficit (SWEDD), questioned the validity of these imaging markers. However, DA
1256 imaging approaches fail to distinguish PD from atypical forms of parkinsonism such as PSP,
1257 MSA, CBD and dementia with LB (Kalia and Lang, 2015). On the other hand, metabolic PET
1258 and diffusion MRI can differentiate relatively well between PD, MSA and PSP (Brooks,
1259 2010; Politis, 2014; Stoessl et al., 2014). PET imaging can also be used to measure regional
1260 cerebral blood flow (CBF). Apart from the main findings highlighted in section 1.1.5, PD is
1261 associated with a linearly increased glucose metabolism in the subthalamic nucleus,
1262 pallidum, pons and motor cortex, and decreased metabolism in prefrontal and parietal

1263 areas. However, metabolic PET has an attenuated ability to track preclinical PD compared
1264 with DAergic PET, the latter preceding clinical diagnosis by about 5 years (Politis, 2014;
1265 Savica et al., 2010).

1266 H₂¹⁵O-PET studies showed a decreased activity of the rostral SMA and right dorsolateral
1267 prefrontal cortex (DLPFC) in non-medicated ("OFF") PD patients moving their hands
1268 without external instructions regarding the type of movement and the onset of the latter
1269 (van Eimeren and Siebner, 2006). To induce a selective release of endogenous DA in the
1270 motor cortico-BG-thalamic loop, focal high-frequency transcranial magnetic stimulation
1271 (TMS) was applied on M1. ¹¹C-raclopride-binding potential in the posterior putamen was
1272 reduced in healthy control (HC) subjects, suggesting an increase in endogenous DA release
1273 caused by repetitive stimulation of cortico-striatal glutamatergic inputs from M1.
1274 Conversely, the same procedure applied in patients with unilateral PD produced a similar
1275 putaminal DA release but of smaller magnitude. Similar to STN lesions, chronic STN
1276 stimulation in PD seems to attenuate metabolic increase in pallidum, thalamus, pons and
1277 cerebellum that co-vary with metabolic decrease in lateral premotor and parieto-occipital
1278 associative areas. A ¹¹C-raclopride PET study showed that DA release increase after
1279 administration of oral levodopa was large and returned to baseline within 4 hours in
1280 patients with motor fluctuations, whereas it was smaller and more sustained in patients
1281 who maintained a stable therapeutic response. PD patients experiencing LIDs, as well as
1282 longer disease duration, were shown to be associated with increased DA release (Stoessl,
1283 2011b).

1284 It is worth noting that DBS effects are detectable using PET, EEG or fMRI (Perlmutter and
1285 Mink, 2006). Mapping of ¹⁸F-Dopa PET before and after STN DBS did not reveal any
1286 difference in nigrostriatal denervation but SPECT imaging showed rCBF increase in rostral
1287 SMA, lateral premotor cortex (PMC) and DLPFC (van Eimeren and Siebner, 2006). Other
1288 PET studies found several neurotransmitter changes in PD associated with various non-
1289 motor symptoms (Stoessl, 2009). Although PET showed an increase in striatal ¹⁸F-dopa
1290 uptake associated with intra-putaminal infusion of recombinant human GDNF, it did not
1291 result in clinical improvements in PD. Striatal transplantation of human fetal DA neurons
1292 hold great promises as ¹⁸F-dopa PET studies revealed that cells survived and stored DA but
1293 double blind controlled trials showed that these changes were not associated with
1294 improvements at the clinical level (Brooks and Pavese, 2011). Carriers of *parkin* mutation
1295 without any clinical manifestation showed reduced presynaptic DA uptake in the posterior
1296 putamen, suggesting a latent nigrostriatal deficit (van Eimeren and Siebner, 2006). In line
1297 with the idea that PD is a multifactorial disease, it has generally been argued that the
1298 combination of multiple imaging methods provides great benefits in terms of specificity
1299 and sensitivity (Weingarten et al., 2015).

1300 Other imaging methods assisting PD diagnosis include notably transcranial B-mode
1301 sonography to detect SN hyper-echogenicity due to iron overload, cardiac imaging to reveal

1302 cardiac denervation, ¹²³I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection
1303 of reduced cardiac postganglionic sympathetic innervation, arterial spin labelling
1304 techniques using perfusion MRI to detect reduced CBF in cortex or BG, magnetic resonance
1305 spectroscopy (MRS) to detect changes in DA, GABA, glutamate and energy metabolism, as
1306 well as various markers in event-related potentials (ERPs) – such as the
1307 Bereitschaftspotential, the contingent negative variation, the lateralized readiness
1308 potential, alpha and beta frequency bands – derived from electroencephalography (EEG)
1309 and magnetoencephalography (MEG) (Auer, 2009; Chahine and Stern, 2011; De Virgilio et
1310 al., 2016; Georgiev et al., 2016; Pavese and Brooks, 2009; Politis, 2014; Pyatigorskaya et al.,
1311 2013; Sharma et al., 2013; Sian-Hülsmann et al., 2011; Weingarten et al., 2015). These
1312 imaging methods will not be discussed further. In the following sections a brief overview of
1313 MRI methods and their use in the study of PD is given. MRI has many advantages: contrarily
1314 to intracranial EEG, it is non-invasive; unlike PET or SPECT imaging that complicates
1315 routine use and intensive patient's follow-up due to radioactive compounds usage, it allows
1316 for longitudinal design studies; MRI potentially provides whole brain coverage at high
1317 spatial resolution, despite limited temporal resolution in comparison to surface EEG or
1318 MEG.

1319 **1.3.1. Functional MRI of the brain**

1320 MRI measures how radio frequency electromagnetic waves affect energy states of dipoles
1321 within a magnetic field. Hydrogen nuclei in water are the main source of signal in the case
1322 of brain MRI (Logothetis, 2008; Logothetis and Wandell, 2004; Logothetis et al., 2001).
1323 Functional MRI (fMRI) is widely available and does not require the injection of a
1324 radiotracer. This technique indirectly measures dynamic changes in neural activity by
1325 detecting the deoxygenated haemoglobin, which is paramagnetic. It interacts with water
1326 molecules surrounding blood vessels, leading to a change in the proton signal (Niethammer
1327 et al., 2012). fMRI signals acquired using traditional acquisition schemes are not
1328 quantitative. The observed blood-oxygen-level dependent (BOLD) effect is the result of
1329 neurovascular coupling, whereby CBF overcompensates for oxygen decrease. The BOLD
1330 effect is thought to reflect primarily neuronal activity through changes involving a complex
1331 interaction between cerebral blood volume (CBV), cerebral metabolic rate of oxygen
1332 consumption (CMRO₂) and CBF (Mullinger et al., 2014). Furthermore, neuro-vascular
1333 coupling might be affected by astrocytes, pericytes, ageing and pathological states (Hillman,
1334 2014).

1335 While increased fMRI signal following stimulation – i.e. a positive BOLD – might be
1336 relatively safely considered as neuronal activity increase, a different neurovascular
1337 coupling mechanism might underlie decreased fMRI signal, i.e. a negative BOLD (Mullinger
1338 et al., 2014). The BOLD effect is often considered as reflecting peri-synaptic activity in the
1339 form of local field potentials rather than spiking rate of individual neurons but the exact


1340 underlying neuronal phenomenon might vary from a brain region to another (Ekstrom,
1341 2010). The common modelling scheme for fMRI data relies on the linear transform model
1342 (Heeger and Ress, 2002). The assumption here is that the fMRI signal is proportional to a
1343 measure of local neural activity, although averaged over a spatial extent of several
1344 millimetres and over a period of few seconds. Although these assumptions might be invalid
1345 in some circumstances, they hold for some recording sites and using certain experimental
1346 protocols.

1347 Recently, a growing interest has emerged into experimental protocols that do not impose a
1348 particular task to perform to subjects lying in the MRI scanner. Typical instructions in
1349 resting-state fMRI (rsfMRI) studies consist of requesting the subject to close the eyes and to
1350 not think about anything in particular while staying awake. Subsequent analyses of such
1351 data classically involve correlation or connectivity analyses, which are usually termed
1352 "functional" or "intrinsic" connectivity. Because such protocols do not involve an
1353 experimental or psychological manipulation like in task-based fMRI, and depending on the
1354 way data analysis is conducted, there is a substantial risk of violation of the construct
1355 validity, i.e. of looking at a vascular rather than psychological effect (Webb et al., 2013).
1356 Task-based fMRI also allows for investigating relationships between brain regions in terms
1357 of brain activity. In the latter case, these connectivity analyses are often referred to as
1358 "effective" functional connectivity analysis (2004).

1359 Besides connectivity, common schemes applied to analyse fMRI data consists of applying
1360 general linear modelling (GLM) after data filtering and spatial registration pre-processing
1361 steps. GLM is essentially a multiple linear regression and is frequently performed
1362 independently at every voxel ("volume element") to produce statistical parametric maps
1363 (Friston et al., 1994). As mentioned above, depending on the acquisition protocol, fMRI
1364 data acquisition can be fast and produce brain images of varying spatial resolution. The
1365 magnetic field strength of the MRI scanner also plays an important role in this context
1366 (Duyn, 2012; Francis and Panchuelo, 2014; Harel, 2012; Olman and Yacoub, 2011).
1367 Recently, several advances were made to optimize fMRI acquisition (Ben-Eliezer et al.,
1368 2012; Feinberg and Setsompop, 2013; Hyde et al., 2001; Jesmanowicz et al., 1998; Lin et al.,
1369 2012; Lutti et al., 2012; Posse, 2012; Posse et al., 2012; Triantafyllou et al., 2005, 2011) and
1370 test complex scientific questions using powerful methods (Davis and Poldrack, 2013).
1371 Lately, remarkable achievements in terms of spatial precision were accomplished with
1372 fMRI, such as the investigation of computational heterogeneity within the mesencephalic
1373 DA system (D'Ardenne et al., 2013) or the mapping of orientation dominance columns in
1374 the visual cortex (Cheng, 2012). Nevertheless, BG remain particularly challenging areas for
1375 fMRI as these small nuclei are located far away from channels of the MRI head coil and are
1376 associated with a complex functional topography and high iron content that reduces signal-
1377 to-noise ratio, especially in the pallidum (Drayer et al., 1986; Dušek et al., 2013).

1378 fMRI has been notably used to compare PD patients to HC subjects, but also to compare
1379 different groups of patients based on the presence or absence of motor or non-motor
1380 symptoms, to investigate neural mechanisms underlying PD-related deficits in various
1381 tasks, as well as to study the effect of various treatments (Christopher and Strafella, 2013;
1382 Lenka et al., 2015; Monchi and Stoessl, 2012; Ray and Strafella, 2012; Ryterska et al., 2013;
1383 Snijders et al., 2016; Weingarten et al., 2015). fMRI studies mostly focused on cognition in
1384 PD (Marino et al., 2012). Besides rsfMRI results which are not considered here, the main
1385 findings using fMRI are that PD patients, due to abnormal pallidal outflow, show impaired
1386 activation of the DLPFC and SMA – which can be restored after apomorphine
1387 administration – during motor imagery and execution, increased activation in M1 and
1388 lateral premotor cortex bilaterally, over-activation of inferolateral parietal and premotor
1389 areas during sequential finger activation – probably due to the facilitation of movement
1390 initiation by external cues (van Eimeren and Siebner, 2006; Nandhagopal et al., 2008).
1391 These results are consistent with findings using PET.

1392 Overall, studies revealed that attention might be responsible for a considerable source of
1393 variation in fMRI results and interpreted most of the activity changes in the cerebral cortex
1394 as a consequence of a compensatory mechanism following altered output in cortico-BG-
1395 thalamic loops. Besides a study showing that effective connectivity between motor regions
1396 in PD is not strikingly affected by DA administration (Rowe et al., 2010), fMRI findings
1397 using effective connectivity globally showed increased connectivity between PFC, pre-SMA,
1398 cingulate motor cortex and cerebellum in PD, as well as decreased coupling between
1399 putamen and M1 – which is conversely increased after levodopa intake in PD who later
1400 develop LIDs (Gao and Wu, 2016). Furthermore, it was reported that attention to action did
1401 not enhance connectivity between PFC, lateral premotor cortex and SMA in PD. Rather than
1402 reviewing more in detail results from fMRI studies in PD, a visual summary of a meta-
1403 analysis based on activity changes coordinates in space is presented with focus on BG
1404 structures (**Figure 5**).



1405

1406 **Figure 5:** Results of a meta-analysis on functional imaging studies including the term “Parkinson’s disease”,
 1407 using reverse inference (<http://neurosynth.org>; Yarkoni et al., 2011). The colour bar indicates z-scores.
 1408 Statistical significance is set to $p < 0.01$, corrected for multiple comparisons using false discovery rate.
 1409 Statistical maps were rendered on a canonical T1-weighted image.

1410 The question of functional topography, especially for motor function in the cortex, has been
 1411 debated through several fMRI studies. The very existence of an iconic homunculus
 1412 (Penfield and Rasmussen, 1950) generated many studies aiming at demonstrating
 1413 segregated representations of different body parts. Some studies, explicitly testing the
 1414 degree of segregation, used metrics such as Euclidean distances between activation
 1415 maxima or centres of gravity to quantify between-limb (Alkadhi et al., 2002a, 2002b; Lotze
 1416 et al., 2000), within-limb (Cunningham et al., 2013; Kapreli et al., 2007; Kleinschmidt et al.,
 1417 1997; Plow et al., 2010; Strother et al., 2012) and finger somatotopy (Beisteiner et al.,
 1418 2001; Dechent and Frahm, 2003; Indovina and Sanes, 2001). Studies investigating
 1419 somatotopy representations of orofacial articulators used similar approaches (Grabski et
 1420 al., 2012). Centers of gravity were sometimes weighted by the strength of the BOLD signal
 1421 at each coordinate (Hlustik et al., 2001). One study developed a similar metric termed
 1422 “selectivity index” to reveal finger somatotopy (Olman et al., 2012). Findings from these
 1423 studies support the idea of segregated representations of body parts in motor cortical areas
 1424 despite substantial overlap, especially between different limbs, whereas finger somatotopy
 1425 is more debated.

1426 A small number of fMRI studies investigated motor somatotopy in the BG and thalamus and
 1427 yielded contradictory findings regarding the amount of overlap between representations
 1428 (Gerardin et al., 2003; Maillard et al., 2000; Oguri et al., 2013; Scholz et al., 2000; Staempfli
 1429 et al., 2008). A flexible framework has been proposed to study what is referred to as
 1430 “representational similarity analysis” (RSA). This approach extends the usage of distance
 1431 metrics to any kind of dissimilarity measure such as linear correlation or Manhattan
 1432 distance and suggests to perform notably clustering or multidimensional scaling methods

1433 to summarize results (Kriegeskorte, 2008; Kriegeskorte and Kievit, 2013; Nili et al., 2014).
1434 The pitfall of geographic approaches and RSA is that they do not take into account for the
1435 presence of noise in the fMRI signal. More specifically, noise in fMRI is known to vary
1436 according to the region of interest (ROI) and the BG, brainstem and cerebellum are
1437 particularly susceptible to be associated with noisy fMRI time courses (Brooks et al., 2013;
1438 Liu, 2016; van der Zwaag et al., 2015). In some circumstances, comparing indices of
1439 dissimilarity across brain regions or group of subjects is invalid because the distance
1440 metric does not only reflect the distance between patterns of brain activity but also
1441 inherent noise in the measurement.

1442 Recently, an extension of RSA, termed “pattern component model” (PCM), has been
1443 developed to overcome this limitation (Diedrichsen et al., 2011). The latter method
1444 provides robust estimates of similarity between brain activity patterns and has shown
1445 promising results when applied to digit somatotopy (Diedrichsen et al., 2013; Ejaz et al.,
1446 2015). However, spatial hypotheses can be tested differently. An alternative framework is
1447 based on Bayesian model comparison and reverses the classical scheme aiming at
1448 predicting the fMRI signal based on experimental factors: instead, signals from multiple
1449 voxels is combined with the objective to predict experimental variables, hence the term
1450 “multivariate Bayes” (MVB) (Friston et al., 2008). This method allows for testing how
1451 information is represented in the brain and to typically test explicitly whether a given set of
1452 brain signals predict better the behavioural outcome as compared to another.

1453 **1.3.2. Diffusion MRI**

1454 A growing interest recently emerged for diffusion MRI in PD. Diffusion MRI, or diffusion-
1455 weighted imaging (DWI), is close to fMRI from the MRI physics point of view and captures
1456 the translational displacement of water molecules (Bammer, 2003; Le Bihan, 2012; Le
1457 Bihan et al., 2001). The basic principle by which DWI allows the reconstruction of
1458 structural connectivity in the human brain relies on the behaviour of water molecules: in
1459 the CSF, the latter move freely according to Brownian motion, whereas when trapped in
1460 axon bundles, they move in a restricted fashion, following the directions of axonal tracts
1461 (Johansen-Berg and Rushworth, 2009). By sampling water diffusion in many directions, an
1462 accurate reconstruction of white matter tracts is possible. Advanced diffusion acquisition
1463 protocols manipulate additionally other factors such as the *b*-value in order to resolve
1464 complex situations such as crossing or “kissing” fibres, as well as to later apply more
1465 complex biophysical models (Frank, 2001, 2002; Nagy et al., 2013; Tournier et al., 2013;
1466 Tuch et al., 2002; Zhang et al., 2012). Tractography is the process of modelling – using one
1467 among several tracking algorithms available (Fillard et al., 2011; Staempfli et al., 2006;
1468 Tournier et al., 2007, 2008) – connections between two locations in the brain. DWI allows
1469 also computing different parameters of diffusivity based on the tensor model, which
1470 essentially extract eigenvalues from the tensor consisting of intensities of diffusion in each

1471 direction (Le Bihan et al., 2001; Soares et al., 2013; Tournier et al., 2011). Common
1472 diffusion tensor imaging (DTI) parameters include fractional anisotropy (FA), mean
1473 diffusivity (MD), radial diffusivity (RD) and the apparent diffusion coefficient (ADC).
1474 Information provided by DWI has shown great efficacy to parcellate thalamic nuclei
1475 (Draganski et al., 2008; Klein et al., 2010; Lambert et al., 2016). Besides the inability of
1476 inferring directionality of connections from diffusion MRI data, the latter have to be
1477 carefully interpreted (Jones and Basser, 2004; Jones and Cercignani, 2010; Jones et al.,
1478 2013).

1479 DTI studies in PD revealed decreased FA and MD in the SN and other cortical, subcortical,
1480 brainstem and cerebellar regions (Duncan et al., 2013; Schwarz et al., 2013; Tessitore et al.,
1481 2016; Weingarten et al., 2015). Reduction of FA was greater in the caudal than rostral SN.
1482 Although diffusion MRI findings are occasionally divergent in PD (Weingarten et al., 2015),
1483 the same study reported a 100% sensitivity and specificity in distinguishing PD from HC
1484 subjects (Wu et al., 2011). Correlations between the latter measures and symptoms
1485 severity generally suggest that increased FA and MD are normally associated with better
1486 clinical function – with few exceptions though. Indeed, PD was associated with increased
1487 MD compared to HC subjects in the corona radiata, internal capsule, cerebral peduncle,
1488 cingulum, uncinate fasciculus, crus fornix stria terminalis, corpus callosum, external capsule,
1489 superior longitudinal fasciculus, posterior thalamic radiation, superior cerebellar peduncle
1490 and tracts near the precuneus and supramarginal gyrus. It is worth mentioning that the
1491 cortico-striatal, cortico-spinal, cortico-pontine and cortico-bulbar tracts are crossing at the
1492 level of the corona radiata. Furthermore, the cingulum, uncinate fasciculus and external
1493 capsule are pathways of cholinergic projections from the nucleus basalis of Meynert
1494 (Weingarten et al., 2015). The presence of symptoms such as depression in PD has shown
1495 to be associated with reduced FA in the frontal cortex (Chagas et al., 2013). DTI might also
1496 detect early subcortical white matter tract degeneration (Duncan et al., 2013; Sharma et al.,
1497 2013). In addition, ADC, notably putaminal diffusivity, seems to differentiate PD from MSA
1498 and PSP (Mahlknecht et al., 2010; Politis, 2014). Reduced probability of connections has
1499 been also reported in PD (Pyatigorskaya et al., 2013). Furthermore, diffusion MRI is helpful
1500 in differentiating PD from atypical parkinsonism and other neurodegenerative diseases (De
1501 Virgilio et al., 2016; Goveas et al., 2015; Kalia and Lang, 2015; Meijer et al., 2013; Sharma et
1502 al., 2013).

1503 **1.3.3. Quantitative MRI**

1504 In this sub-section, findings regarding grey and white matter volume as estimated by voxel-
1505 based morphometry, as well as cortical thickness, are briefly mentioned, while MRI
1506 techniques including relaxometry, susceptibility weighted imaging and multi-parameter
1507 mapping are particularly emphasized. In contrast to sections 1.3.1 and 1.3.2, the detailed

1508 description of imaging sequences would be particularly lengthy and is beyond the scope of
1509 this work. Brain atrophy and various morphological changes associated with PD such as
1510 cortical thickness have been reported in cortical, BG and brainstem regions, consistent with
1511 pathological findings (Stoessel et al., 2014; Weingarten et al., 2015). Obvious atrophy in SN
1512 is visible but, taken alone, does not help differentiating early stage PD neither from HC
1513 subjects, nor from other forms of neurodegeneration (Politis, 2014). Atrophy in other brain
1514 regions such as the cerebral peduncles is found in PSP. VBM results show grey matter
1515 volume (GMV) increases in posterior putamen correlating with reduction in putaminal ¹⁸F-
1516 DA uptake (van Eimeren and Siebner, 2006). Striatal hypertrophy is thought to reflect a
1517 compensatory mechanism promoting motor function in the absence of DAergic
1518 dysfunction. T2 hypo-intensities can differentiate PD from MSA, and VBM allows for
1519 distinguishing PD from PSP, PD and HC based on atrophy patterns in subcortical motor
1520 networks (Hotter et al., 2009; Mahlknecht et al., 2010; Politis, 2014). Reports of decreased
1521 GMV in PD with depression are controversial and some studies found instead white matter
1522 loss in anterior cingulate, frontal and orbitofrontal regions (Kostic and Filippi, 2011).
1523 Dementia and FOG in PD are associated with extensive cortical atrophy in multiple regions,
1524 which may also be present in PD with mild cognitive impairment (MCI) (Duncan et al.,
1525 2013; Ibarretxe-Bilbao et al., 2009, 2011; Kostic et al., 2012; Sharma et al., 2013). Genetic
1526 mutations affecting *parkin*, *PINK1* and *ATP13A2* were associated with GMV changes in the
1527 BG (Godau et al., 2012).

1528 Recent advances in structural MRI include ultra-high field strength imaging at 7 Tesla, new
1529 MRI sequences such as diffusion tensor imaging, susceptibility-weighted imaging (SWI)
1530 and T2*-weighted magnitude imaging (T2*WI), as well as image reconstruction methods
1531 like susceptibility-weighted phase imaging (SWPI) and quantitative susceptibility mapping
1532 (QSM) (Lehéricy et al., 2014; Liu et al., 2014; Reichenbach et al., 2015). The SN appears
1533 hyperintense in proton density-weighted (PDw) images and neuromelanin T1-weighted
1534 spin-echo images (NMw) and hypointense in two-dimensional T2*WI and three-
1535 dimensional T1-weighted MP2RAGE (3DT1w) (Lehéricy et al., 2012, 2014). Other MRI
1536 techniques such as fast spin echo acquisitions have great potential for BG and SN imaging.
1537 Magnetic field strength is particularly important in this context to improve signal-to-noise
1538 ratio (Schuff, 2009). While these new imaging techniques may greatly improve DBS surgery
1539 (Hickey and Stacy, 2016; Rowland et al., 2016), they also have generally confirmed
1540 pathological findings.

1541 Increased susceptibility in the SN, consistent with iron accumulation, alterations in
1542 adiabatic R1 ρ mapping in brainstem, as well as decreased SN magnetization transfer
1543 (MT) values and diminished smoothness in SN borders using T2*WI has been
1544 demonstrated (Tuite et al., 2013; Weingarten et al., 2015). Relaxation along a fictitious field
1545 (RAFF) has also shown great potential in separating the SN from other nuclei (Tuite et al.,
1546 2013). Reduced MT ratio, as well as reduced T2/T2* and increased R2/R2* derived from

1547 relaxometry, were shown in PD (Pyatigorskaya et al., 2013). Moreover, imaging techniques
1548 sensitive to neuromelanin changes has shown decreased SN volumes and locus cœruleus
1549 signals. Other studies using multispectral structural MRI – including multi-echo T1-
1550 weighted, multi-echo proton density, T2-weighted and T2-weighted fluid-attenuated
1551 inversion recovery (FLAIR) sequences) – suggested that degeneration of SNc precedes that
1552 of cholinergic basal forebrain (Sharma et al., 2013). While nigral iron elevation has been
1553 shown to correlate positively with the severity of motor symptoms but not disease
1554 duration, iron content in the STN correlates with the latter (Sian-Hülsmann et al., 2011).
1555 Moreover, MRI field-dependent relaxation rate (R2) (FDRI) in the SN is shown to increase
1556 in early-onset PD and decrease in late-onset PD, suggesting that ferritin iron, known to
1557 increase R2, can differentiate between different forms of parkinsonian syndromes. R2* in
1558 SN and caudal putamen has been recently shown to correlate with PD progression over
1559 several years (Ulla et al., 2013). Iron levels in the putamen seem to correlate also positively
1560 with disease duration as shown by partially refocused interleaved multiple echo (PRIME)
1561 magnetic resonance sequence. This finding contradicts previous results showing iron
1562 content reduction only in the GPe and GPi in PD. While many brain metals such as iron,
1563 copper, zinc, manganese, selenium, magnesium, molybdenum, calcium and potassium have
1564 interesting potential to evaluate therapies for neurodegenerative diseases (Gh Popescu and
1565 Nichol, 2010), careful consideration of iron deposition imaging sensitivity and specificity is
1566 required before interpreting such results derived from MRI (Haacke et al., 2005).
1567 Nevertheless, most of the semi-quantitative MRI methods have completed and reflected
1568 results from biochemical analyses of post-mortem tissue (Sian-Hülsmann et al., 2011).

1569 More generally, MT as assessed using multi-parameter mapping (MPM) showed more
1570 accuracy in delineating BG structures, revealing age-related changes and differentiating
1571 between motor, limbic and associating circuits in terms of tissue properties (Accolla et al.,
1572 2014; Draganski et al., 2011; Helms et al., 2009). These parameters, which include the
1573 longitudinal relaxation rate (R1), the effective transverse relaxation rate (R2*) and
1574 effective proton density (PD*) in addition to MT, are robustly linked to specific tissue
1575 properties, are feasible in clinical settings even at high-resolution imaging (Weiskopf et al.,
1576 2013) and can overcome limitations of standard structural MRI techniques. Indeed, the lack
1577 of specificity of T1-weighted imaging, as well as commonly derived measures of cortical
1578 thickness and GMV, does not solely depend on genuine neurobiological phenomena such as
1579 brain atrophy or neurogenesis (Lorio et al., 2016).

1580 **1.4. Research questions and hypotheses**

1581 In this work, I try to answer pertinent questions on the pathophysiology of PD using state-
1582 of-the-art non-invasive imaging methods. Given recent experimental evidences coming
1583 from primate and rat studies supporting the RDDR model, the main goal of our research
1584 was to validate the LOS hypothesis in PD. Furthermore, I investigated whether DA

1585 substitution would attenuate the LOS in PD. PD is mainly defined as a movement disorder
1586 despite a broad range of non-motor symptoms, therefore motor somatotopy was chosen as
1587 a working example. In what follows, we refer to “functional segregation” as a proxy for
1588 assessing the LOS.

1589 However, reports of motor somatotopy in the BG are conflicting, a preliminary study was
1590 thus performed to objectively evaluate the influence of fMRI spatial resolution on the
1591 effective overlap between representations of different body parts. To maximize the
1592 separation between activation patterns at the representational level, subjects were
1593 instructed to move different limbs. Although finger movements would have been easy to
1594 control and record during fMRI acquisition, the overlap between digit representations
1595 would have probably been too important at baseline to find any difference in PD patients as
1596 finger somatotopy is already debated at M1 level. Subjects were requested to perform
1597 repeated movements of hands, feet and lower facial musculature within block-design
1598 experiments, which are known to maximize activation detection efficiency (Henson, 2011).
1599 Different fMRI protocols were tested, each being optimized for a given isotropic voxel size.
1600 PCM was then performed to find whether the effective overlap between motor somatotopy
1601 representations, in various brain regions throughout the motor cortico-BG-thalamic loop,
1602 would be influenced by the scheme for fMRI acquisition, and if so, to which extent. This
1603 produced similarity – or correlation – estimates, which were transformed into a metric that
1604 we termed “Index of Specificity” (*IoS*), with low values indicating high functional
1605 segregation.

1606 For the main study, I recruited PD patients and tested HC subjects with an optimized
1607 experimental paradigm. Monitoring movements of PD patients was crucial to make valid
1608 inferences at the representational level. Thus, we anticipate potential criticisms arguing
1609 that the loss of functional segregation in PD would be induced by motor performance bias,
1610 such as PD patients performing more often simultaneous movements of different body
1611 parts. A custom device was designed and built to measure to monitor task performance of
1612 HC subjects and PD patients and account for potential differences in movement features.
1613 Additionally, movements of lower facial musculature were not requested due to practical
1614 reasons, the custom device being capable of monitoring only movements of hands and feet.
1615 The duration of the fMRI experiment was also slightly increased to augment the number of
1616 trials, thereby maximizing statistical power. PD patients were tested twice, ON and OFF
1617 medication, to examine the effect off DA therapy on functional segregation. To test
1618 additional hypotheses outlined below, this experiment comprised acquisition of DWI data.
1619 Similarly to the preliminary study, MPM provided MT maps, which, in combination with
1620 advanced spatial registration algorithms, aimed at better delineating BG structures and
1621 improving spatial registration of MRI data across subjects. The main questions were as
1622 follows:

- 1623 - Is PD associated with a loss of functional segregation?
- 1624 - If so, does DA therapy restore functional segregation back to normal?
- 1625 - What is the relationship between LOS and disease severity?

1626 Given the massive connections shared between striatum and insula, the increased
1627 susceptibility of the latter to α -synuclein aggregation, its implication in non-motor
1628 symptoms in PD as well as results from meta-analyses suggesting a shift of insular activity
1629 in PD, we used another multivariate framework, MVB, which can also test for a loss of
1630 functional segregation, to test the hypothesis that PD is also associated with functional
1631 segregation in the insula. This resulted from our definition of the loss of segregation, which
1632 can be conceptualised in two different but complementary ways. According to the
1633 definition we used in the present work, "segregation" relates to spatial independence of
1634 neuronal signals associated to different behavioural events. In the extreme case, it refers to
1635 a one-to-one structure-function mapping (Friston and Price, 2003, 2011; Pessoa, 2014;
1636 Price and Friston, 2002). Conversely, loss of segregation can be defined either as: a) a given
1637 brain structure participating to multiple functions, like exemplified in Bronfeld and
1638 colleagues (2011); b) multiple brain structures involved in the same function, termed by
1639 Friston and Price as "degeneracy". While previous studies suggest a spatial shift of insular
1640 activity from the anterior to the posterior part relating to non-motor manifestations in PD,
1641 we aimed at testing whether this phenomenon is also present in a simple motor execution
1642 task.

1643 Additionally, our objective was to test whether the LOS hypothesis applies, at a more
1644 general level, to the segregation between limbic, associative and motor cortico-BG-thalamic
1645 loops, as well as examining whether LOS extends to structural in addition to functional
1646 topography. To answer this question, we used DWI data acquired in the same study
1647 protocol and investigate the loss of segregation at the connectivity level, hence termed
1648 "structural segregation" in this context, while using the same metric – *IoS*, as derived from
1649 PCM – as for functional segregation. Because PD is associated with several non-motor
1650 symptoms in addition to motor symptoms, an additional goal was to test whether the loss
1651 of structural segregation in cortico-BG-thalamic connections would vary as a function of
1652 the profile of clinical symptoms in each PD patient.

1653 To recapitulate, research questions for this work were as follows:

- 1654 - What is the optimal fMRI spatial resolution to separate motor somatotopy patterns
1655 in the BG? This question was the purpose of Study 1.
- 1656 - Is PD associated with a loss of functional segregation at the BG level? If so, does DA
1657 replacement therapy restores functional segregation back to normal? These
1658 questions were the matter of Study 2.

- 1659 - Is PD further associated with a loss of functional segregation in the insula? We
1660 attempted to answer to this question in Study 3.
1661 - Does the LOS presumably found for motor function extends to other functional
1662 territories as assessed by structural connectivity? Does this effect depend on the
1663 clinical symptomatic profile of PD patients? These topics were investigated in Study
1664 4.

1665 **2. Experimental work**

1666 **2.1. Optimal mapping of motor somatotopy in healthy subjects**

1667 **2.1.1. Study 1**

1668 In this experiment, we evaluate the benefits of high-resolution fMRI to study motor
1669 somatotopy. In contrast to previous studies focusing on activation detection power, we
1670 investigate the trade-off between spatial resolution and SNR by quantifying the effective
1671 overlap between representations of different body parts as a measure of spatial precision.
1672 This allowed us to estimate the advantages of high-resolution fMRI beyond the
1673 considerations about the expected size of the activation cluster and make an informed
1674 decision on the optimal fMRI protocol for motor somatotopy mapping in deep brain nuclei
1675 and cortical areas.

1676

1705 **Abstract**

1706 Although there is a growing motivation to increase the topological precision of functional magnetic
1707 resonance imaging (fMRI) to represent functional sensorimotor brain areas, the particular tissue
1708 properties of subcortical brain regions, notably in terms of iron content, pose significant challenges
1709 in terms of activation detection power. Because functional representations of small size might
1710 benefit from high-resolution fMRI, we test empirically the impact of fMRI's spatial resolution on the
1711 ability to segregate between body part representations in cortex and basal ganglia. Our block-
1712 design paradigm consisted of visually cued movements of facial musculature, upper and lower
1713 limbs. The motor task was repeated in a pseudo-randomized order using 2D/3D echo-planar
1714 imaging (EPI) acquisitions at 1.5mm, 2mm and 3mm spatial resolution. For statistical analysis of
1715 the degree of segregation between the body parts' spatial representations we used a pattern
1716 component model (PCM) to extract pattern similarity estimates. In contrast to cortical motor areas,
1717 the degree of effective similarity between spatial representations in subcortical areas was strongly
1718 impacted by the image resolution. The 1.5mm 3D EPI and 3mm 2D EPI protocol led to enhanced
1719 segregation between motor representations compared to the 2mm 3D EPI protocol. We
1720 recommend that future functional imaging studies with emphasis on motor mapping of subcortical
1721 brain structures take in account the particular importance of image resolution and encoding
1722 scheme when aiming at robustness and topological precision of the obtained results.

1723

1724 **Introduction**

1725 The optimisation of functional MRI (fMRI) protocols for the study of sensorimotor function is a
1726 recurring issue (Hlustik et al., 2001; Kapreli et al., 2007; Kleinschmidt et al., 1997; Meier et al.,
1727 2008; Olman et al., 2012). The inherent inter-individual variability of sensorimotor representations
1728 is one of the main factors that hampers the straightforward comparison of applied imaging
1729 parameters and analytical strategies (Alkadhi et al., 2002; Beisteiner et al., 2001; Picard and Strick,
1730 1996). Other factors influencing the degree of segregation of motor representations depend on the
1731 co-occurrence of limb joint movements that lead to multiple activation foci (Luft et al., 2002) and
1732 the differential organisation of functional representations across brain regions. It was generally
1733 found that BOLD activity patterns elicited during movement of different body parts were relatively
1734 segregated in the primary motor cortex (M1) despite substantial overlap (Cunningham et al., 2013;
1735 Kapreli et al., 2007; Meier et al., 2008; Zeharia et al., 2012), while the same representations in the
1736 supplementary motor area (SMA) were less separated (Indovina and Sanes, 2001; Strother et al.,
1737 2012). In the basal ganglia (BG) and thalamus, the literature shows either negligible (Lehéricy et al.,
1738 1998; Staempfli et al., 2008a) or substantial (Gerardin et al., 2003; Maillard et al., 2000) overlap
1739 between representation. We underline the fact that these studies used fMRI protocols with unequal
1740 spatial resolution parameters. Up to date, there are no reported fMRI findings focusing on deep
1741 brain nuclei and tackling the question about the impact of image resolution on the ability to
1742 spatially discriminate motor somatotopy patterns (Gerardin et al., 2003; Maillard et al., 2000; Oguri
1743 et al., 2013; Scholz et al., 2000; Staempfli et al., 2008b). This might be explained by the decay of the
1744 MRI signal that reduces BOLD sensitivity in these areas and complicates the mapping of fine-
1745 grained motor somatotopy (Pfefferbaum et al., 2010; Sullivan et al., 2009).

1746 To quantify segregation between blood-oxygen-level dependent (BOLD) activity patterns, common
1747 metrics are the Euclidean distance between centers of gravity or activation maxima (Besle et al.,
1748 2013a; Delmaire et al., 2005; Hashimoto et al., 2013), Jaccard or Dice coefficients (Bennett and
1749 Miller, 2010; Bracci et al., 2012; Cunningham et al., 2013; Gorgolewski et al., 2010; Gupta et al.,
1750 2014; Maitra, 2010; Pajula et al., 2012; Plow et al., 2010) and the selectivity index (Olman et al.,
1751 2012). Most of these metrics share the issue of being strongly affected by noise, corrupting thereby
1752 the comparison of estimates across brain regions or groups of subjects (Diedrichsen et al., 2011).

1753 The main aim of our study is to investigate the impact of fMRI spatial resolution on the ability to
1754 differentiate between representations of body parts in cortical and subcortical brain areas.
1755 Specifically, we compare fMRI protocols at 1.5mm, 2mm and 3mm isotropic spatial resolution in a

1756 visually cued motor paradigm. We hypothesise that higher fMRI resolution will improve the ability
1757 to segregate between functional representations of different body parts, especially in deep brain
1758 nuclei, which are associated with fine-grained topographical organisation. For quantification of
1759 spatial precision we use a well-established analytical strategy measuring the degree of similarity
1760 between representations while accounting for differential noise level across brain regions
1761 (Diedrichsen et al., 2011).

1762 **Methods**

1763 Participants

1764 From the recruited 16 right-handed healthy volunteers we discarded one individual due to
1765 insufficient data quality (9 female, mean age: 36.6 years, SEM: 4.47 years). The study was approved
1766 by the local ethics committee and participants gave their written informed consent.

1767 Experimental paradigm

1768 All volunteers performed the same motor execution task consisting of: 1) unilateral foot movement
1769 - flexion and extension of the right or left foot with the legs resting in flexed position on a platform,
1770 2) unilateral hand movement - opening and closing of the hand with the arm kept in a resting
1771 position, or 3) unilateral lower face movement, in three separate sessions corresponding to the
1772 three different spatial resolution fMRI protocols. Each of the 3 experimental sessions comprised 18
1773 blocks of movement repetitions during 16 seconds. Blocks of motor activity were interspersed with
1774 blocks of rest with the same duration. Before each block, the designated body part was shown on
1775 the screen followed by a countdown of 3 seconds. Subjects were instructed to move at a pace of 1Hz
1776 indicated by an icon of the corresponding body part displayed at that rate during the active blocks.
1777 The rest condition was marked by a fixation cross at the centre of the screen and subjects were
1778 asked to fixate it. Motor activity blocks were in pseudo-randomized order to prevent bias induced
1779 by potential effects of learning, performance and attention. This experiment was realised using
1780 Cogent 2000 developed by the Cogent 2000 team at the FIL and the ICN and Cogent Graphics
1781 developed by John Romaya at the LON at the Wellcome Department of Imaging Neuroscience.
1782 Movement execution was practiced before MRI scanning.

1783 MRI acquisition

1784 MRI data was acquired on a Siemens Prisma 3T scanner with a 64-channel head coil. The 3 mm
1785 isotropic resolution fMRI data was acquired using a 2D EPI sequence and the 1.5 and 2 mm

1786 isotropic voxel size data were acquired using a 3D EPI encoding scheme because it provides
1787 enhanced BOLD sensitivity at high resolution (Lutti et al., 2012). The acquisition parameters were
1788 as follows: 1.5 x 1.5 x 1.5 mm³: TE = 63 ms, slice TR = 63 ms, 64 slices, flip angle = 15°; 2 x 2 x 2
1789 mm³: TE = 66 ms, slice TR = 52 ms, 52 slices, flip angle = 15°; 3 x 3 x 3 mm³: TE = 66 ms, slice TR =
1790 66 ms, 30 slices, flip angle = 90°. The order of the 3 EPI sequences was pseudo-randomized across
1791 subjects. The structural MRI data consisted of quantitative images (Weiskopf et al., 2013) or T1-
1792 weighted MPRAGE images (TR = 2000 ms; TI = 920 ms; α = 9°; BW = 250 Hz / pixel; readout in
1793 inferior-superior direction; FoV = 256 x 232 mm; 176 slices) at 1 mm resolution.

1794 MRI data pre-processing

1795 All statistical analyses and data pre-processing were performed using the freely available Statistical
1796 Parametric Mapping software (SPM12; Wellcome Trust Centre for Neuroimaging,
1797 <http://www.fil.ion.ucl.ac.uk/spm/>) running under Matlab 7.13 (The MathWorks, Inc., Natick,
1798 Massachusetts, United States). EPI images were realigned to the subject's average image across
1799 runs, corrected for spatial distortions using the SPM fieldmap toolbox (Hutton, 2002). The
1800 parameters of registration to standardized MNI space were calculated on the anatomical image and
1801 the default settings of the "unified segmentation" framework followed by the diffeomorphic
1802 registration algorithm DARTEL (Ashburner and Friston, 2005; Ashburner, 2007). The spatial
1803 registration parameters were then applied to the functional time-series co-registered to the
1804 corresponding individual's anatomical scan and up-sampled to a uniform 1.5mm isotropic
1805 resolution. Prior to statistical analysis, we applied a spatial smoothing with a Gaussian kernel of 6
1806 mm full-width-at-half-maximum.

1807 Subject-level fMRI modelling

1808 The statistical analysis at subject-specific level was performed using the General Linear Model
1809 (GLM) after convolving the onsets of the active blocks with a canonical hemodynamic response
1810 function (Friston et al., 1994, 1995; Worsley and Friston, 1995). We estimated six differential
1811 contrasts for each body side and body part separately while using the resting blocks as baseline.
1812 Preparation periods and realignment parameters estimated by SPM were included as covariates.

1813 Group-level mass-univariate analysis

1814 We used three identical flexible factorial designs for the group-level analyses corresponding to the
1815 three different EPI protocols and modelling the results from the six differential contrasts as

1816 independent levels. The differential contrasts at the group level tested the positive correlation
1817 between movement and BOLD signal changes.

1818 Pattern component modelling

1819 Levels of segregation between functional representations of different body parts were estimated
1820 using the pattern component modelling (PCM) approach (Diedrichsen et al., 2011). The analysis
1821 required voxel-specific regression coefficients, which were extracted from subject-level GLMs in
1822 each of the following regions-of-interest (ROIs): M1, SMA, putamen, pallidum and thalamus
1823 (ventro-lateral and ventral postero-lateral nucleus). The PCM allowed producing unbiased
1824 estimates of correlation between multivariate voxel pattern decomposed into different
1825 components. The obtained coefficients of representational similarity (or correlation) were
1826 calculated in two ways: a) between movement representations across resolutions; b) between
1827 resolutions across movement representations. Only contralateral representations were considered,
1828 such that for each ROI, PCM was performed with a 3 x 3 factorial design (MOVEMENT x
1829 RESOLUTION) and without any constraint imposed on the variance-covariance matrix. The
1830 correlation coefficients were transformed using the Fisher r-to-z' transform (Sanabria-Diaz et al,
1831 2013) and the absolute value was taken as an Index of Similarity (IoS). In other terms the IoS is the
1832 absolute value of the inverse hyperbolic tangent of the correlation coefficient r between
1833 representations:

1834
$$IoS = |\tanh^{-1}(r)|$$

1835 Low values of IoS indicate high segregation between representations, whereas high values of IoS
1836 indicate high similarity between representations, i.e. lack of functional segregation between
1837 representations. These indices were subsequently converted to Z-statistics to allow for statistical
1838 comparisons (Sanabria-Diaz et al, 2013) using p-values corrected for multiple comparisons using
1839 false discovery rate (Benjamini & Hochberg, 1995). We performed comparisons of IoS Z-scores
1840 between resolutions for all pairs of movements and across resolutions for all types of movements.
1841 All p-values reported for these comparisons are corrected for multiple comparisons using false
1842 discovery rate (FDR).

1843 Detection power analyses

1844 Although activation detection power has been shown to decrease strongly with increased
1845 resolution elsewhere (Lutti et al., 2012; Triantafyllou et al., 2005), we provide as sanity tests

1846 average t-scores per ROI within the 5% most significant voxels (Supplementary figure 3) and
1847 estimates of temporal signal-to-noise ratio (tSNR) at the voxel level (Supplementary figure 4).

1848 **Results**

1849 *Mass-univariate analyses*

1850 The group level analysis demonstrated the expected somatotopy patterns in cortical and
1851 subcortical areas without major differences between different protocols (Figure 1; Supplementary
1852 figure 2). We report activations in primary motor cortical areas, thalamus, putamen and pallidum
1853 (whole brain results as supplementary material).

1854 *Indices of similarity*

1855 There were no significant differences between EPI protocols in cortical ROIs when comparing the
1856 IoS Z-scores across pairs of movements for each resolution and ROIs (Figure 2). We observed
1857 differences in subcortical ROIs where 3 mm provided lower IoS values compared to 1.5 mm in the
1858 left pallidum ($p = 0.01$) and right thalamus ($p = 0.001$). IoS values were significantly lower for 1.5
1859 mm as compared to 2 mm EPI in the left putamen ($p = 0.02$) and right thalamus ($p < 0.001$). We
1860 showed that IoS values were lower for 3 mm compared to 2 mm EPI in the left putamen ($p = 0.01$),
1861 left pallidum ($p = 0.01$) and the right thalamus ($p < 0.001$). All z-scores of motor representations
1862 between EPI protocols were significant ($p < 0.05$, FDR-corrected), except for 3 mm EPI against
1863 other protocols in the thalamus, showing that motor representations were robustly mapped
1864 (Supplementary figure 1).

1865 **Discussion**

1866 In our study we provide empirical evidence for the importance of imaging protocol's spatial
1867 resolution settings when focusing on subcortical brain regions. Image resolution was shown to have
1868 marked effects on the measured segregation between functional representations of different body
1869 parts.

1870 The prerequisite for our comparative analysis of fMRI parameter settings was the demonstration of
1871 a robust somatotopy pattern in cortical and subcortical regions. The obtained somatotopy map
1872 including primary motor cortex, SMA, putamen, pallidum and thalamic motor nuclei are
1873 anatomically plausible and in agreement with previous findings (Grafton et al., 1991; Lotze et al.,
1874 2000; Meier et al., 2008). We then used an established data-driven analytical approach
1875 (Diedrichsen et al, 2011) to obtain an index of segregation between functional representations of

1876 different body parts. Our first observation confirmed that motor representations in cortical regions
1877 - M1 and SMA, show a higher degree of segregation when compared with subcortical structures and
1878 corroborate previous reports (Chainay et al., 2004; Cunningham et al., 2013; Indovina and Sanes,
1879 2001).

1880 Following this, we focused on estimating the impact of image resolution on segregation of
1881 functional representation in the deep brain nuclei. Our findings clearly demonstrate that the
1882 differentiation between cortical somatotopy patterns does not benefit from an increase of fMRI
1883 spatial resolution, however the opposite was true for the subcortical structures. The simplistic view
1884 that the higher spatial resolution will yield better segregation was confirmed when comparing 1.5
1885 mm with 2 mm 3D EPI. However, we also observed that 3 mm 2D EPI provided better
1886 differentiation than 2mm 3D EPI and occasionally outperformed the 1.5 mm 3D EPI. One could
1887 speculate that the observed effects are due to the cumulated effects of image resolution and
1888 encoding scheme, with 3D EPI artificially increasing the effective overlap between representations
1889 in deep brain nuclei. Previous findings showing greater activation spread for 3D as compared to 2D
1890 EPI at identical resolution might support this hypothesis (Hu and Glover, 2007). Nevertheless, it is
1891 impossible to dissociate the respective contributions of image resolution and encoding scheme in
1892 our study. To validate this interpretation, we recommend thorough evaluation of functional
1893 imaging protocols with different encoding schemes and image resolution.

1894 Unlike some of the metrics aiming at measuring functional segregation, the method used here is
1895 independent of an arbitrary threshold for statistical significance (Gorgolewski et al., 2010; Stevens
1896 et al., 2013) to enable the comparison of representational similarity across brain regions with
1897 differential noise distribution (Diedrichsen et al, 2011). There are however several limitations of
1898 our study that should be mentioned. One critical point that has to be addressed is the possibility
1899 that low IoS values could be the result of reduced BOLD signal. This interpretation is contradictory
1900 with several observations. 3 mm EPI systematically produced low IoS estimates while being
1901 associated with a very strong BOLD sensitivity (Supplementary figure 3 and Supplementary figure
1902 4). In addition, comparable IoS values were obtained for all EPI protocols in cortical areas, where
1903 differences in BOLD sensitivity across image resolutions are expected (Triantafyllou et al., 2005)
1904 and were observed in our study (Supplementary figure 4). Thus, there is no systematic relationship
1905 between IoS values and BOLD sensitivity. Moreover, motor activity patterns were robustly mapped
1906 in cortical as well as subcortical regions and most of these patterns were consistent across EPI
1907 protocols (Supplementary figure 1). The only exception is the motor thalamus, where motor

1908 mapping appeared to be consistent only across high-resolution protocols, i.e. between 1.5 mm and
1909 2 mm. Furthermore, PCM reliably furthermore estimates similarity values between representations
1910 even when 75% of the voxels in the ROI are uninformative (Diedrichsen et al, 2011). This gives us
1911 the confidence that even a significant lack of overlap of activity between protocols will not change
1912 IoS values drastically.

1913 We also investigated the interaction between spatial resolution and applied smoothing kernel to
1914 demonstrate that even when different spatial smoothing strategies are used we obtain similar
1915 results (Supplementary figure 5). The correspondences between results obtained using
1916 unsmoothed data, uniformly smoothed data, and data smoothed using a spatial kernel proportional
1917 to the sampling resolution strongly support the statement that the effect being examined in our
1918 study relates closely to fMRI resolution and not spatial smoothing. Nevertheless, the fact that the
1919 observed effects were not always present bilaterally in subcortical ROIs remains to be elucidated.

1920 We show that spatial resolution of fMRI acquisition affects the degree of separation of motor
1921 somatotopy patterns and that this effect was varying across different brain regions. Deep brain
1922 nuclei, containing small-scale motor somatotopy, were affected by the effect of spatial resolution.
1923 Additional factors can modulate the observed similarity between functional representations.
1924 Previous studies have shown that the experimental design (Besle et al., 2013b), the way
1925 neuroimaging data are preprocessed (Geissler et al., 2005) and mass univariate inferences are
1926 conducted (Dechent and Frahm, 2003) can affect the effective overlap between BOLD activity
1927 patterns. In our study, these factors were kept constant.

1928 **Conclusion**

1929 We estimated the impact of fMRI's spatial resolution on the ability to segregate different BOLD
1930 activity patterns at 3T in cortical and subcortical areas. In contrast to cortical areas, motor
1931 somatotopy patterns in deep brain nuclei were more separable at very high and very low spatial
1932 resolution. Future studies might generalize our results to functional imaging of other brain
1933 functions, in other brain areas, at other field strengths, or using other imaging protocols and spatial
1934 resolutions.

1935

1936 **References**

- 1937 Alkadhi, H., Crelier, G.R., Boendermaker, S.H., Golay, X., Hepp-Reymond, M.-C., and Kollias,
1938 S.S. (2002). Reproducibility of primary motor cortex somatotopy under controlled
1939 conditions. *AJNR Am. J. Neuroradiol.* *23*, 1524–1532.
- 1940 Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. *NeuroImage* *38*,
1941 95–113.
- 1942 Ashburner, J., and Friston, K.J. (2005). Unified segmentation. *NeuroImage* *26*, 839–851.
- 1943 Beisteiner, R., Windischberger, C., Lanzenberger, R., Edward, V., Cunnington, R., Erdler, M.,
1944 Gartus, A., Streibl, B., Moser, E., and Deecke, L. (2001). Finger Somatotopy in Human Motor
1945 Cortex. *NeuroImage* *13*, 1016–1026.
- 1946 Bennett, C.M., and Miller, M.B. (2010). How reliable are the results from functional
1947 magnetic resonance imaging? *Ann. N. Y. Acad. Sci.* *1191*, 133–155.
- 1948 Besle, J., Sánchez-Panchuelo, R.-M., Bowtell, R., Francis, S., and Schluppeck, D. (2013a).
1949 Event-related fMRI at 7T reveals overlapping cortical representations for adjacent
1950 fingertips in S1 of individual subjects. *Hum. Brain Mapp.* *35*, 2027–2043.
- 1951 Besle, J., Sanchez-Panchuelo, R.M., Bowtell, R., Francis, S., and Schluppeck, D. (2013b).
1952 Single-subject fMRI mapping at 7 T of the representation of fingertips in S1: a comparison
1953 of event-related and phase-encoding designs. *J. Neurophysiol.* *109*, 2293–2305.
- 1954 Bracci, S., Cavina-Pratesi, C., Ietswaart, M., Caramazza, A., and Peelen, M.V. (2012). Closely
1955 overlapping responses to tools and hands in left lateral occipitotemporal cortex. *J.*
1956 *Neurophysiol.* *107*, 1443–1456.
- 1957 Chainay, H., Krainik, A., Tanguy, M.-L., Gerardin, E., Le Bihan, D., and Lehericy, S. (2004).
1958 Foot, face and hand representation in the human supplementary motor area. *NeuroReport*
1959 *15*, 765–769.
- 1960 Cunningham, D.A., Machado, A., Yue, G.H., Carey, J.R., and Plow, E.B. (2013). Functional
1961 somatotopy revealed across multiple cortical regions using a model of complex motor task.
1962 *Brain Res.* *1531*, 25–36.
- 1963 Dechent, P., and Frahm, J. (2003). Functional somatotopy of finger representations in
1964 human primary motor cortex. *Hum. Brain Mapp.* *18*, 272–283.
- 1965 Delmaire, C., Krainik, A., Tezenas du Montcel, S., Gerardin, E., Meunier, S., Mangin, J.F.,
1966 Sangla, S., Garnero, L., Vidailhet, M., and Lehericy, S. (2005). Disorganized somatotopy in
1967 the putamen of patients with focal hand dystonia. *Neurology* *64*, 1391–1396.
- 1968 Diedrichsen, J., Ridgway, G.R., Friston, K.J., and Wiestler, T. (2011). Comparing the similarity
1969 and spatial structure of neural representations: A pattern-component model. *NeuroImage*
1970 *55*, 1665–1678.

- 1971 Fonov, V., Evans, A.C., Botteron, K., Almli, C.R., Mckinstry, R.C., Collins, D.L., and Group, the
1972 B.D.C. (2011). Unbiased average age-appropriate atlases for pediatric studies. *NeuroImage*
1973 *54*, 313–327.
- 1974 Fonov, V.S., Evans, A.C., McKinstry, R.C., Almli, C.R., and Collins, D.L. (2009). Unbiased
1975 nonlinear average age-appropriate brain templates from birth to adulthood. *NeuroImage*
1976 *47, Supplement 1*, S102-.
- 1977 Friston, K.J., Holmes, A.P., Worsley, K.J., Poline, J.P., Frith, C.D., and Frackowiak, R.S. (1994).
1978 Statistical parametric maps in functional imaging: a general linear approach. *Hum. Brain*
1979 *Mapp. 2*, 189–210.
- 1980 Friston, K.J., Holmes, A.P., Poline, J.B., Grasby, P.J., Williams, S.C., Frackowiak, R.S., and
1981 Turner, R. (1995). Analysis of fMRI time-series revisited. *NeuroImage 2*, 45–53.
- 1982 Geissler, A., Lanzenberger, R., Barth, M., Tahamtan, A.R., Milakara, D., Gartus, A., and
1983 Beisteiner, R. (2005). Influence of fMRI smoothing procedures on replicability of fine scale
1984 motor localization. *NeuroImage 24*, 323–331.
- 1985 Gerardin, E., Lehericy, S., Pochon, J.-B., Tézenas du Montcel, S., Mangin, J.-F., Poupon, F.,
1986 Agid, Y., Le Bihan, D., and Marsault, C. (2003). Foot, hand, face and eye representation in the
1987 human striatum. *Cereb. Cortex 13*, 162–169.
- 1988 Gorgolewski, K.J., Storkey, A.J., Bastin, M.E., Whittle, I., and Pernet, C. (2010). Single subject
1989 fMRI test–retest reliability metrics and confounding factors. *NeuroImage 69*, 1–13.
- 1990 Grafton, S.T., Woods, R.P., Mazziotta, J.C., and Phelps, M.E. (1991). Somatotopic mapping of
1991 the primary motor cortex in humans: activation studies with cerebral blood flow and
1992 positron emission tomography. *J. Neurophysiol. 66*, 735–743.
- 1993 Gupta, L., Besseling, R.M.H., Overvliet, G.M., Hofman, P.A.M., de Louw, A., Vaessen, M.J.,
1994 Aldenkamp, A.P., Ulman, S., Jansen, J.F.A., and Backes, W.H. (2014). Spatial heterogeneity
1995 analysis of brain activation in fMRI. *YNICL 5*, 266–276.
- 1996 Hashimoto, T., Ueno, K., Ogawa, A., Asamizuya, T., Suzuki, C., Cheng, K., Tanaka, M., Taoka,
1997 M., Iwamura, Y., Suwa, G., et al. (2013). Hand before foot? Cortical somatotopy suggests
1998 manual dexterity is primitive and evolved independently of bipedalism. *Philos. Trans. R.*
1999 *Soc. B Biol. Sci. 368*, 20120417–20120417.
- 2000 Hlustik, P., Solodkin, A., Gullapalli, R.P., Noll, D.C., and Small, S.L. (2001). Somatotopy in
2001 human primary motor and somatosensory hand representations revisited. *Cereb. Cortex N.*
2002 *Y. N 1991 11*, 312–321.
- 2003 Hu, Y., and Glover, G.H. (2007). Three-dimensional spiral technique for high-resolution
2004 functional MRI. *Magn. Reson. Med. 58*, 947–951.


- 2005 Hutton, C. (2002). Image Distortion Correction in fMRI: A Quantitative Evaluation.
2006 *NeuroImage* 16, 217–240.
- 2007 Indovina, I., and Sanes, J.N. (2001). On Somatotopic Representation Centers for Finger
2008 Movements in Human Primary Motor Cortex and Supplementary Motor Area. *NeuroImage*
2009 13, 1027–1034.
- 2010 Kapreli, E., Athanasopoulos, S., Papathanasiou, M., Van Hecke, P., Kelekis, D., Peeters, R.,
2011 Strimpakos, N., and Sunaert, S. (2007). Lower Limb Sensorimotor Network: Issues of
2012 Somatotopy and Overlap. *CORTEX* 43, 219–232.
- 2013 Kleinschmidt, A., Nitschke, M.F., and Frahm, J. (1997). Somatotopy in the human motor
2014 cortex hand area. A high-resolution functional MRI study. *Eur. J. Neurosci.* 9, 2178–2186.
- 2015 Lehéricy, S., Van de Moortele, P.F., Lobel, E., Paradis, A.L., Vidailhet, M., Frouin, V., Neveu, P.,
2016 Agid, Y., Marsault, C., and Le Bihan, D. (1998). Somatotopical organization of striatal
2017 activation during finger and toe movement: a 3-T functional magnetic resonance imaging
2018 study. *Ann. Neurol.* 44, 398–404.
- 2019 Lotze, M., Erb, M., Flor, H., Huelsmann, E., Godde, B., and Grodd, W. (2000). fMRI Evaluation
2020 of Somatotopic Representation in Human Primary Motor Cortex. *NeuroImage* 11, 473–481.
- 2021 Luft, A.R., Smith, G.V., Forrester, L., Whittall, J., Macko, R.F., Hauser, T.-K., Goldberg, A.P., and
2022 Hanley, D.F. (2002). Comparing brain activation associated with isolated upper and lower
2023 limb movement across corresponding joints. *Hum. Brain Mapp.* 17, 131–140.
- 2024 Lutti, A., Thomas, D.L., Hutton, C., and Weiskopf, N. (2012). High-resolution functional MRI
2025 at 3 T: 3D/2D echo-planar imaging with optimized physiological noise correction. *Magn.*
2026 *Reson. Med.* 69, 1657–1664.
- 2027 Maillard, L., Ishii, K., Bushara, K., Waldvogel, D., Schulman, A.E., and Hallett, M. (2000).
2028 Mapping the basal ganglia: fMRI evidence for somatotopic representation of face, hand, and
2029 foot. *Neurology* 55, 377–383.
- 2030 Maitra, R. (2010). A re-defined and generalized percent-overlap-of-activation measure for
2031 studies of fMRI reproducibility and its use in identifying outlier activation maps.
2032 *NeuroImage* 50, 124–135.
- 2033 Meier, J.D., Aflalo, T.N., Kastner, S., and Graziano, M.S.A. (2008). Complex Organization of
2034 Human Primary Motor Cortex: A High-Resolution fMRI Study. *J. Neurophysiol.* 100, 1800–
2035 1812.
- 2036 Oguri, T., Sawamoto, N., Tabu, H., Urayama, S., Matsushashi, M., Matsukawa, N., Ojika, K., and
2037 Fukuyama, H. (2013). Overlapping connections within the motor cortico-basal ganglia
2038 circuit: fMRI-tractography analysis. *NeuroImage* 78, 353–362.

- 2039 Olman, C.A., Pickett, K.A., Schallmo, M.-P., and Kimberley, T.J. (2012). Selective BOLD
2040 responses to individual finger movement measured with fMRI at 3T. *Hum. Brain Mapp.* 33,
2041 1594–1606.
- 2042 Pajula, J., Kauppi, J.-P., and Tohka, J. (2012). Inter-Subject Correlation in fMRI: Method
2043 Validation against Stimulus-Model Based Analysis. *PLoS ONE* 8, e41196.
- 2044 Pfefferbaum, A., Adalsteinsson, E., Rohlfing, T., and Sullivan, E.V. (2010). Diffusion tensor
2045 imaging of deep gray matter brain structures: Effects of age and iron concentration.
2046 *Neurobiol. Aging* 31, 482–493.
- 2047 Picard, N., and Strick, P.L. (1996). Motor areas of the medial wall: a review of their location
2048 and functional activation. *Cereb. Cortex N. Y. N* 1991 6, 342–353.
- 2049 Plow, E.B., Arora, P., Pline, M.A., Binstock, M.T., and Carey, J.R. (2010). Within-limb
2050 somatotopy in primary motor cortex - revealed using fMRI. *CORTEX* 46, 310–321.
- 2051 Scholz, V.H., Flaherty, A.W., Kraft, E., Keltner, J.R., Kwong, K.K., Chen, Y.I., Rosen, B.R., and
2052 Jenkins, B.G. (2000). Laterality, somatotopy and reproducibility of the basal ganglia and
2053 motor cortex during motor tasks. *Brain Res.* 879, 204–215.
- 2054 Staempfli, P., Reischauer, C., Jaermann, T., Valavanis, A., Kollias, S., and Boesiger, P. (2008a).
2055 Combining fMRI and DTI: A framework for exploring the limits of fMRI-guided DTI fiber
2056 tracking and for verifying DTI-based fiber tractography results. *NeuroImage* 39, 119–126.
- 2057 Staempfli, P., Reischauer, C., Jaermann, T., Valavanis, A., Kollias, S., and Boesiger, P. (2008b).
2058 Combining fMRI and DTI: A framework for exploring the limits of fMRI-guided DTI fiber
2059 tracking and for verifying DTI-based fiber tractography results. *NeuroImage* 39, 119–126.
- 2060 Stevens, M.T.R., D'Arcy, R.C.N., Stroink, G., Clarke, D.B., and Beyea, S.D. (2013). Thresholds in
2061 fMRI studies: Reliable for single subjects? *J. Neurosci. Methods* 219, 312–323.
- 2062 Strother, L., Medendorp, W.P., Coros, A.M., and Vilis, T. (2012). Double representation of the
2063 wrist and elbow in human motor cortex. *Eur. J. Neurosci.* 36, 3291–3298.
- 2064 Sullivan, E.V., Adalsteinsson, E., Rohlfing, T., and Pfefferbaum, A. (2009). Relevance of Iron
2065 Deposition in Deep Gray Matter Brain Structures to Cognitive and Motor Performance in
2066 Healthy Elderly Men and Women: Exploratory Findings. *Brain Imaging Behav.* 3, 167–175.
- 2067 Triantafyllou, C., Hoge, R.D., Krueger, G., Wiggins, C.J., Potthast, A., Wiggins, G.C., and Wald,
2068 L.L. (2005). Comparison of physiological noise at 1.5 T, 3 T and 7 T and optimization of
2069 fMRI acquisition parameters. *NeuroImage* 26, 243–250.
- 2070 Weiskopf, N., Suckling, J., Williams, G., Correia, M.M., Inkster, B., Tait, R., Ooi, C., Bullmore,
2071 E.T., and Lutti, A. (2013). Quantitative multi-parameter mapping of R1, PD(*), MT, and
2072 R2(*) at 3T: a multi-center validation. *Front. Neurosci.* 7, 95.

- 2073 Worsley, K.J., and Friston, K.J. (1995). Analysis of fMRI time-series revisited—again.
2074 *NeuroImage* 2, 173–181.
- 2075 Zeharia, N., Hertz, U., Flash, T., and Amedi, A. (2012). Negative blood oxygenation level
2076 dependent homunculus and somatotopic information in primary motor cortex and
2077 supplementary motor area. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18565–18570.
- 2078

2079 **Figures**


2080



2081

2082 **Figure 1:** Motor somatotopy patterns across resolutions and brain regions. Group results obtained
 2083 using the flexible factorial design showing the binarized statistical parametric maps (t values)
 2084 thresholded at $\alpha = 0.05$ (corrected for multiple comparisons, family-wise error rate) for each
 2085 resolution and overlaid on a skull-stripped canonical anatomical image (Fonov et al., 2011, 2009).
 2086 Left and right hemibody movements are merged (red : toes ; yellow : fingers ; green : lower face).
 2087 The statistical threshold used ($p < 0.05$, FWE-corrected) is the same on all renderings.

The topography of cortico-subcortical loops in Parkinson's disease



2088


2089 **Figure 2:** Z-scores of IoS for Fingers against Toes, Fingers against Lower face and Toes against
 2090 Lower face per resolution and ROI. Bar plots on the left are for left ROIs, bar plots on the right are
 2091 for right ROIs. Surface renderings of the putamen (magenta), pallidum (orange), motor nuclei of the

The topography of cortico-subcortical loops in Parkinson's disease

2092 thalamus (cyan), SMA (mid-tone blue) and M1 (violet) are shown on a canonical anatomical image
2093 (Fonov et al., 2011, 2009) and on SPM12 cortical surface rendering (20484 vertices). The scale is
2094 identical for all bar plots and is shown on the middle left of the figure. Legend for the different EPI
2095 protocols (1.5 mm (hatched light grey); 2 mm (mid-tone grey); 3 mm (black)) is shown on the
2096 middle right of the figure. Stars indicate significantly different Z-scores ($p < 0.05$, FDR-corrected).

2097

2098 **Supplementary figures and tables**
 2099




2100

2101 **Supplementary figure 1:** Z-scores of IoS for 1.5 mm against 2 mm, 1.5 mm against 3 mm and 2 mm
 2102 against 3 mm per type of movement (fingers, toes, lower face) and ROI. Bar plots on the left are for
 2103 left ROIs, bar plots on the right are for right ROIs. Again, only contralateral activity is shown.
 2104 Surface renderings of the putamen (magenta), pallidum (orange), motor nuclei of the thalamus

The topography of cortico-subcortical loops in Parkinson's disease

2105 (cyan), SMA (mid-tone blue) and M1 (violet) are shown on a canonical anatomical image (Fonov et
2106 al., 2011, 2009) and on SPM12 cortical surface rendering (20484 vertices). The scale is identical for
2107 all bar plots and is shown on the middle left of the figure. Legend for the different EPI protocols (1.5
2108 mm (hatched light grey); 2 mm (mid-tone grey); 3 mm (black)) is shown on the middle right of the
2109 figure. Dotted lines indicate significance of correlation ($p < 0.05$ uncorrected for multiple
2110 comparisons, bilateral test). All Z-scores significant at uncorrected $p < 0.05$ level survived FDR-
2111 correction.

2112




2113

2114 **Supplementary figure 2:** Motor somatotopy patterns across resolutions and brain regions. Group
 2115 results obtained using the flexible factorial designs showing the binarized statistical parametric
 2116 maps (t values) thresholded at $\alpha = 0.001$ (uncorrected for multiple comparisons, minimal cluster
 2117 extent of 10 voxels) for each resolution and overlaid on a skull-stripped canonical anatomical image
 2118 (Fonov et al., 2011, 2009). Left and right hemibody movements are merged (red : toes ; yellow :
 2119 fingers ; green : lower face). The statistical threshold used ($p < 0.001$) is the same on all renderings.

2120


The topography of cortico-subcortical loops in Parkinson's disease



2121

2122 **Supplementary figure 3:** average t-score for all movements in each ROI as a function of EPI
 2123 protocol. The average t-score was calculated for each subject (error bars indicate standard error of
 2124 the mean) in the 5% most significant voxels within the ROI.

2125




2126

2127 **Supplementary figure 4:** voxel-wise temporal signal-to-noise ratio (tSNR) maps (averaged across
2128 all subjects) computed by dividing the average signal intensity across time points by the standard
2129 deviation of the residuals from the GLM fit. As expected, 3 mm EPI provides greater tSNR as
2130 compared to 2 mm EPI, the latter providing bigger tSNR than 1.5 mm EPI.

2131

The topography of cortico-subcortical loops in Parkinson's disease



2132

2133 **Supplementary figure 5:** shows the effect of different spatial smoothing strategies on PCM results.

2134 Z-scores of IoS across all ROIs as a function of EPI protocol and pairs of movement representations

2135 compared, using: a 6 mm FWHM Gaussian kernel (top); a Gaussian kernel whose FWHM is

2136 proportional to the resolution of the EPI protocol (4.5, 6 and 9 mm for 1.5, 2 and 3 mm EPI

2137 respectively) (middle); no spatial smoothing. PCM results are very similar regardless of the spatial

2138 smoothing strategy used, except that: a) proportional smoothing kernel and absence of smoothing

2139 seem to produce more bilateral differences between EPI protocols in the basal ganglia; b) without

2140 spatial smoothing, representational similarity in the SMA resembles more the one found in deep

2141 brain nuclei, except for 3 mm EPI.

2142

2143 **2.2. Functional segregation in Parkinson's disease**

2144 **2.2.1. Study 2**

2145 This study tests and validates the LOS hypothesis in PD using motor somatotopy as a
2146 working example. It shows that PD is associated with a loss of functional segregation in the
2147 striatum, SN and thalamus but not in the cortex. DA substitution is shown to restore only
2148 partially functional segregation. Estimates of functional segregation allow predicting the
2149 severity of motor symptoms and cortico-striatal connectivity. This study provides the first
2150 evidence in favour of the LOS hypothesis in PD at the functional level.

2151

2152 **Somatotopy shaken up: segregation and integration of information**
2153 **in Parkinson's disease**

2154 Renaud Marquis¹, Sara Lorio^{1,2}, Deepa Pothalil^{3,4}, Rémi Castella¹, Elisabeth Roggenhofer^{1,5}, Maya
2155 Jastrzębowska^{1,6}, Lester Melie-Garcia¹, François Vingerhoets⁴, Christian WIDER⁴, Antoine Lutti¹,
2156 Ferath Kherif¹, Bogdan Draganski^{1,7}

2157 ¹ *Laboratory of Research in Neuroimaging (LREN) – Department of Clinical Neuroscience, Lausanne*
2158 *University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland*

2159 ² *Institute of Child Health (ICH), University College London (UCL), London, United Kingdom*

2160 ³ *Department of Neurology, Clinique Saint Jean, Brussels, Belgium*

2161 ⁴ *Department of Neurology, Lausanne University Hospital (CHUV), Lausanne, Switzerland*

2162 ⁵ *Department of Neurology, Geneva University Hospital (HUG), Geneva, Switzerland*

2163 ⁶ *Laboratory of Psychophysics, Brain Mind Institute, École Polytechnique Fédérale de Lausanne*
2164 *(EPFL), Lausanne, Switzerland*

2165 ⁷ *Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany*

2166

2167 Running title: Loss of functional segregation in Parkinson's disease

2168 Title: Somatotopy shaken up: segregation and integration of information in cortico-subcortical
2169 circuits of Parkinson's disease

2170 Abstract: 214

2171 Text body: 3688

2172 References: 59

2173 Tables: 6

2174 Figures: 2

2175 Supplementary material: supplementary methods and results, 7 tables, 6 figures, 23 tables in 2
2176 separate Excel workbooks

2177

2178 Keywords: Parkinson's disease; functional magnetic resonance imaging; segregation; dopamine

The topography of cortico-subcortical loops in Parkinson's disease

2179

2180 Corresponding author:
2181 Bogdan Draganski
2182 LREN - Département des Neurosciences Cliniques
2183 CHUV, Université de Lausanne
2184 Mont Paisible 16
2185 1011 Lausanne
2186 Switzerland
2187 email: bogdan.draganski@chuv.ch
2188 phone: +41-21-314 9638
2189

2190 **Abstract**

2191 There is much controversy about the root causes and consequences of basal ganglia dysfunction
2192 aiming to unify hypokinetic and hyperkinetic movement disorders into a unique generative model.
2193 Recent empirical evidence suggests that movement disorders are associated with loss of neuronal
2194 specificity in basal ganglia that results in abnormal functional representation of body parts in the
2195 brain. Main aim of our study is to test the hypothesis of motor somatotopy changes in Parkinson's
2196 disease (PD) using functional magnetic resonance imaging (fMRI) and behavioural testing while
2197 modulating patients' dopaminergic state. Using a data-driven metric of spatial segregation between
2198 functional representations of upper and lower limbs we observed greater overlap between motor
2199 representations within putamen, thalamus and substantia nigra in PD patients OFF medication
2200 compared with healthy controls. Dopaminergic treatment in the very same patients restored the
2201 level of segregation in thalamus back to normal, but only partially in the basal ganglia. We show
2202 that the proposed index of similarity predicts both the degree of bradykinesia and the magnitude of
2203 effective cortico-striatal connectivity in PD patients when OFF dopamine. Our study provides
2204 evidence supporting the recent theoretical framework suggesting loss of segregation in movement
2205 disorders, which we validate empirically demonstrating the strong link between the proposed
2206 index of similarity and the motor symptoms severity in PD patients.

2207

2208 **Introduction**

2209 Despite an impressive number of theoretical approaches attempting to explain the pathophysiology
2210 of movement disorders, up to date there is no unique concept that unifies hypo- and hyperkinetic
2211 movement disorders into a single generative model (Albin et al., 1989; DeLong, 1990; Mink, 1996).
2212 Common models do not explain abnormal basal ganglia (BG) activity patterns and lead to
2213 predictions that are contradictory with experimental findings (Bronfeld and Bar-Gad, 2011; Nambu,
2214 2008; Nelson and Kreitzer, 2014; Obeso et al., 2008). Furthermore, the effectiveness of available
2215 therapeutic options is puzzling in such frameworks (Hickey and Stacy, 2016; Kalia and Lang, 2015).
2216 Recent studies using animal models brought empirical evidence about loss of neuronal specificity
2217 (LOS) in BG as governing pathophysiological mechanism in movement disorders (Bar-Gad and
2218 Bergman, 2001; Bronfeld and Bar-Gad, 2011). Under this hypothesis, the loss of the ability of BG to
2219 decorrelate cortical inputs results in abnormal motor behaviour, such as motor tics in Tourette
2220 syndrome, tremor and bradykinesia in PD, and choreic movements in Huntington's disease.
2221 Dimensionality reduction might be subserved by inter-nuclei mechanisms such as subthalamic
2222 input or dopaminergic innervation, as well as intra-nuclei processing implemented by lateral
2223 connections between striatal neurons or cholinergic interneurons (Bar-Gad et al., 2003a, 2003a;
2224 Bergman et al., 1998; Morris et al., 2004). However, investigations on the topic are hampered by the
2225 complex structural and functional organisation of BG showing not only co-existence of segregated
2226 and integrated motor, associative and limbic representations (Alexander et al., 1986; Draganski et
2227 al., 2008), but also a consistent somatotopy pattern throughout the entire cortico-BG circuitry
2228 (Obeso et al., 2008). Studies in non-human primates demonstrate LOS in the GPi (Leblois et al.,
2229 2006) and BG-recipient – but not cerebellar – thalamus (Pessiglione et al., 2005) associated with
2230 parkinsonism. In the latter study, activity and receptive fields of thalamic neurons were shown to
2231 increase even in the asymptomatic state. In addition, the LOS hypothesis in PD is supported by a
2232 larger proportion of neurons responding to more than a single body part (Baker et al., 2010;
2233 Boraud et al., 2000; Filion et al., 1988; Levy et al., 2001; Taha et al., 1996) and a higher relative
2234 number of active pallidal neurons during movements (Baker et al., 2010; Erez et al., 2011; Filion et
2235 al., 1988; Williams et al., 2005).

2236 Previous functional imaging studies in humans supported the notion of abnormal BG function in
2237 movement disorders demonstrating abnormal motor somatotopy in subcortical areas of patients
2238 with dystonia (Delmaire et al., 2005; Nelson et al., 2009; Quartarone et al., 2008; Tamburin et al.,
2239 2002). Nevertheless, there is currently no evidence confirming that other movement disorders,
2240 such as Parkinson's disease (PD), lead to a disruption of motor somatotopy patterns in the BG. This
2241 may be partly explained by the fact that the BG are challenging areas for fMRI because they contain
2242 substantial iron content, which reduces the signal-to-noise ratio, and are distant from MRI head coil
2243 channels (Drayer et al., 1986; Dušek et al., 2013).

2244 Many data-driven methods for investigation of differential functional representations have a
2245 susceptibility to be biased by noise in the measurements (Diedrichsen et al., 2011). This
2246 methodological issue parallels the one hindering accurate estimation of correlation between
2247 neuronal pairs in electrophysiological recordings (Bar-Gad et al., 2003b). Pattern component
2248 modelling (PCM) incorporates a noise term that accounts for noise influence in the signal measured

2249 (Diedrichsen et al., 2011). This method has shown to be very successful in restoring the true
2250 similarity between statistical maps even at high noise level (Diedrichsen et al., 2011) and has been
2251 extensively validated (Diedrichsen et al., 2013a, 2013b; Ejaz et al., 2015).

2252 We use high-resolution fMRI to investigate motor somatotopy in cortical and subcortical brain
2253 areas to test the hypothesis of abnormal functional segregation in Parkinson's disease. Under the
2254 assumption that DA modulates the degree of information segregation at the BG level we further
2255 hypothesized that functional segregation in the BG would be at least partially recovered under DA
2256 therapy. For analysis of the whole-brain fMRI data we use established mass-univariate statistics
2257 framework additionally to data-driven multi-variate pattern recognition tools. Given the
2258 importance of behavioural changes, we carefully monitored motor performance of PD patients and
2259 health controls aiming at correlational analysis and prediction of motor symptom's severity
2260 undergoing modulation by DA.

2261 **Methods**

2262 *Participants*

2263 Among the recruited 32 PD patients and 21 healthy controls (HC) we excluded 1 HC with low-
2264 quality MRI data due to motion artefacts. From the 32 PD patients 13 dropped out after the first
2265 scan, 1 was not included in the final analysis due to suspicion of underlying disorder other than PD,
2266 another 4 - due to lack of compliance in task performance. The final analysis consisted of 14 PD
2267 patients (6 female; age = 58.75 ± 1.89 standard error, SEM) and 20 HCs (10 female; age = $61.79 \pm$
2268 2.11 SEM). Although there was no significant age difference between groups (2-tailed 2-samples t-
2269 test, $t(32) = 1.0593$; $p = 0.2974$) all subsequent analyses were controlled for the linear effects of
2270 age. The Edinburgh inventory (Oldfield, 1971) indicated that all PD patients except 1 were right-
2271 handed. 17 HC subjects were right-handed and 3 - left-handed. The average handedness scores
2272 were 55.88 ± 12.52 SEM for HCs and 79.79 ± 14.29 SEM for PD patients. There was no significant
2273 handedness difference between groups (2-tailed 2-samples t-test, $t(32) = 1.2479$, $p = 0.2211$). The
2274 local Ethics committee approved the study and all volunteers gave written informed consent prior
2275 to participation.

2276 The neurological assessment comprising UPDRS parts III and IV was performed by 3 board-
2277 certified neurologists. Accordingly, 11 PD patients were predominantly affected on the left body
2278 side and 3 - on the right, consistently with their lateralized bradykinesia sub-score (Buck et al.,
2279 2011). The MRI data of patients with predominantly right-sided symptoms were flipped along the
2280 x-axis for all subsequent analyses besides the whole-brain analyses focusing on lateralisation of
2281 movement-related activity. All obtained results are therefore presented relative to the most
2282 affected body side except for the whole-brain mass-univariate group analyses.

2283 To study the DA-related effects we used a cross-over design where 6 patients were scanned first
2284 OFF DA medication and 8 - ON. When tested OFF medication, patients were requested to stop
2285 medication the day before. The time interval between the two scanning sessions was kept constant
2286 (number of days (mean \pm SEM): 64.5 ± 12.95). There was no significant difference between patients

2287 first scanned off (PD_{first OFF}) and patients first scanned on (PD_{first ON}) in terms of time interval
2288 between the two scanning sessions (number of days (mean \pm SEM): PD_{first OFF} = 60 \pm 23.07; PD_{first ON}
2289 = 67.86 \pm 16.02); $t(12) = 0.2900$; $p = 0.7767$). UPDRS III scores were significantly greater in patients
2290 off medication (PD OFF) as compared to patients on medication (PD ON) (1-tailed paired t-test:
2291 $t(13) = 3.4545$; $p = 0.0021$).

2292 *Experimental paradigm*

2293 Participants performed every 2 seconds visual cue- paced unilateral flexion/extension of hand and
2294 foot within blocks of 8 movements. The 20 blocks of motor activity were separated by rest periods
2295 with 16 seconds duration where participants were asked to fixate a cross at the centre of the
2296 screen. We indicated on the screen the start of each active movement block by a countdown of 3
2297 seconds. The pseudo-randomized order of tested body parts was balanced within and across
2298 participants and movements were practiced prior to scanning.

2299 To avoid potential performance biases, we continuously monitored the behavioural performance
2300 during fMRI acquisition using an in-house developed MR-compatible pneumatic device. The hand
2301 movements consisted of squeezing a rubber ball connected to air pressure sensors; for the feet we
2302 used a similar system installed underneath foot pedals. The air pressure sensors transduced
2303 pressure into electrical signal via CED MICRO3 1401 data acquisition unit (Cambridge Electronic
2304 Design Limited, UK) at 500 Hz sampling rate and the resulting output was sent to Signal 6 software
2305 (Cambridge Electronic Design Limited, UK). We used a peak detection algorithm identified to detect
2306 automatically motor responses using event-related moving averages with dynamic threshold (after
2307 Elgendi et al. (2013), see Supplementary methods). After classification of motor responses in cued
2308 and non-cued movements we excluded from further analysis participants missing more than 50%
2309 of trials or performing more than 50 non-cued movements. This resulted in exclusion of 4 PD
2310 patients: 2 patients missed on average 65% and 73.13% of trials in one experimental session while
2311 2 other performed an average of 89.75 and 72.5 non-cued movements in one experimental session.

2312 Under the supposition that the applied muscle force level correlates with neural activity (Keisker et
2313 al., 2009), all subsequent analyses were controlled for the linear effects of force measured within-
2314 subject locked to individual's peak and averaged across trials. Given that velocity of movement is
2315 causally linked to the very nature of PD (Hallett and Khoshbin, 1980), we did not control for the
2316 effects of movement velocity in our statistical analyses (distributions of peak force and velocity
2317 across subjects and per group are shown in Supplementary figure 2).

2318 *MRI data acquisition and processing*

2319 We used a Siemens Prisma 3T scanner with 64-channel head coil to acquire fMRI data using 3D
2320 multi-shot EPI at 2 mm isotropic voxel size (60 slices; slice TR 52 ms; volume TR 3.328 ms; slice
2321 oversampling: 6.7%). For brain anatomy imaging we used multi-echo 3D FLASH acquisitions with
2322 1.5 mm voxel size (matrix size: 160 x 150 x 120; FoV 256 x 240 x 176 mm) to quantitatively map
2323 longitudinal relaxation rate, effective proton density, magnetization transfer and effective
2324 transverse relaxation rate. We applied parallel imaging along the phase-encoding direction with 8
2325 equidistant TEs (Lorio et al. 2016); the repetition time (TR) and flip angle (α) were $TR/\alpha = 24.5$

2326 ms/6° (for PD-weighted); TR/α = 24.5 ms/21° (for T1-weighted). For correction of the effects of
2327 RF transmit inhomogeneities we used the acquired radio frequency (RF) transmit field map, and a
2328 static magnetic field map - for geometric distortion and off-resonance effects.

2329 All steps of MRI data processing and analysis were performed in the framework of SPM12
2330 (Wellcome Trust Center for Neuroimaging, www.fil.ion.ucl.ac.uk/spm) running under Matlab 7.13
2331 (The MathWorks, Inc., Natick, Massachusetts, United States). The fMRI data was realigned to the
2332 session mean, corrected for receive coil inhomogeneities and EPI distortion, and co-registered to
2333 the brain anatomy data. The calculated individuals' head motion parameters led to the exclusion of
2334 1 HC with more than 5mm of head movement along a principal axis during the motor task (Van Dijk
2335 et al., 2012). For further stringent control of the effects of excessive head movements we carried
2336 out additional analyses (see Supplementary material). We used the diffeomorphic spatial
2337 registration algorithm DARTEL to achieve optimal anatomical precision within the study cohort
2338 (Ashburner, 2007). The resulting spatial registration parameters were applied to the functional
2339 data for transformation into standardised Montreal Neurological Institute (MNI) space. Before
2340 statistical analysis we applied spatial smoothing using a Gaussian kernel of 3mm full-width-at-half-
2341 maximum.

2342 Whole-brain mass-univariate fMRI analyses

2343 *Within-subject analysis:* All cued and non-cued movements as detected by the peak detection
2344 algorithm were included as separate events in the fMRI design matrix, the preparation periods
2345 were modelled as epochs of 3 seconds, and the estimated realignment parameters were included as
2346 additional regressors. For the pattern component modelling at the subject-level we created a
2347 separate subject-level analysis that included only the realignment parameters as regressors, thus
2348 removing the confounding linear effects from the time series and leaving only variance related to
2349 the motor somatotopy paradigm.

2350 *Group-level analysis:* To verify the anatomical plausibility of the obtained motor somatotopy
2351 patterns we included the contrasts for positive effect of each cued movement with age and peak
2352 force as covariates in a flexible factorial design across all study participants. Additionally, effects of
2353 age and peak force were tested and are available as supplementary materials. We report
2354 statistically significant results surviving the threshold of $p < .05$ after family-wise error (FWE)
2355 correction for multiple comparisons. Results below $p < .001$, uncorrected for multiple comparisons
2356 are reported as trends.

2357 ROI-based multivariate fMRI analyses

2358 For our region-of-interest (ROI) approach we selected nodes of the motor circuitry including the
2359 primary motor cortex (M1), supplementary motor area (SMA), putamen, pallidum, subthalamic
2360 nucleus (STN), thalamus and the substantia nigra (SN). The ROI definition was based on the
2361 Harvard-Oxford atlas (fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), the ATAG atlas (Keuken et al., 2014)
2362 and Morel's atlas of the thalamus (Krauth et al., 2010; Niemann et al., 2000). The presence of brain
2363 activity during the motor somatotopy task in all these ROIs was verified using whole-brain
2364 univariate analyses (Supplementary table 1).

2365 We measured the representational similarity between brain activity patterns using the established
2366 PCM strategy (Diedrichsen et al., 2011). The multivariate analysis was performed at the subject
2367 level on the residuals of the GLM including only the realignment parameters. All cued, non-cued
2368 movements and preparation epochs were modelled using the same parameters as for subject-level
2369 fMRI modelling except head motion parameters. There was no shared variance component added
2370 as constraint. We estimated the variance and covariance between ipsilateral representations of
2371 hand and foot in the ROI contralateral to the corresponding body part. The variance-covariance
2372 matrices were transformed to correlation matrices.

2373 Aiming to obtain a metric of segregation between motor representations, the magnitudes of the
2374 correlation coefficients from the PCM were transformed using the Fisher r -to- z' transform
2375 (Sanabria-Diaz et al. 2013). The resulting metric - Index of Similarity (IoS) represents the inverse
2376 hyperbolic tangent of the magnitude of the correlation coefficient r between representations:

2377
$$IoS = |\tanh^{-1}(r)|$$

2378 High segregation between representations results in low IoS values, whereas high similarity
2379 between representations (i.e. lack of functional segregation between representations) produces
2380 high values of IoS.

2381 Additionally, we extracted volume-of-interest data represented by the 1st eigenvariate of the fMRI
2382 time course from putamen and M1. The extraction was based on the results of a F-test across all
2383 cued movements adjusting the data for the effects of interests. We calculated normalized mutual
2384 information (NMI) between cortex and putamen time courses dividing the mutual information by
2385 the geometric mean entropies (Strehl and Ghosh, 2002).

2386 Given the non-normal distribution of IoS values (see Supplementary figure 5), we applied bilateral
2387 Wilcoxon sum of ranks and signed rank tests across groups for each ROI after having removed the
2388 linear effects of age and peak force. Statistical significance threshold was set to $p < 0.05$,
2389 uncorrected for multiple comparisons.

2390 The relationship between IoS and bradykinesia sub-score in PD patients OFF was assessed using
2391 multiple regression models with age and peak force as covariate in ROIs yielding significant group
2392 differences. Spearman's rank correlation coefficients were calculated between IoS values and
2393 bradykinesia, which was adjusted for linear effects of age and peak force. The same procedure was
2394 used to test the prediction of UPDRS III score and tremor sub-score. All multiple linear regression
2395 models used the IoS in the SN contralateral to the most affected body side in PD patients as
2396 predictor, and lateralized versions of the UPDRS III scores, bradykinesia and tremor sub-scores.

2397 We tested multiple regression models in PD OFF using IoS in ROIs with significant group effect as
2398 predictor, NMI estimates between M1 and the putamen in the hemisphere contralateral to the most
2399 affected body side as dependent variable, and age and peak force as covariates. We report non-
2400 linear correlation coefficient between IoS and NMI estimates adjusted for linear effects of age and
2401 peak force.

2402 **Results**

2403 *Clinical and behavioural performance*

2404 The UPDRS III, UPDRS IV scores, Hoehn & Yahr stage and Levodopa Equivalent Dose represented
2405 the expected differentiation between patients ON and OFF medication (Table 1). The observed side
2406 predominance of symptom distribution in PD patients was confirmed by the absolute difference in
2407 bradykinesia sub-score between body sides (mean = 2.39; SEM = 0.53). Accordingly, there was a
2408 differential performance between cohorts and body parts tested (Table 2).

2409 *Whole-brain results*

2410 We observed robust motor somatotopy pattern extending over M1, SMA, putamen, GPe, GPi, the
2411 thalamus, the STN and the SN (Table 3; Supplementary figure 4). Reliable motor activity patterns
2412 were also found in the insula, parietal operculum, and cerebellum. The F-contrast performed to test
2413 for differences across cohorts did not show any significant results. There was a significant
2414 interaction between cohort and movement within the motor cortex contralateral to the most
2415 affected side in PD (see Supplementary material). Age and peak force were associated with unique
2416 spatial patterns of motor activity (Supplementary figure 4).

2417 *Region-of-interest results*

2418 The PCM performed on the residuals of the simple GLM converged for all subjects and for all ROIs.

2419 *Effects of disease and DA:* The non-parametric tests demonstrated higher IoS scores in PD OFF as
2420 compared to HC in the putamen ($W = 280, Z = -2.43, p = 0.015$), thalamus ($W = 288, Z = -2.15, p =$
2421 0.031) and SN ($W = 293, Z = -1.98, p = 0.048$), in the hemisphere contralateral to the most affected
2422 body side as compared to HC (i.e. in the right hemisphere for 11 out of 14 patients). The effects of
2423 PD ON patients were mostly in-between HC and PD OFF (Figure 1). We did not find any differences
2424 in the hemisphere ipsilateral to the most affected side in PD patients ($p > 0.05$). There was an effect
2425 of DA medication status in the thalamus contralateral to the most affected body side, where PD
2426 patients ON had lower IoS scores as compared to PD OFF ($W = 17, p = 0.025$).

2427 *Prediction of symptoms severity:* The results of the multiple linear regression model showed a
2428 significant regression equation (Table 4, Table 6 and Supplementary figure 6). There was a positive
2429 correlation between IoS in the SN contralateral to the predominantly affected body side and the
2430 bradykinesia sub-score (Table 4). High values of IoS in the SN were associated with high values of
2431 lateralized bradykinesia sub-score in PD OFF (Figure 2). The nonlinear correlation coefficient also
2432 demonstrated a positive relationship ($\rho = 0.60, p = 0.023$). Results of the equivalent multiple linear
2433 regression model for lateralized UPDRS III scores showed a significant model fit and a significant
2434 effect of IoS score in SN on UPDRS III (Supplementary table 3). Tremor was not predicted by IoS in
2435 the SN (Supplementary table 2). All multiple linear regression models using IoS in putamen or
2436 thalamus in PD OFF did not show any significant results.

2437 *Prediction of cortico-striatal connectivity:* The regression equations and the effects of IoS were not
2438 significant in multiple linear regression models on M1-putamen NMI using IoS in the SN ($\beta = -$

2439 0.004, $t(4,10) = -0.69$, $p = 0.5$, see Table 6) and thalamus ($\beta = 0.003$, $t(4,10) = 1.12$, $p = 0.29$, see
2440 Table 6). Conversely, the corresponding regression equation of the model using IoS in putamen as
2441 predictor was significant (Table 6). IoS in the putamen was negatively correlated with M1-putamen
2442 NMI estimates (Table 5). Additionally, Spearman's correlation coefficient between putaminal IoS
2443 and NMI values – adjusted for age and peak force effects – was significant ($\rho = -0.66$; $p = 0.01$). In
2444 PD OFF, high values of IoS in the putamen were associated with low values of M1-putamen NMI
2445 (Figure 2, see also Supplementary figure 6).

2446 Discussion

2447 In our study we provide unique evidence supporting the notion of dopamine related loss of
2448 functional segregation in Parkinson's disease. The impact of disease and dopaminergic modulation
2449 was most evident in the SN and putamen contralateral to the predominantly affected body side.
2450 Furthermore, PD patients ON medication lying most frequently in between PD OFF and HC, the
2451 motor thalamus was the only region where dopaminergic therapy was restoring functional
2452 segregation back to normal. While the predominant thalamic target for PD is the Vim, other
2453 thalamic nuclei have been considered for deep brain stimulation (DBS) (Kovanlikaya et al., 2014;
2454 Perlmutter and Mink, 2006; Rivlin-Etzion et al., 2006), such as the VPL for chronic pain (Bittar et al.,
2455 2005; Kovanlikaya et al., 2014) or the VL_a for dystonia (Mure et al., 2014). Notwithstanding the
2456 density of thalamic connections that might cause Vim DBS to influence adjacent nuclei (Perlmutter
2457 and Mink, 2006) and although the main source of thalamo-striatal projections are thought to lie in
2458 the centromedian-parafascicular complex (Smith et al., 2009), the Vim has also been shown to
2459 project to the striatum (Perlmutter and Mink, 2006) and there are growing evidences suggesting a
2460 pivotal role of thalamo-striatal connections in cortico-BG circuitry as a node subserving integration
2461 (Haber and Calzavara, 2009).

2462 We then showed that functional segregation in the SN is linked to the severity of motor symptoms
2463 in PD OFF, but more specifically to bradykinesia. The latter is the cardinal symptom mostly
2464 correlated with loss of striatal dopamine (Pahwa and Lyons, 2003). Although dissociating
2465 bradykinesia from rigidity, akinesia and hypokinesia is not trivial, each motor symptoms may be
2466 viewed as resulting from different profiles of loss of specificity (Bronfeld and Bar-Gad, 2011).

2467 Finally, we demonstrated that in PD OFF putaminal loss of functional segregation predicted a loss of
2468 connectivity between M1 and the putamen. We interpret this finding as suggesting that loss of
2469 functional segregation in the putamen – potentially induced by the lack of functional segregation in
2470 the SN – causes a disconnection between M1 and putamen, inducing a faulty putaminal processing
2471 of cortical information.

2472 In our study, differences in functional segregation in the pallidum and STN were not observed. This
2473 could be due to technical limitations or to the fact that we grouped patients according to the body
2474 side most affected by bradykinesia, not tremor. Knowing that tremor is relatively independent from
2475 other motor symptoms in PD (Helmich et al., 2012), future studies might investigate the links
2476 between tremor severity and the loss of functional segregation.

2477 Although we controlled for task performance using an automated algorithm for motor responses
2478 detection and included individual force level as a covariate in all analyses, more precise monitoring
2479 could potentially be achieved through EMG recordings (Dirkx et al., 2016). Though head motion
2480 parameters were included in the fMRI design and couldn't account for IoS differences (see Head
2481 motion as a confounding factor in the Supplementary results section), more sophisticated methods
2482 are available for removal of head motion artifacts (Power et al., 2014). It has also to be noted that
2483 the PCM is shown to be relatively robust to the size of the smoothing kernel used for spatial
2484 smoothing of fMRI images (Diedrichsen et al., 2011), hence advocating for the generalizability of
2485 our findings.

2486 We strongly recommend future studies to validate these findings using larger sample sizes,
2487 investigate the evolution of functional segregation in PD using longitudinal study designs, and
2488 explore the consequences of these findings to develop new therapeutic solutions.

2489 **Acknowledgements**

2490 We would like to thank all participants for their contribution to the study and to E. Dupuis for her
2491 essential help with MRI data acquisition. BD is supported by the Swiss National Science Foundation
2492 (NCCR Synapsy, project grant Nr 32003B_159780), Foundation Parkinson Switzerland and
2493 Foundation Synapsis. The research leading to these results has received funding from the European
2494 Union Seventh Framework Programme (FP7/2015-2018) under grant agreement no. 604102
2495 (Human Brain Project). LREN is very grateful to the Roger De Spoelberch and Partridge
2496 Foundations for their generous financial support.

2497

2498 **References**

- 2499 Albin, R.L., Young, A.B., and Penney, J.B. (1989). The functional anatomy of basal ganglia
2500 disorders. *Trends Neurosci.* *12*, 366–375.
- 2501 Alexander, G.E., DeLong, M.R., and Strick, P.L. (1986). Parallel organization of functionally
2502 segregated circuits linking basal ganglia and cortex. *Annu. Rev. Neurosci.* *9*, 357–381.
- 2503 Ashburner, J. (2007). A fast diffeomorphic image registration algorithm. *NeuroImage* *38*,
2504 95–113.
- 2505 Baker, K.B., Lee, J.Y.K., Mavinkurve, G., Russo, G.S., Walter, B., DeLong, M.R., Bakay, R.A.E.,
2506 and Vitek, J.L. (2010). Somatotopic organization in the internal segment of the globus
2507 pallidus in Parkinson's disease. *Exp. Neurol.* *222*, 219–225.
- 2508 Bar-Gad, I., and Bergman, H. (2001). Stepping out of the box: information processing in the
2509 neural networks of the basal ganglia. *Curr. Opin. Neurobiol.* *11*, 689–695.
- 2510 Bar-Gad, I., Morris, G., and Bergman, H. (2003a). Information processing, dimensionality
2511 reduction and reinforcement learning in the basal ganglia. *Prog. Neurobiol.* *71*, 439–473.
- 2512 Bar-Gad, I., Heimer, G., Ritov, Y., and Bergman, H. (2003b). Functional correlations between
2513 neighboring neurons in the primate globus pallidus are weak or nonexistent. *J. Neurosci.*
2514 *23*, 4012–4016.
- 2515 Bergman, H., Feingold, A., Nini, A., Raz, A., Slovin, H., Abeles, M., and Vaadia, E. (1998).
2516 Physiological aspects of information processing in the basal ganglia of normal and
2517 parkinsonian primates. *Trends Neurosci.* *21*, 32–38.
- 2518 Bittar, R.G., Burn, S.C., Bain, P.G., Owen, S.L., Joint, C., Shlugman, D., and Aziz, T.Z. (2005).
2519 Deep brain stimulation for movement disorders and pain. *J. Clin. Neurosci.* *12*, 457–463.
- 2520 Boraud, T., Bézard, E., Bouliac, B., and Gross, C.E. (2000). Ratio of inhibited-to-activated
2521 pallidal neurons decreases dramatically during passive limb movement in the MPTP-
2522 treated monkey. *J. Neurophysiol.* *83*, 1760–1763.
- 2523 Bronfeld, M., and Bar-Gad, I. (2011). Loss of specificity in Basal Ganglia related movement
2524 disorders. *Front. Syst. Neurosci.* *5*, 38.
- 2525 Buck, P.O., Wilson, R.E., Seeberger, L.C., Conner, J.B., and Castelli-Haley, J. (2011).
2526 Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity. *J.*
2527 *Park. Dis.* *1*, 253–258.
- 2528 Delmaire, C., Krainik, A., Tezenas du Montcel, S., Gerardin, E., Meunier, S., Mangin, J.F.,
2529 Sangla, S., Garnero, L., Vidailhet, M., and Lehericy, S. (2005). Disorganized somatotopy in
2530 the putamen of patients with focal hand dystonia. *Neurology* *64*, 1391–1396.

- 2531 DeLong, M.R. (1990). Primate models of movement disorders of basal ganglia origin.
2532 Trends Neurosci.
- 2533 Diedrichsen, J., Ridgway, G.R., Friston, K.J., and Wiestler, T. (2011). Comparing the similarity
2534 and spatial structure of neural representations: A pattern-component model. *NeuroImage*
2535 *55*, 1665–1678.
- 2536 Diedrichsen, J., Wiestler, T., and Ejaz, N. (2013a). A multivariate method to determine the
2537 dimensionality of neural representation from population activity. *NeuroImage* *76*, 225–
2538 235.
- 2539 Diedrichsen, J., Wiestler, T., and Krakauer, J.W. (2013b). Two Distinct Ipsilateral Cortical
2540 Representations for Individuated Finger Movements. *Cereb. Cortex* *23*, 1362–1377.
- 2541 Dirkx, M.F., den Ouden, H., Aarts, E., Timmer, M., Bloem, B.R., Toni, I., and Helmich, R.C.
2542 (2016). The Cerebral Network of Parkinson's Tremor: An Effective Connectivity fMRI
2543 Study. *J. Neurosci.* *36*, 5362–5372.
- 2544 Draganski, B., Kherif, F., Klöppel, S., Cook, P.A., Alexander, D.C., Parker, G.J.M., Deichmann, R.,
2545 Ashburner, J., and Frackowiak, R.S.J. (2008). Evidence for Segregated and Integrative
2546 Connectivity Patterns in the Human Basal Ganglia. *J. Neurosci.* *28*, 7143–7152.
- 2547 Drayer, B., Burger, P., Darwin, R., Riederer, S., Herfkens, R., and Johnson, G.A. (1986). MRI of
2548 brain iron. *AJR Am. J. Roentgenol.* *147*, 103–110.
- 2549 Dušek, P., Dezortova, M., and Wuerfel, J. (2013). Imaging of iron. *Int. Rev. Neurobiol.* *110*,
2550 195–239.
- 2551 Ejaz, N., Hamada, M., and Diedrichsen, J. (2015). Hand use predicts the structure of
2552 representations in sensorimotor cortex. *Nat. Publ. Group*.
- 2553 Elgendi, M., Norton, I., Brearley, M., Abbott, D., and Schuurmans, D. (2013). Systolic Peak
2554 Detection in Acceleration Photoplethysmograms Measured from Emergency Responders in
2555 Tropical Conditions. *PLoS ONE* *8*, e76585.
- 2556 Erez, Y., Tischler, H., Bebelovsky, K., and Bar-Gad, I. (2011). Dispersed Activity during
2557 Passive Movement in the Globus Pallidus of the 1-Methyl-4-Phenyl-1,2,3,6-
2558 Tetrahydropyridine (MPTP)-Treated Primate. *PLoS ONE* *6*, e16293.
- 2559 Filion, M., Tremblay, L., and Bédard, P.J. (1988). Abnormal influences of passive limb
2560 movement on the activity of globus pallidus neurons in parkinsonian monkeys. *Brain Res.*
2561 *444*, 165–176.
- 2562 Haber, S.N., and Calzavara, R. (2009). The cortico-basal ganglia integrative network: The
2563 role of the thalamus. *Brain Res. Bull.* *78*, 69–74.

- 2564 Hallett, M., and Khoshbin, S. (1980). A physiological mechanism of bradykinesia. *Brain* 103,
2565 301–314.
- 2566 Helmich, R.C., Hallett, M., Deuschl, G., Toni, I., and Bloem, B.R. (2012). Cerebral causes and
2567 consequences of parkinsonian resting tremor: a tale of two circuits? *Brain* 135, 3206–3226.
- 2568 Hickey, P., and Stacy, M. (2016). Deep Brain Stimulation: A Paradigm Shifting Approach to
2569 Treat Parkinson's Disease. *Front. Neurosci.* 10, 76.
- 2570 Kalia, L.V., and Lang, A.E. (2015). Parkinson's disease. *The Lancet* 386, 896–912.
- 2571 Keisker, B., Hepp-Reymond, M.-C., Blickenstorfer, A., Meyer, M., and Kollias, S.S. (2009).
2572 Differential force scaling of fine-graded power grip force in the sensorimotor network.
2573 *Hum. Brain Mapp.* 30, 2453–2465.
- 2574 Keuken, M.C., Bazin, P.L., Crown, L., Hootsmans, J., Laufer, A., Müller-Axt, C., Sier, R., van der
2575 Putten, E.J., Schäfer, A., Turner, R., et al. (2014). Quantifying inter-individual anatomical
2576 variability in the subcortex using 7T structural MRI. *NeuroImage* 94, 40–46.
- 2577 Kovanlikaya, I., Heier, L., and Kaplitt, M. (2014). Treatment of Chronic Pain: Diffusion
2578 Tensor Imaging Identification of the Ventroposterolateral Nucleus Confirmed with
2579 Successful Deep Brain Stimulation. *Stereotact. Funct. Neurosurg.* 92, 365–371.
- 2580 Krauth, A., Blanc, R., Poveda, A., Jeanmonod, D., Morel, A., and Székely, G. (2010). A mean
2581 three-dimensional atlas of the human thalamus: Generation from multiple histological data.
2582 *NeuroImage* 49, 2053–2062.
- 2583 Leblois, A., Meissner, W., Bezard, E., Bioulac, B., Gross, C.E., and Boraud, T. (2006). Temporal
2584 and spatial alterations in GPi neuronal encoding might contribute to slow down movement
2585 in Parkinsonian monkeys. *Eur. J. Neurosci.* 24, 1201–1208.
- 2586 Levy, R., Dostrovsky, J.O., Lang, A.E., Sime, E., Hutchison, W.D., and Lozano, A.M. (2001).
2587 Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in
2588 patients with Parkinson's disease. *J. Neurophysiol.* 86, 249–260.
- 2589 Lorio, S., Kherif, F., Ruef, A., Melie-Garcia, L., Frackowiak, R., Ashburner, J., Helms, G., Lutti,
2590 A., and Draganski, B. (2016). Neurobiological origin of spurious brain morphological
2591 changes: A quantitative MRI study. *Hum. Brain Mapp.* 37, 1801–1815.
- 2592 Mink, J.W. (1996). The basal ganglia: focused selection and inhibition of competing motor
2593 programs. *Prog. Neurobiol.* 50, 381–425.
- 2594 Morris, G., Arkadir, D., Nevet, A., Vaadia, E., and Bergman, H. (2004). Coincident but distinct
2595 messages of midbrain dopamine and striatal tonically active neurons. *Neuron* 43, 133–143.

- 2596 Mure, H., Morigaki, R., Koizumi, H., Okita, S., Kawarai, T., Miyamoto, R., Kaji, R., Nagahiro, S.,
2597 and Goto, S. (2014). Deep Brain Stimulation of the Thalamic Ventral Lateral Anterior
2598 Nucleus for DYT6 Dystonia. *Stereotact. Funct. Neurosurg.* 92, 393–396.
- 2599 Nambu, A. (2008). Seven problems on the basal ganglia. *Curr. Opin. Neurobiol.* 18, 595–604.
- 2600 Nelson, A.B., and Kreitzer, A.C. (2014). Reassessing Models of Basal Ganglia Function and
2601 Dysfunction. *Annu. Rev. Neurosci.* 37, 117–135.
- 2602 Nelson, A.J., Blake, D.T., and Chen, R. (2009). Digit-specific aberrations in the primary
2603 somatosensory cortex in Writer's cramp. *Ann. Neurol.* 66, 146–154.
- 2604 Niemann, K., Mennicken, V.R., Jeanmonod, D., and Morel, A. (2000). The Morel Stereotactic
2605 Atlas of the Human Thalamus: Atlas-to-MR Registration of Internally Consistent Canonical
2606 Model. *NeuroImage* 12, 601–616.
- 2607 Obeso, J.A., Rodríguez-Oroz, M.C., Benitez-Temino, B., Blesa, F.J., Guridi, J., Marin, C., and
2608 Rodríguez, M. (2008). Functional organization of the basal ganglia: Therapeutic
2609 implications for Parkinson's disease. *Mov. Disord.* 23, S548–S559.
- 2610 Oldfield, R.C. (1971). The assessment and analysis of handedness: the Edinburgh inventory.
2611 *Neuropsychologia* 9, 97–113.
- 2612 Pahwa, R., and Lyons, K.E. (2003). *Handbook of Parkinson's Disease, Third Edition* (Kansas
2613 City, Kansas, USA: CRC Press).
- 2614 Perlmutter, J.S., and Mink, J.W. (2006). Deep brain stimulation. *Annu. Rev. Neurosci.* 29,
2615 229–257.
- 2616 Pessiglione, M., Guehl, D., Rolland, A.-S., Francois, C., Hirsch, E.C., Féger, J., and Tremblay, L.
2617 (2005). Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of
2618 functional segregation within basal ganglia circuits. *J. Neurosci.* 25, 1523–1531.
- 2619 Power, J.D., Mitra, A., Laumann, T.O., Snyder, A.Z., Schlaggar, B.L., and Petersen, S.E. (2014).
2620 Methods to detect, characterize, and remove motion artifact in resting state fMRI.
2621 *NeuroImage* 84, 320–341.
- 2622 Quartarone, A., Morgante, F., Sant'Angelo, A., Rizzo, V., Bagnato, S., Terranova, C., Siebner,
2623 H.R., Berardelli, A., and Girlanda, P. (2008). Abnormal plasticity of sensorimotor circuits
2624 extends beyond the affected body part in focal dystonia. *J. Neurol. Neurosurg. Psychiatry*
2625 79, 985–990.
- 2626 Rivlin-Etzion, M., Marmor, O., Heimer, G., Raz, A., Nini, A., and Bergman, H. (2006). Basal
2627 ganglia oscillations and pathophysiology of movement disorders. *Curr. Opin. Neurobiol.* 16,
2628 629–637.

- 2629 Sanabria-Diaz, G., Martínez-Montes, E., Melie-Garcia, L., and Alzheimer's Disease
2630 Neuroimaging Initiative (2013). Glucose metabolism during resting state reveals abnormal
2631 brain networks organization in the Alzheimer's disease and mild cognitive impairment.
2632 PLoS ONE 8, e68860.
- 2633 Smith, Y., Raju, D., Nanda, B., Pare, J.-F., Galván, A., and Wichmann, T. (2009). The
2634 thalamostriatal systems: Anatomical and functional organization in normal and
2635 parkinsonian states. *Brain Res. Bull.* 78, 60–68.
- 2636 Strehl, A., and Ghosh, J. (2002). Cluster ensembles - a knowledge reuse framework for
2637 combining multiple partitions. *J. Mach. Learn. Res.*
- 2638 Taha, J.M., Favre, J., Baumann, T.K., and Burchiel, K.J. (1996). Characteristics and
2639 somatotopic organization of kinesthetic cells in the globus pallidus of patients with
2640 Parkinson's disease. *J. Neurosurg.* 85, 1005–1012.
- 2641 Tamburin, S., Manganotti, P., Marzi, C.A., Fiaschi, A., and Zanette, G. (2002). Abnormal
2642 somatotopic arrangement of sensorimotor interactions in dystonic patients. *Brain* 125,
2643 2719–2730.
- 2644 Van Dijk, K.R.A., Sabuncu, M.R., and Buckner, R.L. (2012). The influence of head motion on
2645 intrinsic functional connectivity MRI. *NeuroImage* 59, 431–438.
- 2646 Williams, Z.M., Neimat, J.S., Cosgrove, G.R., and Eskandar, E.N. (2005). Timing and direction
2647 selectivity of subthalamic and pallidal neurons in patients with Parkinson disease. *Exp.*
2648 *Brain Res.* 162, 407–416.

2649 **Tables**

2650

			PD OFF	PD ON
UPDRS III	Total		19.00 ± 2.12	13.57 ± 2.08
	Upper limbs	Right	3.64 ± 0.79	2.14 ± 0.64
		Left	6.29 ± 1.08	4.93 ± 0.98
	Lower limbs	Right	0.79 ± 0.40	0.43 ± 0.23
		Left	1.86 ± 0.35	1.57 ± 0.43
Bradykinesia	Total		8.93 ± 1.14	6.07 ± 0.95
	Upper limbs	Right	3.71 ± 0.59	2.07 ± 0.39
		Left	5.07 ± 0.71	3.93 ± 0.71
	Lower limbs	Right	1.57 ± 0.23	1.21 ± 0.21
		Left	2.21 ± 0.28	1.86 ± 0.28
Tremor	Total		2.71 ± 0.54	2.43 ± 0.72
	Upper limbs	Right	0.36 ± 0.17	0.36 ± 0.20
		Left	1.14 ± 0.35	0.93 ± 0.32
	Lower limbs	Right	0.21 ± 0.16	0.14 ± 0.14
		Left	0.29 ± 0.13	0.43 ± 0.20
UPDRS IV			1.14 ± 0.44	
Hoehn & Yahr stadium			1.64 ± 0.16	
Levodopa Equivalent Dose			684.86 ± 95.73	

2651

2652 **Table 1**: average and standard error of UPDRS III, bradykinesia sub-score, tremor sub-score
 2653 separately for PD patients ON and OFF. Average and standard error of UPDRS IV, Hoehn and Yahr
 2654 stadium, and Levodopa Equivalent Dose were measured once for all PD patients and are also
 2655 reported.

2656

2657

		All	HC	PD ON	PD OFF
Percentage of cued movements	mean ± SEM	88.72 ± 0.81	88.91 ± 1.19	87.28 ± 1.82	89.91 ± 1.26
	minimum	66.25	75.63	66.25	78.75
	maximum	96.25	95.63	95.00	96.25
Number of uncued movements	mean ± SEM	10.58 ± 1.35	6.09 ± 0.65	11.40 ± 1.94	16.20 ± 3.65
	minimum	2.50	2.50	3.50	3.25
	maximum	41.50	13.75	28.75	41.50

2658

2659 **Table 2** : percentage of cued movements and number of uncued movements summarised with the
 2660 average, standard error (SEM), minimum and maximum, across all groups of subjects and
 2661 separately for each group.

2662

2663

Region		<i>F</i>	x [mm]	y [mm]	z [mm]	
M1	right hemisphere	hand area	69.71	38	-25	56
		foot area	61.78	11	-31	70
	left hemisphere	hand area	69.11	-38	-25	54
		foot area	64.27	-9	-33	68
SMA		44.47	0	1	56	
putamen	right hemisphere	30.94	-31	-9	5	
	left hemisphere	38.87	-30	-7	7	
GPe	right hemisphere	21.32	22	-4	3	
	left hemisphere	23.41	-24	-4	3	
GPi	right hemisphere	13.46	22	-9	-2	
	left hemisphere	17.62	-17	-6	-4	
thalamus	right hemisphere	16.81	13	-14	7	
	left hemisphere	26.63	-14	-17	9	
STN		12.74	-8	-15	-11	
SN		12.19	12	-14	-7	

2664

2665 **Table 3**: whole-brain univariate results for the flexible factorial design including HC subjects
 2666 summarised with the F-statistic and MNI coordinates of cluster maxima within each ROI selected.
 2667 Complete tables of all significant clusters (at $p < 0.001$, $k \geq 10$) are available as separate
 2668 supplementary material in “group_results_mass_univariate_full_fact.xls” and
 2669 “group_results_mass_univariate_HC_flexible_fact.xls”.

2670

2671

	Coefficient (β)	Standard error	t	p
Intercept	4.112	1.14	3.606	0.005
SN IoS	0.237	0.084	2.82	0.018
Age	0.69	0.52	1.328	0.214
Peak force	-0.923	0.521	1.771	0.107

2672

2673 **Table 4** : Results table for the multiple linear regression model in PD OFF with the regression
 2674 equation $Bradykinesia \sim Intercept + IoS_{SN} + Age + PeakForce$.

2675

2676

2677

	Coefficient (β)	Standard error	t	p
Intercept	0.32	0.048	6.746	< 0.001
Putamen IoS	-0.009	0.003	-2.904	0.016
Age	0.036	0.018	1.986	0.075
Force	-0.033	0.018	1.792	0.104

2678

2679 **Table 5** : Results table for the multiple linear regression model in PD OFF with the regression
 2680 equation $NMI_{M1-putamen} \sim Intercept + IoS_{putamen} + Age + PeakForce$.

2681

2682


Model	R ²	R ² adjusted	RMSE	F	p
<i>Bradykinesia ~ Intercept + IoS_{SN} + Age + PeakForce</i>	0.55	0.41	1.87	4.07	0.04
<i>UPDRSIII ~ Intercept + IoS_{SN} + Age + PeakForce</i>	0.55	0.41	3	4.06	0.04
<i>NMI_{M1-putamen} ~ Intercept + IoS_{SN} + Age + PeakForce</i>	0.31	0.103	0.09	1.5	0.28
<i>NMI_{M1-putamen} ~ Intercept + IoS_{thalamus} + Age + PeakForce</i>	0.36	0.16	0.08	1.85	0.29
<i>NMI_{M1-putamen} ~ Intercept + IoS_{putamen} + Age + PeakForce</i>	0.61	0.49	0.07	5.16	0.02

2683

2684 **Table 6:** Model fitting results for all multiple linear regression models performed in PD OFF to
 2685 predict symptom severity and cortico-striatal connectivity estimates.

2686

2687 **Figures**



2688


2689 **Figure 1** : boxplots of IoS estimates per group for each ROI. Subcortical (top) and cortical (bottom)
 2690 ROI masks used are rendered using custom Matlab code, following neurological convention. Left

The topography of cortico-subcortical loops in Parkinson's disease

2691 boxplots represent IoS estimates in left ROIs and reversely for the right, although left and right ROIs
2692 were flipped in 3 PD patients affected mostly on the left body side. Dark green: putamen; dark
2693 orange: GPe; light yellow: GPi; light blue: thalamus (VL and VPL nuclei); dark blue: STN; magenta:
2694 SN; mid-tone blue: SMA; violet: M1. Black squares in box plots represent the average. Significance
2695 ($p < 0.05$) is marked with an asterisk.

2696

The topography of cortico-subcortical loops in Parkinson's disease



2697

2698 **Figure 2**: scatter plots summarising results of the multiple linear regression models. Left
2699 part shows lateralized bradykinesia sub-score in PD OFF, adjusted for effects of age and force, as a
2700 function of IoS in the SN contralateral to the most affected body side. Right part depicts adjusted
2701 cortico-striatal connectivity as measured by M1-putamen NMI (adjusted for effects of age and
2702 force), as a function of IoS in the putamen contralateral to the most affected hemibody in PD
2703 patients OFF medication. In all scatter plots, the black dotted line represents the regression line.

2704

2705

2706 **Supplementary material**

2707 Supplementary methods

2708 *Kinematic analyses*

2709 Motor response peaks were detected using a modified version of the algorithm proposed by Elgendi
2710 and colleagues (2013). We provide here details about the procedure employed. For our purpose,
2711 the outcome of the peak detection was optimized by setting parameters to the following values: W_1
2712 = 700; $W_2 = 3500$; $\beta = 0.35$. The following cut-off frequencies were used for the Butterworth band-
2713 pass filter: low-pass = 0.1 Hz, high-pass = 30 Hz. The formula for parameters THR_1 and THR_2 were
2714 modified such that:

2715
$$THR_1 = \gamma \cdot MA_{beat}[n] + \alpha$$

2716 Where $\gamma = 0.45$. And:

2717
$$THR_2 = \frac{W_1}{4}$$

2718 These parameter values were adjusted manually to maximize detection accuracy according to a
2719 visual inspection of every dataset done by the experimenter. An example of motor responses
2720 detected in three subjects is shown in Supplementary figure 1. Peri-response peak time histograms
2721 (PRTH) were extracted from task performance recordings by averaging over time windows
2722 comprised 1000 ms before to 1000 ms after each motor response captured by the peak detection
2723 algorithm. These responses were filtered using a Butterworth bandpass filter (highpass cutoff = 15
2724 Hz ; lowpass cutoff = 0 Hz). Because units of motor responses were arbitrarily defined by the
2725 experimental setup – i.e the gain applied to each channel was adjusted to provide an approximately
2726 similar response for all body parts –, maximal and minimal values were estimated among all
2727 recordings for each channel and all PRTH were scaled to convert units in percentage of air pressure.
2728 From the latter force PRTH, response velocity (velocity PRTH) was estimated as the absolute value
2729 of the derivative across time points. Right and left body part channels were flipped for the 3 PD
2730 patients mostly affected on the right body side, and linear effects of age were removed at the
2731 baseline level (i.e taking into account the average across time points for each PRTH). Removing age
2732 effects at each time point separately was not performed to prevent distortion of the response shape.
2733 T-tests between groups were then performed at each time point for force and velocity PRTHs. A p-
2734 value threshold was set to $p < 0.001$ and a minimal time extent for each difference was set to 50 ms
2735 (50 samples).

2736 Supplementary results

2737 *Kinematic analyses*

2738 Two-samples t-tests on force level showed a significant difference between PD OFF and HC on the
2739 right (least affected) hand between -84 and 342 ms (relative to response peak), while paired t-tests
2740 showed significant differences between PD OFF and PD ON on the least affected hand between -30
2741 and 484 ms (Supplementary figure 3). The velocity of motor responses was significantly different
2742 between PD OFF and PD ON on the most affected hand between -368 and -278 ms (Supplementary
2743 figure 3). Additionally, correlation analyses were conducted at each time point of the PRTM for
2744 response velocity of PD OFF and the corresponding bradykinesia sub-score for each body part.
2745 Spearman's rank correlation coefficients were used and the same p-value and minimal time extent
2746 thresholds were applied. We found significant negative correlations between response velocity and
2747 bradykinesia sub-score at for the least affected hand in between -286 and -196 ms (Supplementary
2748 figure 3). During this period, Spearman's coefficient was bounded between -0.6798 and -0.7454 (on
2749 average, $\rho = -0.7060$ with a standard deviation of 0.0189). The fact that group differences were
2750 observed on the most affected body side is not surprising, but observing significant correlation
2751 between velocity and bradykinesia only on the least affected body side is relatively puzzling. This
2752 could however be explained by the fact that the least affected body side is the one which yielded the
2753 highest variation in terms of bradykinesia severity, as shown in Supplementary table 4.

2754 *Control analyses*

2755 Handedness as a confounding factor

2756 The subtle difference in IoS estimates between the two hemispheres might be caused by
2757 handedness. Furthermore, the IoS in each ROI could potentially be affected by handedness in a
2758 different way. As shown in Supplementary table 5, this is apparently not the case, as none of the
2759 Pearson's linear correlation coefficients between handedness and IoS estimates were found
2760 significant in any ROI considered (neither before nor after flipping ROIs for the 3 patients affected
2761 mostly on the left).

2762 Head motion as a confounding factor

2763 Although head motion during scanning would most likely affect spatial frequencies of functional
2764 images, IoS estimates might have been biased by a spurious combination of head motion and spatial
2765 smoothing. However, in this specific case we expect a global effect across all ROIs. We calculated
2766 head motion metrics as defined in Van Dijk et al (2012) and estimated Pearson's linear correlation
2767 coefficient between each metric and the average IoS across ROIs. No significant correlation between
2768 IoS and head motion metrics was found as shown in Supplementary table 6.

2769 To further rule out the possibility that head motion might have biased results regarding functional
2770 imaging, we tested whether any head motion metric was significantly different between groups
2771 using two-samples and paired t-tests and although subjects moved substantially during the motor
2772 task, only trends towards significant differences between groups were observed as shown in
2773 Supplementary table 7.

2774 *Prediction of symptoms severity with putaminal and thalamic IoS*

The topography of cortico-subcortical loops in Parkinson's disease

2775 As noted above, none of the results for multiple linear regressions using IoS in the putamen or
2776 thalamus were significant contrarily to the ones obtained using IoS in the SN. Age and gender were
2777 also used as covariates. For IoS in the putamen (contralateral to the most affected body side),
2778 results were as follows: a) for lateralized bradykinesia subcore, $F(4,10) = 0.8$, $p = 0.522$, $R^2 = 0.194$,
2779 adjusted $R^2 = -0.0484$, $RMSE = 2.51$, $\beta = 0.014581$, $t(4,10) = 0.14686$, $p = 0.88616$; b) for lateralized
2780 UPDRS III score, $F(4,10) = 1.25$, $p = 0.342$, $R^2 = 0.273$, adjusted $R^2 = 0.0552$, $RMSE = 3.81$, $\beta =$
2781 0.015577 , $t(4,10) = 0.10341$, $p = 0.91968$; c) for lateralized tremor sub-score, $F(4,10) = 0.703$, $p =$
2782 0.571 , $R^2 = 0.174$, adjusted $R^2 = -0.0735$, $RMSE = 1.43$, $\beta = 0.012666$, $t(4,10) = 0.22332$, $p =$
2783 0.82778 . Regression results for IoS in the thalamus (contralateral to the most affected body side)
2784 were as follows: a) for lateralized bradykinesia subcore, $F(4,10) = 0.798$, $p = 0.523$, $R^2 = 0.193$,
2785 adjusted $R^2 = -0.049$, $RMSE = 2.51$, $\beta = -0.014401$, $t(4,10) = -0.12627$, $p = 0.90202$; b) for lateralized
2786 UPDRS III score, $F(4,10) = 1.83$, $p = 0.206$, $R^2 = 0.354$, adjusted $R^2 = 0.16$, $RMSE = 3.59$, $\beta = 0.18332$,
2787 $t(4,10) = 1.1242$, $p = 0.28718$; c) for lateralized tremor sub-score, $F(4,10) = 1.39$, $p = 0.303$, $R^2 =$
2788 0.294 , adjusted $R^2 = 0.0817$, $RMSE = 1.33$, $\beta = 0.079644$, $t(4,10) = 1.3222$, $p = 0.21555$.

2789

2790 *Supplementary tables*

2791

ROI	Number of voxels	Volume [mm ³]
M1 L	3647	15843.37
M1 R	3975	17268.27
putamen L	1595	6929.03
putamen R	1512	6568.46
SMA L	1237	5373.80
SMA R	1506	6542.39
thalamus L	464	2015.72
thalamus R	475	2063.50
GPe L	210	912.29
GPe R	193	838.43
GPi L	62	269.34
GPi R	67	291.06
SN L	50	217.21
SN R	57	247.62
STN L	21	91.23
STN R	22	95.57

2792

2793 **Supplementary table 1** : number of voxels and volume in mm³ for all ROIs selected for the PCM.

2794

2795

	Coefficient (β)	Standard error	t	p
Intercept	1.091	0.846	1.289	0.226
SN IoS	0.051	0.063	0.821	0.431
Age	0.312	0.386	0.81	0.437
Peak force	-0.501	0.387	-1.3	0.225

2796

2797 **Supplementary table 2** : Results table for the multiple linear regression model in PD OFF with the
 2798 regression equation $tremor \sim Intercept + IoS_{SN} + Age + PeakForce$.

2799

2800

	Coefficient (β)	Standard error	t	p
Intercept	5.585	1.824	3.063	0.012
SN IoS	0.334	0.135	2.477	0.033
Age	0.932	0.8313	1.121	0.289
Peak force	-1.968	0.834	2.361	0.04

2801

2802 **Supplementary table 3** : Results table for the multiple linear regression model in PD OFF with the
 2803 regression equation $UPDRSIII \sim Intercept + IoS_{SN} + Age + PeakForce$.

2804

2805

		Coefficient of variation (σ / μ)	Average
Upper limbs	Least affected	0.662	2.929
	Most affected	0.366	5.857
Lower limbs	Least affected	0.596	1.429
	Most affected	0.394	2.357

2806

2807 **Supplementary table 4** : shows the dispersion and severity of bradykinesia sub-scores per body
 2808 part (most affected vs. least affected) in PD OFF. The least affected hand is associated with the
 2809 highest coefficient of variation of bradykinesia in the studied sample of patients. This may explain
 2810 why correlation analyses between velocity PRTH and bradykinesia sub-scores revealed significant
 2811 relationships only for the least affected hand. On the contrary, results for velocity PRTH revealed by
 2812 group comparisons may be driven by the intensity of bradykinesia, the average of the latter being
 2813 higher on the most affected hand.

2814

2815

	<i>r</i>	<i>p</i>
Left M1 (BA4)	-0.19	0.197
Left SMA	0.13	0.397
Left putamen	-0.01	0.941
Left thalamus	0.13	0.383
Left GPe	0.002	0.989
Left GPi	-0.12	0.432
Left STN	0.04	0.766
Left substantia nigra	-0.05	0.714
Right M1 (BA4)	-0.16	0.287
Right SMA	0.12	0.417
Right putamen	0.05	0.716
Right thalamus	-0.04	0.804
Right GPe	-0.07	0.651
Right GPi	0.09	0.547
Right STN	-0.1	0.503
Right substantia nigra	-0.1	0.483

2816

2817 **Supplementary table 5** : Pearson's *r* between handedness and (unflipped) IoS with associated *p*-
 2818 values.

2819

2820

	<i>r</i>	<i>p</i>
Mean motion	-0.183	0.211
Maximum motion	-0.105	0.479
Number of motions	0.029	0.844
Rotations	0.003	0.984

2821

2822 **Supplementary table 6** : Pearson's *r* between average IoS and head motion metrics and associated
2823 *p*-values

2824

2825

	HC (mean ± std)	PD ON (mean ± std)	PD OFF (mean ± std)	HC vs PD ON (<i>p</i>)	HC vs PD OFF (<i>p</i>)	PD ON vs PD OFF (<i>p</i>)
Mean head motion	0.95 ± 0.41	1.45 ± 1.16	1.19 ± 0.79	0.128	0.147	0.896
Maximum head motion	1.78 ± 0.75	2.42 ± 1.59	2.39 ± 1.59	0.401	0.539	0.713
Number of head motions	189.25 ± 41.09	200.71 ± 34.83	197 ± 26.2	0.05001	0.268	0.455
Head rotations	0.01 ± 0.01	0.01 ± 0.01	0.01 ± 0.01	0.086	0.253	0.069


2826

2827 **Supplementary table 7** : mean and standard deviation (std) for each head motion metric for each
 2828 group and t-tests results (*p*-value) for the comparisons of head motion metrics between groups.

2829

2830 *Supplementary figures*

2831



2832


2833 **Supplementary figure 1:** examples of motor performance recordings of the right and left hands in
 2834 3 subjects (top: HC subject; middle: PD patient ON; bottom: PD patient OFF), with motor responses

The topography of cortico-subcortical loops in Parkinson's disease

2835 detected by the algorithm using event-related moving averages with dynamic threshold. Figure
2836 legend is embedded in each graph.

2837

The topography of cortico-subcortical loops in Parkinson's disease



2838


2839 **Supplementary figure 2:** smoothed histograms (made using Matlab function `ksdensity` with
2840 default parameters) of the distribution of peak force (top graphs) and peak velocity (bottom
2841 graphs), averaged across body parts, across all subjects (left graphs, black) and per group of
2842 subjects (right graphs; light green: HC; light orange: PD ON; dark red: PD OFF). There is trend
2843 suggesting that HC subjects elicit motor responses with the highest force and velocity and PD
2844 patients OFF the lowest, PD patients ON lying in between the two.

2845

2846

2847

The topography of cortico-subcortical loops in Parkinson's disease




2848

2849 **Supplementary figure 3:** Results of the kinematic analyses between groups over the PRTH for
 2850 each limb. Light green: HC; light orange: PD ON; dark red: PD OFF. Top 4 graphs: force differences;

The topography of cortico-subcortical loops in Parkinson's disease

2851 middle 4 graphs: velocity differences; bottom 4 graphs: correlation with severity of bradykinesia in
2852 PD OFF. Dashed lines represent the average force or velocity per group accordingly, and shaded
2853 patches with the corresponding colour represent the standard error around the mean. Shaded grey
2854 rectangles highlight the periods in time yielding prolonged significant results – i.e. all time points
2855 within the grey rectangles show a significant difference between groups or a significant correlation
2856 with symptoms, accordingly. To help visualizing the results, strokes of curves characterizing the
2857 average time course of groups concerned with the significant differences are made thicker.
2858 Statistical threshold was set to $p < 0.01$ with a minimal time extent of 25 time points (50
2859 milliseconds). Regarding correlation analyses (4 graphs on the bottom), the correlation coefficient
2860 within the time period yielding significance was always negative. The average (mean), minimal
2861 (min) and maximal (max) value of Spearman's ρ , as well as its standard deviation (std), is shown in
2862 the appropriate graph.

2863



2864


2865 **Supplementary figure 4:** group results of whole-brain analyses in HC subjects, rendered on a
 2866 canonical T1-weighted image (mni152_2009_256.nii.gz) clipped in three dimensions using
 2867 MRICroGL (Mac OS X version 1.150909). Upper scale legend in the centre applies to all renderings
 2868 except the one in the bottom centre: the red-to-yellow scale represents the F -statistic for hand
 2869 movements while the blue-to-green is the equivalent for feet movements. Bottom centre rendering
 2870 reveals regions where the brain response during the motor somatotopy task correlates with age
 2871 (blue-to-light green (“winter”) scale) or force (black-to-white (“hot”) scale). Bottom right scale
 2872 legend indicates the corresponding F -statistic as before. Statistical maps are overlaid in an additive

The topography of cortico-subcortical loops in Parkinson's disease

2873 manner, i.e. magenta depicts regions where hand and foot representations overlap at the group
2874 level. For display purposes, statistical threshold was set to $p < 0.001$ with a minimal cluster extent
2875 of 10 voxels.

2876

The topography of cortico-subcortical loops in Parkinson's disease





2877

2878 **Supplementary figure 5:** Smoothed histograms (made using Matlab function `ksdensity` with a
2879 bandwidth of 2 samples) showing the distribution of IoS scores per ROI across all subjects. One can
2880 see that even after the r -to- z' Fisher transform, many distributions are skewed and potentially
2881 multimodal, henceforth justifying the use of non-parametric tests. This arises – at least partially –
2882 from the fact that we use the absolute value of z' .



2883

The topography of cortico-subcortical loops in Parkinson's disease

A



B



2884

2885 **Supplementary figure 6:** plots of residuals against fitted values (left graphs) and normality plots
2886 of residuals (right graphs) for the multiple linear regression models performed on bradykinesia
2887 sub-score as a function of IoS in SN (A) and M1-putamen estimates as a function of IoS in putamen
2888 (B).

2889

2890 **2.2.2. Study 3**

2891 In this work, we show that PD is associated with a loss of functional segregation not only at
2892 the BG level but also in the insula, a hub region densely connected to the striatum and with
2893 high susceptibility to degeneration. This study confirms the idea that PD induces a shift of
2894 insular activity from anterior to posterior regions, even in the context of a simple motor
2895 task. Here, DA substitution does not affect functional segregation estimates. This work
2896 highlights the insula as playing a key role in PD.

2897

2898 **Antero-posterior shift of insular cortex activity during motor somatotopy task**
2899 **in Parkinson's disease patients**

2900 Renaud Marquis*¹, Sandrine Muller*¹, Ferath Kherif¹, Bogdan Draganski^{1,2}

2901 *¹ Laboratory of Research in Neuroimaging (LREN) – Department of Clinical Neuroscience,*
2902 *Neuroscience Research Center, Lausanne University Hospital (CHUV), University of Lausanne (UNIL),*
2903 *Lausanne, Switzerland*

2904 *² Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany*

2905

2906 * Authors contributed equally to the work

2907

2908 Running title: PD causes a shift of motor activity in the insula

2909 Title: Antero-posterior shift of insular cortex activity during motor somatotopy task in Parkinson's
2910 disease patients

2911 Abstract: 149

2912 Text body: 2808

2913 References: 28

2914 Tables: 1

2915 Figures: 2

2916 Supplementary material: 1 figure, 2 tables in a separate Excel file

2917

2918 Keywords: Parkinson's disease; functional magnetic resonance imaging; multivariate Bayes; insula

2919

2920 Corresponding author:

2921 Bogdan Draganski

2922 LREN - Département des Neurosciences Cliniques

2923 CHUV, Université de Lausanne

2924 Mont Paisible 16

2925 1011 Lausanne

2926 Switzerland

2927 email: bogdan.draganski@chuv.ch

2928 phone: +41-21-314 9638

2929

2930 **Abstract**

2931 There is mounting evidence about the pivotal role of insula in Parkinson's disease (PD) to suggest a
2932 spatial modulation of brain activity in this region. Using Multivariate Bayes (MVB) and Bayesian
2933 Model Selection (BMS), functional MRI data were decoded in 11 PD patients tested ON and OFF
2934 medication and compared to 20 healthy control (HC) subjects performing the very same externally
2935 paced motor task. We show that in both PD OFF and PD ON the posterior and anterior parts of the
2936 insula are equally predictive of motor activity, in contrast to HC. Further, this shift towards the
2937 posterior part of the insula was observed only while patients were moving limbs on the most
2938 affected body side. Together, these results confirm that functional topography of motor activity in
2939 the insula may be altered in PD, and suggest that the directionality of this shift could be
2940 independent of dopaminergic medication status.

2941

2942 **Introduction**

2943 Recent studies highlight the potential role of the insula in Parkinson's disease (PD) (Christopher et
2944 al., 2014). The insular cortex sends massive projections to the striatum. These are topographically
2945 organised, such that the posterior insula projects to the posterior dorsal striatum and the anterior
2946 insula projects to the more anterior and ventral portions of the striatum. The insula has been
2947 mainly seen as an integrating hub involved in processing emotional, cognitive and visceral
2948 information. Furthermore, this region participates to motor behaviour, as insular activity has been
2949 reported in simple motor tasks (Criaud et al., 2016; Fink et al., 1997; Kurth et al., 2010) and PD
2950 seems to alter connectivity between the insula and the pre-SMA (Chang et al., 2013). The
2951 contribution of the insula in PD recently gained more attention and this growing interest is
2952 supported by the fact that it is one of the first and most affected cortical regions by alpha-synuclein
2953 deposition according to Braak's staging hypothesis (Braak et al., 2006; Christopher et al., 2014).
2954 More recently Criaud and colleagues (2016) used activation likelihood estimation (ALE), a
2955 coordinate-based quantitative meta-analysis approach, and showed that in PD patients,
2956 convergence of activation maxima was differentially located in the insula compared to normal
2957 control subjects, especially when considering cognitive and affective symptoms. Furthermore,
2958 convergence of activation maxima was observed in ventral anterior portions of the insula in PD on
2959 medication, whereas for PD off medication it was more in the dorsal posterior insula. In contrast,
2960 activation maxima generally converged in the left mid-insula and right anterior insula for
2961 sensorimotor function and were not influenced by disease or medication status. Criaud et al. (2016)
2962 acknowledged that ALE, although overcoming typical limitations of neuroimaging studies such as
2963 small sample size or heterogeneity of patient population, does not allow looking at brain activations
2964 per se. The goal of our research was to test for the very presence of a spatial shift of brain activity in
2965 the insula in PD. Although Parkinson's disease is associated with a range of non-motor symptoms
2966 (Burn, 2002; Christopher et al., 2014; Goldman and Litvan, 2011; Kaji and Hirata, 2011; Lieberman,
2967 2006; Voon et al., 2011), it is primarily a movement disorders, therefore our objective was to
2968 examine insular cortex activity during a simple motor task and determine whether PD would
2969 produce a shift of the brain response in space within this region. In this study, we acquired
2970 functional MRI data while normal control subjects and PD patients, tested on and off dopaminergic
2971 medication, performed movements of upper and lower limbs on each body side. We then applied
2972 the multivariate Bayesian decoding scheme proposed by Friston and colleagues (MVB, 2008) that
2973 allows the mapping of brain activity patterns to a psychological variable. The advantage of MVB, in
2974 combination with Bayesian model comparison (Rigoux et al., 2014; Stephan et al., 2009), is that it
2975 provides an appropriate procedure to explicitly test spatial hypotheses by comparing model
2976 evidences, e.g. infer the most plausible model characterizing the way information is distributed in a
2977 brain region (FitzGerald et al., 2012) or compare the contribution of different brain structure
2978 elements in the production of a cognitive process or motor command (Morcom and Friston, 2012;
2979 Park et al., 2015). By separating the insula into an anterior and posterior portions using atlas-based
2980 priors and comparing the model evidences for each insular subregion, we hypothesized, following
2981 Criaud et al. (2016), that PD would be associated with a shift of motor activity in the posterior part
2982 of the insula, henceforth increasing the ability to predict movements from the posterior insula.
2983 Based on results of Criaud and colleagues (2016), we also predicted that dopaminergic medication
2984 would shift insular activity back to the anterior insula.

2985 **Methods**

2986 Participants

2987 Participants in the study comprised 19 PD patients tested on and off dopaminergic medication, as
2988 well as 21 healthy control (HC) subjects. One HC subject presented severe head motion while
2989 scanning and was excluded. Neurologists suspected essential tremor in one patient, leading to the
2990 exclusion of the case. Neurological assessment comprising UPDRS III and IV and performed by 3
2991 neurologists indicated that 5 patients were predominantly affected on the right body side. The
2992 latter cases were not included in the analyses, because flipping data for these patients would have
2993 required assuming that the model evidences decoding movements of right and left limbs have the
2994 same target to predict, which is not the case. The lack of compliance in performing the motor task
2995 led to further exclusion of 2 patients. There remained 11 PD patients (6 men, 5 women; age = 61.19
2996 ± 2.62 standard error, or SEM) and 20 HC subjects (10 men, 10 women; age = 58.75 ± 1.89 SEM) of
2997 comparable age ranges (2-tailed 2-samples t-test, $t(29) = 0.76$; $p = 0.4534$). The Edinburgh
2998 inventory (Oldfield, 1971) indicated comparable handedness scores (L.Q._{PD} = 74.27 ± 18 SEM; L.Q._{HC}
2999 = 55.88 ± 12.52 SEM; 2-tailed 2-samples t-test, $t(29) = 0.8554$, $p = 0.3993$), with 17 right-handed
3000 and 3 left-handed HC subjects, together with 10 right-handed and 1 left-handed PD patients. All
3001 participants gave written informed consent and the local ethics committee approved the study.

3002 Study design

3003 5 patients were scanned first off medication and 6 – on medication. Patients tested off medication
3004 were asked to stop dopaminergic therapy the day before at noon, while they were asked to
3005 continue it as normal when tested on medication. The two scanning sessions were separated by
3006 68.8 ± 16.1 SEM days on average, a time interval which was similar in patients tested first off and
3007 patients first tested on medication (PD_{first OFF} = 63.8 ± 27.87 SEM days; PD_{first ON} = 73 ± 20.6 SEM
3008 days; 2-tailed 2-sample t-tests, $t(9) = 0.2712$; $p = 0.7924$). UPDRS III scores increased when patients
3009 were off medication as compared to on medication (PD OFF = 19.91 ± 2.39 SEM; PD ON = $15.36 \pm$
3010 2.35 SEM; 1-tailed paired t-test: $t(10) = 2.7310$; $p = 0.0106$).

3011 Experimental paradigm

3012 Unilateral grasping movements on the right and left hands and flexion/extension of the right and
3013 left ankle feet were performed during each block, consisting of 8 movements of the same body part.
3014 Flickering visual symbol depicting the body part to move appeared every 2 seconds to pace
3015 movements externally. Blocks were repeated 5 times for each body part, intermixed with equally
3016 numbered rest periods of the same duration, during which a fixation cross was displayed. A
3017 preparation phase informed the subject before each block about the next task to perform, together
3018 with a countdown lasting 3 seconds. Blocks of movements were ordered in a pseudo-random and
3019 balanced fashion. Subjects practiced movements before scanning and were requested to fixate the
3020 centre of the screen.

3021 Behavioural performance monitoring

3022 We used a custom MR-compatible pneumatic device to monitor behavioural performance during
3023 fMRI acquisition. While performing grasping movements, subjects held in each hand rubber balls
3024 connected to air pressure sensors via plastic tubes. To capture feet movements, a similar system
3025 was installed underneath foot pedals. Pressure sensors transduced air pressure into electrical
3026 signal, whose gain was amplified and which was sent to Signal 6 software via a CED MICRO3 1401
3027 (Cambridge Electronic Design Limited) data acquisition unit. The latter digitalized the waveforms
3028 at 500 Hz sampling rate. Motor responses were detected using event-related moving averages with
3029 dynamic threshold adapted from Elgendi et al. (2013). Peak detection on the datasets was
3030 optimized by setting the algorithm parameters as follows: $W_1 = 700$; $W_2 = 3500$; $\beta = 0.35$. The
3031 Butterworth band-pass filter used low- and high-pass cut-off at 0.1 and 30 Hz respectively. The
3032 formulas giving parameters THR_1 and THR_2 were adapted such that $THR_1 = \gamma \cdot MA_{beat}[n] + \alpha$,
3033 where $\gamma = 0.45$, and $THR_2 = \frac{W_1}{4}$. Detected peaks divided motor responses into cued and uncued
3034 movements.

3035 Imaging protocol

3036 We acquired MR images on a Siemens Prisma 3T scanner with a 64-channel head coil, using a 3D
3037 multishot EPI sequence at 2 mm isotropic voxel size (number of volumes: 239; 60 slices; slice TR =
3038 52 ms; volume TR = 3.328 ms; slice oversampling: 6.7%) for functional images. We used
3039 multiparameter mapping (MPM) protocol at 1.5 mm voxel size (FoV 256 x 240 x 176 mm; matrix
3040 size: 160 x 150 x 120) for anatomical imaging, obtaining the longitudinal relaxation rate, effective
3041 proton density, magnetization transfer and effective transverse relaxation rate using multiecho 3D
3042 FLASH sequences. We chose suitable flip angle (α) and repetition time (TR) for mostly proton
3043 density-weighted (PDw) and T1-weighted contrast (PDw: TR/ α = 24.5 ms/6°; T1w: TR/ α = 24.5
3044 ms/21°). As in the study of Lorio and colleagues (2016), we used parallel imaging along the phase-
3045 encoding direction and 8 equidistant echo time to acquire multiple gradient echoes. To correct
3046 quantitative maps for the effects of RF transmit inhomogeneities, a radio frequency transmit field
3047 map was acquired and corrected for geometric distortion and off-resonance effects using a static
3048 magnetic field map.

3049 Image preprocessing

3050 Data processing and analysis was performed using SPM12 (Wellcome Trust Center for
3051 Neuroimaging, <http://www.fil.ion.ucl.ac.uk/spm/>) and Matlab 7.13 (The MathWorks, Inc., Natick,
3052 Massachusetts, United States). Functional images were realigned to the mean, corrected for EPI
3053 distortion and receive coil inhomogeneities, and coregistered to the anatomical image. We built a
3054 study-specific template using DARTEL (Ashburner, 2007), warped functional images to MNI space
3055 with the resulting flow fields and applied spatial smoothing using a Gaussian kernel with full width
3056 at half maximum of 3mm. One healthy control subject was excluded from subsequent analyses
3057 because of an average head motion during functional imaging (Van Dijk et al., 2012) above 5mm.

3058 Within-subject whole-brain univariate fMRI analyses

3059 The design matrix for fMRI modelling comprised motor responses peak for cued and uncued
3060 movements as identified by the peak detection algorithm. We modelled preparation periods as

3061 epochs of 3 seconds and included realignment parameters as covariates. Contrasts for positive
3062 effects of each cued movement (right and left hand and foot) were tested. Furthermore, we tested
3063 the effects of moving right and left limbs in 2 separate F-contrasts.

3064 Group-level whole-brain univariate fMRI analysis

3065 We performed a random effects analysis with contrasts for the positive effects of each cued
3066 movement at the group level to verify the presence of motor activity in the insula across all groups
3067 of subjects.

3068 Regions of interest

3069 Regions of interest (ROIs) for the left and right anterior and posterior insula were defined using the
3070 atlas provided by Neuromorphometrics, Inc. (<http://neuromorphometrics.com/>) under academic
3071 subscription and originating from the OASIS project (<http://www.oasis-brains.org/>).

3072 Canonical Variate Analysis

3073 To confirm the existence of a multivariate mapping between the voxels and the movements to
3074 predict, we performed canonical variate analysis (CVA) for each body part movement within each
3075 ROI (Friston et al., 1995).

3076 Multivariate Bayesian decoding

3077 We applied multivariate Bayes (MVB) (Friston et al., 2008) at the subject-level to predict the
3078 movements of right and left limbs in separate analyses. The model log-evidences were assessed for
3079 4 candidate models – one for each ROI within the insula. Given the complex topography of brain
3080 functions in the insula, sparse spatial priors over voxels were used in each ROI, such that each
3081 activity pattern is composed of subsets of individual voxel without neither assuming that the latter
3082 should be neighbouring nor that the patterns should follow a smooth Gaussian response. The same
3083 design matrix was used for each MVB analyses aiming at predicting the movement of right and left
3084 limbs. Therefore, for each decoding analysis, the movements of body parts other than the predicted
3085 targets, as well as preparation periods and realignment parameters constituted the space of
3086 confounding variables that were accounted for.

3087 Bayesian Model Selection

3088 First, we combined the anterior and posterior portions of the insula to obtain two families of
3089 models: the contralateral family of models predicted the movements of right and left limbs using
3090 the left – respectively right – insula, and vice versa for the ipsilateral family of models. Family-level
3091 inference based on model space partitioning (`spm_compare_families.m`) was performed to compare
3092 these two families of models using fixed and random effects Bayesian model comparison at the
3093 group level (Penny et al., 2010; Stephan et al., 2010). Secondly, as the elected family of models was
3094 the contralateral one, we performed random effects Bayesian model selection (BMS, `spm_BMS.m`)
3095 at the group level (Rigoux et al., 2014) between the contralateral anterior and posterior parts of the
3096 insula in predicting right and left limbs movements in each group of subjects. Group Bayes Factors
3097 (Stephan et al., 2009), computed as the sum of log-evidences across subjects, were also reported.

3098 **Results**

3099 Whole-brain univariate analyses

3100 Reliable patterns of motor-related brain activity were found in the insula. Clusters of active voxels
3101 surviving FWE-correction were present in all ROIs as shown by an F-test on all movements across
3102 all groups (Figure 1, detailed results table is available as supplementary material).

3103 CVA

3104 We observed significant mappings in each ROI for the movement of each body part across all
3105 groups ($p < 0.001$, except for predicting right hand movements using the right posterior insula for
3106 which $p = 0.00333$).

3107 MVB

3108 Across all subjects and ROIs, 99.4 – respectively 100% – of the negative free energy approximation
3109 to the model log-evidences produced by MVB for predicting movements of right – respectively left –
3110 limbs had a Bayes Factor above 20, denoting strong evidence in favour of the alternative hypothesis
3111 against the null model. There was only one model predicting movements of right limbs for which
3112 the Bayes Factor against the null model was equal to 7.4102.

3113 BMS: comparison of contralateral and ipsilateral families of models

3114 Fixed effects BMS revealed that contralateral families of model were strongly more predictive than
3115 ipsilateral ones. Posterior probabilities were equal to 1 and 0 for contralateral – respectively
3116 ipsilateral – families of models for right as well as left limbs movements. Random effects BMS
3117 endorsed these results with identical posterior probabilities except for right limbs movements, for
3118 which exceedance probabilities were 0.98 and 0.02 for contralateral and ipsilateral families of
3119 models respectively (Supplementary figure 1).

3120 BMS: comparison of anterior and posterior models

3121 Group Bayes Factors indicated a bigger discrepancy between anterior and posterior insula models
3122 in HC as compared to PD patients (Table 1). Random effects BMS confirmed this observation,
3123 electing the anterior insula as the most predictive model in HC, but not in PD patients. More
3124 specifically, the anterior insula was the winning model in all analyses except for predicting the
3125 movement of left limbs in PD patients, both ON and OFF medication (Figure 2).

3126 **Discussion**

3127 Using MVB and BMS, we first showed that the contralateral insula better predicts the movements of
3128 upper and lower limbs as compared to the ipsilateral insula. We then demonstrated that the elected
3129 model to predict externally cued movements in normal control subjects was the anterior insula.
3130 Because Neuromorphometrics atlas divides the insula into a posterior and anterior region, the
3131 sensorimotor part of this region – i.e. the mid-insula – lies primarily in the anterior ROIs (Criaud et
3132 al., 2016; Fink et al., 1997; Kurth et al., 2010). This might explain why the latter ROIs were more
3133 predictive than the posterior ROIs. In contrast to HC subjects, we showed that in PD patients the

3134 anterior and posterior insular cortex are equally contributing in the execution of movements. Our
3135 results suggest a shift of motor activity in the insula to the posterior part, similarly to the results of
3136 Criaud and colleagues (2016) who reported a comparable shift of insular activity associated with
3137 cognitive and affective symptoms. The latter study did not report differential loci for the
3138 convergence of activation maxima related to sensorimotor function. Assuming that the definition of
3139 insula subregions we used separated the anterior and posterior portions in a sufficiently accurate
3140 fashion, the reason we found different results for PD patients and normal controls might lie in the
3141 outstanding sensitivity of MVB (Friston et al., 2008). Nevertheless, in contradiction with ALE
3142 results, dopaminergic medication was not found to reverse the location of brain activity back to the
3143 anterior insula, neither bringing it back to the mid-insula, nor bringing it further anteriorly. This
3144 could suggest that contrary to cognitive and limbic function, insular activity patterns related to
3145 sensorimotor function are not affected by dopaminergic medication. Our results suggest therefore
3146 that the posterior insula may be involved in a mechanism of compensation in PD, mirroring the
3147 caudorostral gradient of progressive nigrostriatal denervation (Cools, 2006; Vaillancourt et al.,
3148 2013). Interestingly, dopaminergic medication seems to neither reverse nor cancel this process in
3149 the insular cortex. Altogether, our study provides evidence for a loss of functional segregation in the
3150 insular cortex in PD: the antero-posterior gradient of response selectivity in the insula, seen in
3151 normal controls, seems to be lost in PD; such that both the anterior and posterior insula are
3152 involved in the movement of distal body parts. Given the importance of the insula as an integrating
3153 hub massively connected to the striatum and other cortical regions, future investigations might use
3154 multivariate methods and examine in detail whether the loss of segregation caused by PD in the
3155 insula can be detected in other fMRI tasks – extending to other brain functions such as attentions or
3156 reward –, if it occurs also in patients mostly affected on the right body side – or affected bilaterally –
3157 , and whether other neurological disorders are also associated with a loss of functional segregation.

3158

3159 **References**

- 3160 Braak, H., Bohl, J.R., Müller, C.M., Rüb, U., de Vos, R.A.I., and Del Tredici, K. (2006). Stanley Fahn
3161 Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic
3162 Parkinson's disease reconsidered. *Mov. Disord.* *21*, 2042–2051.
- 3163 Burn, D.J. (2002). Depression in Parkinson's disease. *Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc.* *9*
3164 *Suppl 3*, 44–54.
- 3165 Chang, L.J., Yarkoni, T., Khaw, M.W., and Sanfey, A.G. (2013). Decoding the Role of the Insula in
3166 Human Cognition: Functional Parcellation and Large-Scale Reverse Inference. *Cereb. Cortex* *23*,
3167 739–749.
- 3168 Christopher, L., Koshimori, Y., Lang, A.E., Criaud, M., and Strafella, A.P. (2014). Uncovering the role
3169 of the insula in non-motor symptoms of Parkinson's disease. *Brain* *137*, 2143–2154.
- 3170 Cools, R. (2006). Dopaminergic modulation of cognitive function-implications for L-DOPA treatment
3171 in Parkinson's disease. *Neurosci. Biobehav. Rev.* *30*, 1–23.
- 3172 Criaud, M., Christopher, L., Boulinguez, P., Ballanger, B., Lang, A.E., Cho, S.S., Houle, S., and Strafella,
3173 A.P. (2016). Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. *Hum.*
3174 *Brain Mapp.* *37*, 1375–1392.
- 3175 Elgendi, M., Norton, I., Brearley, M., Abbott, D., and Schuurmans, D. (2013). Systolic Peak Detection
3176 in Acceleration Photoplethysmograms Measured from Emergency Responders in Tropical
3177 Conditions. *PLoS ONE* *8*, e76585.
- 3178 Fink, G.R., Frackowiak, R.S., Pietrzyk, U., and Passingham, R.E. (1997). Multiple nonprimary motor
3179 areas in the human cortex. *J. Neurophysiol.* *77*, 2164–2174.
- 3180 FitzGerald, T.H.B., Friston, K.J., and Dolan, R.J. (2012). Action-Specific Value Signals in Reward-
3181 Related Regions of the Human Brain. *J. Neurosci.* *32*, 16417–16423.
- 3182 Fonov, V., Evans, A.C., Botteron, K., Almli, C.R., Mckinstry, R.C., Collins, D.L., and the Brain
3183 Development Cooperative Group (2011). Unbiased average age-appropriate atlases for pediatric
3184 studies. *NeuroImage* *54*, 313–327.
- 3185 Fonov, V.S., Evans, A.C., McKinstry, R.C., Almli, C.R., and Collins, D.L. (2009). Unbiased nonlinear
3186 average age-appropriate brain templates from birth to adulthood. *NeuroImage* *47*, *Supplement 1*,
3187 S102-.
- 3188 Friston, K., Chu, C., Mourão-Miranda, J., Hulme, O., Rees, G., Penny, W., and Ashburner, J. (2008).
3189 Bayesian decoding of brain images. *NeuroImage* *39*, 181–205.
- 3190 Friston, K.J., Frith, C.D., Frackowiak, R.S., and Turner, R. (1995). Characterizing dynamic brain
3191 responses with fMRI: a multivariate approach. *NeuroImage* *2*, 166–172.
- 3192 Goldman, J.G., and Litvan, I. (2011). Mild cognitive impairment in Parkinson's disease. *Minerva Med.*
3193 *102*, 441.

The topography of cortico-subcortical loops in Parkinson's disease

- 3194 Kaji, Y., and Hirata, K. (2011). Apathy and Anhedonia in Parkinson's Disease. *ISRN Neurol.* 2011, 1-9.
3195
- 3196 Kurth, F., Zilles, K., Fox, P.T., Laird, A.R., and Eickhoff, S.B. (2010). A link between the systems:
3197 functional differentiation and integration within the human insula revealed by meta-analysis. *Brain*
3198 *Struct. Funct.* 214, 519-534.
- 3199 Lieberman, A. (2006). Depression in Parkinson's disease - a review. *Acta Neurol. Scand.* 113, 1-8.
- 3200 Lorio, S., Kherif, F., Ruef, A., Melie-Garcia, L., Frackowiak, R., Ashburner, J., Helms, G., Lutti, A., and
3201 Draganski, B. (2016). Neurobiological origin of spurious brain morphological changes: A
3202 quantitative MRI study. *Hum. Brain Mapp.* 37, 1801-1815.
- 3203 Morcom, A.M., and Friston, K.J. (2012). Decoding episodic memory in ageing: A Bayesian analysis of
3204 activity patterns predicting memory. *NeuroImage* 59, 1772-1782.
- 3205 Oldfield, R.C. (1971). The assessment and analysis of handedness: the Edinburgh inventory.
3206 *Neuropsychologia* 9, 97-113.
- 3207 Park, C., Chang, W.H., Lee, M., Kwon, G.H., Kim, L., Kim, S.T., and Kim, Y.-H. (2015). Which motor
3208 cortical region best predicts imagined movement? *NeuroImage* 113, 101-110.
- 3209 Penny, W.D., Stephan, K.E., Daunizeau, J., Rosa, M.J., Friston, K.J., Schofield, T.M., and Leff, A.P. (2010).
3210 Comparing Families of Dynamic Causal Models. *PLoS Comput. Biol.* 6, e1000709.
- 3211 Rigoux, L., Stephan, K.E., Friston, K.J., and Daunizeau, J. (2014). Bayesian model selection for group
3212 studies - Revisited. *NeuroImage* 84, 971-985.
- 3213 Stephan, K.E., Penny, W.D., Daunizeau, J., Moran, R.J., and Friston, K.J. (2009). Bayesian model
3214 selection for group studies. *NeuroImage* 46, 1004-1017.
- 3215 Stephan, K.E., Penny, W.D., Moran, R.J., den Ouden, H.E.M., Daunizeau, J., and Friston, K.J. (2010). Ten
3216 simple rules for dynamic causal modeling. *NeuroImage* 49, 3099-3109.
- 3217 Vaillancourt, D.E., Schonfeld, D., Kwak, Y., Bohnen, N.I., and Seidler, R. (2013). Dopamine overdose
3218 hypothesis: Evidence and clinical implications. *Mov. Disord.* 28, 1920-1929.
- 3219 Van Dijk, K.R.A., Sabuncu, M.R., and Buckner, R.L. (2012). The influence of head motion on intrinsic
3220 functional connectivity MRI. *NeuroImage* 59, 431-438.
- 3221 Voon, V., Mehta, A.R., and Hallett, M. (2011). Impulse control disorders in Parkinson's disease. *Curr.*
3222 *Opin. Neurol.* 24, 324-330.
- 3223

3224 **Tables**


3225

	Limbs	ROI	HC	PD ON	PD OFF
Summed log-evidences	Right	AIns L	1742.185	699.811	718.318
		PIns L	1140.434	481.939	509.186
	Left	AIns R	1876.741	658.539	726.991
		PIns R	1324.545	543.841	569.339
Exceedance probabilities	Right	AIns L	0.999	0.984	0.994
		PIns L	0.001	0.016	0.006
	Left	AIns R	1.000	0.784	0.759
		PIns R	0.000	0.216	0.241
Protected exceedance probabilities	Right	AIns L	0.973	0.872	0.929
		PIns L	0.027	0.128	0.071
	Left	AIns R	0.998	0.591	0.579
		PIns R	0.002	0.409	0.421
Bayesian omnibus risk	Right	Ins L	0.052	0.231	0.132
	Left	Ins R	0.004	0.679	0.696

3226 **Table 1** : summary of BMS comparing anterior and posterior insula models for each group of
 3227 subjects and for movements of each body side. AIns L: left anterior insula; AIns R: right anterior
 3228 insula; PIns L: left posterior insula; PIns R: right posterior insula.

3229

3230 **Figures**
 3231




3232

3233 **Figure 1**: whole-brain univariate group results overlaid on a skull-stripped canonical image
 3234 (Fonov et al., 2011, 2009), showing clusters of voxels significantly active ($p < 0.001$, minimal cluster
 3235 extent of 10 voxels) during limbs movement across all groups of subjects. Insular cortex subregions

The topography of cortico-subcortical loops in Parkinson's disease

3236 are delineated in different colors: red = left anterior insula; yellow = right anterior insula; green =
3237 left posterior insula; magenta = right posterior insula. L = left ; R = right ; A = anterior ; P =
3238 posterior.

The topography of cortico-subcortical loops in Parkinson's disease




3239

3240 **Figure 2** : BMS results comparing anterior and posterior portions of the contralateral insula for
3241 each group. ROIs are rendered (centre) on a skull-stripped canonical image (Fonov et al., 2011,
3242 2009) following neurological convention. Protected exceedance probabilities are represented with
3243 bar plots right and left from the center for left and right limb movements respectively. Colour of bar
3244 plots corresponds to ROI colour. AIns L: left anterior insula; AIns R: right anterior insula; PIns L:
3245 left posterior insula; PIns R: right posterior insula.

3246

3247 **Supplementary figures**

3248



3249

3250 **Supplementary figure 1** : fixed and random effects BMS results comparing contralateral and
 3251 ipsilateral families of models. Bar plots on the top represent each model's posterior probabilities
 3252 and exceedance probabilities. Bottom graphs show the elected family for left and right limbs
 3253 movements. Color code is the same as in Figure 2. Alns L: left anterior insula; Alns R: right anterior
 3254 insula; Plns L: left posterior insula; Plns R: right posterior insula.
 3255

3256 **2.3. Structural segregation in Parkinson's disease**

3257 **2.3.1. Study 4**

3258 In this study, we test the LOS hypothesis in PD at the structural connectivity level. This
3259 experiment shows that limbic, associative and sensorimotor circuits are rewired across
3260 cortico-striatal and thalamo-cortical level in PD. In addition, different clinical symptoms
3261 profiles in patients are associated with distinct changes in structural connectivity patterns.
3262 This work provides the first evidence supporting the LOS hypothesis in PD at the structural
3263 level.

3264

3265 **Parkinson's disease rewires cortico-striatal and thalamo-cortical connectivity**

3266 Renaud Marquis*¹, David A. Slater*¹, Ferath Kherif¹, Bogdan Draganski^{1,2}

3267 ¹ *Laboratory of Research in Neuroimaging (LREN) – Department of Clinical Neuroscience,*
3268 *Neuroscience Research Center, Lausanne University Hospital (CHUV), University of Lausanne (UNIL),*
3269 *Lausanne, Switzerland*

3270 ² *Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany*

3271

3272 * Authors contributed equally to the work

3273

3274 Running title: PD rewires cortico-subcortical connectivity

3275 Title: Parkinson's disease rewires cortico-striatal and thalamo-cortical connectivity

3276 Abstract: 125

3277 Text body: 4378

3278 References: 71

3279 Tables: 1

3280 Figures: 6

3281 Supplementary material: 9 figures, 5 tables in a separate Excel file

3282

3283 Keywords: Parkinson's disease; diffusion-weighted imaging; tractography; segregation; cognition;
3284 motivation; sensorimotor

3285

3286 Corresponding author:

3287 Bogdan Draganski

3288 LREN - Département des Neurosciences Cliniques

3289 CHUV, Université de Lausanne

3290 Mont Paisible 16

3291 1011 Lausanne

3292 Switzerland

3293 email: bogdan.draganski@chuv.ch

3294 phone: +41-21-314 9638

3295 **Abstract**

3296 Given the steadily growing number of studies demonstrating that diffusion tractography can reveal
3297 the topography of cortico-basal ganglia connectivity patterns in vivo in humans we aim to test the
3298 loss of specificity hypothesis in movement disorders at the structural level. We propose here that
3299 Parkinson's disease (PD) is associated with remapping of cortico-striatal and thalamo-cortical
3300 connectivity between limbic, associative and sensorimotor territories. Using constrained spherical
3301 deconvolution, we compare covariance components of connectivity patterns in 19 healthy control
3302 subjects and 19 PD patients, and show how the spatial distribution of these connections relate to
3303 clinical symptoms. Our results demonstrate that PD affects structural segregation in the striatum
3304 and thalamus, and that different profiles of clinical manifestations are linked to specific patterns of
3305 rewiring in cortico-subcortical loops.
3306

3307 **Introduction**

3308 Parkinson's disease (PD), the second most common neurodegenerative disease, is caused by the
3309 loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). Its cardinal symptoms
3310 are slowness and poverty of movements, muscle rigidity, postural instability and rest tremor.
3311 However PD features also a range of non-motor symptoms including apathy (Kaji and Hirata, 2011),
3312 depression (Burn, 2002; Lieberman, 2006), anxiety (Marsh, 2000), cognitive impairment (Goldman
3313 and Litvan, 2011), impulse control disorders (Sharma et al., 2013; Voon et al., 2009, 2011),
3314 hyposmia (Sharma et al., 2013), sleep disorders (Sharma et al., 2013), dementia (Munhoz et al.,
3315 2015), psychosis (Munhoz et al., 2015), pain, gastrointestinal and autonomic disturbances (Sethi,
3316 2002). Based on these various manifestations, some studies suggested different subtypes of PD
3317 (Marras and Chaudhuri, 2016; Moustafa and Poletti, 2013).

3318 Dopaminergic cells in the SNc project to the striatum, the main input station of the basal ganglia.
3319 The functional architecture of the latter notably involves limbic, associative and motor circuits
3320 (Jahanshahi et al., 2015). Dopamine, together with striatal interneurons, modulate the structure
3321 and function of striatal circuitry through different mechanisms of synaptic plasticity (Calabresi et
3322 al., 2007; Lim et al., 2014; Morikawa and Paladini, 2011; Obeso et al., 2008; Surmeier et al., 2010).
3323 Within cortico-basal ganglia circuits, segregation (Alexander et al., 1986; Redgrave et al., 2010) and
3324 integration (Haber, 2003; Haber et al., 2000) of information seem to coexist (Draganski et al., 2008).

3325 Recent evidences suggest that PD and other movement disorders are associated with a loss of
3326 neuronal specificity in the basal ganglia (Bar-Gad and Bergman, 2001; Bar-Gad et al., 2000, 2003;
3327 Bronfeld and Bar-Gad, 2011). Studies in non-human primates showed a loss of functional
3328 segregation following MPTP intoxication (Pessiglione et al., 2005), and recent studies in humans
3329 report that dopamine depletion in PD could lead to a remapping of cortico-striatal circuitry
3330 (Helmich et al., 2010). More recently, abnormal patterns of structural connectivity have been
3331 observed in Gilles de la Tourette syndrome (Worbe et al., 2015). While the value of diffusion-
3332 weighted imaging (DWI) in detecting alterations of white matter integrity in PD (Tessitore et al.,
3333 2016) and in differentiating PD from atypical parkinsonism (Meijer et al., 2013) has been
3334 acknowledged, there is currently no study addressing the question of segregation of structural
3335 connectivity in PD.

3336 The goal of our research was therefore to test whether PD was associated with a loss of segregation
3337 in structural connectivity patterns within cortico-subcortical circuits. We hypothesized that PD
3338 affects the segregation of cortico-striatal and thalamo-cortical circuits into limbic, associative and
3339 motor functions. First, we used spherical deconvolution – an advanced diffusion tractography
3340 technique that has shown more sensitivity than DTI-based tractography detecting fibre pathways in
3341 the motor system (Farquharson et al., 2013) –, built an Index of Similarity to quantify structural
3342 segregation between connectivity patterns, and compared PD patients to healthy volunteers.
3343 Secondly, because motor symptoms in PD are initially unilateral, we estimated structural
3344 segregation with patients divided into right- and left-affected. Thirdly, we aimed at finding whether
3345 different profiles of clinical symptoms could be linked to different patterns of structural
3346 segregation.

3347 **Methods**

3348 *Participants*

3349 32 patients and 27 healthy control (HC) subjects participated in the study after giving written
3350 informed consent. 3 patients were excluded because of diagnostic criterion (suspicion of essential
3351 tremor, multiple system atrophy and Alzheimer's disease) and one because of incomplete
3352 neuropsychological tests. Of the remaining 55 datasets, 10 were excluded because of bad image
3353 quality, head motion artefacts, gross tissue misclassifications in cortical targets for the
3354 tractography, or failures of spatial registration algorithms. There remained 19 patients passing data
3355 quality visual check done by R.M. and D.S. Among the remaining 26 HC subjects, the 19 oldest
3356 volunteers were selected to obtain balanced groups with comparable age ranges (age PD: $64.47 \pm$
3357 1.74 standard error, or SEM; age HC: 62.89 ± 1.56 SEM; 2-tailed 2-sample t-test, $t(36) = 0.6748$, $p =$
3358 0.57709).

3359

3360 *Clinical measures*

3361 Neurological assessment comprised Unified Parkinson's Disease Rating Scale (UPDRS) parts III and
3362 IV. Three neurologists additionally scored the patients' Hoehn and Yahr stage and assigned 11
3363 patients as predominantly affected on the left body side and 8 – on the right, consistently with their
3364 lateralized bradykinesia subscore (Buck et al., 2011). Age ranges were similar across patients
3365 affected on each side (age PD L: 62.27 ± 1.87 ; age PD R: 67.5 ± 1.36) and with healthy volunteers (p
3366 > 0.05 for all pairwise-comparisons using 2-tailed 2-sample t-tests). Neuropsychological
3367 assessment was carried out by the experimenter and included the Montreal Cognitive Assessment
3368 (MoCA; Nasreddine et al., 2005), the self-assessment part of the Apathy Inventory (Robert et al.,
3369 2002) and the Hospital Anxiety and Depression scale (HADS; Zigmond and Snaith, 1983). MoCA
3370 scores were binarised with a cut-off at < 26 to maximise the distinction between patients with and
3371 without mild cognitive impairment (Dalrymple-Alford et al., 2010).

3372

3373 *MRI acquisition*

3374 We collected MRI data on a 3T Prisma MRI scanner (Siemens Medical Solutions, Erlangen,
3375 Germany). The diffusion-weighted images (DWI) were acquired using a 2D echo-planar imaging
3376 sequence with the following parameters: TR/TE = 7420/69ms, parallel GRAPPA acceleration factor
3377 = 2, FOV = 192 x 212 mm², matrix size = 96 x 106, 70 axial slices, 2 mm isotropic voxel dimension,
3378 118 diffusion sensitization directions (15 at $b = 650$ s/mm², 30 at $b = 1000$ s/mm² and 60 at $b =$
3379 2000 s/mm²) and 13 $b=0$ images interleaved throughout the acquisition. Diffusion directions were
3380 isotropically distributed for each b -value shell using an electrostatic repulsion algorithm (Jones et
3381 al., 1999). We acquired multiparameter maps (MPM) at 1.5 mm voxel size using multiecho 3D
3382 FLASH acquisitions to get quantitative mapping of the magnetization transfer, effective proton
3383 density, longitudinal and effective transverse relaxation rate (FoV: 256 x 240 x 176 mm; matrix
3384 size: 160 x 150 x 120mm). Predominantly T1-weighted and proton density-weighted (PDw)
3385 contrasts were obtained by choosing appropriate repetition time (TR) and flip angle (α) (T1w:

3386 TR/ α = 24.5 ms/21°; PDw: TR/ α = 24.5 ms/6°) as in Lorio and colleagues (2016). We acquired
3387 multiple gradient echoes using 8 equidistant echo times and parallel imaging along the phase-
3388 encoding direction. Quantitative maps were corrected for radio frequency (RF) transmit
3389 inhomogeneities using a RF transmit field (B1) map, whose geometric distortions and off-resonance
3390 effects were removed by acquiring a static magnetic field (B0) map (Lutti et al., 2010, 2012).

3391

3392 MPM preprocessing

3393 Each participant's MT image was processed using the FreeSurfer version 5.3.0 software package
3394 pipeline (<http://surfer.nmr.mgh.harvard.edu/>). The standard pipeline reconstructs an individual's
3395 cortical and white matter surfaces from the participant's structural image data. The following steps
3396 comprise the surface preprocessing pipeline: correction of image intensity variations due to MR
3397 inhomogeneities (Dale et al., 1999); skull stripping (Ségonne et al., 2004); cortical grey and white
3398 matter segmentation (Dale et al., 1999); separation of the brain hemispheres and subcortical
3399 structures (Dale et al., 1999; Fischl et al., 2002, 2004); and finally a set of grey/white matter
3400 interface and pial surfaces for both brain hemispheres (Dale et al., 1999). After surface
3401 reconstruction the individual participant's surfaces were used to estimate the transformation
3402 which achieved maximal correspondence between the sulcal and gyral patterns of the individual
3403 and those of an average brain (Fischl et al., 1999a, 1999b). This information was later used to bring
3404 a gyri based cortical parcellation (Desikan et al., 2006) into each individual's native image space.

3405

3406 DWI preprocessing

3407 DWIs were corrected for eddy currents and subject motion using the FSL EDDY tool (Andersson
3408 and Sotiropoulos, 2016) and the gradient directions were appropriately rotated to correct for
3409 subject movement (Leemans and Jones, 2009). The B0 maps acquired as part of the structural
3410 imaging session were used to correct for EPI susceptibility distortions with the SPM field mapping
3411 toolbox (Hutton, 2002). The DWI images were then rigid body aligned to the MT image with the aid
3412 of the mean $b=0$ image using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/software/spm12>).

3413

3414 Tractography

3415 All processing procedures described within this section were performed using the MRTrix3
3416 software package (www.mrtrix.org; Tournier et al., 2012). The constrained spherical deconvolution
3417 (CSD; Tournier et al., 2004, 2007) FODs were calculated using a multi-shell, multi-tissue CSD
3418 (MSMT-CSD) algorithm which has been shown to reduce the presence of spurious fODF peaks in
3419 voxels containing GM and/or CSF partial volumes (Jeurissen et al., 2014). The spherical harmonic
3420 degrees used for the WM multi-shell fibre response functions were $l_{max} = [0, 2, 6, 10]$ for each b -
3421 value shell respectively. GM and CSF response functions were assumed to be isotropic with $l_{max} = 0$
3422 for each shell. All tractography streamline reconstructions were made using the probabilistic 2nd-
3423 order Integration over Fibre Orientation Distributions (iFOD2) algorithm (Tournier et al., 2010) in
3424 conjunction with the ACT framework (Smith et al., 2012). The following parameters were used for
3425 streamline tracking of each study participant: step size 1 mm, maximum curvature per step 45°,

3426 length 5-250 mm, FOD amplitude threshold 0.1. Subcortical seed regions comprised the caudate,
3427 putamen and thalamus, based on the Harvard-Oxford atlas provided with FSL. To keep the caudate
3428 and putamen as separate ROIs, voxels in the nucleus accumbens were not considered. For each
3429 subcortical seed, tractography was run with a seeding density of 51'653 streamlines per voxel.
3430 Streamlines were projected unidirectionally and accepted if they reached an ipsilateral cortical
3431 mask, defining all cortical areas of the corresponding hemisphere as potential targets. We selected a
3432 set of cortical targets, identified using Desikan-Killiany atlas (Desikan et al., 2006), and grouped
3433 them into sensorimotor (paracentral, postcentral and precentral gyrus), associative (caudal and
3434 rostral middle frontal gyrus) and limbic areas (caudal anterior cingulate gyrus, lateral and medial
3435 orbitofrontal gyrus), similarly to Draganski, Kherif and colleagues (2008). The superior frontal
3436 gyrus was not considered as a target because it comprised the supplementary motor area, making it
3437 difficult to attribute the region to the sensorimotor or associative group. Only the subset of fibres
3438 terminating in these cortical locations was included in further analysis. Because subsequent needed
3439 the data to be in the same anatomical space, SPM routines used the flow fields estimated by
3440 DARTEL to warp images indicating the number of tracts connected to each group of cortical areas
3441 into MNI space using nearest neighbour interpolation. For display purposes, an additional
3442 tractography was generated in one participant with 100 tracks per voxel by using the exact same
3443 processing constraints.

3444 Structural segregation

3445 We defined structural segregation as the presence of topographically organized connectivity
3446 patterns to the different groups of cortical targets. More specifically, let v be the total number of
3447 voxels in a seed ROI r , and let i and j be two sets of voxels in r such that $i \cap j = \emptyset$ and $i \cup j = U$
3448 where U is the set comprising all v voxels in r . If according to the tractography results, two sets of
3449 voxels i and j in r are connected specifically to different cortical areas, i.e. target t_1 (e.g. limbic) and
3450 respectively target t_2 (e.g. associative), patterns of connectivity for t_1 and t_2 in r are segregated. This
3451 ideal case of segregation can be extended to three targets, such that three different sets of voxels i, j
3452 and k are specifically connected to t_1 (e.g. limbic), t_2 (e.g. associative) and t_3 (e.g. sensorimotor)
3453 respectively (Figure 1A). Again, sets of voxels i, j and k would be mutually exclusive, such that $i \cap$
3454 $j = \emptyset, i \cap k = \emptyset, j \cap k = \emptyset$ and $i \cup j \cup k = U$. If one set of voxels, e.g. j , is not only connected to
3455 target t_2 but also to t_3 , and to a lesser extent to t_1 , then connectivity patterns are less segregated
3456 (Figure 1B). One can then imagine a situation in which patterns are even less segregated, e.g. the set
3457 of voxels j is equally connected to all targets, and other sets of voxels are also connected to multiple
3458 targets (Figure 1C). Consequently, when connectivity patterns are segregated, voxel-wise
3459 correlation between the number of connections for each target should be low, whereas it should be
3460 high when patterns are overlapping.

3461 Pattern component modelling

3462 To quantify structural segregation as defined above, we used the pattern component model (PCM;
3463 Diedrichsen et al., 2011). Some notable advantages of this method are its robustness to noise and
3464 that it does not require that all voxels in the ROI contain an informative signal (Diedrichsen et al.,
3465 2011). We therefore used the PCM in each seed region to assess the similarity between
3466 representations of limbic, associative and sensorimotor connections. This method extends

3467 representational similarity analysis (RSA; Kriegeskorte, 2008; Nili et al., 2014) by estimating the
3468 variance and covariance associated with pattern components and accounting for possible noise in
3469 the signal. Using the PCM, if for example two patterns are similar in their distribution over voxels
3470 but the signals are noisier in one brain region as compared to another, the coefficients of
3471 correlation – i.e. similarity – between the two patterns will remain similar (Diedrichsen et al.,
3472 2011). This method has been previously applied on regression coefficients estimated from
3473 functional MRI data, but there is essentially no reason to restrict its use to brain activity data.
3474 Images containing the number of connections to the different cortical targets at each voxel, once
3475 normalised to a standardised space, can be treated as brain activity maps if the aim is to measure
3476 the similarity between patterns distributed over voxels. With brain activity data, the regression
3477 coefficient at each voxel indicates the relationship with each psychological variable that is
3478 manipulated in the experimental paradigm, while with tractography results, each voxel denotes the
3479 number of successful connections to each group of cortical targets. Although specifying shared
3480 variance between patterns can be useful under some circumstances, no constraint on the variance-
3481 covariance matrix was imposed in the PCM analyses we performed. Three two-factors (TARGET x
3482 GROUP) PCM were performed to estimate the similarity between groups of cortical targets for each
3483 group of subjects. The first divided subjects in two groups: PD patients and HC subjects. The second
3484 further split patients into left- (PD L, n = 11) and right-affected (PD R, n = 8) (see Clinical measures).
3485 The last separated patients according to their profile of clinical symptoms (see Clustering of
3486 patients based on clinical symptoms).

3487 Index of Similarity

3488 Correlation coefficients between connectivity patterns obtained using PCM were transformed using
3489 the Fisher r-to-z' transform as described in Sanabria-Diaz and colleagues (2013). In order to
3490 measure segregation between patterns, we defined the Index of Similarity as follows:

$$3491 \quad IoS = |\tanh^{-1}(r)|$$

3492 Such that highly segregated patterns produce low *IoS* values, and overlapping patterns corresponds
3493 to high *IoS* values. We subsequently converted *IoS* values to Z-statistics (Sanabria-Diaz et al., 2013)
3494 and compared, across groups, each Z-score of *IoS* between pairs of cortical targets, adjusting *p*-
3495 values for multiple comparisons using Bonferroni correction.

3496 Clustering of patients based on clinical symptoms

3497 We applied principal component analysis (PCA) on standardized clinical scores including Hoehn
3498 and Yahr stage, apathy, depression, anxiety and binarized MoCA. Because 8 patients were tested off
3499 and 11 on dopaminergic medication, we did not use UPDRS scores to generate subgroups of
3500 patients but rather used the Hoehn and Yahr stage, which is independent from dopaminergic
3501 medication status. Concerning other clinical measures, dopaminergic treatment is often considered
3502 to be of little effect on non-motor symptoms (Goldman and Litvan, 2011). Based on Jolliffe's
3503 criterion (Jolliffe, 2002), three components were retained because they explained together more
3504 than 80% of the variance. K-means clustering was applied on these 3-dimensional PCA scores and
3505 repeated 100 times with different starting centroids to avoid local minimum problem. Based on

3506 silhouette analysis and within-cluster sums of points-to-centroid distances (WCD; Saitta et al,
3507 2007), and in order to obtain subgroups of comparable size with specific clinical symptoms,
3508 patients were divided into three subgroups: patients with motivational or mood disorders-
3509 predominant symptoms (PD MDp, n = 3), patients with mild cognitive impairment-predominant
3510 symptoms (PD MCIp, n = 7), and patients with motor-predominant symptoms (PD Mp, n = 9). Age
3511 ranges were similar across all subgroups of patients (PD MDp: 58.33 ± 1.18 ; PD MCIp: 65.71 ± 2.36 ;
3512 PD Mp: 65.56 ± 1.19) and with healthy volunteers ($p > 0.05$ for all pairwise-comparisons using 2-
3513 tailed 2-sample t-tests).

3514 Univariate voxel-based analyses of connection density

3515 Additionally, to verify that topography of connections were consistent across subjects, images of
3516 the number of tracts for each group of cortical targets were modelled three times using voxel-based
3517 approach as a function of two factors: group of cortical targets (TARGET) and group of subjects
3518 (GROUP). The three factorial designs differed in the number of levels in the GROUP factor: two
3519 levels (PD, HC) in the first analysis, three levels (HC, PD L, PD R) in the second analysis, and four
3520 levels (HC, PD MDp, PD MCIp, PD Mp) in the third analysis. In each group of subjects, T-contrasts
3521 were performed for each level of the TARGET factor against the other two. Moreover, in order to
3522 assess possible differences in terms of number of tracts across groups of subjects, F-contrasts
3523 testing the main effect of GROUP and the interaction effect between GROUP and TARGET were
3524 performed. Statistical threshold for the univariate voxel-based analyses was set to $p < 0.001$,
3525 uncorrected for multiple comparisons, with a minimal cluster extent (k) of 10 voxels.

3526 **Results**

3527 Topographically organised connectivity in the striatum and thalamus

3528 Tractography revealed anatomically plausible segregated connectivity patterns, with sensorimotor,
3529 associative and limbic cortical areas being connected to different portions within each subcortical
3530 ROI (Figure 2). The rostroventral caudate and putamen, close to the nucleus accumbens, were
3531 mostly connected to limbic cortical areas, whereas the dorsolateral putamen, tail of the caudate and
3532 posterolateral portions of the thalamus had connections to sensorimotor areas. The intermediate
3533 caudate and putamen, as well as the medial anterior portion of the thalamus seemed to be mostly
3534 connected to associative cortical regions. Across all seed ROIs, most of the voxels had between 100
3535 and 1'000 streamlines reaching motor, associative and limbic cortical areas (Figure 2D).

3536 Structural segregation in PD

3537 Results demonstrated higher *IoS* estimates in PD compared to HC between sensorimotor and
3538 associative targets in the right caudate ($p = 0.00233$) and between associative and limbic targets in
3539 the right putamen ($p < 0.001$). In the left putamen, PD had lower *IoS* between associative and limbic
3540 targets ($p < 0.001$) (Figure 3).

3541 Structural segregation as a function of disease laterality

3542 When separating patients into left- and right-affected, both PD groups were associated, as
3543 compared to HC, with higher *IoS* estimates between sensorimotor and associative targets in the
3544 right caudate ($p = 0.02789$ for PD L against HC, $p < 0.001$ for PD R against HC) and between
3545 associative and limbic in the right putamen ($p < 0.001$ for both groups against HC) (Figure 4).
3546 However, while PD L showed higher *IoS* between associative and limbic as compared to HC in the
3547 left thalamus ($p < 0.001$), PD R showed lower *IoS* between the same targets as compared to HC in
3548 the same region ($p = 0.00240$). Therefore PD L had higher *IoS* between associative and limbic
3549 targets as compared to PD R ($p < 0.001$) in the left thalamus, whereas PD R had higher *IoS* between
3550 sensorimotor and associative targets than PD L in the right caudate ($p = 0.00701$).

3551 Clusters of patients based on clinical symptoms

3552 Anxiety, depression and apathy seem to be related to each other, and Hoehn and Yahr stage had a
3553 relatively uniform distribution across patients (Figure 5E). Some MoCA scores clearly suggested a
3554 cognitive impairment (Table 1), the minimal score being equal to 21. PCA revealed that principal
3555 components explained respectively 37.9%, 23.1%, 19.2%, 13.5% and 6.4% of the variance in
3556 clinical scores. Principal component vectors for depression, apathy and anxiety scores were very
3557 close together, whereas MoCA scores and Hoehn and Yahr stage were rather two other dissociable
3558 dimensions (Figure 5A). Normalized varimax rotation indicated that loadings for the 1st component
3559 were indeed high for Anxiety, Depression and Apathy (0.70, 0.65 and 0.27 respectively) and low for
3560 MoCA and Hoehn and Yahr stage (0.1 and 0.12 respectively), whereas for the 2nd component
3561 loadings were respectively 0.09, -0.03, -0.4, 0.9 (MoCA) and -0.17, and for the 3rd component
3562 respectively 0.23, -0.17, -0.5, -0.1 and 0.81 (Hoehn and Yahr stage). The first three components
3563 explained together 80.1% of variance (see scree plot in Figure 5B) and were therefore kept for *k*-
3564 means clustering. The latter showed an optimal solution with $k = 3$ (Figure 5C) by producing groups
3565 of relatively equivalent size, without introducing groups of only one patient, and with relatively
3566 high silhouette values (Figure 5D and Supplementary figure 1). Within-cluster sums of point-to-
3567 centroid distances linearly decreased as k increased (Supplementary figure 1). Each cluster of
3568 patients was then associated with a different profile of clinical symptoms (Figure 5F).

3569 Structural segregation as a function of clinical symptoms

3570 When dividing patients according to their clinical symptoms, PD MDp had extremely high *IoS*
3571 estimates bilaterally in the caudate, regardless of the group of cortical targets compared (Figure 6).
3572 *IoS* for PD MDp were higher than all other groups for each pair of cortical targets ($p < 0.001$).
3573 However PD MDp were associated with lower *IoS* between associative and limbic targets in the
3574 right thalamus as compared to HC ($p < 0.001$) and PD MCIp ($p = 0.00845$). In the right putamen, all
3575 groups of PD patients had higher *IoS* between associative and limbic targets as compared to HC ($p <$
3576 0.001 for PD MDp, PD MCIp and PD Mp), whereas in the left putamen, *IoS* values between
3577 associative and limbic targets were lower for PD MDp and PD Mp as compared to PD MCIp ($p <$
3578 0.001 and $p = 0.00357$ respectively) and compared to HC ($p < 0.001$). In the left thalamus, PD MCIp
3579 had higher *IoS* estimates between associative and limbic targets compared to all other groups ($p <$
3580 0.001 against HC, PD MDp and PD Mp). Furthermore, in HC as compared to PD Mp, *IoS* between
3581 sensorimotor and associative targets were higher in the left ($p = 0.03214$) but lower in the right (p
3582 < 0.001) caudate.

3583 Univariate voxel-based analyses of connection density

3584 Robust topographical patterns were present consistently in each group of subject (Supplementary
3585 figure 2 to Supplementary figure 9). In the striatum, the most ventral and anterior portions – close
3586 to the nucleus accumbens –, were more connected to limbic cortical areas than any other group of
3587 targets, while the most dorsal and posterior portions – comprising notably the dorsolateral
3588 putamen and the tail of the caudate –, were more connected to sensorimotor areas compared to any
3589 other cortical target. The intermediate portions of the striatum were more connected to associative
3590 cortical areas compared to any other group of targets. In the thalamus, medial anterior nuclei were
3591 preferentially connected to associative areas, while posterior lateral nuclei were mostly connected
3592 to sensorimotor cortical regions. The main effect of GROUP and interaction effect between GROUP
3593 and TARGET were not significant ($p < 0.001$, $k \geq 10$), in any model built (detailed results tables
3594 available as Supplementary material).

3595 **Discussion**

3596 Results showed that cortico-striatal and thalamo-cortical connectivity patterns are affected in PD.
3597 We demonstrated that PD affects structural segregation between sensorimotor and associative
3598 targets in the right caudate, and between associative and limbic targets in the putamen bilaterally.
3599 When splitting PD patients into left- and right-affected, whereas both groups of patients had an
3600 equivalent loss of structural segregation in the right putamen, the loss of structural segregation was
3601 greater in the right caudate for right-affected patients, and left-affected patients had decreased
3602 structural segregation between associative and limbic targets in the left thalamus. After having
3603 grouped patients based on their clinical symptoms, we observed different changes in structural
3604 segregation across groups. Altogether, except for PD with motivational symptoms in the caudate,
3605 we mostly observed differences in structural segregation between associative and limbic but almost
3606 never between sensorimotor and limbic brain functions. Knowing that cortical areas supporting the
3607 latter functions converge to very distant locations at the striatal level – the most dorsal and
3608 posterior, and most ventral and anterior portions respectively –, it is possible that these two
3609 antipodal connectivity patterns are too segregated at baseline to be strongly affected by PD.
3610 Further, while the reasons underlying asymmetric changes in structural segregation associated
3611 with PD remain unclear, previous reports suggest a higher prevalence of apathy in right-affected PD
3612 patients (Harris et al., 2013). The authors of this study suggest that it might be due to the fact that
3613 the right striatum, evidencing less dopamine at baseline even in healthy subjects, might be more
3614 vulnerable, and they link their findings with reports of motor symptoms severity being also
3615 associated with side of PD onset (Haaxma et al., 2010). It has to be noted that in our sample, the
3616 proportion of patients affected on the right was 66.7% in PD with motivational symptoms, 57.1% in
3617 PD with cognitive symptoms, and 33.3% in PD with motor symptoms. Consistently with the above
3618 percentages and in line with the results of Harris and colleagues (2013), PD with motivational
3619 symptoms were similar to PD affected on the right in terms of structural segregation. Interestingly,
3620 percentages of side of onset follow the spatial progression of nigrostriatal denervation in PD
3621 (Redgrave et al., 2010; Vaillancourt et al., 2013).

3622 Furthermore, changes in structural segregation of connectivity patterns were not mirrored by
3623 changes in the density of connections. Indeed, robust and consistent patterns of connectivity were

3624 found in all groups of subjects, with a spatial distribution in line with the known anatomy of
3625 subcortical connectivity (Draganski et al., 2008; Lambert et al., 2016; Lehericy et al., 2004), but no
3626 difference between groups in terms of connection density was found. The alternative explanation
3627 that PD affects connection density and henceforth biases results in terms of structural segregation
3628 is therefore less likely. Our results rather support the idea that cortico-subcortical tracts
3629 differentially connect the thalamus and striatum to our group of cortical areas.

3630 Because in our sample 8 PD patients were tested off – respectively 11 on – dopaminergic
3631 medication, the assumption on which our study relies is that acute withdrawal of dopaminergic
3632 drugs does not strongly affects DWI data. Knowing that even long-term effects of dopaminergic
3633 treatment on diffusivity measures remains controversial (Meijer et al., 2013), we think it is
3634 reasonable to assume that stopping dopaminergic medication for only 1 day cannot strongly alter
3635 structural connectivity, and that it cannot therefore constitute a bias in the reported tractography
3636 results.

3637 In our study, clustering of patients was done based on results from cognitive tests and mood
3638 questionnaires, as well as on the progression of motor disability. The categories we used do not
3639 perfectly match the different subtypes of PD (Marras and Chaudhuri, 2016; Moustafa and Poletti,
3640 2013) but rather links some of the proposed categories to the brain functions supported by the
3641 cortical areas considered for tractography. While the choice of cortical targets was mostly driven by
3642 the goal to simplify basal ganglia functional architecture based on previous findings (Jahanshahi et
3643 al., 2015; Obeso et al., 2000, 2008), other clinical measures might help disentangling effects of
3644 multiple factors on structural segregation, such as the predominance of akinesia or tremor, the
3645 presence of postural instabilities, dyskinesia, hallucinations, or impulse control disorders. Future
3646 studies might collect data in more various groups of PD patients, increase sample size for each
3647 profile of clinical symptoms, and investigate further structural segregation between other groups of
3648 cortical areas at the basal ganglia level.

3649 **References**

- 3650 Alexander, G.E., DeLong, M.R., and Strick, P.L. (1986). Parallel organization of functionally
3651 segregated circuits linking basal ganglia and cortex. *Annu. Rev. Neurosci.* 9, 357–381.
- 3652 Andersson, J.L.R., and Sotiropoulos, S.N. (2016). An integrated approach to correction for off-
3653 resonance effects and subject movement in diffusion MR imaging. *NeuroImage* 125, 1063–1078.
- 3654 Bar-Gad, I., and Bergman, H. (2001). Stepping out of the box: information processing in the neural
3655 networks of the basal ganglia. *Curr. Opin. Neurobiol.* 11, 689–695.
- 3656 Bar-Gad, I., Havazelet-Heimer, G., Goldberg, J.A., Ruppin, E., and Bergman, H. (2000). Reinforcement-
3657 driven dimensionality reduction -a model for information processing in the basal ganglia. *J. Basic*
3658 *Clin. Physiol. Pharmacol.* 11, 305–320.
- 3659 Bar-Gad, I., Morris, G., and Bergman, H. (2003). Information processing, dimensionality reduction
3660 and reinforcement learning in the basal ganglia. *Prog. Neurobiol.* 71, 439–473.
- 3661 Bronfeld, M., and Bar-Gad, I. (2011). Loss of specificity in Basal Ganglia related movement
3662 disorders. *Front. Syst. Neurosci.* 5, 38.
- 3663 Buck, P.O., Wilson, R.E., Seeberger, L.C., Conner, J.B., and Castelli-Haley, J. (2011). Examination of the
3664 UPDRS bradykinesia subscale: equivalence, reliability and validity. *J. Park. Dis.* 1, 253–258.
- 3665 Burn, D.J. (2002). Depression in Parkinson's disease. *Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc.* 9
3666 *Suppl* 3, 44–54.
- 3667 Calabresi, P., Picconi, B., Tozzi, A., and Di Filippo, M. (2007). Dopamine-mediated regulation of
3668 corticostriatal synaptic plasticity. *Trends Neurosci.* 30, 211–219.
- 3669 Dale, A.M., Fischl, B., and Sereno, M.I. (1999). Cortical surface-based analysis. I. Segmentation and
3670 surface reconstruction. *NeuroImage* 9, 179–194.
- 3671 Dalrymple-Alford, J.C., MacAskill, M.R., Nakas, C.T., Livingston, L., Graham, C., Crucian, G.P., Melzer,
3672 T.R., Kirwan, J., Keenan, R., Wells, S., et al. (2010). The MoCA: well-suited screen for cognitive
3673 impairment in Parkinson disease. *Neurology* 75, 1717–1725.
- 3674 Desikan, R.S., Ségonne, F., Fischl, B., Quinn, B.T., Dickerson, B.C., Blacker, D., Buckner, R.L., Dale, A.M.,
3675 Maguire, R.P., Hyman, B.T., et al. (2006). An automated labeling system for subdividing the human
3676 cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* 31, 968–980.
- 3677 Diedrichsen, J., Ridgway, G.R., Friston, K.J., and Wiestler, T. (2011). Comparing the similarity and
3678 spatial structure of neural representations: A pattern-component model. *NeuroImage* 55, 1665–
3679 1678.
- 3680 Draganski, B., Kherif, F., Klöppel, S., Cook, P.A., Alexander, D.C., Parker, G.J.M., Deichmann, R.,
3681 Ashburner, J., and Frackowiak, R.S.J. (2008). Evidence for Segregated and Integrative Connectivity
3682 Patterns in the Human Basal Ganglia. *J. Neurosci.* 28, 7143–7152.

The topography of cortico-subcortical loops in Parkinson's disease

- 3683 Farquharson, S., Tournier, J.-D., Calamante, F., Fابینی, G., Schneider-Kolsky, M., Jackson, G.D., and
3684 Connelly, A. (2013). White matter fiber tractography: why we need to move beyond DTI. *J.*
3685 *Neurosurg.* *118*, 1367–1377.
- 3686 Fischl, B., Sereno, M.I., and Dale, A.M. (1999a). Cortical Surface-Based Analysis: II: Inflation,
3687 Flattening, and a Surface-Based Coordinate System. *NeuroImage* *9*, 195–207.
- 3688 Fischl, B., Sereno, M.I., Tootell, R.B.H., and Dale, A. M. (1999b). High-resolution inter-subject
3689 averaging and a surface-based coordinate system. *Hum. Brain Mapp.* *8*, 272–284.
- 3690 Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R.,
3691 Kennedy, D., Klaveness, S., et al. (2002). Whole Brain Segmentation: Automated Labeling of
3692 Neuroanatomical Structures in the Human Brain. *Neuron* *33*, 341–355.
- 3693 Fischl, B., Salat, D.H., Van Der Kouwe, A.J.W., Makris, N., Ségonne, F., Quinn, B.T., and Dale, A.M.
3694 (2004). Sequence-independent segmentation of magnetic resonance images. *NeuroImage* *23*, 69–
3695 84.
- 3696 Goldman, J.G., and Litvan, I. (2011). Mild cognitive impairment in Parkinson's disease. *Minerva Med.*
3697 *102*, 441.
- 3698 Haaxma, C.A., Helmich, R.C.G., Borm, G.F., Kappelle, A.C., Horstink, M.W.I.M., and Bloem, B.R. (2010).
3699 Side of symptom onset affects motor dysfunction in Parkinson's disease. *NSC* *170*, 1282–1285.
- 3700 Haber, S.N. (2003). The primate basal ganglia: parallel and integrative networks. *J. Chem.*
3701 *Neuroanat.* *26*, 317–330.
- 3702 Haber, S.N., Fudge, J.L., and McFarland, N.R. (2000). Striatonigrostriatal pathways in primates form
3703 an ascending spiral from the shell to the dorsolateral striatum. *J. Neurosci.* *20*, 2369–2382.
- 3704 Harris, E., McNamara, P., and Durso, R. (2013). Apathy in Patients With Parkinson Disease as a
3705 Function of Side of Onset. *J. Geriatr. Psychiatry Neurol.* *26*, 95–104.
- 3706 Helmich, R.C., Derikx, L.C., Bakker, M., Scheeringa, R., Bloem, B.R., and Toni, I. (2010). Spatial
3707 Remapping of Cortico-striatal Connectivity in Parkinson's Disease. *Cereb. Cortex* *20*, 1175–1186.
- 3708 Hutton, C. (2002). Image Distortion Correction in fMRI: A Quantitative Evaluation. *NeuroImage* *16*,
3709 217–240.
- 3710 Jahanshahi, M., Obeso, I., Rothwell, J.C., and Obeso, J.A. (2015). A fronto–striato–subthalamic–
3711 pallidal network for goal-directed and habitual inhibition. *Nat. Publ. Group* *16*, 719–732.
- 3712 Jeurissen, B., Tournier, J.-D., Dhollander, T., Connelly, A., and Sijbers, J. (2014). Multi-tissue
3713 constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data.
3714 *NeuroImage* *103*, 411–426.
- 3715 Jolliffe, I.T. (2002). *Principal Component Analysis* (Springer).
- 3716 Jones, D.K., Horsfield, M. A, and Simmons, A. (1999). Optimal strategies for measuring diffusion in
3717 anisotropic systems by magnetic resonance imaging. *Magn. Reson. Med. Off. J. Soc. Magn. Reson.*
3718 *Med. Soc. Magn. Reson. Med.* *42*, 515–525.

The topography of cortico-subcortical loops in Parkinson's disease

- 3719 Kaji, Y., and Hirata, K. (2011). Apathy and Anhedonia in Parkinson's Disease. *ISRN Neurol.* 2011, 1–
3720 9.
- 3721 Kriegeskorte, N. (2008). Representational similarity analysis – connecting the branches of systems
3722 neuroscience. *Front. Syst. Neurosci.* 2, 4.
- 3723 Lambert, C., Simon, H., Colman, J., and Barrick, T.R. (2016). Defining Thalamic Nuclei and
3724 Topographic Connectivity Gradients in vivo. *NeuroImage* 1–40.
- 3725 Leemans, A., and Jones, D.K. (2009). The B-matrix must be rotated when correcting for subject
3726 motion in DTI data. *Magn. Reson. Med.* 61, 1336–1349.
- 3727 Lehéricy, S., Ducros, M., Van de Moortele, P.-F., Francois, C., Thivard, L., Poupon, C., Swindale, N.,
3728 Ugurbil, K., and Kim, D.-S. (2004). Diffusion tensor fiber tracking shows distinct corticostriatal
3729 circuits in humans. *Ann. Neurol.* 55, 522–529.
- 3730 Lieberman, A. (2006). Depression in Parkinson's disease - a review. *Acta Neurol. Scand.* 113, 1–8.
- 3731 Lim, S.A.O., Kang, U.J., and McGehee, D.S. (2014). Striatal cholinergic interneuron regulation and
3732 circuit effects. *Front. Synaptic Neurosci.* 6, 22.
- 3733 Lorio, S., Kherif, F., Ruef, A., Melie-Garcia, L., Frackowiak, R., Ashburner, J., Helms, G., Lutti, A., and
3734 Draganski, B. (2016). Neurobiological origin of spurious brain morphological changes: A
3735 quantitative MRI study. *Hum. Brain Mapp.* 37, 1801–1815.
- 3736 Lutti, A., Hutton, C., Finsterbusch, J., Helms, G., and Weiskopf, N. (2010). Optimization and validation
3737 of methods for mapping of the radiofrequency transmit field at 3T. *Magn. Reson. Med.* 64, 229–238.
- 3738 Lutti, A., Stadler, J., Josephs, O., Windischberger, C., Speck, O., Bernarding, J., Hutton, C., and
3739 Weiskopf, N. (2012). Robust and Fast Whole Brain Mapping of the RF Transmit Field B1 at 7T. *PLoS*
3740 *ONE* 7, e32379.
- 3741 Marras, C., and Chaudhuri, K.R. (2016). Nonmotor features of Parkinson's disease subtypes. *Mov.*
3742 *Disord.* 31, 1095–1102.
- 3743 Marsh, L. (2000). Anxiety disorders in Parkinson's disease. *Int. Rev. Psychiatry* 12, 307–318.
- 3744 Meijer, F.J.A., Bloem, B.R., Mahlknecht, P., Seppi, K., and Goraj, B. (2013). Update on diffusion MRI in
3745 Parkinson's disease and atypical parkinsonism. *J. Neurol. Sci.* 1–9.
- 3746 Morikawa, H., and Paladini, C.A. (2011). Dynamic regulation of midbrain dopamine neuron activity:
3747 intrinsic, synaptic, and plasticity mechanisms. *NEUROSCIENCE* 198, 95–111.
- 3748 Moustafa, A.A., and Poletti, M. (2013). Neural and behavioral substrates of subtypes of Parkinson's
3749 disease. *Front. Syst. Neurosci.* 7, 117.
- 3750 Munhoz, R.P., Moro, A., Silveira-Moriyama, L., and Teive, H.A. (2015). Non-motor signs in
3751 Parkinson's disease: a review. *Arq. Neuropsiquiatr.* 73, 454–462.

The topography of cortico-subcortical loops in Parkinson's disease

- 3752 Nasreddine, Z.S., Phillips, N.A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.L.,
3753 and Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild
3754 cognitive impairment. *J. Am. Geriatr. Soc.* *53*, 695–699.
- 3755 Nili, H., Wingfield, C., Walther, A., Su, L., Marslen-Wilson, W., and Kriegeskorte, N. (2014). A Toolbox
3756 for Representational Similarity Analysis. *PLoS Comput. Biol.* *10*, e1003553.
- 3757 Obeso, J.A., Rodríguez-Oroz, M.C., Rodríguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N., and Olanow,
3758 C.W. (2000). Pathophysiology of the basal ganglia in Parkinson's disease. *Trends Neurosci.* *23*, S8–
3759 19.
- 3760 Obeso, J.A., Rodríguez-Oroz, M.C., Benitez-Temino, B., Blesa, F.J., Guridi, J., Marin, C., and Rodriguez,
3761 M. (2008). Functional organization of the basal ganglia: Therapeutic implications for Parkinson's
3762 disease. *Mov. Disord.* *23*, S548–S559.
- 3763 Pessiglione, M., Guehl, D., Rolland, A.-S., Francois, C., Hirsch, E.C., Féger, J., and Tremblay, L. (2005).
3764 Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional
3765 segregation within basal ganglia circuits. *J. Neurosci.* *25*, 1523–1531.
- 3766 Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M.C., Lehericy, S., Bergman, H., Agid, Y.,
3767 DeLong, M.R., and Obeso, J.A. (2010). Goal-directed and habitual control in the basal ganglia:
3768 implications for Parkinson's disease. *Nat. Publ. Group* *11*, 760–772.
- 3769 Robert, P.H., Clairet, S., Benoit, M., Koutaich, J., Bertogliati, C., Tible, O., Caci, H., Borg, M., Brocker, P.,
3770 and Bedoucha, P. (2002). The Apathy Inventory: assessment of apathy and awareness in
3771 Alzheimer's disease, Parkinson's disease and mild cognitive impairment. *Int. J. Geriatr. Psychiatry*
3772 *17*, 1099–1105.
- 3773 Saitta, S., Raphael, B., and Smith, I.F. (2007). A bounded index for cluster validity. In *International*
3774 *Workshop on Machine Learning and Data Mining in Pattern Recognition*, (Springer), pp. 174–187.
- 3775 Sanabria-Diaz, G., Martínez-Montes, E., Melie-Garcia, L., and Alzheimer's Disease Neuroimaging
3776 Initiative (2013). Glucose metabolism during resting state reveals abnormal brain networks
3777 organization in the Alzheimer's disease and mild cognitive impairment. *PLoS ONE* *8*, e68860.
- 3778 Ségonne, F., Dale, A.M., Busa, E., Glessner, M., Salat, D., Hahn, H.K., and Fischl, B. (2004). A hybrid
3779 approach to the skull stripping problem in MRI. *NeuroImage* *22*, 1060–1075.
- 3780 Sethi, K.D. (2002). Clinical aspects of Parkinson disease. *Curr. Opin. Neurol.* *15*, 457–460.
- 3781 Sharma, S., Moon, C.S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y., and
3782 Ebadi, M. (2013). Biomarkers in Parkinson's disease (recent update). *Neurochem. Int.* *63*, 201–229.
- 3783 Smith, R.E., Tournier, J.-D., Calamante, F., and Connelly, A. (2012). Anatomically-constrained
3784 tractography: improved diffusion MRI streamlines tractography through effective use of anatomical
3785 information. *NeuroImage* *62*, 1924–1938.
- 3786 Surmeier, D.J., Shen, W., Day, M., Gertler, T., Chan, S., Tian, X., and Plotkin, J.L. (2010). The role of
3787 dopamine in modulating the structure and function of striatal circuits. *Prog. Brain Res.* *183*, 149–
3788 167.

The topography of cortico-subcortical loops in Parkinson's disease

- 3789 Tessitore, A., Giordano, A., Russo, A., and Tedeschi, G. (2016). Structural connectivity in Parkinson's
3790 disease. *Park. Realt. Disord.* 22, S56–S59.
- 3791 Tournier, J.-D., Calamante, F., Gadian, D.G., and Connelly, A. (2004). Direct estimation of the fiber
3792 orientation density function from diffusion-weighted MRI data using spherical deconvolution.
3793 *NeuroImage* 23, 1176–1185.
- 3794 Tournier, J.-D., Calamante, F., and Connelly, A. (2007). Robust determination of the fibre orientation
3795 distribution in diffusion MRI: non-negativity constrained super-resolved spherical deconvolution.
3796 *NeuroImage* 35, 1459–1472.
- 3797 Tournier, J.-D., Calamante, F., and Connelly, A. (2010). Improved probabilistic streamlines
3798 tractography by 2nd order integration over fibre orientation distributions. In *Proceedings of the*
3799 *International Society for Magnetic Resonance in Medicine*, p. 1670.
- 3800 Tournier, J.-D., Calamante, F., and Connelly, A. (2012). MRtrix: Diffusion tractography in crossing
3801 fiber regions. *Int. J. Imaging Syst. Technol.* 22, 53–66.
- 3802 Vaillancourt, D.E., Schonfeld, D., Kwak, Y., Bohnen, N.I., and Seidler, R. (2013). Dopamine overdose
3803 hypothesis: Evidence and clinical implications. *Mov. Disord.* 28, 1920–1929.
- 3804 Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J.L., Obeso, J.A., and
3805 Bezard, E. (2009). Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to
3806 impulse control disorders. *Lancet Neurol.* 8, 1140–1149.
- 3807 Voon, V., Mehta, A.R., and Hallett, M. (2011). Impulse control disorders in Parkinson's disease. *Curr.*
3808 *Opin. Neurol.* 24, 324–330.
- 3809 Worbe, Y., Marrakchi-Kacem, L., Lecomte, S., Valabregue, R., Poupon, F., Guevara, P., Tucholka, A.,
3810 Mangin, J.F., Vidailhet, M., Lehericy, S., et al. (2015). Altered structural connectivity of cortico-
3811 striato-pallido-thalamic networks in Gilles de la Tourette syndrome. *Brain* 138, 472–482.
- 3812 Yeatman, J.D., Dougherty, R.F., Myall, N.J., Wandell, B.A., and Feldman, H.M. (2012). Tract Profiles of
3813 White Matter Properties: Automating Fiber-Tract Quantification. *PLoS ONE* 7, e49790.
- 3814 Zigmond, A.S., and Snaithe, R.P. (1983). The Hospital Anxiety and Depression Scale. *Acta Psychiatr.*
3815 *Scand.* 67, 361–370.
- 3816

3817 **Tables**

3818


	Average	Standard deviation	Minimum	Maximum
Hoehn and Yahr stage	1.68	0.58	1	2.5
Anxiety	6.11	2.94	0	13
Depression	2.68	2.43	0	9
Apathy	1.99	4.50	0	16.52
MOCA	25.58	2.32	21	29

3819

3820 **Table 1:** summary of clinical scores in PD patients. Average, standard deviation, minimum and
3821 maximum score are given for motor (Hoehn and Yahr stage), motivational (anxiety, depression,
3822 apathy) and executive (MOCA) symptoms.

3823


3824 **Figures**
 3825



3826

3827 **Figure 1:** theoretical examples of various levels of structural segregation. For each panel, the colour
 3828 of segments for bars representing the seed ROI in the subcortex illustrate the mixing of connections
 3829 in a red-green-blue scheme fashion. By definition, segments of bars representing the target ROI in
 3830 the cortex are always pure colours. A) Fibres connecting the seed and target follow a one-to-one
 3831 mapping, a case of extremely high segregation. B) Relative segregation between connectivity
 3832 patterns, the light green segment is less segregated than the light blue segment, which is itself less
 3833 segregated than the dark orange segment. C) Particularly low segregation between connectivity
 3834 patterns. The white segment is a case of total absence of segregation, whereas the yellow and cyan
 3835 segments are situations in between cases presented in B) and the white segment in C).

3836




3837

3838 **Figure 2** : cortico-striatal and thalamo-cortical tracts to sensorimotor (blue), associative (green)
 3839 and limbic (red) cortical targets in the caudate (A), putamen (B) and thalamus (C) for a
 3840 representative healthy control subject. Tracts were generated using the exact same procedure as
 3841 the main tractography but only with 100 streamlines per voxel. Tracts were then cleaned using AFQ
 3842 (Yeatman et al., 2012), keeping only fibres with maximum 4 standard deviations above the mean
 3843 tract length and maximum ± 4 standard deviations of distance from the average tract core. Panel D)
 3844 shows the average connection density across all seed ROIs for limbic, associative and sensorimotor
 3845 cortical targets.

3846

3847

The topography of cortico-subcortical loops in Parkinson's disease




3848

3849 **Figure 3** : structural segregation in PD and HC. 3-dimensional renderings of average number of
 3850 fibres per voxel for each cortical target in all seed ROI are shown on the upper left. Colour codes the
 3851 number of connections to limbic (red), associative (green) and sensorimotor (blue) cortical targets
 3852 in an additive fashion. The colour scale cylinder on the lower left represents the number of fibres
 3853 coded by each colour in the upper renderings: black = 0 fibres to all targets, blue = 0 fibres to all
 3854 targets but more than 500 to sensorimotor cortical areas, green = 0 fibres to all targets but more
 3855 than 500 to associative areas, red = 0 fibres to all targets but more than 500 to limbic areas, cyan =
 3856 more than 500 fibres to all targets but 0 to limbic areas, yellow = more than 500 fibres to all targets
 3857 but 0 to sensorimotor areas, magenta = more than 500 fibres to all targets but 0 to associative
 3858 areas, white = more than 500 fibres to all targets. IoS estimates per pair of cortical targets and for
 3859 each group and seed ROI are shown on the right, following the same red-green-blue colour scheme.
 3860 Significance stars indicate Bonferroni-corrected p-values: $p < 0.05$ (*), $p < 0.01$ (**) and $p < 0.001$
 3861 (***)).

3862

The topography of cortico-subcortical loops in Parkinson's disease




3863

3864 **Figure 4** : structural segregation in left-affected and right-affected PD patients. Legends for colour
 3865 scheme and significance stars are identical to Figure 2.

3866

The topography of cortico-subcortical loops in Parkinson's disease



3867


3868 **Figure 5 :** A) PCA results displaying the projection of PD patients in components space, together
 3869 with principal component vectors for Hoehn and Yahr stage (blue), anxiety score (dark red),

The topography of cortico-subcortical loops in Parkinson's disease

3870 depression score (red), apathy score (dark orange) and MOCA score (green). B) Scree plot showing
3871 the cumulative percentage of variance explained as a function of number of components. Jolliffe's
3872 criterion is marked in red. C) Results of *k*-means clustering with 3 components and 3 groups.
3873 Principal component scores of individuals are filled with red for MD-predominant, green for MCI-
3874 predominant and blue for M-predominant PD patients. Centroids are marked with black crosses
3875 outlined with black circles. D) Silhouette plots for *k*-means clustering with 3 groups. Color legend as
3876 in panel C). E) Distribution of clinical scores and relationships between them, showed by
3877 histograms and scatter plots. Color legend as in panel C). F) Averaged standardized clinical score
3878 per cluster of PD patients. Note that low MOCA score is an indicator of possible cognitive
3879 impairment, whereas high values in other clinical scores suggests impairment in the corresponding
3880 brain function. Color legend is identical to panel A).

3881

The topography of cortico-subcortical loops in Parkinson's disease




3882

3883 **Figure 6** : structural segregation in MD-, MCI- and M-predominant PD patients. Legends for colour
 3884 scheme and significance stars are identical to Figure 2.

3885

3886 **Supplementary figures**

3887



3888


3889 **Supplementary figure 1** : *k*-means clustering solutions for one up to seven clusters. Starting from
 3890 five clusters, groups of one subject are generated (upper graphs). When *k* = 2, group size is

The topography of cortico-subcortical loops in Parkinson's disease

3891 particularly imbalanced, and when $k = 4$ and above – except for $k = 5$ –, negative silhouette values
3892 are observed, indicating a particularly bad assignment for those individuals. Altogether, these
3893 results suggest that setting parameter k to 3 provides a reasonable solution balancing group size
3894 and avoiding clusters with only one individual.

3895

The topography of cortico-subcortical loops in Parkinson's disease




3896

3897 **Supplementary figure 2** : T-contrasts testing the effect of each brain function against the two
3898 others across all subjects, applying mass-univariate voxel-based analysis on the number of tracts
3899 images. Robust topographical patterns are observed, which survive a statistical threshold of $p <$
3900 0.001 with a minimal cluster extent of 10 voxels. Note how spatial distributions of patterns are
3901 similar to previous reports on subcortical connectivity (Draganski et al., 2008), with the most
3902 ventral and anterior part of the striatum being connected mostly to limbic cortical areas (rostral
3903 and ventral striatum, close to the nucleus accumbens), the most dorsal and posterior part to
3904 sensorimotor areas (tail of the caudate, dorsolateral putamen), and the intermediate part of the to
3905 associative areas. Note also the anterior-medial to posterior-lateral gradient from associative to
3906 sensorimotor areas. Statistical maps are rendered using MRICroGL (Mac OS X version 1.150909) on
3907 a canonical T1-weighted image (mni152_2009_256.nii.gz).

3908

The topography of cortico-subcortical loops in Parkinson's disease




3909

3910 **Supplementary figure 3** : T-contrasts testing the effect of each brain function against the two
3911 others in HC subjects, the rest of figure legend being identical to Supplementary figure 2. Note the
3912 similarity with Supplementary figure 2.

3913

The topography of cortico-subcortical loops in Parkinson's disease




3914

3915 **Supplementary figure 4** : T-contrasts testing the effect of each brain function against the two
3916 others across all PD patients, the rest of figure legend being identical to Supplementary figure 2.
3917 Note the similarity with Supplementary figure 2.

3918

The topography of cortico-subcortical loops in Parkinson's disease




3919

3920 **Supplementary figure 5** : T-contrasts testing the effect of each brain function against the two
3921 others in PD patients mostly affected on the left body side, the rest of figure legend being identical
3922 to Supplementary figure 2. Note the relative similarity with Supplementary figure 2.

3923

The topography of cortico-subcortical loops in Parkinson's disease




3924

3925 **Supplementary figure 6** : T-contrasts testing the effect of each brain function against the two
3926 others in PD patients mostly affected on the right body side, the rest of figure legend being identical
3927 to Supplementary figure 2. Note the relative similarity with Supplementary figure 2.

3928

The topography of cortico-subcortical loops in Parkinson's disease




3929

3930 **Supplementary figure 7** : T-contrasts testing the effect of each brain function against the two
3931 others in PD patients with predominantly motivational symptoms, the rest of figure legend being
3932 identical to Supplementary figure 2. Note the relative similarity with Supplementary figure 2
3933 despite low sample size.

3934

The topography of cortico-subcortical loops in Parkinson's disease




3935

3936 **Supplementary figure 8** : T-contrasts testing the effect of each brain function against the two
3937 others in PD patients with predominantly cognitive symptoms, the rest of figure legend being
3938 identical to Supplementary figure 2. Although these maps were less similar to patterns observed in
3939 Supplementary figure 2, with possibly slightly fewer connections to associative areas, no difference
3940 between PD MCIp and other groups was observed ($p < 0.001$, $k \geq 10$).

3941

The topography of cortico-subcortical loops in Parkinson's disease



3942

3943 **Supplementary figure 9** : T-contrasts testing the effect of each brain function against the two
3944 others in PD patients with predominantly motor symptoms, the rest of figure legend being identical
3945 to Supplementary figure 2. Although there may be a slight trend towards fewer fibres connected to
3946 sensorimotor cortical areas in the dorsolateral putamen, spatial distribution of patterns resembles
3947 maps shown in Supplementary figure 2 and no difference between PD Mp and other groups was
3948 observed ($p < 0.001$, $k \geq 10$ voxels).

3949

3950 **3. General discussion**

3951 **3.1. Interpretations and limitations**

3952 With my studies using non-invasive MRI, I tackled methodological challenges of basal
3953 ganglia imaging and provided empirical evidence at the brain structure and function level
3954 supporting the LOS hypothesis in PD.

3955 Results of Study 1 showed an inverted U-shaped curve of *IoS* values in the BG, suggesting
3956 that higher fMRI spatial resolution improves spatial accuracy in these regions but that 3D
3957 EPI protocols artificially increases the effective overlap between somatotopy
3958 representations. Further studies are needed to better understand the source of this effect.

3959 There are some limitations regarding results in Study 1. The way images are acquired in 3D
3960 and 2D EPI protocols may be problematic for choosing a kernel size for spatial smoothing
3961 during fMRI data pre-processing because the number of effective independent samples is
3962 not strictly the same (Kirilina et al., 2016). This issue remains unresolved at present and
3963 would require further thinking and methodological developments.

3964 In Study 2, we demonstrate a loss of functional segregation in PD patients with and without
3965 DA substitution. Despite reports of LOS in the GPi, there are reports suggesting that PD
3966 does not alter motor somatotopy in the pallidum (Taha et al., 1996b) and STN (Rodriguez-
3967 Oroz et al., 2001). In line with these findings and with a previous study showing that MPTP
3968 do not increase synchronous activity in the pallidum (Mitelman et al., 2011), our results did
3969 not show evidence of LOS in the GPi, GPe and STN. In contrast, converging evidence
3970 implicates the motor thalamus in PD and suggests that it might be affected by a loss of
3971 functional segregation (Bosch-Bouju et al., 2013). Given the importance of age in PD and
3972 the similarity between neurobiological processes underlying PD and ageing, controlling for
3973 age effects was crucial. Recent studies further showed that ageing is accompanied by
3974 functional reorganisation (Morcom and Friston, 2012).

3975 *IoS* is a potential biomarker of PD that may provide additional information on disease
3976 severity and responsiveness to DA therapy. *IoS* was found to differ between HC subjects
3977 and PD patients, appeared to be sensitive to DA and symptoms laterality, and further
3978 correlated with symptoms severity. Despite the crucial role of the SN in PD, differences in
3979 terms of *IoS* observed in the latter brain structure necessitate some important remarks.
3980 The SNr is known to contain highly overlapping motor somatotopy patterns (Kaneda et al.,
3981 2002; Nambu, 2011), while the SNc is associated with only weak evidence of topographical
3982 organization (Nambu, 2011; Rommelfanger, 2010). We found that segregation of motor
3983 representations in the SN of PD patients OFF was reduced compared to HC. The degree of
3984 loss of functional segregation was positively correlated with motor symptoms severity.

3985 This additional evidence strengthens the notion of a loss of functional segregation in PD,
3986 particularly when in "OFF". A possible explanation is that the source of the observed
3987 differences lies in the SNr rather than the SNc. Even with greater spatial precision for the
3988 definition of the ROIs, distinguishing the SNr from the SNc is particularly challenging using
3989 fMRI and one could not rule out the possibility of signals from the two regions
3990 contaminating each other.

3991 Our results did not show a significant relationship between functional segregation and
3992 tremor scores in PD. Tremor is a sporadic symptom in PD, as it is not present in 25% of
3993 patients. It does not respond to DA therapy and its progression is not comparable to that of
3994 other motor symptoms. The coherence between BG oscillations and tremor has been
3995 shown to be inconsistent (Helmich et al., 2012). Given the singularity of rest tremor in PD,
3996 its subtle effects might be more difficult to capture with the coarse spatial resolution of
3997 fMRI compared to electrophysiological studies. One could further speculate that tremor in
3998 PD results from an interaction between LOS at different BG levels. To demonstrate such a
3999 relationship, larger sample size might be necessary. Relationships between LOS and rigidity
4000 were not tested, as the effects of the latter are difficult to dissociate from bradykinesia.
4001 Further studies are required to identify the contributions of LOS to each motor symptom in
4002 PD. In addition, we showed a negative relationship between cortico-striatal connectivity
4003 and IoS values, confirming that efficient reconstruction of input patterns when the
4004 putamen, which is perhaps associated with the highest information compression ratio in
4005 BG circuitry (Bar-Gad et al., 2003a), loses its topographical organization.

4006 One might interpret these findings as supporting the idea that LOS is induced by DA
4007 depletion. In the scenario, SNc neurons die, inducing LOS in the SN and putamen through
4008 striato-nigro-striatal pathways, and consequently LOS reaches the motor thalamus via
4009 thalamo-striatal pathways. Alternatively, DA depletion might induce LOS as a result of
4010 synchronous activity by weakening of collaterals between MSN, changing the preferential
4011 target of FSIs from MSNs of the direct pathway to MSNs of the indirect pathway, or by
4012 increasing ACh due to reduced auto-receptor function in cholinergic interneurons driving
4013 NPY-expressing interneurons (Gittis and Kreitzer, 2012). LTS interneurons and TH-positive
4014 interneurons might also play a role in striatal micro-circuitry dysfunction and induce LOS
4015 after DA depletion. How does the LOS further propagate to the motor thalamus? Given that
4016 direct thalamo-striatal connections are not bidirectional, impaired dimensionality
4017 reduction should in principle be transferred via the pallidum, presumably inducing thereby
4018 abnormal IoS values in the latter region. Several explanations may be considered.
4019 Abnormal IoS values in the SN are driven by LOS in the SNr, henceforth LOS propagates
4020 from the putamen to the thalamus via the direct pathway. This is surely a speculative
4021 explanation, given the underlying assumption of differential impact of LOS on the SNr but
4022 not on the GPi, particularly in the context of the performed motor task. Alternatively,

4023 compensatory mechanisms operate at the level of the pallidum, which mask the LOS in BG
4024 output. Given the high level of integration in the GPi, it is equally probable that we reached
4025 the limits of the applied methods and that higher spatial resolution or increased number of
4026 subjects would be needed to detect the presumed effect of LOS at the pallidal level.

4027 Another speculation is that the impaired dimensionality reduction in the striatum might be
4028 caused indirectly by cholinergic interneurons inducing plastic changes at the cortico-
4029 striatal level via DAergic neurotransmission (Surmeier and Graybiel, 2012) or directly by
4030 GABAergic interneurons, which coordinate MSN spiking activity (Clarke and Adermark,
4031 2015) or cholinergic interneurons by specifying the polarity of plasticity towards LTD or
4032 LTP via activation of MSN muscarinic postsynaptic receptors (Deffains and Bergman,
4033 2015). High levels of LRRK2 are expressed in cholinergic interneurons and the physiology
4034 of the latter might be pathologically affected by abnormal kinase activity (Lim et al., 2014).
4035 More evidence is brought by a study showing that DA therapy does not restore the full
4036 spectrum of normal pallidal activity in MPTP-intoxicated monkeys (Heimer et al., 2006).
4037 Assuming that LOS is the central pathophysiological process underlying PD, one might
4038 speculate that this neurodegenerative disease is due to striatal interneuron dysfunction
4039 rather than DA depletion. The presence of recurrent striato-nigro-striatal connections and
4040 the reports of loss of function and integrity in the striatum preceding SN degeneration
4041 support this speculation. Apoptotic mechanisms in the SNc might be triggered remotely via
4042 striatonigrostriatal pathways. Dysfunction of cholinergic and GABAergic striatal
4043 interneurons has been found to play a role not only in PD but also in dystonia, HD, attention
4044 deficit hyperactivity disorder (ADHD), AD, GTS, OCD, bipolar disorders, schizophrenia and
4045 major depressive disorders (Clarke and Adermark, 2015; Deffains and Bergman, 2015).
4046 Indeed, changes in DA and ACh might underlie abnormal plasticity in dystonia (Peterson et
4047 al., 2010). Cholinergic signalling might impact the expression of LIDs (Lim et al., 2014).
4048 Regarding this potential explanation, it is worth recalling the reduced risk of developing PD
4049 in smokers (Fujita et al., 2005; Mary Ann Chapman, 2009; Miwa et al., 2011; Quik et al.,
4050 2008). Other neurotransmitters can modulate cholinergic interneurons, including GABA,
4051 glutamate, DA – notably from the SNc –, serotonin – from the dorsal raphe –, histamine,
4052 noradrenaline – from the locus cœruleus –, adenosine, ATP, nitric oxide, enkephalin – from
4053 D₂ MSNs –, substance P and dynorphin – from D₁ MSNs (Lim et al., 2014). Like in the first
4054 explanatory scheme, this speculation does not fully resolve the issue of absence of LOS in
4055 the pallidum concurrent to LOS in the motor thalamus. LOS in PD might affect multiple sites
4056 simultaneously via non-synaptic pathways, albeit α -synuclein deposition in the thalamus in
4057 PD is unlikely to underlie differences in IoS values in the VL and VPL nuclei of the thalamus
4058 (Halliday, 2009). A possible explanation is that the loss of functional segregation in the
4059 striatum is propagated through thalamostriatal projections and originates in the thalamus.
4060 Very recently, it was shown that thalamic cholinergic integrity predicted performance

4061 during a sustained attention task, even after controlling for age, disease severity and
4062 DAergic innervation (Kim et al., 2017).

4063 Alternatively, the PPN is a common denominator regarding ROIs affected by a loss of
4064 functional segregation and was not considered in our analyses. This heterogeneous
4065 structure, located in the upper brainstem and characterized by a topographical
4066 organization of its connections, concurrently projects to a broad range of BG and thalamic
4067 nuclei, including the striatum, SN as well as to the ventrolateral, centro-median, and para-
4068 fascicular nuclei of the thalamus (Benarroch, 2008, 2013; Martinez-Gonzalez et al., 2011;
4069 Mena-Segovia et al., 2004; Pahapill and Lozano, 2000). The PPN, which has been
4070 considered as a target for DBS in PD, also projects to the STN, pallidum, as well as other
4071 thalamic nuclei and multiple structures in the brainstem, tectum and forebrain (Martinez-
4072 Gonzalez et al., 2011; Nakano, 2000). Although the role of the PPN remains largely unclear,
4073 it has a clear contribution in the control of locomotion (Obeso et al., 2008; Snijders et al.,
4074 2016). In primates, akinesia follows PPN lesions whereas chemical disinhibition and
4075 stimulation of the PPN alleviates the latter symptom (Zrinzo et al., 2008). About 50% of
4076 cholinergic neurons are lost in PD patients (Obeso et al., 2008). A very recent study
4077 suggests abnormal PPN connectivity in PD patients with sleep disorders and postural and
4078 impaired postural control (Gallea et al., 2017). Still, the absence of LOS at the level of M1
4079 remains an open issue. Even if compensatory mechanisms supported by the SMA or
4080 cerebellum can be postulated, longitudinal studies are required to validate our findings in
4081 bigger cohorts and decipher the potential mechanisms of propagation of LOS in PD.

4082 The use of electromyography (EMG) might provide additional information for data analysis
4083 performed in Study 2. Tremor episodes could be extracted from EMG recordings and added
4084 as confounding factor or directly tested. Moreover, additional anatomical precision might
4085 be reached by dividing the putamen into an anterior and posterior part, as done in previous
4086 studies (Helmich et al., 2010). The latter study suggests that controlling for tremor and
4087 head motion using derivatives of realignment parameters improves model fitting in fMRI
4088 data analysis.

4089 In Study 3 we showed that PD is associated with a loss of functional segregation not only at
4090 the BG level but also in a cortical region considered to be a hub in brain networks, the
4091 insula. As discussed above, alterations to DAergic, cholinergic or serotonergic pathways
4092 projecting to the insula may underlie loss of functional segregation observed in the insula
4093 (Christopher et al., 2014). This region, which integrates information from multiple brain
4094 regions, is likely affected by changes in cortico-subcortical loops, as it sends massive and
4095 topographically organized projections to the striatum. Study 2 showed that loss of
4096 functional segregation is observed in the putamen of PD patients. This could have an
4097 impact on the insula. Alternatively, the loss of functional segregation in the insula might be

4098 caused by α -synuclein deposition, though the latter occurs relatively late in terms of
4099 disease time course as it would correspond to Braak stage 5 (Christopher et al., 2014).
4100 Aberrant cortico-striatal plasticity resulting in a general increase in cortical activity might
4101 explain, at least partially, the loss of functional segregation in the insula with PD (Beeler et
4102 al., 2012, 2013). The fact that DA therapy did not seem to affect functional segregation in
4103 the insula remains to be elucidated.

4104 In Study 4 we showed that LOS possibly also affects structural connectivity patterns and is
4105 not limited to motor circuitry. Besides the anatomical plausibility of the obtained
4106 parcellation, the location of functional territories in the striatum corroborates a recent
4107 functional connectivity study based on a huge sample (Malherbe et al., 2014). Similarly to
4108 remarks made for Study 2, plastic changes affecting cortico-striatal connectivity may
4109 explain some of our results. Given the role of DA, ACh and GABAergic interneurons in
4110 striatal synaptic plasticity, reorganization of striatal structural connectivity might be
4111 induced by the mechanisms like the ones causing loss of functional segregation between
4112 motor representations of different body parts. Based on the presence of D₁ and D₅
4113 receptors in the thalamus (Missale et al., 1998) and the existence of DAergic afferent
4114 projections in the thalamus, notably from the VTA, SNc and hypothalamus (Sanchez-
4115 Gonzalez, 2005), speculate a reorganization of thalamo-cortical connectivity is not totally
4116 unreasonable. A nonselective DAergic axon lattice makes thalamo-striatal synapses as
4117 much likely to be influenced by DA release as cortico-striatal synapses (Moss and Bolam,
4118 2008). Changes in structural connectivity patterns observed in the thalamus might
4119 therefore result from an abnormal transfer of information between the striatum and
4120 thalamus triggering synaptic plasticity and reorganization of thalamo-cortico-thalamic
4121 pathways (Haber, 2003). Previous findings accumulated evidences that DA neurons in the
4122 midbrain integrate sensory, motor and cognitive information from multiple brain regions
4123 (Morikawa and Paladini, 2011). As an alternative interpretation, one may speculate that
4124 plastic changes in structural connectivity patterns underlie functional changes associated
4125 with PD as observed in Study 2 and Study 3. The mechanisms underlying LOS at the
4126 structural level in PD remain unclear and would require further investigations. Future
4127 work may include the pallidum as a seed ROI for tractography, as the GPe has been
4128 suggested to receive also direct input from the cortex (Kita, 2007). Although the tracking of
4129 the latter connections is not trivial, a recent work suggests that it may be feasible using
4130 constrained spherical (Milardi et al., 2014), yet the role of this direct cortico-pallidal
4131 remains to be clarified. There are also several limitations to Study 4. Although results in
4132 terms of structural segregation cannot be explained by differences in terms of connection
4133 density, we cannot definitely rule out the possibility that alterations of microstructural
4134 tissue properties induced a bias in the tracking algorithm. At present, however, a unified
4135 model linking MRI-derived metrics and biological tissue properties is still lacking. While
4136 additional analyses might refine our interpretations, they would heavily rely on an

4137 indecent number of speculations. General caveats encountered in tractography as
4138 mentioned previously also apply to Study 4 (Eickhoff et al., 2015). Impaired detection of
4139 sharply curved, very long, closely neighbouring or poorly myelinated fibre bundles may
4140 have affected our results despite the robustness of the chosen tracking algorithm.

4141 **3.2. Future directions**

4142 Future work may focus on segregation between limbic, associative and sensorimotor
4143 territories at the functional level using for example tasks combining multiple behavioural
4144 functions (Schmidt et al., 2012). Studies could also investigate structural segregation at the
4145 motor somatotopy level, as recent studies demonstrated the feasibility of cortico-striatal
4146 tracts reconstruction for different body parts (Staempfli et al., 2008). A remaining question
4147 relates to elucidating the presence of loss of functional segregation in the thalamus and
4148 determining which thalamic nucleus is affected by LOS. With respect to this question, LOS
4149 might primarily resides in the pallidal thalamus given previous reports in the anatomical
4150 connectivity of thalamic nuclei. In addition, the presence of a loss of functional segregation
4151 in the cerebellum might be investigated and possibly show links with tremor. The same
4152 atlas of the thalamus that we used in our studies may be used for this purpose. The PD-
4153 related rewiring process suggested in Study 4 might be completed by additional analyses of
4154 white matter tract integrity at the level of tissue properties. As PD has been associated with
4155 an impaired interhemispheric inhibition (Lieu and Subramanian, 2012), further studies
4156 could focus on investigating the link between functional segregation and the lack of
4157 interhemispheric inhibition. Based on findings of structural changes in PD and the possible
4158 mechanisms inducing LOS, relationships between functional segregation and tissue
4159 properties might also exist. We are convinced that one of the most pressings needs is to
4160 validate the predictive ability of the loss of functional segregation at the prodromal stage
4161 and its relationship with symptoms severity and neurodegeneration over the disease
4162 course. In this sense, patients with SWEDD or mutations affecting genes such as *VPS35*
4163 might be of particular interest. Given the complexity of pathogenic processes proposed to
4164 underlie PD, it might also be especially valuable – once the LOS hypothesis confirmed in a
4165 more definite manner – to search for the most likely sequence of events from different
4166 biomarkers. The latter may include for instance striatal DA innervation as assessed by PET
4167 or SPECT imaging, iron deposition as measured by R2* and functional as well as structural
4168 segregation estimates.

4169 Segregation has been defined differently according to other views, promoting studies on
4170 information topology in PD that complement the work presented here (Balduzzi and
4171 Tononi, 2009; Bullmore and Sporns, 2009, 2009; Deco et al., 2015; Edelman and Gally,
4172 2001; Fornito and Bullmore, 2014; Fornito et al., 2015; Green et al., 2006; Hagmann et al.,
4173 2008, 2010; Meunier et al., 2010; Oizumi et al., 2014; Rubinov and Sporns, 2010; Sporns,

4174 2012, 2013, 2015, Sporns et al., 2000, 2000, Tononi, 2004, 2008, Tononi et al., 1994, 1998,
4175 1999; Wei et al., 2014; Whitacre, 2010). Future studies on functional segregation might
4176 either extend our results to the mapping of different body parts, or investigate it from a
4177 perspective that considers for example the relevance of movements in a ethological
4178 framework (Aflalo and Graziano, 2006; Graziano and Aflalo, 2007a, 2007b). The limbic and
4179 associative loops may embed further granularity, for example concerning representations
4180 of different types of rewards or punishments. We believe that studying topography of
4181 information in PD at the structural and functional level will help to better understand PD
4182 pathophysiology and improve the monitoring of disease progression.

List of figures and tables

1. Number of publications referenced in the U.S. National Library of Medicine MEDLINE. A query was performed at <http://dan.corlan.net/medline-trend.html> using the keywords "Parkinson's disease". (page 12)
2. Genes involved in PD. (page 16)
3. Anatomy of basal ganglia, thalamus and midbrain nuclei rendered on a canonical T1-weighted image. The thalamus (light green) is rendered in a semi-transparent fashion to make apparent the STN, SN and RN. The Harvard-Oxford atlas provided with FSL (<https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases>) is used to represent the putamen, caudate, NAcc and thalamus. The GPe, GPi, STN, SN and RN are rendered using the ATAG atlas (Keuken et al., 2014). (page 32)
4. Simplified schematic of BG circuitry based on the reviewed literature, focusing on main BG intrinsic connections, as well as its afferents from and efferents to the thalamus, cortex, midbrain and hindbrain. DAergic, GABAergic, glutamatergic and cholinergic projections are shown in green, red, blue and black respectively. Neurotransmitter in play for connections in grey is unknown. Some projections may involve multiple neurotransmitters, which are not thoroughly shown. Reciprocal connections are shown with double-headed arrows. (page 36)
5. Functional topography in cortico-BG-thalamo-cerebellar circuits following the concept of parallel channels. Legend on the upper left shows the colour codes for the different functional territories. Symbols of hand and foot designate the presence of somatotopy. For the simplicity of the schematic, multiple nuclei are grouped into single entities and the presence of somatotopy is not mentioned for each nucleus separately but rather for the whole entity. (page 38)
6. Results of a meta-analysis on functional imaging studies including the term "Parkinson's disease", using reverse inference (<http://neurosynth.org>; Yarkoni et al., 2011). The colour bar indicates z-scores. Statistical significance is set to $p < 0.01$, corrected for multiple comparisons using false discovery rate. Statistical maps were rendered on a canonical T1-weighted image. (page 51)

References

- Abou-Sleiman, P.M., Muqit, M.M.K., and Wood, N.W. (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. *Nat. Rev. Neurosci.* 7, 207–219.
- Accolla, E.A., Dukart, J., Helms, G., Weiskopf, N., Kherif, F., Lutti, A., Chowdhury, R., Hetzer, S., Haynes, J.-D., Kühn, A.A., et al. (2014). Brain tissue properties differentiate between motor and limbic basal ganglia circuits. *Hum. Brain Mapp.* 35, 5083–5092.
- Afifi, A.K. (1994a). Basal ganglia: functional anatomy and physiology. Part 1. *J. Child Neurol.* 9, 249–260.
- Afifi, A.K. (1994b). Basal ganglia: functional anatomy and physiology. Part 2. *J. Child Neurol.* 9, 352–361.
- Aflalo, T.N., and Graziano, M.S.A. (2006). Possible Origins of the Complex Topographic Organization of Motor Cortex: Reduction of a Multidimensional Space onto a Two-Dimensional Array. *J. Neurosci.* 26, 6288–6297.
- Albin, R.L., Young, A.B., and Penney, J.B. (1989). The functional anatomy of basal ganglia disorders. *Trends Neurosci.* 12, 366–375.
- Alexander, G.E., and Crutcher, M.D. (1990). Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends Neurosci.* 13, 266–271.
- Alexander, G.E., DeLong, M.R., and Strick, P.L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annu. Rev. Neurosci.* 9, 357–381.
- Alexander, G.E., Crutcher, M.D., and DeLong, M.R. (1989). Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. *Prog. Brain Res.* 85, 119–146.
- Algarni, M.A., and Stoessl, A.J. (2016). The role of biomarkers and imaging in Parkinson's disease. *Expert Rev. Neurother.* 16, 187–203.
- Alkadhi, H., Crelier, G.R., Boendermaker, S.H., Golay, X., Hepp-Reymond, M.-C., and Kollias, S.S. (2002a). Reproducibility of primary motor cortex somatotopy under controlled conditions. *AJNR Am. J. Neuroradiol.* 23, 1524–1532.
- Alkadhi, H., Crelier, G.R., Boendermaker, S.H., Hepp-Reymond, M.-C., and Kollias, S.S. (2002b). Somatotopy in the ipsilateral primary motor cortex. *NeuroReport* 13, 2065–2070.
- Alves, G., Forsaa, E.B., Pedersen, K.F., Dreetz Gjerstad, M., and Larsen, J.P. (2008). Epidemiology of Parkinson's disease. *J. Neurol.* 255, 18–32.
- Amano, S., Kegelmeyer, D., and Hong, S.L. (2014). Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits. *Front. Syst. Neurosci.* 8, 242.

- Amemori, K.-I., Gibb, L.G., and Graybiel, A.M. (2011). Shifting responsibly: the importance of striatal modularity to reinforcement learning in uncertain environments. *Front. Hum. Neurosci.* *5*, 47.
- Antzoulatos, E.G., and Miller, E.K. (2011). Differences between Neural Activity in Prefrontal Cortex and Striatum during Learning of Novel Abstract Categories. *Neuron* *71*, 243–249.
- Apps, R., and Hawkes, R. (2009). Cerebellar cortical organization: a one-map hypothesis. *Nat. Publ. Group* *10*, 670–681.
- Ashby, F.G., Alfonso-Reese, L.A., Turken, A.U., and Waldron, E.M. (1998). A neuropsychological theory of multiple systems in category learning. *Psychol. Rev.* *105*, 442–481.
- Ashby, F.G., Ennis, J.M., and Spiering, B.J. (2007). A neurobiological theory of automaticity in perceptual categorization. *Psychol. Rev.* *114*, 632–656.
- Ataie, A., Shadifar, M., and Atae, R. (2016). Polyphenolic Antioxidants and Neuronal Regeneration. *Basic Clin. Neurosci.* *7*, 81–90.
- Auer, D.P. (2009). In vivo imaging markers of neurodegeneration of the substantia nigra. *Exp. Gerontol.* *44*, 4–9.
- Baas, H. (2000). Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors. *J. Neurol.* *247*, IV12–IV16.
- Badre, D., and D'Esposito, M. (2009). Is the rostro-caudal axis of the frontal lobe hierarchical? *Nat. Publ. Group* *10*, 659–669.
- Bainbridge, J.L., Page II, R.L., and Ruscin, J.M. (2008). Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors. *Neurol. Clin.* *26*, 85–96.
- Baker, K.B., Lee, J.Y.K., Mavinkurve, G., Russo, G.S., Walter, B., DeLong, M.R., Bakay, R.A.E., and Vitek, J.L. (2010). Somatotopic organization in the internal segment of the globus pallidus in Parkinson's disease. *Exp. Neurol.* *222*, 219–225.
- Balduzzi, D., and Tononi, G. (2009). Qualia: The Geometry of Integrated Information. *PLoS Comput. Biol.* *5*, e1000462.
- Bammer, R. (2003). Basic principles of diffusion-weighted imaging. *Eur. J. Radiol.* *45*, 169–184.
- Bar-Gad, I., and Bergman, H. (2001). Stepping out of the box: information processing in the neural networks of the basal ganglia. *Curr. Opin. Neurobiol.* *11*, 689–695.
- Bar-Gad, I., Havazelet-Heimer, G., Goldberg, J.A., Rupp, E., and Bergman, H. (2000). Reinforcement-driven dimensionality reduction -a model for information processing in the basal ganglia. *J. Basic Clin. Physiol. Pharmacol.* *11*, 305–320.

- Bar-Gad, I., Morris, G., and Bergman, H. (2003a). Information processing, dimensionality reduction and reinforcement learning in the basal ganglia. *Prog. Neurobiol.* *71*, 439–473.
- Bar-Gad, I., Heimer, G., Ritov, Y., 'acov, and Bergman, H. (2003b). Functional correlations between neighboring neurons in the primate globus pallidus are weak or nonexistent. *J. Neurosci.* *23*, 4012–4016.
- Bargiotas, P., and Konitsiotis, S. (2013). Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. *Neuropsychiatr. Dis. Treat.* *9*, 1605–1617.
- Barto, A.G. (1995). Adaptive Critics and the Basal Ganglia. In *Models of Information Processing in the Basal Ganglia*, J.C. Houk, J. Davis, and D. Beiser, eds. (Cambridge, MA: MIT Press), pp. 215–232.
- Bartus, R.T., Weinberg, M.S., and Samulski, R.J. (2013). Parkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy. *Mol. Ther.* *22*, 487–497.
- Basso, M.A., and Sommer, M.A. (2011). Exploring the role of the substantia nigra pars reticulata in eye movements. *NEUROSCIENCE* *198*, 205–212.
- Baumgartner, U., Iannetti, G.D., Zambreanu, L., Stoeter, P., Treede, R.D., and Tracey, I. (2010). Multiple Somatotopic Representations of Heat and Mechanical Pain in the Operculo-Insular Cortex: A High-Resolution fMRI Study. *J. Neurophysiol.* *104*, 2863–2872.
- Beal, M.F. (2001). Experimental models of Parkinson's disease. *Nat. Rev. Neurosci.* *2*, 325–334.
- Beck, S., and Hallett, M. (2011). Surround inhibition in the motor system. *Exp. Brain Res.* *210*, 165–172.
- Beeler, J.A., Frank, M.J., McDaid, J., Alexander, E., Turkson, S., Bernandez, M.S., McGehee, D.S., and Zhuang, X. (2012). A Role for Dopamine-Mediated Learning in the Pathophysiology and Treatment of Parkinson's Disease. *CellReports* *2*, 1747–1761.
- Beeler, J.A., Petzinger, G., and Jakowec, M.W. (2013). The Enemy within: Propagation of Aberrant Corticostriatal Learning to Cortical Function in Parkinson's Disease. *Front. Neurol.* *4*.
- Beisteiner, R., Windischberger, C., Lanzenberger, R., Edward, V., Cunnington, R., Erdler, M., Gartus, A., Streibl, B., Moser, E., and Deecke, L. (2001). Finger Somatotopy in Human Motor Cortex. *NeuroImage* *13*, 1016–1026.
- Belin, D., Jonkman, S., Dickinson, A., Robbins, T.W., and Everitt, B.J. (2009). Parallel and interactive learning processes within the basal ganglia: Relevance for the understanding of addiction. *Behav. Brain Res.* *199*, 89–102.

- Belluscio, M.A., Escande, M.V., Keifman, E., Riquelme, L.A., Murer, M.G., and Zold, C.L. (2013). Oscillations in the basal ganglia in Parkinson's disease: Role of the striatum. *Biochem. Pharmacol.* 1–10.
- Benarroch, E.E. (2008). The midline and intralaminar thalamic nuclei: anatomic and functional specificity and implications in neurologic disease. *Neurology* 71, 944–949.
- Benarroch, E.E. (2009). Brain iron homeostasis and neurodegenerative disease. *Neurology* 72, 1436–1440.
- Benarroch, E.E. (2013). Pedunculopontine nucleus: Functional organization and clinical implications. *Neurology* 80, 1148–1155.
- Ben-Eliezer, N., Goerke, U., Ugurbil, K., and Frydman, L. (2012). Functional MRI using super-resolved spatiotemporal encoding. *Magn. Reson. Imaging* 30, 1401–1408.
- Bergman, H., and Deuschl, G. (2002). Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. *Mov. Disord.* 17, S28–S40.
- Bergman, H., Feingold, A., Nini, A., Raz, A., Slovin, H., Abeles, M., and Vaadia, E. (1998a). Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. *Trends Neurosci.* 21, 32–38.
- Bergman, H., Raz, A., Feingold, A., Nini, A., Nelken, I., Hansel, D., Ben-Pazi, H., and Reches, A. (1998b). Physiology of MPTP tremor. *Mov. Disord. Off. J. Mov. Disord. Soc.* 13 Suppl 3, 29–34.
- Berke, J.D. (2011). Functional properties of striatal fast-spiking interneurons. *Front. Syst. Neurosci.* 5, 45.
- Bernard, J.A., and Mittal, V.A. (2014). Cerebellar-motor dysfunction in schizophrenia and psychosis-risk: the importance of regional cerebellar analysis approaches. *Front. Psychiatry* 5, 160.
- Berns, G.S., and Sejnowski, T.J. (1998). A computational model of how the basal ganglia produce sequences. *Cogn. Neurosci. J. Of* 10, 108–121.
- di Biase, L., and Fasano, A. (2016). Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope? *Mov. Disord.* 31, 962–967.
- Bittar, R.G., Burn, S.C., Bain, P.G., Owen, S.L., Joint, C., Shlugman, D., and Aziz, T.Z. (2005). Deep brain stimulation for movement disorders and pain. *J. Clin. Neurosci.* 12, 457–463.
- Blandini, F., and Armentero, M.-T. (2014). Dopamine receptor agonists for Parkinson's disease. *Expert Opin. Investig. Drugs* 23, 387–410.
- Bolam, J.P., Smith, Y., Ingham, C.A., von Krosigk, M., and Smith, A.D. (1993). Chapter 5 Convergence of synaptic terminals from the striatum and the globus pallidus onto single

neurones in the substantia nigra and the entopeduncular nucleus. In *Chemical Signalling in the Basal Ganglia*, G.W. Arbuthnott, and P.C. Emson, eds. (Elsevier), pp. 73–88.

Bonifati, V. (2013). Genetics of Parkinson's disease - state of the art, 2013. *Parkinsonism Relat. Disord.* 20, S23–S28.

Boraud, T., Bézard, E., Bouliac, B., and Gross, C.E. (2000). Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. *J. Neurophysiol.* 83, 1760–1763.

Bosboom, J.L.W., Stoffers, D., and Wolters, E.C. (2004). Cognitive dysfunction and dementia in Parkinson's disease. *J. Neural Transm. Vienna Austria 1996* 111, 1303–1315.

Bosch-Bouju, C., Hyland, B.I., and Parr-Brownlie, L.C. (2013). Motor thalamus integration of cortical, cerebellar and basal ganglia information: implications for normal and parkinsonian conditions. *Front. Comput. Neurosci.* 7, 163.

Bose, A., and Beal, M.F. (2016). Mitochondrial dysfunction in Parkinson's disease. *J. Neurochem.* 139 Suppl 1, 216–231.

Bostan, A.C., Dum, R.P., and Strick, P.L. (2013). Cerebellar networks with the cerebral cortex and basal ganglia. *Trends Cogn. Sci.* 1–14.

Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., and Braak, E. (2003a). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol. Aging* 24, 197–211.

Braak, H., Rüb, U., Gai, W.P., and Del Tredici, K. (2003b). Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J. Neural Transm.* 110, 517–536.

Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., and Del Tredici, K. (2004). Stages in the development of Parkinson's disease-related pathology. *Cell Tissue Res.* 318, 121–134.

Bromberg-Martin, E.S., Matsumoto, M., and Hikosaka, O. (2010). Dopamine in Motivational Control: Rewarding, Aversive, and Alerting. *Neuron* 68, 815–834.

Bronfeld, M., and Bar-Gad, I. (2011). Loss of specificity in Basal Ganglia related movement disorders. *Front. Syst. Neurosci.* 5, 38.

Brooks, D.J. (2010). Imaging Approaches to Parkinson Disease. *J. Nucl. Med.* 51, 596–609.

Brooks, D.J., and Pavese, N. (2011). Imaging biomarkers in Parkinson's disease. *Prog. Neurobiol.* 95, 614–628.

Brooks, J.C.W., Zambreanu, L., Godinez, A., Craig, A.D.B., and Tracey, I. (2005). Somatotopic organisation of the human insula to painful heat studied with high resolution functional imaging. *NeuroImage* 27, 201–209.

- Brooks, J.C.W., Faull, O.K., Pattinson, K.T.S., and Jenkinson, M. (2013). Physiological noise in brainstem FMRI. *Front. Hum. Neurosci.* *7*, 623.
- Broussard, J.I., Jenson, D., and Dani, J.A. (2013). Dopaminergic influence over hippocampal synaptic plasticity and function. *Clin. Exp. Neurosci.*
- Brown, P. (2007). Abnormal oscillatory synchronisation in the motor system leads to impaired movement. *Curr. Opin. Neurobiol.* *17*, 656–664.
- Brown, J., Bullock, D., and Grossberg, S. (1999). How the basal ganglia use parallel excitatory and inhibitory learning pathways to selectively respond to unexpected rewarding cues. *J. Neurosci. Off. J. Soc. Neurosci.* *19*, 10502–10511.
- Brown, J.W., Bullock, D., and Grossberg, S. (2004). How laminar frontal cortex and basal ganglia circuits interact to control planned and reactive saccades. *Neural Netw.* *17*, 471–510.
- Brundin, P., Ma, J., and Kordower, J.H. (2016). How strong is the evidence that Parkinson's disease is a prion disorder? *Curr. Opin. Neurol.* *29*, 459–466.
- Bullmore, E., and Sporns, O. (2009). Complex brain networks: graph theoretical analysis of structural and functional systems. *Nat. Publ. Group* *10*, 186–198.
- Burke, R.E., Dauer, W.T., and Vonsattel, J.P.G. (2008). A critical evaluation of the Braak staging scheme for Parkinson's disease. *Ann. Neurol.* *64*, 485–491.
- Burn, D.J. (2002a). Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease. *Mov. Disord.* *17*, 445–454.
- Burn, D.J. (2002b). Depression in Parkinson's disease. *Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc.* *9 Suppl 3*, 44–54.
- Calabresi, P., Centonze, D., Gubellini, P., Pisani, A., and Bernardi, G. (2000). Acetylcholine-mediated modulation of striatal function. *Trends Neurosci.* *23*, 120–126.
- Calabresi, P., Picconi, B., Tozzi, A., and Di Filippo, M. (2007). Dopamine-mediated regulation of corticostriatal synaptic plasticity. *Trends Neurosci.* *30*, 211–219.
- Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., and Di Filippo, M. (2014). Direct and indirect pathways of basal ganglia: a critical reappraisal. *Nat. Publ. Group* *17*, 1022–1030.
- Calabresi, P., Ghiglieri, V., Mazzocchetti, P., Corbelli, I., and Picconi, B. (2015). Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? *Philos. Trans. R. Soc. B Biol. Sci.* *370*, 20140184.
- Cali, T., Ottolini, D., and Brini, M. (2011). Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease. *BioFactors* *37*, 228–240.

- Cavanagh, J.F., Wiecki, T.V., Cohen, M.X., Figueroa, C.M., Samanta, J., Sherman, S.J., and Frank, M.J. (2011). Subthalamic nucleus stimulation reverses mediofrontal influence over decision threshold. *Nat. Publ. Group* 14, 1462–1467.
- Chagas, M.H.N., Linares, I.M.P., Garcia, G.J., Hallak, J.E.C., Tumas, V., and Crippa, J.A.S. (2013). Neuroimaging of depression in Parkinson's disease: a review. *Int. Psychogeriatr.* 25, 1953–1961.
- Chahine, L.M., and Stern, M.B. (2011). Diagnostic markers for Parkinson's disease. *Curr. Opin. Neurol.* 24, 309–317.
- Chahine, L.M., Stern, M.B., and Chen-Plotkin, A. (2013). Blood-based biomarkers for Parkinson's disease. *Parkinsonism Relat. Disord.* 20, S99–S103.
- Chan, C.S., Surmeier, D.J., and Yung, W. (2006). Striatal Information Signaling and Integration in Globus Pallidus: Timing Matters. *Neurosignals* 14, 281–289.
- Chaudhuri, K.R., Healy, D.G., Schapira, A.H.V., and National Institute for Clinical Excellence (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol.* 5, 235–245.
- Cheng, K. (2012). Revealing human ocular dominance columns using high-resolution functional magnetic resonance imaging. *NeuroImage* 62, 1029–1034.
- Chevalier, G., and Deniau, J.M. (1990). Disinhibition as a basic process in the expression of striatal functions. *Trends Neurosci.* 13, 277–280.
- Christopher, L., and Strafella, A.P. (2013). Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease. *J. Neuropsychol.* 7, 225–240.
- Christopher, L., Koshimori, Y., Lang, A.E., Criaud, M., and Strafella, A.P. (2014). Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. *Brain* 137, 2143–2154.
- Chung, C.L., and Mak, M.K.Y. (2016). Effect of Repetitive Transcranial Magnetic Stimulation on Physical Function and Motor Signs in Parkinson's Disease: A Systematic Review and Meta-Analysis. *Brain Stimulat.* 9, 475–487.
- Clarke, R., and Adermark, L. (2015). Dopaminergic Regulation of Striatal Interneurons in Reward and Addiction: Focus on Alcohol. *Neural Plast.* 1–11.
- Cleary, D.R., Ozpinar, A., Raslan, A.M., and Ko, A.L. (2015). Deep brain stimulation for psychiatric disorders: where we are now. *Neurosurg. Focus* 38, E2.
- Cohen, M.R., and Kohn, A. (2011). Measuring and interpreting neuronal correlations. *Nat. Neurosci.* 14, 811–819.

- Conant, D., Bouchard, K.E., and Chang, E.F. (2014). Speech map in the human ventral sensory-motor cortex. *Curr. Opin. Neurobiol.* *24*, 63–67.
- Conn, P.J., Battaglia, G., Marino, M.J., and Nicoletti, F. (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. *Nat. Publ. Group* *6*, 787–798.
- Contreras-Vidal, J.L., and Schultz, W. (1999). A predictive reinforcement model of dopamine neurons for learning approach behavior. *J. Comput. Neurosci.* *6*, 191–214.
- Cools, R. (2006). Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. *Neurosci. Biobehav. Rev.* *30*, 1–23.
- Corti, O., Hampe, C., Darios, F., Ibanez, P., Ruberg, M., and Brice, A. (2005). Parkinson's disease: from causes to mechanisms. *C. R. Biol.* *328*, 131–142.
- Crittenden, J.R., and Graybiel, A.M. (2011). Basal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. *Front. Neuroanat.* *5*, 59.
- Cunningham, D.A., Machado, A., Yue, G.H., Carey, J.R., and Plow, E.B. (2013). Functional somatotopy revealed across multiple cortical regions using a model of complex motor task. *Brain Res.* *1531*, 25–36.
- Cyron, D. (2016). Mental Side Effects of Deep Brain Stimulation (DBS) for Movement Disorders: The Futility of Denial. *Front. Integr. Neurosci.* *10*, 1722.
- Darbin, O., Soares, J., and Wichmann, T. (2006). Nonlinear analysis of discharge patterns in monkey basal ganglia. *Brain Res.* *1118*, 84–93.
- Darbin, O., Dees, D., Martino, A., Adams, E., and Naritoku, D. (2013a). An Entropy-Based Model for Basal Ganglia Dysfunctions in Movement Disorders. *BioMed Res. Int.* *2013*, 1–5.
- Darbin, O., Adams, E., Martino, A., Naritoku, L., Dees, D., and Naritoku, D. (2013b). Non-linear dynamics in parkinsonism. *Front. Neurol.* *4*, 211.
- D'Ardenne, K., Eshel, N., Luka, J., Lenartowicz, A., Nystrom, L.E., and Cohen, J.D. (2012). Role of prefrontal cortex and the midbrain dopamine system in working memory updating. *Proc. Natl. Acad. Sci. U. S. A.* *109*, 19900–19909.
- D'Ardenne, K., Lohrenz, T., Bartley, K.A., and Montague, P.R. (2013). Computational heterogeneity in the human mesencephalic dopamine system. *Cogn. Affect. Behav. Neurosci.* *13*, 747–756.
- Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. *Neuron* *39*, 889–909.
- Davie, C.A. (2008). A review of Parkinson's disease. *Br. Med. Bull.* *86*, 109–127.

Davis, T., and Poldrack, R.A. (2013). Measuring neural representations with fMRI: practices and pitfalls. *Ann. N. Y. Acad. Sci.* *1296*, 108–134.

Daw, N.D., Niv, Y., and Dayan, P. (2005). Uncertainty-based competition between prefrontal and dorsolateral striatal systems for behavioral control. *Nat. Neurosci.* *8*, 1704–1711.

Dawson, T.M., Ko, H.S., and Dawson, V.L. (2010). Genetic Animal Models of Parkinson's Disease. *Neuron* *66*, 646–661.

Dayan, P., and Daw, N.D. (2008). Decision theory, reinforcement learning, and the brain. *Cogn. Affect. Behav. Neurosci.* *8*, 429–453.

De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M.I., Gallo, A., Conte, M., Rosato, C., Appiani, M.C., and de Vincentiis, M. (2016). Parkinson's disease: Autoimmunity and neuroinflammation. *Autoimmun. Rev.* *15*, 1005–1011.

Dechent, P., and Frahm, J. (2003). Functional somatotopy of finger representations in human primary motor cortex. *Hum. Brain Mapp.* *18*, 272–283.

Deco, G., Tononi, G., Boly, M., and Kringelbach, M.L. (2015). Rethinking segregation and integration: contributions of whole-brain modelling. *Nat. Publ. Group* *16*, 430–439.

Deffains, M., and Bergman, H. (2015). Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease. *Mov. Disord.* *30*, 1014–1025.

Dejean, C., Gross, C.E., Bioulac, B., and Boraud, T. (2008). Dynamic Changes in the Cortex-Basal Ganglia Network After Dopamine Depletion in the Rat. *J. Neurophysiol.* *100*, 385–396.

Dejean, C., Nadjar, A., Le Moine, C., Bioulac, B., Gross, C.E., and Boraud, T. (2012). Evolution of the dynamic properties of the cortex–basal ganglia network after dopaminergic depletion in rats. *Neurobiol. Dis.* *46*, 402–413.

Del Tredici, K., and Braak, H. (2008). A not entirely benign procedure: progression of Parkinson's disease. *Acta Neuropathol. (Berl.)* *115*, 379–384.

Delmaire, C., Krainik, A., Tezenas du Montcel, S., Gerardin, E., Meunier, S., Mangin, J.F., Sangla, S., Garnero, L., Vidailhet, M., and Lehericy, S. (2005). Disorganized somatotopy in the putamen of patients with focal hand dystonia. *Neurology* *64*, 1391–1396.

DeLong, M.R. (1990). Primate models of movement disorders of basal ganglia origin. *Trends Neurosci.*

DeLong, M., and Wichmann, T. (2009). Update on models of basal ganglia function and dysfunction. *Parkinsonism Relat. Disord.* *15*, S237–S240.

Denny-Brown, D., and Yanagisawa, N. (1976). The role of the basal ganglia in the initiation of movement. *Res. Publ. - Assoc. Res. Nerv. Ment. Dis.* *55*, 115–149.

- Deuschl, G., and Bergman, H. (2002). Pathophysiology of nonparkinsonian tremors. *Mov. Disord. Off. J. Mov. Disord. Soc.* 17 *Suppl 3*, S41–8.
- Devan, B.D., Hong, N.S., and McDonald, R.J. (2011). Parallel associative processing in the dorsal striatum: Segregation of stimulus-response and cognitive control subregions. *Neurobiol. Learn. Mem.* 96, 95–120.
- Dias, V., Junn, E., and Mouradian, M.M. (2013). The role of oxidative stress in Parkinson's disease. *J. Park. Dis.* 3, 461–491.
- Diedrichsen, J., Ridgway, G.R., Friston, K.J., and Wiestler, T. (2011). Comparing the similarity and spatial structure of neural representations: A pattern-component model. *NeuroImage* 55, 1665–1678.
- Diedrichsen, J., Wiestler, T., and Krakauer, J.W. (2013). Two Distinct Ipsilateral Cortical Representations for Individuated Finger Movements. *Cereb. Cortex* 23, 1362–1377.
- Disbrow, E.A., Sigvardt, K.A., Franz, E.A., Turner, R.S., Russo, K.A., Hinkley, L.B., Herron, T.J., Ventura, M.I., Zhang, L., and Malhado-Chang, N. (2013). Movement activation and inhibition in Parkinson's disease: a functional imaging study. *J. Park. Dis.* 3, 181–192.
- Doya, K. (2000). Complementary roles of basal ganglia and cerebellum in learning and motor control. *Curr. Opin. Neurobiol.*
- Doyon, J. (2008). Motor sequence learning and movement disorders. *Curr. Opin. Neurol.* 21, 478–483.
- Doyon, J., Bellec, P., Amsel, R., Penhune, V., Monchi, O., Carrier, J., Lehericy, S., and Benali, H. (2009). Contributions of the basal ganglia and functionally related brain structures to motor learning. *Behav. Brain Res.* 199, 61–75.
- Draganski, B., Kherif, F., Klöppel, S., Cook, P.A., Alexander, D.C., Parker, G.J.M., Deichmann, R., Ashburner, J., and Frackowiak, R.S.J. (2008). Evidence for Segregated and Integrative Connectivity Patterns in the Human Basal Ganglia. *J. Neurosci.* 28, 7143–7152.
- Draganski, B., Ashburner, J., Hutton, C., Kherif, F., Frackowiak, R.S.J., Helms, G., and Weiskopf, N. (2011). Regional specificity of MRI contrast parameter changes in normal ageing revealed by voxel-based quantification (VBQ). *NeuroImage* 55, 1423–1434.
- Drayer, B., Burger, P., Darwin, R., Riederer, S., Herfkens, R., and Johnson, G.A. (1986). MRI of brain iron. *AJR Am. J. Roentgenol.* 147, 103–110.
- Dudman, J.T., and Krakauer, J.W. (2016). The basal ganglia: from motor commands to the control of vigor. *Curr. Opin. Neurobiol.* 37, 158–166.
- Duncan, G.W., Firbank, M.J., O'Brien, J.T., and Burn, D.J. (2013). Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease? *Mov. Disord.* 28, 425–438.

- Dušek, P., Jankovic, J., and Le, W. (2012). Iron dysregulation in movement disorders. *Neurobiol. Dis.* 46, 1–18.
- Dušek, P., Dezortova, M., and Wuerfel, J. (2013). Imaging of iron. *Int. Rev. Neurobiol.* 110, 195–239.
- Duyn, J.H. (2012). The future of ultra-high field MRI and fMRI for study of the human brain. *NeuroImage* 62, 1241–1248.
- Edelman, G.M., and Gally, J.A. (2001). Degeneracy and complexity in biological systems. *Proc. Natl. Acad. Sci. U. S. A.* 98, 13763–13768.
- Eickhoff, S.B., Thirion, B., Varoquaux, G., and Bzdok, D. (2015). Connectivity-based parcellation: Critique and implications. *Hum. Brain Mapp.* 36, 4771–4792.
- van Eimeren, T., and Siebner, H.R. (2006). An update on functional neuroimaging of parkinsonism and dystonia. *Curr. Opin. Neurol.* 19, 412–419.
- Ejaz, N., Hamada, M., and Diedrichsen, J. (2015). Hand use predicts the structure of representations in sensorimotor cortex. *Nat. Publ. Group.*
- Ekstrom, A. (2010). How and when the fMRI BOLD signal relates to underlying neural activity: the danger in dissociation. *Brain Res. Rev.* 62, 233–244.
- Ellens, D.J., and Leventhal, D.K. (2013). Electrophysiology of basal ganglia and cortex in models of Parkinson disease. *J. Park. Dis.* 3, 241–254.
- Erez, Y., Tischler, H., Bebelovsky, K., and Bar-Gad, I. (2011). Dispersed Activity during Passive Movement in the Globus Pallidus of the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Primate. *PLoS ONE* 6, e16293.
- Eriksen, J.L., Wszolek, Z., and Petrucelli, L. (2005). Molecular pathogenesis of Parkinson disease. *Arch. Neurol.* 62, 353–357.
- Fahn, S., Elton, R.L., and Members of the UPDRS committee (1987). The Unified Parkinson's Disease Rating Scale. In *Recent Developments in Parkinson's Disease*, S. Fahn, C.D. Marsden, D.B. Calne, and M. Goldstein, eds. (Florham Park, NJ: Macmillan Healthcare Information), pp. 153–163.
- Feany, M.B. (2004). New genetic insights into Parkinson's disease. *N. Engl. J. Med.* 351, 1937–1940.
- Fearnley, J.M., and Lees, A.J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain* 114 (Pt 5), 2283–2301.
- Feinberg, D.A., and Setsompop, K. (2013). Ultra-fast MRI of the human brain with simultaneous multi-slice imaging. *J. Magn. Reson.* 229, 90–100.

- Feng, L.R., and Maguire-Zeiss, K.A. (2010). Gene Therapy in Parkinson's Disease. *CNS Drugs* 24, 177–192.
- Fernandez, H.H., and Chen, J.J. (2007). Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease. *Pharmacother. J. Ldots*.
- Filion, M., Tremblay, L., and Bédard, P.J. (1988). Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. *Brain Res.* 444, 165–176.
- Fillard, P., Descoteaux, M., Goh, A., Gouttard, S., Jeurissen, B., Malcolm, J., Ramirez-Manzanares, A., Reisert, M., Sakaie, K., Tensaouti, F., et al. (2011). Quantitative evaluation of 10 tractography algorithms on a realistic diffusion MR phantom. *NeuroImage* 56, 220–234.
- Filograna, R., Beltramini, M., Bubacco, L., and Bisaglia, M. (2016). Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View. *Curr. Neurpharmacology* 14, 260–271.
- Fink, G.R., Frackowiak, R.S., Pietrzyk, U., and Passingham, R.E. (1997). Multiple nonprimary motor areas in the human cortex. *J. Neurophysiol.* 77, 2164–2174.
- Fornito, A., and Bullmore, E.T. (2014). Connectomics_ A new paradigm for understanding brain disease. *Eur. Neuropsychopharmacol.* 1–16.
- Fornito, A., Zalesky, A., and Breakspear, M. (2015). The connectomics of brain disorders. *Nat. Publ. Group* 16, 159–172.
- Forno, L.S. (1996). Neuropathology of Parkinson's disease. *J. Neuropathol. Exp. Neurol.* 55, 259–272.
- Francis, S., and Panchuelo, R.S. (2014). Physiological measurements using ultra-high field fMRI: a review. *Physiol. Meas.* 35, R167–R185.
- Frank, L.R. (2001). Anisotropy in high angular resolution diffusion-weighted MRI. *Magn. Reson. Med.* 45, 935–939.
- Frank, L.R. (2002). Characterization of anisotropy in high angular resolution diffusion-weighted MRI. *Magn. Reson. Med.* 47, 1083–1099.
- Frank, M. (2005). Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. *Cogn. Neurosci. J. Of* 17, 51–72.
- Frank, M.J. (2004). By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism. *Science* 306, 1940–1943.

- Frank, M.J., Loughry, B., and O'Reilly, R.C. (2001). Interactions between frontal cortex and basal ganglia in working memory: a computational model. *Cogn. Affect. Behav. Neurosci.* *1*, 137–160.
- Frank, M.J., Samanta, J., Moustafa, A.A., and Sherman, S.J. (2007). Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism. *Science* *318*, 1309–1312.
- Friston, K.J., and Price, C.J. (2003). Degeneracy and redundancy in cognitive anatomy. *Trends Cogn. Sci.* *7*, 151–152.
- Friston, K.J., and Price, C.J. (2011). Modules and brain mapping. *Cogn. Neuropsychol.* *28*, 241–250.
- Friston, K., Chu, C., Mourão-Miranda, J., Hulme, O., Rees, G., Penny, W., and Ashburner, J. (2008). Bayesian decoding of brain images. *NeuroImage* *39*, 181–205.
- Friston, K.J., Holmes, A.P., Worsley, K.J., Poline, J.P., Frith, C.D., and Frackowiak, R.S. (1994). Statistical parametric maps in functional imaging: a general linear approach. *Hum. Brain Mapp.* *2*, 189–210.
- Fudge, J.L., Kunishio, K., Walsh, P., Richard, C., and Haber, S.N. (2002). Amygdaloid projections to ventromedial striatal subterritories in the primate. *NEUROSCIENCE* *110*, 257–275.
- Fujita, M., Ichise, M., Zoghbi, S.S., Liow, J.-S., Ghose, S., Vines, D.C., Sangare, J., Lu, J.-Q., Cropley, V.L., Iida, H., et al. (2005). Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. *Ann. Neurol.* *59*, 174–177.
- Gallea, C., Ewencyk, C., Degos, B., Welter, M.-L., Grabli, D., Leu-Semenescu, S., Valabregue, R., Berroir, P., Yahia-Cherif, L., Bertasi, E., et al. (2017). Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders. *Mov. Disord.*
- Galvan, A., Devergnas, A., and Wichmann, T. (2015). Alterations in neuronal activity in basal ganglia-thalamocortical circuits in the parkinsonian state. *Front. Neuroanat.* *9*, 5.
- Gandhi, S. (2005). Molecular pathogenesis of Parkinson's disease. *Hum. Mol. Genet.* *14*, 2749–2755.
- Ganos, C., Bongert, J., Asmuss, L., Martino, D., Haggard, P., and Münchau, A. (2015). The somatotopy of tic inhibition: Where and how much? *Mov. Disord.* *30*, 1184–1189.
- Gao, L., and Wu, T. (2016). The study of brain functional connectivity in Parkinson's disease. *Transl. Neurodegener.* 1–7.

- Garbayo, E., Ansorena, E., and Blanco-Prieto, M.J. (2013). Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems. *Maturitas* 76, 272–278.
- Gelb, D.J., Oliver, E., and Gilman, S. (1999). Diagnostic criteria for Parkinson disease. *Arch. Neurol.* 56, 33–39.
- Georgiev, D., Lange, F., Seer, C., Kopp, B., and Jahanshahi, M. (2016). Movement-related potentials in Parkinson's disease. *Clin. Neurophysiol. Off. J. Int. Fed. Clin. Neurophysiol.* 127, 2509–2519.
- Gerardin, E., Lehericy, S., Pochon, J.-B., Tézenas du Montcel, S., Mangin, J.-F., Poupon, F., Agid, Y., Le Bihan, D., and Marsault, C. (2003). Foot, hand, face and eye representation in the human striatum. *Cereb. Cortex* 13, 162–169.
- Gerfen, C.R., and Surmeier, D.J. (2011). Modulation of Striatal Projection Systems by Dopamine. *Annu. Rev. Neurosci.* 34, 441–466.
- Gh Popescu, B.F., and Nichol, H. (2010). Mapping Brain Metals to Evaluate Therapies for Neurodegenerative Disease. *CNS Neurosci. Ther.* 17, 256–268.
- Gillies, A., and Arbuthnott, G. (2000). Computational models of the basal ganglia. *Mov. Disord. Off. J. Mov. Disord. Soc.* 15, 762–770.
- Gittis, A.H., and Kreitzer, A.C. (2012). Striatal microcircuitry and movement disorders. *Trends Neurosci.* 35, 557–564.
- Gläscher, J., Daw, N., Dayan, P., and Doherty, J.P.O. (2010). States versus Rewards: Dissociable Neural Prediction Error Signals Underlying Model-Based and Model-Free Reinforcement Learning. *Neuron* 66, 585–595.
- Godau, J., Hussl, A., Lolekha, P., Stoessl, A.J., and Seppi, K. (2012). Neuroimaging: Current role in detecting pre-motor Parkinson's disease. *Mov. Disord.* 27, 634–643.
- Goedert, M., Spillantini, M.G., Del Tredici, K., and Braak, H. (2012). 100 years of Lewy pathology. *Nat. Rev. Neurol.* 9, 13–24.
- Goetz, C.G. (2011). The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. *Cold Spring Harb. Perspect. Med.* 1, a008862–a008862.
- Goetz, C.G., Tilley, B.C., Shaftman, S.R., Stebbins, G.T., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., Stern, M.B., Dodel, R., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. *Mov. Disord.* 23, 2129–2170.
- Golbe, L.I. (1999). Alpha-synuclein and Parkinson's disease. *Mov. Disord.* 14, 6–9.

- Goldberg, J.A., Boraud, T., Maraton, S., Haber, S.N., Vaadia, E., and Bergman, H. (2002). Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. *J. Neurosci.* *22*, 4639–4653.
- Goldberg, J.H., Farries, M.A., and Fee, M.S. (2013). Basal ganglia output to the thalamus: still a paradox. *Trends Neurosci.* *36*, 695–705.
- Goto, Y., Otani, S., and Grace, A.A. (2007). The Yin and Yang of dopamine release: a new perspective. *Neurophysiol. Clin. Neurophysiol.* *53*, 583–587.
- Goveas, J., O'Dwyer, L., Mascalchi, M., Cosottini, M., Diciotti, S., De Santis, S., Passamonti, L., Tessa, C., Toschi, N., and Giannelli, M. (2015). Diffusion-MRI in neurodegenerative disorders. *Magn. Reson. Imaging* *33*, 853–876.
- Grabski, K., Lamalle, L., Vilain, C., Schwartz, J.-L., Vallée, N., Tropres, I., Baciú, M., Le Bas, J.-F., and Sato, M. (2012). Functional MRI assessment of orofacial articulators: neural correlates of lip, jaw, larynx, and tongue movements. *Hum. Brain Mapp.* *33*, 2306–2321.
- Graybiel, A.M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. *Trends Neurosci.* *13*, 244–254.
- Graybiel, A.M. (1998). The basal ganglia and chunking of action repertoires. *Neurobiol. Learn. Mem.* *70*, 119–136.
- Graybiel, A.M. (2008). Habits, Rituals, and the Evaluative Brain. *Annu. Rev. Neurosci.* *31*, 359–387.
- Graybiel, A.M., Aosaki, T., Flaherty, A.W., and Kimura, M. (1994). The basal ganglia and adaptive motor control. *Science* *265*, 1826–1831.
- Graziano, M.S.A., and Aflalo, T.N. (2007a). Mapping Behavioral Repertoire onto the Cortex. *Neuron* *56*, 239–251.
- Graziano, M.S.A., and Aflalo, T.N. (2007b). Rethinking Cortical Organization: Moving Away from Discrete Areas Arranged in Hierarchies. *The Neuroscientist* *13*, 138–147.
- Green, D.W., Crinion, J., and Price, C.J. (2006). Convergence, degeneracy and control. *Lang. Learn.* *56*, 99–125.
- Grillner, S., and Robertson, B. (2016). The Basal Ganglia Over 500 Million Years. *Curr. Biol.* *26*, R1088–R1100.
- Grill-Spector, K., and Malach, R. (2004). The human visual cortex. *Annu. Rev. Neurosci.* *27*, 649–677.
- Gruber, A.J. (2003). Modulation of Striatal Single Units by Expected Reward: A Spiny Neuron Model Displaying Dopamine-Induced Bistability. *J. Neurophysiol.* *90*, 1095–1114.

- Guillery, R.W., and Sherman, S.M. (2002). The thalamus as a monitor of motor outputs. *Philos. Trans. R. Soc. B Biol. Sci.* *357*, 1809–1821.
- Gurney, K., Prescott, T.J., and REDGRAVE, P. (2001a). A computational model of action selection in the basal ganglia. I. A new functional anatomy. *Biol. Cybern.* *84*, 401–410.
- Gurney, K., Prescott, T.J., and REDGRAVE, P. (2001b). A computational model of action selection in the basal ganglia. II. Analysis and simulation of behaviour. *Biol. Cybern.* *84*, 411–423.
- Guthrie, M., Myers, C.E., and Gluck, M.A. (2009). A neurocomputational model of tonic and phasic dopamine in action selection: a comparison with cognitive deficits in Parkinson's disease. *Behav. Brain Res.* *200*, 48–59.
- Haacke, E.M., Cheng, N.Y.C., House, M.J., Liu, Q., Neelavalli, J., Ogg, R.J., Khan, A., Ayaz, M., Kirsch, W., and Obenaus, A. (2005). Imaging iron stores in the brain using magnetic resonance imaging. *Magn. Reson. Imaging* *23*, 1–25.
- Haber, S.N. (2003). The primate basal ganglia: parallel and integrative networks. *J. Chem. Neuroanat.* *26*, 317–330.
- Haber, S.N. (2016). Corticostriatal circuitry. *Dialogues Clin. Neurosci.* *18*, 7–21.
- Haber, S.N., and Calzavara, R. (2009). The cortico-basal ganglia integrative network: The role of the thalamus. *Brain Res. Bull.* *78*, 69–74.
- Haber, S.N., and Knutson, B. (2009). The Reward Circuit: Linking Primate Anatomy and Human Imaging. *Neuropsychopharmacology* *35*, 4–26.
- Haber, S.N., Fudge, J.L., and McFarland, N.R. (2000). Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. *J. Neurosci.* *20*, 2369–2382.
- Haegelen, C., Rouaud, T., Darnault, P., and Morandi, X. (2009). The subthalamic nucleus is a key-structure of limbic basal ganglia functions. *Med. HYPOTHESES* *72*, 421–426.
- Haelterman, N.A., Yoon, W.H., Sandoval, H., Jaiswal, M., Shulman, J.M., and Bellen, H.J. (2014). A Mitocentric View of Parkinson's Disease. *Annu. Rev. Neurosci.* *37*, 137–159.
- Hagmann, P., Cammoun, L., Gigandet, X., Meuli, R., Honey, C.J., Wedeen, V.J., and Sporns, O. (2008). Mapping the structural core of human cerebral cortex. *PLoS Biol.* *6*, e159.
- Hagmann, P., Cammoun, L., Gigandet, X., Gerhard, S., Grant, P.E., Wedeen, V., Meuli, R., Thiran, J.-P., Honey, C.J., and Sporns, O. (2010). MR connectomics: Principles and challenges. *J. Neurosci. Methods* *194*, 34–45.
- Halliday, G.M. (2009). Thalamic changes in Parkinson's disease. *Park. Realt. Disord.* *15*, S152–S155.

- Halliday, G.M., Leverenz, J.B., Schneider, J.S., and Adler, C.H. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. *Mov. Disord.* 29, 634–650.
- Hardy, J. (2010). Genetic Analysis of Pathways to Parkinson Disease. *Neuron* 68, 201–206.
- Hare, D.J., and Double, K.L. (2016). Iron and dopamine: a toxic couple. *Brain* 139, 1026–1035.
- Harel, N. (2012). Ultra high resolution fMRI at ultra-high field. *NeuroImage* 62, 1024–1028.
- Hauser, R.A. (2009). Levodopa: Past, Present, and Future. *Eur. Neurol.* 62, 1–8.
- Hawkes, C.H., Del Tredici, K., and Braak, H. (2009). Parkinson's disease: the dual hit theory revisited. *Ann. N. Y. Acad. Sci.* 1170, 615–622.
- Hazy, T.E., Frank, M.J., and O'Reilly, R.C. (2007). Towards an executive without a homunculus: computational models of the prefrontal cortex/basal ganglia system. *Philos. Trans. R. Soc. B Biol. Sci.* 362, 1601–1613.
- Heeger, D.J., and Ress, D. (2002). What does fMRI tell us about neuronal activity? *Nat. Rev. Neurosci.* 3, 142–151.
- Heimer, G., Rivlin-Etzion, M., Bar-Gad, I., Goldberg, J.A., Haber, S.N., and Bergman, H. (2006). Dopamine Replacement Therapy Does Not Restore the Full Spectrum of Normal Pallidal Activity in the 1-Methyl-4-Phenyl-1,2,3,6-Tetra-Hydropyridine Primate Model of Parkinsonism. *J. Neurosci.* 26, 8101–8114.
- Hélie, S., Paul, E.J., and Ashby, F.G. (2011). Simulating Parkinson's disease patient deficits using a COVIS-based computational model. 207–214.
- Helmich, R.C., Derikx, L.C., Bakker, M., Scheeringa, R., Bloem, B.R., and Toni, I. (2010). Spatial Remapping of Cortico-striatal Connectivity in Parkinson's Disease. *Cereb. Cortex* 20, 1175–1186.
- Helmich, R.C., Hallett, M., Deuschl, G., Toni, I., and Bloem, B.R. (2012). Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? *Brain* 135, 3206–3226.
- Helms, G., Draganski, B., Frackowiak, R., Ashburner, J., and Weiskopf, N. (2009). Improved segmentation of deep brain grey matter structures using magnetization transfer (MT) parameter maps. *NeuroImage* 47, 194–198.
- Henderson, L.A., Gandevia, S.C., and Macefield, V.G. (2007). Somatotopic organization of the processing of muscle and cutaneous pain in the left and right insula cortex: A single-trial fMRI study. *Pain* 128, 20–30.
- Henderson, L.A., Rubin, T.K., and Macefield, V.G. (2010). Within-limb somatotopic representation of acute muscle pain in the human contralateral dorsal posterior insula. *Hum. Brain Mapp.* 32, 1592–1601.

- Henson, R.N.A. (2011). Efficient experimental design for fMRI. In *Statistical Parametric Mapping: The Analysis of Functional Brain Images: The Analysis of Functional Brain Images*, (Academic Press), p.
- Herrero, M.-T., Barcia, C., and Navarro, J.M. (2002). Functional anatomy of thalamus and basal ganglia. *Childs Nerv. Syst. ChNS Off. J. Int. Soc. Pediatr. Neurosurg.* 18, 386–404.
- Hickey, P., and Stacy, M. (2016). Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease. *Front. Neurosci.* 10, 76.
- Higuchi, Y., Matsuda, S., and Serizawa, T. (2016). Gamma knife radiosurgery in movement disorders: Indications and limitations. *Mov. Disord.* 32, 28–35.
- Hikosaka, O., Kim, H.F., Yasuda, M., and Yamamoto, S. (2014). Basal Ganglia circuits for reward value-guided behavior. *Annu. Rev. Neurosci.* 37, 289–306.
- Hillman, E.M.C. (2014). Coupling Mechanism and Significance of the BOLD Signal: A Status Report. *Annu. Rev. Neurosci.* 37, 161–181.
- Hjorth, J., Blackwell, K.T., and Hellgren Kotaleski, J. (2009). Gap Junctions between Striatal Fast-Spiking Interneurons Regulate Spiking Activity and Synchronization as a Function of Cortical Activity. *J. Neurosci.* 29, 5276–5286.
- Hlustik, P., Solodkin, A., Gullapalli, R.P., Noll, D.C., and Small, S.L. (2001). Somatotopy in human primary motor and somatosensory hand representations revisited. *Cereb. Cortex N. Y. N* 1991 11, 312–321.
- Hoehn, M.M., and Yahr, M.D. (1967). Parkinsonism: onset, progression and mortality. *Neurology* 17, 427–442.
- Hollerman, J.R., and Schultz, W. (1998). Dopamine neurons report an error in the temporal prediction of reward during learning. *Nat. Neurosci.* 1, 304–309.
- Hoover, J.E., and Strick, P.L. (1993). Multiple output channels in the basal ganglia. *Science.*
- Horvitz, J.C., Stewart, T., and Jacobs, B.L. (1997). Burst activity of ventral tegmental dopamine neurons is elicited by sensory stimuli in the awake cat. *Brain Res.* 759, 251–258.
- Hotter, A., Esterhammer, R., Schocke, M.F.H., and Seppi, K. (2009). Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism. *Mov. Disord.* 24, S711–S720.
- Houk, J.C. (2005). Agents of the mind. *Biol. Cybern.* 92, 427–437.
- Houk, J.C., Adams, J.L., and Barto, A.G. (1995). A model of how the basal ganglia generate and use neural signals that predict reinforcement. In *Models of Information Processing in the Basal Ganglia*, (Cambridge, MA: MIT Press), pp. 249–274.

Houk, J.C., Bastianen, C., Fansler, D., Fishbach, A., Fraser, D., Reber, P.J., Roy, S.A., and Simo, L.S. (2007). Action selection and refinement in subcortical loops through basal ganglia and cerebellum. *Philos. Trans. R. Soc. B Biol. Sci.* *362*, 1573–1583.

Hughes, A.J., Daniel, S.E., and Kilford, L. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* *181*–184.

Humphries, M.D., Stewart, R.D., and Gurney, K.N. (2006). A Physiologically Plausible Model of Action Selection and Oscillatory Activity in the Basal Ganglia. *J. Neurosci.* *26*, 12921–12942.

Hyde, J.S., Biswal, B.B., and Jesmanowicz, A. (2001). High-resolution fMRI using multislice partial k-space GR-EPI with cubic voxels. *Magn. Reson. Med.* *46*, 114–125.

Ibarretxe-Bilbao, N., Tolosa, E., Junque, C., and Martí, M.J. (2009). MRI and cognitive impairment in Parkinson's disease. *Mov. Disord.* *24*, S748–S753.

Ibarretxe-Bilbao, N., Junque, C., Martí, M.J., and Tolosa, E. (2011). Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. *J. Neurol. Sci.* *310*, 70–74.

Indovina, I., and Sanes, J.N. (2001). On Somatotopic Representation Centers for Finger Movements in Human Primary Motor Cortex and Supplementary Motor Area. *NeuroImage* *13*, 1027–1034.

Irwin, D.J., Y, L.V.M., and Trojanowski, J.Q. (2013). Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. *Nat. Publ. Group* *14*, 626–636.

Iwamuro, H. (2011). Electrophysiological evidences of organization of cortical motor information in the Basal Ganglia. *J. Mov. Disord.* *4*, 8–12.

Jagmag, S.A., Tripathi, N., Shukla, S.D., Maiti, S., and Khurana, S. (2016). Evaluation of Models of Parkinson's Disease. *Front. Neurosci.* *9*, 6428.

Jahanshahi, M., Obeso, I., Rothwell, J.C., and Obeso, J.A. (2015). A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. *Nat. Publ. Group* *16*, 719–732.

Jaidar, O., Carrillo-Reid, L., Hernandez, A., Drucker-Colin, R., Bargas, J., and Hernandez-Cruz, A. (2010). Dynamics of the Parkinsonian Striatal Microcircuit: Entrainment into a Dominant Network State. *J. Neurosci.* *30*, 11326–11336.

Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. *J. Neurol. Neurosurg. Psychiatry* *79*, 368–376.

Jellinger, K.A. (2009). Formation and development of Lewy pathology: a critical update. *J. Neurol.* *256*, 270–279.

- Jellinger, K.A. (2011). Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. *Mov. Disord.* 27, 8–30.
- Jesmanowicz, A., Bandettini, P.A., and Hyde, J.S. (1998). Single-shot half k-space high-resolution gradient-recalled EPI for fMRI at 3 Tesla. *Magn. Reson. Med.* 40, 754–762.
- Joel, D., and Weiner, I. (1997). The connections of the primate subthalamic nucleus: indirect pathways and the open-interconnected scheme of basal ganglia-thalamocortical circuitry. *Brain Res. Brain Res. Rev.* 23, 62–78.
- Joel, D., and Weiner, I. (2000). The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. *NEUROSCIENCE* 96, 451–474.
- Joel, D., Niv, Y., and Ruppin, E. (2002). Actor-critic models of the basal ganglia: new anatomical and computational perspectives. *Neural Netw. Off. J. Int. Neural Netw. Soc.* 15, 535–547.
- Johansen-Berg, H., and Rushworth, M.F.S. (2009). Using Diffusion Imaging to Study Human Connectional Anatomy. *Annu. Rev. Neurosci.* 32, 75–94.
- Jones, D.K., and Basser, P.J. (2004). “Squashing peanuts and smashing pumpkins”: how noise distorts diffusion-weighted MR data. *Magn. Reson. Med.* 52, 979–993.
- Jones, D.K., and Cercignani, M. (2010). Twenty-five pitfalls in the analysis of diffusion MRI data. *NMR Biomed.* 23, 803–820.
- Jones, D.K., Knösche, T.R., and Turner, R. (2013). White matter integrity, fiber count, and other fallacies: The do's and don'ts of diffusion MRI. *NeuroImage* 73, 239–254.
- Kaakkola, S. (2010). Problems with the Present Inhibitors and a Relevance of New and Improved COMT Inhibitors in Parkinson's Disease. In *Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of Its Inhibitors*, E. Nissinen, ed. (Academic Press), pp. 207–225.
- Kaji, Y., and Hirata, K. (2011). Apathy and Anhedonia in Parkinson's Disease. *ISRN Neurol.* 2011, 1–9.
- Kalia, L.V., and Lang, A.E. (2015). Parkinson's disease. *The Lancet* 386, 896–912.
- Kamali Sarvestani, I., Lindahl, M., Hellgren-Kotaleski, J., and Ekeberg, O. (2011). The arbitration-extension hypothesis: a hierarchical interpretation of the functional organization of the Basal Ganglia. *Front. Syst. Neurosci.* 5, 13.
- Kaneda, K., Nambu, A., Tokuno, H., and Takada, M. (2002). Differential processing patterns of motor information via striatopallidal and striatonigral projections. *J. Neurophysiol.* 88, 1420–1432.

Kanold, P.O., Nelken, I., and Polley, D.B. (2014). Local versus global scales of organization in auditory cortex. *Trends Neurosci.* *37*, 502–510.

Kapreli, E., Athanasopoulos, S., Papathanasiou, M., Van Hecke, P., Kelekis, D., Peeters, R., Strimpakos, N., and Sunaert, S. (2007). Lower Limb Sensorimotor Network: Issues of Somatotopy and Overlap. *CORTEX* *43*, 219–232.

Kassavetis, P., Sadnicka, A., Saifee, T.A., Belvisi, D., van den Bos, M., Pareés, I., Kojovic, M., Rothwell, J.C., and Edwards, M.J. (2014). Motor “surround inhibition” is not correlated with activity in surround muscles. *Eur. J. Neurosci.* *40*, 2541–2547.

Ke, Y., and Ming Qian, Z. (2003). Iron misregulation in the brain: a primary cause of neurodegenerative disorders. *Lancet Neurol.* *2*, 246–253.

Keeler, J.F., Pretsell, D.O., and Robbins, T.W. (2014). Functional implications of dopamine D1 vs. D2 receptors: A “prepare and select” model of the striatal direct vs. indirect pathways. *NEUROSCIENCE* *282*, 156–175.

Kempster, P.A., O’Sullivan, S.S., Holton, J.L., Revesz, T., and Lees, A.J. (2010). Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. *Brain* *133*, 1755–1762.

Keuken, M.C., Bazin, P.L., Crown, L., Hootsmans, J., Laufer, A., Müller-Axt, C., Sier, R., van der Putten, E.J., Schäfer, A., Turner, R., et al. (2014). Quantifying inter-individual anatomical variability in the subcortex using 7T structural MRI. *NeuroImage* *94*, 40–46.

Kim, K., Müller, M.L.T.M., Bohnen, N.I., Sarter, M., and Lustig, C. (2017). Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection_ Evidence from Parkinson’s disease patients with defined cholinergic losses. *NeuroImage* *149*, 295–304.

Kincaid, A.E., Zheng, T., and Wilson, C.J. (1998). Connectivity and convergence of single corticostriatal axons. *J. Neurosci. Off. J. Soc. Neurosci.* *18*, 4722–4731.

Kirilina, E., Lutti, A., Poser, B.A., Blankenburg, F., and Weiskopf, N. (2016). The quest for the best: The impact of different EPI sequences on the sensitivity of random effect fMRI group analyses. *NeuroImage* *126*, 49–59.

Kirsch-Darrow, L., Marsiske, M., Okun, M.S., Bauer, R., and Bowers, D. (2011). Apathy and Depression: Separate Factors in Parkinson’s Disease. *J. Int. Neuropsychol. Soc.* *17*, 1058–1066.

Kita, H. (2007). Globus pallidus external segment. In *Gaba and the Basal Ganglia: From Molecules to Systems*, E.D.A. James M Tepper, and J.P. Bolam, eds. (Elsevier), pp. 111–133.

Klein, J.C., Rushworth, M.F.S., Behrens, T.E.J., Mackay, C.E., de Crespigny, A.J., D’Arceuil, H., and Johansen-Berg, H. (2010). Topography of connections between human prefrontal

cortex and mediodorsal thalamus studied with diffusion tractography. *NeuroImage* 51, 555–564.

Kleinschmidt, A., Nitschke, M.F., and Frahm, J. (1997). Somatotopy in the human motor cortex hand area. A high-resolution functional MRI study. *Eur. J. Neurosci.* 9, 2178–2186.

Koller, W.C., and Rueda, M.G. (1998). Mechanism of action of dopaminergic agents in Parkinson's disease. *Neurology* 50, S11–4– NaN–8.

Kolomiets, B.P., Deniau, J.M., Mailly, P., Ménétrey, A., Glowinski, J., and Thierry, A.M. (2001). Segregation and convergence of information flow through the cortico-subthalamic pathways. *J. Neurosci.* 21, 5764–5772.

Kolomiets, B.P., Deniau, J.M., Glowinski, J., and Thierry, A.M. (2003). Basal ganglia and processing of cortical information: functional interactions between trans-striatal and trans-subthalamic circuits in the substantia nigra pars reticulata. *NEUROSCIENCE* 117, 931–938.

Kostic, V.S., and Filippi, M. (2011). Neuroanatomical correlates of depression and apathy in Parkinson's disease: Magnetic resonance imaging studies. *J. Neurol. Sci.* 310, 61–63.

Kostic, V.S., Agosta, F., Pievani, M., Stefanova, E., Jecmenica-Lukic, M., Scarale, A., Spica, V., and Filippi, M. (2012). Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. *Neurology* 78, 409–416.

Kreitzer, A.C. (2009). Physiology and Pharmacology of Striatal Neurons. *Annu. Rev. Neurosci.* 32, 127–147.

Kreitzer, A.C., and Berke, J.D. (2011). Investigating striatal function through cell-type-specific manipulations. *NEUROSCIENCE* 198, 19–26.

Kreitzer, A.C., and Malenka, R.C. (2008). Striatal Plasticity and Basal Ganglia Circuit Function. *Neuron* 60, 543–554.

Kriegeskorte, N. (2008). Representational similarity analysis – connecting the branches of systems neuroscience. *Front. Syst. Neurosci.* 2, 4.

Kriegeskorte, N., and Kievit, R.A. (2013). Representational geometry: integrating cognition, computation, and the brain. *Trends Cogn. Sci.* 17, 401–412.

Kurth, F., Zilles, K., Fox, P.T., Laird, A.R., and Eickhoff, S.B. (2010). A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis. *Brain Struct. Funct.* 214, 519–534.

Lambert, C., Zrinzo, L., Nagy, Z., Lutti, A., Hariz, M., Foltynie, T., Draganski, B., Ashburner, J., and Frackowiak, R. (2012). Confirmation of functional zones within the human subthalamic nucleus: Patterns of connectivity and sub-parcellation using diffusion weighted imaging. *NeuroImage* 60, 83–94.

- Lambert, C., Simon, H., Colman, J., and Barrick, T.R. (2016). Defining Thalamic Nuclei and Topographic Connectivity Gradients in vivo. *NeuroImage* 1–40.
- Lanciego, J.L., Luquin, N., and Obeso, J.A. (2012). Functional Neuroanatomy of the Basal Ganglia. *Cold Spring Harb. Perspect. Med.* 2, a009621–a009621.
- Lang, A.E., and Lozano, A.M. (1998a). Parkinson's disease. First of two parts. *N. Engl. J. Med.* 339, 1044–1053.
- Lang, A.E., and Lozano, A.M. (1998b). Parkinson's disease. Second of two parts. *N. Engl. J. Med.* 339, 1130–1143.
- Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219, 979–980.
- de Lau, L.M., and Breteler, M.M. (2006). Epidemiology of Parkinson's disease. *Lancet Neurol.* 5, 525–535.
- Le Bihan, D. (2012). Diffusion, confusion and functional MRI. *NeuroImage* 62, 1131–1136.
- Le Bihan, D., Mangin, J.F., Poupon, C., Clark, C.A., Pappata, S., Molko, N., and Chabriat, H. (2001). Diffusion tensor imaging: concepts and applications. *J. Magn. Reson. Imaging* 13, 534–546.
- Leblois, A., Meissner, W., Bezard, E., Bioulac, B., Gross, C.E., and Boraud, T. (2006). Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. *Eur. J. Neurosci.* 24, 1201–1208.
- Leblois, A., Meissner, W., Bioulac, B., Gross, C.E., Hansel, D., and Boraud, T. (2007). Late emergence of synchronized oscillatory activity in the pallidum during progressive parkinsonism. *Eur. J. Neurosci.* 26, 1701–1713.
- Lees, A.J. (1989). The on-off phenomenon. *J. Neurol. Neurosurg. Psychiatry Suppl*, 29–37.
- Lehéricy, S., Sharman, M.A., Santos, C.L.D., Paquin, R., and Gallea, C. (2012). Magnetic resonance imaging of the substantia nigra in Parkinson's disease. *Mov. Disord.* 27, 822–830.
- Lehéricy, S., Bardinet, E., Poupon, C., Vidailhet, M., and Francois, C. (2014). 7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease. *Mov. Disord.* 29, 1574–1581.
- Lei, W. (2004). Evidence for Differential Cortical Input to Direct Pathway versus Indirect Pathway Striatal Projection Neurons in Rats. *J. Neurosci.* 24, 8289–8299.
- Lenglet, C., Abosch, A., Yacoub, E., De Martino, F., Sapiro, G., and Harel, N. (2012). Comprehensive in vivo Mapping of the Human Basal Ganglia and Thalamic Connectome in Individuals Using 7T MRI. *PLoS ONE* 7, e29153.

- Lenka, A., Jhunjhunwala, K.R., Saini, J., and Pal, P.K. (2015). Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review. *Park. Realt. Disord.* *21*, 683–691.
- Levine, A.J., Lewallen, K.A., and Pfaff, S.L. (2012). Spatial organization of cortical and spinal neurons controlling motor behavior. *Curr. Opin. Neurobiol.* *22*, 812–821.
- Levy, R., Hutchison, W.D., Lozano, A.M., and Dostrovsky, J.O. (2000). High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor. *J. Neurosci.* *20*, 7766–7775.
- Levy, R., Dostrovsky, J.O., Lang, A.E., Sime, E., Hutchison, W.D., and Lozano, A.M. (2001). Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. *J. Neurophysiol.* *86*, 249–260.
- Levy, R., Hutchison, W.D., Lozano, A.M., and Dostrovsky, J.O. (2002). Synchronized neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. *J. Neurosci.* *22*, 2855–2861.
- LeWitt, P.A., and Fahn, S. (2016). Levodopa therapy for Parkinson disease: A look backward and forward. *Neurology* *86*, S3–12.
- Lieu, C.A., and Subramanian, T. (2012). The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias. *Brain Res. Bull.* *87*, 1–9.
- Lilienfeld, D.E., and Perl, D.P. (1994). Projected neurodegenerative disease mortality among minorities in the United States, 1990-2040. *Neuroepidemiology* *13*, 179–186.
- Lill, C.M. (2016). Genetics of Parkinson's disease. *Mol. Cell. Probes* *30*, 386–396.
- Lim, S.A.O., Kang, U.J., and McGehee, D.S. (2014). Striatal cholinergic interneuron regulation and circuit effects. *Front. Synaptic Neurosci.* *6*, 22.
- Lima, M., Martins, E., Delattre, A., Proença, M., Mori, M., Carabelli, B., and Ferraz, A. (2012). Motor and non-motor features of Parkinson's disease—a review of clinical and experimental studies. *CNS Neurol. Disord.-Drug Targets Former. Curr. Drug Targets-CNS Neurol. Disord.* *11*, 439–449.
- Lin, F.-H., Tsai, K.W.K., Chu, Y.-H., Witzel, T., Nummenmaa, A., Raij, T., Ahveninen, J., Kuo, W.-J., and Belliveau, J.W. (2012). Ultrafast inverse imaging techniques for fMRI. *NeuroImage* *62*, 699–705.
- Lipsman, N., Woodside, B., and Lozano, A.M. (2013). Chapter 22 - Evaluating the potential of deep brain stimulation for treatment-resistant anorexia nervosa. In *Brain Stimulation*, A.M. Lozano, and M. Hallett, eds. (Elsevier), pp. 271–276.

- Liu, T.T. (2016). Noise contributions to the fMRI signal: An overview. *NeuroImage* 143, 141–151.
- Liu, C., Li, W., Tong, K.A., Yeom, K.W., and Kuzminski, S. (2014). Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. *J. Magn. Reson. Imaging* 42, 23–41.
- Logothetis, N.K. (2008). What we can do and what we cannot do with fMRI. *Nature* 453, 869–878.
- Logothetis, N.K., and Wandell, B.A. (2004). Interpreting the BOLD Signal. *Annu. Rev. Physiol.* 66, 735–769.
- Logothetis, N.K., Pauls, J., Augath, M., Trinath, T., and Oeltermann, A. (2001). Neurophysiological investigation of the basis of the fMRI signal. *Nature* 412, 150–157.
- Lorio, S., Kherif, F., Ruef, A., Melie-Garcia, L., Frackowiak, R., Ashburner, J., Helms, G., Lutti, A., and Draganski, B. (2016). Neurobiological origin of spurious brain morphological changes: A quantitative MRI study. *Hum. Brain Mapp.* 37, 1801–1815.
- Lotharius, J., and Brundin, P. (2002). Pathogenesis of parkinson's disease: dopamine, vesicles and α -synuclein. *Nat. Rev. Neurosci.* 3, 932–942.
- Lotze, M., Erb, M., Flor, H., Huelsmann, E., Godde, B., and Grodd, W. (2000). fMRI Evaluation of Somatotopic Representation in Human Primary Motor Cortex. *NeuroImage* 11, 473–481.
- Lozano, A.M., Dostrovsky, J., Chen, R., and Ashby, P. (2002). Deep brain stimulation for Parkinson's disease: disrupting the disruption. *Lancet Neurol.* 1, 225–231.
- Lutti, A., Thomas, D.L., Hutton, C., and Weiskopf, N. (2012). High-resolution functional MRI at 3 T: 3D/2D echo-planar imaging with optimized physiological noise correction. *Magn. Reson. Med.* 69, 1657–1664.
- Macpherson, T., Morita, M., and Hikida, T. (2014). Striatal direct and indirect pathways control decision-making behavior. *Front. Psychol.* 5, 1301.
- Magalingam, K.B., Radhakrishnan, A.K., and Haleagrahara, N. (2015). Protective Mechanisms of Flavonoids in Parkinson's Disease. *Oxid. Med. Cell. Longev.* 2015, 1–14.
- Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., and Tamburin, S. (2016). Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Park. Dis.* 1–18.
- Mahlknecht, P., Hotter, A., Hussl, A., Esterhammer, R., Schocke, M., and Seppi, K. (2010). Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson's Disease. *Neurodegener. Dis.* 7, 300–318.

- Maia, T.V., and Frank, M.J. (2011). From reinforcement learning models to psychiatric and neurological disorders. *Nat. Neurosci.* *14*, 154–162.
- Maillard, L., Ishii, K., Bushara, K., Waldvogel, D., Schulman, A.E., and Hallett, M. (2000). Mapping the basal ganglia: fMRI evidence for somatotopic representation of face, hand, and foot. *Neurology* *55*, 377–383.
- Malherbe, C., Messe, A., Bardinet, E., Péligrini-Issac, M., Perlberg, V., Marrelec, G., Worbe, Y., Yelnik, J., Lehericy, S., and Benali, H. (2014). Combining Spatial Independent Component Analysis with Regression to Identify the Subcortical Components of Resting-State fMRI Functional Networks. *Brain Connect.* *4*, 181–192.
- Mandir, A.S., and Vaughan, C. (2000). Pathophysiology of Parkinson's disease. *Int. Rev. Psychiatry* *12*, 270–280.
- Mannella, F., Gurney, K., and Baldassarre, G. (2013). The nucleus accumbens as a nexus between values and goals in goal-directed behavior: a review and a new hypothesis. *Front. Behav. Neurosci.* *7*, 135.
- Manni, E., and Petrosini, L. (2004). A century of cerebellar somatotopy: a debated representation. *Nat. Rev. Neurosci.* *5*, 241–249.
- Marino, S., Ciurleo, R., Di Lorenzo, G., Barresi, M., De Salvo, S., Giacoppo, S., Bramanti, A., Lanzafame, P., and Bramanti, P. (2012). Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. *Neural Regen. Res.* *7*, 611–619.
- Marras, C., and Chaudhuri, K.R. (2016). Nonmotor features of Parkinson's disease subtypes. *Mov. Disord.* *31*, 1095–1102.
- Marsden, C.D. (1982). The mysterious motor function of the basal ganglia: The Robert Wartenberg Lecture. *Neurology* *32*, 514.
- Marsden, C.D., and Obeso, J.A. (1994). The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. *Brain* *117*, 877–879.
- Martí, M.J., and Tolosa, E. (2013). Parkinson disease: New guidelines for diagnosis of Parkinson disease. *Nat. Publ. Group* *9*, 190–191.
- Martinez-Gonzalez, C., Bolam, J.P., and Mena-Segovia, J. (2011). Topographical organization of the pedunculopontine nucleus. *Front. Neuroanat.* *5*, 22.
- Martini, K., and Monchi, O. (2013). Cortico-basal ganglia and cortico-cerebellar circuits in Parkinson's disease: Pathophysiology or compensation? *Behav. Neurosci.* *127*, 222–236.
- Mary Ann Chapman (2009). Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin-proteasome system? *Med. HYPOTHESES* *73*, 887–891.

- Matsumoto, N., Hanakawa, T., Maki, S., Graybiel, A.M., and Kimura, M. (1999). Nigrostriatal dopamine system in learning to perform sequential motor tasks in a predictive manner. *J. Neurosci.* 19, 978–998.
- Mazzoni, P., Hristova, A., and Krakauer, J.W. (2007). Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation. *J. Neurosci.* 27, 7105–7116.
- Mazzoni, P., Shabbott, B., and Cortes, J.C. (2012). Motor Control Abnormalities in Parkinson's Disease. *Cold Spring Harb. Perspect. Med.* 2, a009282–a009282.
- McGhee, D.J., Royle, P.L., Thompson, P.A., Wright, D.E., Zajicek, J.P., and Counsell, C.E. (2013). A systematic review of biomarkers for disease progression in Parkinson's disease. *BMC Neurol.* 13, 1–13.
- McHaffie, J., Stanford, T., Stein, B., Coizet, V., and Redgrave, P. (2005). Subcortical loops through the basal ganglia. *Trends Neurosci.* 28, 401–407.
- van der Meer, M.A., and Redish, A.D. (2011). Ventral striatum: a critical look at models of learning and evaluation. *Curr. Opin. Neurobiol.* 21, 387–392.
- Meijer, F.J.A., Bloem, B.R., Mahlknecht, P., Seppi, K., and Goraj, B. (2013). Update on diffusion MRI in Parkinson's disease and atypical parkinsonism. *J. Neurol. Sci.* 1–9.
- Mena-Segovia, J., Bolam, J.P., and Magill, P.J. (2004). Pedunculo-pontine nucleus and basal ganglia: distant relatives or part of the same family? *Trends Neurosci.* 27, 585–588.
- Mena-Segovia, J., Winn, P., and Bolam, J.P. (2008). Cholinergic modulation of midbrain dopaminergic systems. *Brain Res. Rev.* 58, 265–271.
- Meunier, D., Lambiotte, R., and Bullmore, E.T. (2010). Modular and Hierarchically Modular Organization of Brain Networks. *Front. Neurosci.* 4.
- Middleton, F.A., and Strick, P.L. (2000). Basal ganglia and cerebellar loops: motor and cognitive circuits. *Brain Res. Brain Res. Rev.* 31, 236–250.
- Milardi, D., Gaeta, M., Marino, S., Arrigo, A., Vaccarino, G., Mormina, E., Rizzo, G., Milazzo, C., Finocchio, G., Baglieri, A., et al. (2014). Basal ganglia network by constrained spherical deconvolution: A possible cortico-pallidal pathway? *Mov. Disord.* n/a–n/a.
- Miller, D.B., and O'Callaghan, J.P. (2015). Biomarkers of Parkinson's disease: Present and future. *Metabolism* 64, S40–S46.
- Mink, J.W. (1996). The basal ganglia: focused selection and inhibition of competing motor programs. *Prog. Neurobiol.* 50, 381–425.
- Mink, J.W. (2003). The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. *Arch. Neurol.* 60, 1365–1368.

- Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., and Caron, M.G. (1998). Dopamine receptors: from structure to function. *Physiol. Rev.* *78*, 189–225.
- Mitelman, R., Rosin, B., Zadka, H., Slovik, M., Heimer, G., Ritov, Y., 'akov, Bergman, H., and Elias, S. (2011). Neighboring Pallidal Neurons Do Not Exhibit more Synchronous Oscillations than Remote Ones in the MPTP Primate Model of Parkinson's Disease. *Front. Syst. Neurosci.* *5*, 54.
- Miwa, J.M., Freedman, R., and Lester, H.A. (2011). Neural Systems Governed by Nicotinic Acetylcholine Receptors: Emerging Hypotheses. *Neuron* *70*, 20–33.
- Mizuno, Y., Hattori, N., Kubo, S. i, Sato, S., Nishioka, K., Hatano, T., Tomiyama, H., Funayama, M., Machida, Y., and Mochizuki, H. (2008). Progress in the pathogenesis and genetics of Parkinson's disease. *Philos. Trans. R. Soc. B Biol. Sci.* *363*, 2215–2227.
- Mochizuki, H. (2009). Parkin gene therapy. *Park. Realt. Disord.* *15*, S43–S45.
- Mochizuki, H., and Yasuda, T. (2012). Iron accumulation in Parkinson's disease. *J. Neural Transm.* *119*, 1511–1514.
- Molochnikov, I., and Cohen, D. (2014). Hemispheric differences in the mesostriatal dopaminergic system. *Front. Syst. Neurosci.* *8*, 110.
- Monchi, O., and Stoessl, A.J. (2012). Imaging neural correlates of mild cognitive impairment in Parkinson's disease. *Lancet Neurol.* *11*, 653–655.
- Moore, D.J., West, A.B., Dawson, V.L., and Dawson, T.M. (2005). Molecular pathophysiology of Parkinson's disease. *Annu. Rev. Neurosci.* *28*, 57–87.
- Moran, A., Stein, E., Tischler, H., and Bar-Gad, I. (2012). Decoupling neuronal oscillations during subthalamic nucleus stimulation in the parkinsonian primate. *Neurobiol. Dis.* *45*, 583–590.
- Morcom, A.M., and Friston, K.J. (2012). Decoding episodic memory in ageing: A Bayesian analysis of activity patterns predicting memory. *NeuroImage* *59*, 1772–1782.
- Morikawa, H., and Paladini, C.A. (2011). Dynamic regulation of midbrain dopamine neuron activity: intrinsic, synaptic, and plasticity mechanisms. *NEUROSCIENCE* *198*, 95–111.
- Morris, G., Nevet, A., and Bergman, H. (2003). Anatomical funneling, sparse connectivity and redundancy reduction in the neural networks of the basal ganglia. *J. Physiol.-Paris* *97*, 581–589.
- Morris, G., Arkadir, D., Nevet, A., Vaadia, E., and Bergman, H. (2004). Coincident but distinct messages of midbrain dopamine and striatal tonically active neurons. *Neuron* *43*, 133–143.
- Moss, J., and Bolam, J.P. (2008). A Dopaminergic Axon Lattice in the Striatum and Its Relationship with Cortical and Thalamic Terminals. *J. Neurosci.* *28*, 11221–11230.

- Moustafa, A.A., and Poletti, M. (2013). Neural and behavioral substrates of subtypes of Parkinson's disease. *Front. Syst. Neurosci.* 7, 117.
- Moustafa, A.A., Herzallah, M.M., and Gluck, M.A. (2013). Dissociating the Cognitive Effects of Levodopa versus Dopamine Agonists in a Neurocomputational Model of Learning in Parkinson's Disease. *Neurodegener. Dis.* 11, 102–111.
- Moustafa, A.A., Herzallah, M.M., and Gluck, M.A. (2014). A model of reversal learning and working memory in medicated and unmedicated patients with Parkinson's disease. *J. Math. Psychol.* 59, 120–131.
- Moustafa, A.A., Chakravarthy, S., Phillips, J.R., Gupta, A., Kéri, S., Polner, B., Frank, M.J., and Jahanshahi, M. (2016). Motor symptoms in Parkinson's disease: A unified framework. *Neurosci. Biobehav. Rev.* 68, 727–740.
- Müller, T. (2002). Dopaminergic substitution in Parkinson's disease. *Expert Opin. Pharmacother.* 3, 1393–1403.
- Müller, T. (2015). Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease. *Drugs* 75, 157–174.
- Mullinger, K.J., Mayhew, S.D., Bagshaw, A.P., Bowtell, R., and Francis, S.T. (2014). Evidence that the negative BOLD response is neuronal in origin: A simultaneous EEG–BOLD–CBF study in humans. *NeuroImage* 94, 263–274.
- Nagy, Z., Alexander, D.C., Thomas, D.L., Weiskopf, N., and Sereno, M.I. (2013). Using High Angular Resolution Diffusion Imaging Data to Discriminate Cortical Regions. *PLoS ONE* 8, e63842.
- Nakano, K. (2000). Neural circuits and topographic organization of the basal ganglia and related regions. *BRAIN Dev.* 22 *Suppl* 1, S5–16.
- Nakano, K., Kayahara, T., Tsutsumi, T., and Ushiro, H. (2000). Neural circuits and functional organization of the striatum. *J. Neurol.* 247 *Suppl* 5, V1–15.
- Nambu, A. (2004). A new dynamic model of the cortico-basal ganglia loop. In *Brain Mechanisms for the Integration of Posture and Movement*, (Elsevier), pp. 461–466.
- Nambu, A. (2005). A new approach to understand the pathophysiology of Parkinson's disease. *J. Neurol.* 252, iv1–iv4.
- Nambu, A. (2008). Seven problems on the basal ganglia. *Curr. Opin. Neurobiol.* 18, 595–604.
- Nambu, A. (2011). Somatotopic Organization of the Primate Basal Ganglia. *Front. Neuroanat.* 5, 1–9.

- Nambu, A., and Tachibana, Y. (2014). Mechanism of parkinsonian neuronal oscillations in the primate basal ganglia: some considerations based on our recent work. *Front. Syst. Neurosci.* *8*, 74.
- Nambu, A., Tokuno, H., and Takada, M. (2002). Functional significance of the cortico-subthalamo-pallidal "hyperdirect" pathway. *Neurosci. Res.* *43*, 111–117.
- Nandhagopal, R., McKeown, M.J., and Stoessl, A.J. (2008). Invited Article: Functional imaging in Parkinson disease. *Neurology* *70*, 1478–1488.
- Nelson, A.B., and Kreitzer, A.C. (2014). Reassessing Models of Basal Ganglia Function and Dysfunction. *Annu. Rev. Neurosci.* *37*, 117–135.
- Nelson, A.B., Hammack, N., Yang, C.F., Shah, N.M., Seal, R.P., and Kreitzer, A.C. (2014). Striatal Cholinergic Interneurons Drive GABA Release from Dopamine Terminals. *Neuron* *82*, 63–70.
- Nelson, A.J., Blake, D.T., and Chen, R. (2009). Digit-specific aberrations in the primary somatosensory cortex in Writer's cramp. *Ann. Neurol.* *66*, 146–154.
- Nevet, A., Morris, G., Saban, G., Arkadir, D., and Bergman, H. (2007). Lack of Spike-Count and Spike-Time Correlations in the Substantia Nigra Reticulata Despite Overlap of Neural Responses. *J. Neurophysiol.* *98*, 2232–2243.
- Nicola, S.M., Surmeier, J., and Malenka, R.C. (2000). Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. *Annu. Rev. Neurosci.* *23*, 185–215.
- Niethammer, M., Feigin, A., and Eidelberg, D. (2012). Functional Neuroimaging in Parkinson's Disease. *Cold Spring Harb. Perspect. Med.* *2*, a009274–a009274.
- Nili, H., Wingfield, C., Walther, A., Su, L., Marslen-Wilson, W., and Kriegeskorte, N. (2014). A Toolbox for Representational Similarity Analysis. *PLoS Comput. Biol.* *10*, e1003553.
- Nini, A., Feingold, A., and Slovin, H. (1995). Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism. *J. Neurosci.*
- Niv, Y., Joel, D., Meilijson, I., and Ruppin, E. (2002). Evolution of reinforcement learning in uncertain environments: A simple explanation for complex foraging behaviors. *Adapt. Behav.*
- Nonnekes, J., Timmer, M.H.M., de Vries, N.M., Rascol, O., Helmich, R.C., and Bloem, B.R. (2016). Unmasking levodopa resistance in Parkinson's disease. *Mov. Disord.* *31*, 1602–1609.

Norman, D.A., and Shallice, T. (1986). Attention to Action. In *Consciousness and Self-Regulation*, R.J. Davidson, G.E. Schwartz, and D. Shapiro, eds. (New York, NY: Springer Science & Business Media), pp. 1–18.

Nyholm, D. (2012). Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety. *Parkinsonism Relat. Disord.* 18, 916–929.

Obeso, J.A., Rodríguez-Oroz, M.C., Rodríguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N., and Olanow, C.W. (2000). Pathophysiology of the basal ganglia in Parkinson's disease. *Trends Neurosci.* 23, S8–19.

Obeso, J.A., Rodríguez-Oroz, M.C., Benitez-Temino, B., Blesa, F.J., Guridi, J., Marin, C., and Rodriguez, M. (2008). Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease. *Mov. Disord.* 23, S548–S559.

Obeso, J.A., Rodriguez-Oroz, M.C., Goetz, C.G., Marin, C., Kordower, J.H., Rodriguez, M., Hirsch, E.C., Farrer, M., Schapira, A.H.V., and Halliday, G. (2010). Missing pieces in the Parkinson's disease puzzle. *Nat. Med.* 16, 653–661.

Obeso, J.A., Rodriguez-Oroz, M.C., Stamelou, M., Bhatia, K.P., and Burn, D.J. (2014). The expanding universe of disorders of the basal ganglia. *The Lancet* 384, 523–531.

O'Doherty, J. (2004). Dissociable Roles of Ventral and Dorsal Striatum in Instrumental Conditioning. *Science* 304, 452–454.

O'Doherty, J.P., Buchanan, T.W., Seymour, B., and Dolan, R.J. (2006). Predictive Neural Coding of Reward Preference Involves Dissociable Responses in Human Ventral Midbrain and Ventral Striatum. *Neuron* 49, 157–166.

Oguri, T., Sawamoto, N., Tabu, H., Urayama, S., Matsushashi, M., Matsukawa, N., Ojika, K., and Fukuyama, H. (2013). Overlapping connections within the motor cortico-basal ganglia circuit: fMRI-tractography analysis. *NeuroImage* 78, 353–362.

Oizumi, M., Albantakis, L., and Tononi, G. (2014). From the Phenomenology to the Mechanisms of Consciousness: Integrated Information Theory 3.0. *PLoS Comput. Biol.* 10, e1003588.

Olman, C.A., and Yacoub, E. (2011). High-field fMRI for human applications: an overview of spatial resolution and signal specificity. *Open Neuroimaging J.* 5, 74–89.

Olman, C.A., Pickett, K.A., Schallmo, M.-P., and Kimberley, T.J. (2012). Selective BOLD responses to individual finger movement measured with fMRI at 3T. *Hum. Brain Mapp.* 33, 1594–1606.

Oorschot, D.E. (1996). Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. *J. Comp. Neurol.* 366, 580–599.

- O'Reilly, R.C., and Frank, M.J. (2006). Making working memory work: a computational model of learning in the prefrontal cortex and basal ganglia. *Neural Comput.* *18*, 283–328.
- O'Reilly, R.C., Frank, M.J., Hazy, T.E., and Watz, B. (2007). PVLV: The Primary Value and Learned Value Pavlovian Learning Algorithm. *Behav. Neurosci.* *121*, 31–49.
- Pahapill, P.A., and Lozano, A.M. (2000). The pedunculopontine nucleus and Parkinson's disease. *Brain* *123* (Pt 9), 1767–1783.
- Palminteri, S., Justo, D., Jauffret, C., Pavlicek, B., Dauta, A., Delmaire, C., Czernecki, V., Karachi, C., Capelle, L., Durr, A., et al. (2012). Critical Roles for Anterior Insula and Dorsal Striatum in Punishment-Based Avoidance Learning. *Neuron* *76*, 998–1009.
- Pan, P.-Y., and Yue, Z. (2013). Genetic causes of Parkinson's disease and their links to autophagy regulation. *Parkinsonism Relat. Disord.* *20*, S154–S157.
- Parent, A., and Hazrati, L.N. (1995a). Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. *Brain Res. Brain Res. Rev.* *20*, 91–127.
- Parent, A., and Hazrati, L.N. (1995b). Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. *Brain Res. Brain Res. Rev.* *20*, 128–154.
- Parent, A., Sato, F., Wu, Y., Gauthier, J., Lévesque, M., and Parent, M. (2000). Organization of the basal ganglia: the importance of axonal collateralization. *Trends Neurosci.* *23*, S20–7.
- Parent, M., Lévesque, M., and Parent, A. (1999). The pallidofugal projection system in primates: evidence for neurons branching ipsilaterally and contralaterally to the thalamus and brainstem. *J. Chem. Neuroanat.* *16*, 153–165.
- Parent, M., Lévesque, M., and Parent, A. (2001). Two types of projection neurons in the internal pallidum of primates: single-axon tracing and three-dimensional reconstruction. *J. Comp. Neurol.* *439*, 162–175.
- Parkinson, J. (1817). *An Essay on the Shaking Palsy*. Lond. Whittingham Rowland.
- Parush, N., Tishby, N., and Bergman, H. (2011). Dopaminergic Balance between Reward Maximization and Policy Complexity. *Front. Syst. Neurosci.* *5*, 22.
- Pasupathy, A., and Miller, E.K. (2005). Different time courses of learning-related activity in the prefrontal cortex and striatum. *Nature* *433*, 873–876.
- Pavese, N., and Brooks, D.J. (2009). Imaging neurodegeneration in Parkinson's disease. *BBA - Mol. Basis Dis.* *1792*, 722–729.
- Pelzer, E.A., Melzer, C., Timmermann, L., von Cramon, Y.D., and Tittgemeyer, M. (2016). Basal ganglia and cerebellar interconnectivity within the human thalamus. *Brain Struct. Funct.*

- Penfield, W., and Rasmussen, T. (1950). The cerebral cortex of man; a clinical study of localization of function.
- Percheron, G., and Filion, M. (1991). Parallel processing in the basal ganglia: up to a point. *Trends Neurosci.* *14*, 55–56.
- Perlmutter, J.S., and Mink, J.W. (2006). Deep brain stimulation. *Annu. Rev. Neurosci.* *29*, 229–257.
- Pessiglione, M., Guehl, D., Rolland, A.-S., Francois, C., Hirsch, E.C., Féger, J., and Tremblay, L. (2005). Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. *J. Neurosci.* *25*, 1523–1531.
- Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., and Frith, C.D. (2006). Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. *Nature* *442*, 1042–1045.
- Pessoa, L. (2014). Understanding brain networks and brain organization. *Phys. Life Rev.* *11*, 400–435.
- Peterson, D.A., Sejnowski, T.J., and Poizner, H. (2010). Convergent evidence for abnormal striatal synaptic plasticity in dystonia. *Neurobiol. Dis.* *37*, 558–573.
- Petzinger, G.M., Fisher, B.E., McEwen, S., Beeler, J.A., Walsh, J.P., and Jakowec, M.W. (2013). Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. *Lancet Neurol.* *12*, 716–726.
- Plenz, D. (2003). When inhibition goes incognito: feedback interaction between spiny projection neurons in striatal function. *Trends Neurosci.* *26*, 436–443.
- Plow, E.B., Arora, P., Pline, M.A., Binenstock, M.T., and Carey, J.R. (2010). Within-limb somatotopy in primary motor cortex - revealed using fMRI. *CORTEX* *46*, 310–321.
- Politis, M. (2014). Neuroimaging in Parkinson disease: from research setting to clinical practice. *Nat. Publ. Group* *10*, 708–722.
- Posse, S. (2012). Multi-echo acquisition. *NeuroImage* *62*, 665–671.
- Posse, S., Ackley, E., Mutihac, R., Rick, J., Shane, M., Murray-Krezan, C., Zaitsev, M., and Speck, O. (2012). Enhancement of temporal resolution and BOLD sensitivity in real-time fMRI using multi-slab echo-volumar imaging. *NeuroImage* *61*, 115–130.
- Postuma, R.B., and Berg, D. (2016). Advances in markers of prodromal Parkinson disease. *Nat. Publ. Group* *12*, 622–634.
- Price, C.J., and Friston, K.J. (2002). Degeneracy and cognitive anatomy. *Trends Cogn. Sci.* *6*, 416–421.

- Pyatigorskaya, N., Gallea, C., Garcia-Lorenzo, D., Vidailhet, M., and Lehericy, S. (2013). A review of the use of magnetic resonance imaging in Parkinson's disease. *Ther. Adv. Neurol. Disord.* 1756285613511507.
- Quartarone, A., Morgante, F., Sant'Angelo, A., Rizzo, V., Bagnato, S., Terranova, C., Siebner, H.R., Berardelli, A., and Girlanda, P. (2008). Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. *J. Neurol. Neurosurg. Psychiatry* 79, 985–990.
- Quik, M., O'Leary, K., and Tanner, C.M. (2008). Nicotine and Parkinson's disease: Implications for therapy. *Mov. Disord.* 23, 1641–1652.
- Ramnani, N. (2006). The primate cortico-cerebellar system: anatomy and function. *Nat. Rev. Neurosci.* 7, 511–522.
- Rascol, O., Payoux, P., Ory, F., Ferreira, J.J., Brefel-Courbon, C., and Montastruc, J.-L. (2003). Limitations of current Parkinson's disease therapy. *Ann. Neurol.* 53, S3–S15.
- Ray, N.J., and Strafella, A.P. (2012). The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging. *Mov. Disord.* 27, 1484–1492.
- Redgrave, P., and Gurney, K. (2006). The short-latency dopamine signal: a role in discovering novel actions? *Nat. Rev. Neurosci.* 7, 967–975.
- Redgrave, P., Prescott, T.J., and Gurney, K. (1999). The basal ganglia: a vertebrate solution to the selection problem? *NEUROSCIENCE* 89, 1009–1023.
- Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M.C., Lehericy, S., Bergman, H., Agid, Y., DeLong, M.R., and Obeso, J.A. (2010). Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. *Nat. Publ. Group* 11, 760–772.
- Redgrave, P., Vautrelle, N., and Reynolds, J.N.J. (2011). Functional properties of the basal ganglia's re-entrant loop architecture: selection and reinforcement. *NEUROSCIENCE* 198, 138–151.
- Reeve, A., Simcox, E., and Turnbull, D. (2014). Ageing and Parkinson's disease: Why is advancing age the biggest risk factor? *Ageing Res. Rev.* 14, 19–30.
- Reichenbach, J.R., Schweser, F., Serres, B., and Deistung, A. (2015). Quantitative Susceptibility Mapping: Concepts and Applications. *Clin. Neuroradiol.* 25, 225–230.
- Reynolds, J.N.J., and Wickens, J.R. (2002). Dopamine-dependent plasticity of corticostriatal synapses. *Neural Netw. Off. J. Int. Neural Netw. Soc.* 15, 507–521.
- Rice, M.E., Patel, J.C., and Cragg, S.J. (2011). Dopamine release in the basal ganglia. *NEUROSCIENCE* 198, 112–137.

- Rijsman, R.M., Schoolderman, L.F., Rundervoort, R.S., and Louter, M. (2013). Restless legs syndrome in Parkinson's disease. *Parkinsonism Relat. Disord.* *20*, S5–S9.
- Robbins, T.W., and Cools, R. (2014). Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective. *Mov. Disord.* *29*, 597–607.
- Rodriguez, M., Rodriguez-Sabate, C., Morales, I., Sanchez, A., and Sabate, M. (2015). Parkinson's disease as a result of aging. *Aging Cell* *14*, 293–308.
- Rodríguez-Nogales, C., Garbayo, E., Carmona-Abellán, M.M., Luquin, M.R., and Blanco-Prieto, M.J. (2015). Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems. 1–7.
- Rodriguez-Oroz, M.C., Rodriguez, M., Guridi, J., Mewes, K., Chockkman, V., Vitek, J., DeLong, M.R., and Obeso, J.A. (2001). The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. *Brain* *124*, 1777–1790.
- Romanelli, P., Esposito, V., Schaal, D.W., and Heit, G. (2005). Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. *Brain Res. Rev.* *48*, 112–128.
- Rommelfanger, K.S. (2010). Extrastriatal dopaminergic circuits of the basal ganglia. *Front. Neuroanat.* *4*.
- Root, D.H., Melendez, R.I., Zaborszky, L., and Napier, T.C. (2015). The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors. *Prog. Neurobiol.* *130*, 29–70.
- Ross, C.A., and Pickart, C.M. (2004). The ubiquitin–proteasome pathway in Parkinson's disease and other neurodegenerative diseases. *Trends Cell Biol.* *14*, 703–711.
- Rouault, T.A. (2013). Iron metabolism in the CNS: implications for neurodegenerative diseases. *Nat. Publ. Group* *14*, 551–564.
- Rowe, J.B., Hughes, L.E., Barker, R.A., and Owen, A.M. (2010). Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? *NeuroImage* *52*, 1015–1026.
- Rowland, N.C., Sammartino, F., and Lozano, A.M. (2016). Advances in surgery for movement disorders. *Mov. Disord.*
- Rubinov, M., and Sporns, O. (2010). Complex network measures of brain connectivity: Uses and interpretations. *NeuroImage* *52*, 1059–1069.
- Russo, S.J., and Nestler, E.J. (2013). The brain reward circuitry in mood disorders. *Nat. Publ. Group* *14*, 609–625.

- Ryterska, A., Jahanshahi, M., and Osman, M. (2013). What are people with Parkinson's disease really impaired on when it comes to making decisions? A meta-analysis of the evidence. *Neurosci. Biobehav. Rev.* *37*, 2836–2846.
- Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., Challis, C., Schretter, C.E., Rocha, S., Gradinaru, V., et al. (2017). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. 1–25.
- Sanchez-Gonzalez, M.A. (2005). The Primate Thalamus Is a Key Target for Brain Dopamine. *J. Neurosci.* *25*, 6076–6083.
- Savica, R., Rocca, W.A., and Ahlskog, J.E. (2010). When does Parkinson disease start? *Arch. Neurol.* *67*, 798–801.
- Schapira, A.H.V. (2006). Etiology of Parkinson's disease. *Neurology* *66*, S10–S23.
- Schapira, A.H., and Jenner, P. (2011). Etiology and pathogenesis of Parkinson's disease. *Mov. Disord.* *26*, 1049–1055.
- Schapira, A.H.V., and Gegg, M. (2011). Mitochondrial Contribution to Parkinson's Disease Pathogenesis. *Park. Dis.* *2011*, 1–7.
- Schmidt, L., Lebreton, M., Cléry-Melin, M.-L., Daunizeau, J., and Pessiglione, M. (2012). Neural Mechanisms Underlying Motivation of Mental Versus Physical Effort. *PLoS Biol.* *10*, e1001266.
- Scholz, V.H., Flaherty, A.W., Kraft, E., Keltner, J.R., Kwong, K.K., Chen, Y.I., Rosen, B.R., and Jenkins, B.G. (2000). Laterality, somatotopy and reproducibility of the basal ganglia and motor cortex during motor tasks. *Brain Res.* *879*, 204–215.
- Schroll, H., and Hamker, F.H. (2013). Computational models of basal-ganglia pathway functions: focus on functional neuroanatomy. *Front. Syst. Neurosci.* *7*, 122.
- Schuff, N. (2009). Potential role of high-field MRI for studies in Parkinson's disease. *Mov. Disord.* *24*, S684–S690.
- Schwab, R.S., and England, A.C. (1969). Projection technique for evaluating surgery in Parkinson's disease. In *Third Symposium on Parkinson's Disease*, F. Gillingham, and I. Donaldson, eds. (Edinburgh: E&S Livingstone), pp. 152–157.
- Schwarz, S.T., Abaei, M., Gontu, V., Morgan, P.S., Bajaj, N., and Auer, D.P. (2013). Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3T and systematic review with meta-analysis. *YNICL* *3*, 481–488.
- Seamans, J.K., and Yang, C.R. (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. *Prog. Neurobiol.* *74*, 1–58.

- Seger, C.A. (2008). How do the basal ganglia contribute to categorization? Their roles in generalization, response selection, and learning via feedback. *Neurosci. Biobehav. Rev.* *32*, 265–278.
- Seger, C.A. (2013). The visual corticostriatal loop through the tail of the caudate: circuitry and function. *Front. Syst. Neurosci.* *7*, 104.
- Seger, C.A., and Peterson, E.J. (2013). Categorization=decision making+generalization. *Neurosci. Biobehav. Rev.* 1–14.
- Seger, C.A., and Spiering, B.J. (2011). A critical review of habit learning and the Basal Ganglia. *Front. Syst. Neurosci.* *5*, 66.
- Seo, M., Lee, E., and Averbeck, B.B. (2012). Action Selection and Action Value in Frontal-Striatal Circuits. *Neuron* *74*, 947–960.
- Sharifi, S., Nederveen, A.J., Booij, J., and van Rootselaar, A.-F. (2010). Neuroimaging essentials in essential tremor: A systematic review. *YNICL* *5*, 217–231.
- Sharma, S., Moon, C.S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., Jelebinkov, M., Kurdi, Y., and Ebadi, M. (2013). Biomarkers in Parkinson's disease (recent update). *Neurochem. Int.* *63*, 201–229.
- Sharott, A., Gulberti, A., Zittel, S., Tudor Jones, A.A., Fickel, U., Munchau, A., Koppen, J.A., Gerloff, C., Westphal, M., Buhmann, C., et al. (2014). Activity Parameters of Subthalamic Nucleus Neurons Selectively Predict Motor Symptom Severity in Parkinson's Disease. *J. Neurosci.* *34*, 6273–6285.
- Shen, W., Flajolet, M., Greengard, P., and Surmeier, D.J. (2008). Dichotomous dopaminergic control of striatal synaptic plasticity. *Science* *321*, 848–851.
- Sherman, S.M. (2004). Interneurons and triadic circuitry of the thalamus. *Trends Neurosci.* *27*, 670–675.
- Shin, H.-W., Kang, S.Y., Hallett, M., and Sohn, Y.H. (2012). Reduced surround inhibition in musicians. *Exp. Brain Res.* *219*, 403–408.
- Shohamy, D., and Adcock, R.A. (2010). Dopamine and adaptive memory. *Trends Cogn. Sci.* *14*, 464–472.
- Shohamy, D., Myers, C.E., Kalanithi, J., and Gluck, M.A. (2008). Basal ganglia and dopamine contributions to probabilistic category learning. *Neurosci. Biobehav. Rev.* *32*, 219–236.
- Sian-Hülsmann, J., Mandel, S., Youdim, M.B.H., and Riederer, P. (2011). The relevance of iron in the pathogenesis of Parkinson's disease. *J. Neurochem.* *118*, 939–957.
- Sidhu, A., Wersinger, C., Moussa, C.E.-H., and Vernier, P. (2004). The role of alpha-synuclein in both neuroprotection and neurodegeneration. *Ann. N. Y. Acad. Sci.* *1035*, 250–270.

- Smith, Y., Bevan, M.D., Shink, E., and Bolam, J.P. (1998). Microcircuitry of the direct and indirect pathways of the basal ganglia. *NEUROSCIENCE* 86, 353–387.
- Smith, Y., Raju, D.V., Pare, J.-F., and Sidibe, M. (2004). The thalamostriatal system: a highly specific network of the basal ganglia circuitry. *Trends Neurosci.* 27, 520–527.
- Smith, Y., Raju, D., Nanda, B., Pare, J.-F., Galván, A., and Wichmann, T. (2009). The thalamostriatal systems: Anatomical and functional organization in normal and parkinsonian states. *Brain Res. Bull.* 78, 60–68.
- Smith, Y., Galván, A., Ellender, T.J., Doig, N., Villalba, R.M., Huerta-Ocampo, I., Wichmann, T., and Bolam, J.P. (2014). The thalamostriatal system in normal and diseased states. *Front. Syst. Neurosci.* 8, 5.
- Snijders, A.H., Takakusaki, K., Debû, B., Lozano, A.M., Krishna, V., Fasano, A., Aziz, T.Z., Papa, S.M., Factor, S.A., and Hallett, M. (2016). Physiology of freezing of gait. *Ann. Neurol.* 80, 644–659.
- Soares, J.M., Marques, P., Alves, V., and Sousa, N. (2013). A hitchhiker's guide to diffusion tensor imaging. *Front. Neurosci.* 7, 31.
- Solari, V.H., and Rich Stoner, S. (2014). Cognitive consilience: primate non-primary neuroanatomical circuits underlying cognition. 1–23.
- Spatola, M., and Wider, C. (2013). Genetics of Parkinson's disease: the yield. *Parkinsonism Relat. Disord.* 20, S35–S38.
- Spillantini, M.G., Schmidt, M.L., Y, L.V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. 1–2.
- Sporns, O. (2012). From simple graphs to the connectome: Networks in neuroimaging. *NeuroImage* 62, 881–886.
- Sporns, O. (2013). Network attributes for segregation and integration in the human brain. *Curr. Opin. Neurobiol.* 23, 162–171.
- Sporns, O. (2015). Cerebral cartography and connectomics. *Philos. Trans. R. Soc. B Biol. Sci.* 370, 20140173–20140173.
- Sporns, O., Tononi, G., and Edelman, G.M. (2000). Connectivity and complexity: the relationship between neuroanatomy and brain dynamics. *Neural Netw. Off. J. Int. Neural Netw. Soc.* 13, 909–922.
- Staempfli, P., Jaermann, T., Crelier, G.R., Kollias, S., Valavanis, A., and Boesiger, P. (2006). Resolving fiber crossing using advanced fast marching tractography based on diffusion tensor imaging. *NeuroImage* 30, 110–120.

- Staempfli, P., Reischauer, C., Jaermann, T., Valavanis, A., Kollias, S., and Boesiger, P. (2008). Combining fMRI and DTI: A framework for exploring the limits of fMRI-guided DTI fiber tracking and for verifying DTI-based fiber tractography results. *NeuroImage* 39, 119–126.
- Steece-Collier, K., Maries, E., and Kordower, J.H. (2002). Etiology of Parkinson's Disease: Genetics and Environment Revisited. *Proc. Natl. Acad. Sci. U. S. A.* 99, 13972–13974.
- Stefanis, L. (2012). α -Synuclein in Parkinson's disease. *Cold Spring Harb. Perspect. Med.* 2, a009399.
- Stein, E., and Bar-Gad, I. (2013). Beta oscillations in the cortico-basal ganglia loop during parkinsonism. *Exp. Neurol.* 245, 52–59.
- Stocchi, F., Jenner, P., and Obeso, J.A. (2010). When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease. *Eur. Neurol.* 63, 257–266.
- Stocco, A. (2012). Acetylcholine-based entropy in response selection: a model of how striatal interneurons modulate exploration, exploitation, and response variability in decision-making. 1–19.
- Stoeckel, M.C., Seitz, R.J., and Buetefisch, C.M. (2009). Congenitally altered motor experience alters somatotopic organization of human primary motor cortex. *Proc. Natl. Acad. Sci. U. S. A.* 106, 2395–2400.
- Stoessl, A.J. (2009). Functional imaging studies of non-motoric manifestations of Parkinson's Disease. *Park. Relat. Disord.* 15, S13–S16.
- Stoessl, A.J. (2011a). Neuroimaging in Parkinson's disease: from pathology to diagnosis. *Parkinsonism Relat. Disord.* 18, S55–S59.
- Stoessl, A.J. (2011b). Neuroimaging in Parkinson's Disease. *Neurotherapeutics* 8, 72–81.
- Stoessl, A.J., Lehericy, S., and Strafella, A.P. (2014). Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. *The Lancet* 384, 532–544.
- Stoodley, C.J., and Schmahmann, J.D. (2009). Functional topography in the human cerebellum: A meta-analysis of neuroimaging studies. *NeuroImage* 44, 489–501.
- Stoodley, C.J., and Schmahmann, J.D. (2010). Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. *CORTEX* 46, 831–844.
- Stoodley, C.J., Valera, E.M., and Schmahmann, J.D. (2012). Functional topography of the cerebellum for motor and cognitive tasks: An fMRI study. *NeuroImage* 59, 1560–1570.
- Strother, L., Medendorp, W.P., Coros, A.M., and Vilis, T. (2012). Double representation of the wrist and elbow in human motor cortex. *Eur. J. Neurosci.* 36, 3291–3298.

- Sulzer, D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. *Trends Neurosci.* *30*, 244–250.
- Suri, R.E., and Schultz, W. (1998). Learning of sequential movements by neural network model with dopamine-like reinforcement signal. *Exp. Brain Res.* *121*, 350–354.
- Suri, R.E., and Schultz, W. (1999). A neural network model with dopamine-like reinforcement signal that learns a spatial delayed response task. *NSC* *91*, 871–890.
- Suri, R.E., Vargas, J., and Arbib, M.A. (2001). Modeling functions of striatal dopamine modulation in learning and planning. *NSC* *103*, 65–85.
- Surmeier, J.D., and Graybiel, A.M. (2012). A Feud that Wasn't: Acetylcholine Evokes Dopamine Release in the Striatum. *Neuron* *75*, 1–3.
- Surmeier, D.J., Mercer, J.N., and Chan, C.S. (2005). Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway? *Curr. Opin. Neurobiol.* *15*, 312–318.
- Surmeier, D.J., Ding, J., Day, M., Wang, Z., and Shen, W. (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. *Trends Neurosci.* *30*, 228–235.
- Surmeier, D.J., Shen, W., Day, M., Gertler, T., Chan, S., Tian, X., and Plotkin, J.L. (2010). The role of dopamine in modulating the structure and function of striatal circuits. *Prog. Brain Res.* *183*, 149–167.
- Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J., and Schumacker, P.T. (2011a). The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. *NEUROSCIENCE* *198*, 221–231.
- Surmeier, D.J., Carrillo-Reid, L., and Vargas, J. (2011b). Dopaminergic modulation of striatal neurons, circuits, and assemblies. *NEUROSCIENCE* *198*, 3–18.
- Sutton, R.S. (1988). Learning to predict by the methods of temporal differences. *Mach. Learn.* *3*, 9–44.
- Sveinbjornsdottir, S. (2016). The clinical symptoms of Parkinson's disease. *J. Neurochem.* *139 Suppl 1*, 318–324.
- Svensson, E., Horváth-Puhó, E., Thomsen, R.W., Djurhuus, J.C., Pedersen, L., Borghammer, P., and Sørensen, H.T. (2015). Vagotomy and subsequent risk of Parkinson's disease. *Ann. Neurol.* *78*, 522–529.
- Taha, J.M., Favre, J., Baumann, T.K., and Burchiel, K.J. (1996a). Characteristics and somatotopic organization of kinesthetic cells in the globus pallidus of patients with Parkinson's disease. *J. Neurosurg.* *85*, 1005–1012.

- Taha, J.M., Favre, J., Baumann, T.K., and Burchiel, K.J. (1996b). Functional anatomy of the pallidal base in Parkinson's disease. *Neurosurgery* 39, 1164–7– NaN–8.
- Takada, M., Tokuno, H., Nambu, A., and Inase, M. (1998). Corticostriatal projections from the somatic motor areas of the frontal cortex in the macaque monkey: segregation versus overlap of input zones from the primary motor cortex, the supplementary motor area, and the premotor cortex. *Exp. Brain Res.* 120, 114–128.
- Takada, M., Tokuno, H., Hamada, I., Inase, M., Ito, Y., Imanishi, M., Hasegawa, N., Akazawa, T., Hatanaka, N., and Nambu, A. (2001). Organization of inputs from cingulate motor areas to basal ganglia in macaque monkey. *Eur. J. Neurosci.* 14, 1633–1650.
- Tamburin, S., Manganotti, P., Marzi, C.A., Fiaschi, A., and Zanette, G. (2002). Abnormal somatotopic arrangement of sensorimotor interactions in dystonic patients. *Brain* 125, 2719–2730.
- Tan, E.K., Lum, S.Y., and Wong, M.C. (2002). Restless legs syndrome in Parkinson's disease. *J. Neurol. Sci.* 196, 33–36.
- Tanaka, S.C., Doya, K., Okada, G., Ueda, K., Okamoto, Y., and Yamawaki, S. (2004). Prediction of immediate and future rewards differentially recruits cortico-basal ganglia loops. *Nat. Neurosci.* 7, 887–893.
- Telford, R., and Vattoth, S. (2014). MR Anatomy of Deep Brain Nuclei with Special Reference to Specific Diseases and Deep Brain Stimulation Localization. *Neuroradiol. J.* 27, 29.
- Tepper, J.M., and Bolam, J.P. (2004). Functional diversity and specificity of neostriatal interneurons. *Curr. Opin. Neurobiol.* 14, 685–692.
- Tessitore, A., Giordano, A., Russo, A., and Tedeschi, G. (2016). Structural connectivity in Parkinson's disease. *Park. Realt. Disord.* 22, S56–S59.
- Thenganatt, M.A., and Jankovic, J. (2014). Parkinson Disease Subtypes. *JAMA Neurol.* 71, 499.
- Theodosopoulos, P.V., Marks, W.J., Christine, C., and Starr, P.A. (2003). Locations of movement-related cells in the human subthalamic nucleus in Parkinson's disease. *Mov. Disord.* 18, 791–798.
- Thomas, B., and Beal, M.F. (2007). Parkinson's disease. *Hum. Mol. Genet.* 16, R183–R194.
- Timpka, J., Mundt-Petersen, U., and Odin, P. (2016). Continuous dopaminergic stimulation therapy for Parkinson's disease – recent advances. *Curr. Opin. Neurol.* 29, 474–479.
- Tinazzi, M. (2006). Pain and motor complications in Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* 77, 822–825.

- Titova, N., Padmakumar, C., Lewis, S.J.G., and Chaudhuri, K.R. (2017). Parkinson's: a syndrome rather than a disease? *J. Neural Transm.* 1–8.
- Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R., and Clarke, C.E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov. Disord.* 25, 2649–2653.
- Tononi, G. (2004). An information integration theory of consciousness. *BMC Neurosci.* 5, 42.
- Tononi, G. (2008). Consciousness as integrated information: a provisional manifesto. *Biol. Bull.* 215, 216–242.
- Tononi, G., Sporns, O., and Edelman, G.M. (1994). A measure for brain complexity: relating functional segregation and integration in the nervous system. *Proc. Natl. Acad. Sci. U. S. A.* 91, 5033–5037.
- Tononi, G., Edelman, G.M., and Sporns, O. (1998). Complexity and coherency: integrating information in the brain. *Trends Cogn. Sci.* 2, 474–484.
- Tononi, G., Sporns, O., and Edelman, G.M. (1999). Measures of degeneracy and redundancy in biological networks. *Proc. Natl. Acad. Sci. U. S. A.* 96, 3257–3262.
- Tournier, J.-D., Calamante, F., and Connelly, A. (2007). Robust determination of the fibre orientation distribution in diffusion MRI: Non-negativity constrained super-resolved spherical deconvolution. *NeuroImage* 35, 1459–1472.
- Tournier, J.-D., Yeh, C.-H., Calamante, F., Cho, K.-H., Connelly, A., and Lin, C.-P. (2008). Resolving crossing fibres using constrained spherical deconvolution: Validation using diffusion-weighted imaging phantom data. *NeuroImage* 42, 617–625.
- Tournier, J.-D., Mori, S., and Leemans, A. (2011). Diffusion tensor imaging and beyond. *Magn. Reson. Med.* 65, 1532–1556.
- Tournier, J.-D., Calamante, F., and Connelly, A. (2013). Determination of the appropriate b-value and number of gradient directions for high-angular-resolution diffusion-weighted imaging. *NMR Biomed.* 26, 1775–1786.
- Trapp, S., Schroll, H., and Hamker, F.H. (2012). Open and closed loops: A computational approach to attention and consciousness. *Adv. Cogn. Psychol.* 8, 1–8.
- Tremblay, L., Worbe, Y., Thobois, S., Sgambato-Faure, V., and Féger, J. (2015). Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders. *Mov. Disord.* 30, 1155–1170.
- Tremblay, P.-L., Bedard, M.-A., Langlois, D., Blanchet, P.J., Lemay, M., and Parent, M. (2010). Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson's disease. *Exp. Brain Res.* 205, 375–385.

- Triantafyllou, C., Hoge, R.D., Krueger, G., Wiggins, C.J., Potthast, A., Wiggins, G.C., and Wald, L.L. (2005). Comparison of physiological noise at 1.5 T, 3 T and 7 T and optimization of fMRI acquisition parameters. *NeuroImage* 26, 243–250.
- Triantafyllou, C., Polimeni, J.R., and Wald, L.L. (2011). Physiological noise and signal-to-noise ratio in fMRI with multi-channel array coils. *NeuroImage* 55, 597–606.
- Tuch, D.S., Reese, T.G., Wiegell, M.R., Makris, N., Belliveau, J.W., and Wedeen, V.J. (2002). High angular resolution diffusion imaging reveals intravoxel white matter fiber heterogeneity. *Magn. Reson. Med.* 48, 577–582.
- Tuite, P., Mangia, S., and Michaeli, S. (2013). Magnetic Resonance Imaging (MRI) in Parkinson's Disease. *J. Alzheimers Dis. Park.* 3.
- Turner, R.S., and Desmurget, M. (2010). Basal ganglia contributions to motor control: a vigorous tutor. *Curr. Opin. Neurobiol.* 20, 704–716.
- Tykocki, T., Mandat, T., and Nauman, P. (2011). Pedunculopontine nucleus deep brain stimulation in Parkinson's disease. *Arch. Med. Sci. AMS* 7, 555–564.
- Ulla, M., Bonny, J.M., Ouchchane, L., Rieu, I., Claise, B., and Durif, F. (2013). Is R2* a New MRI Biomarker for the Progression of Parkinson's Disease? A Longitudinal Follow-Up. *PLoS ONE* 8, e57904.
- Updyke, B.V. (1993). Organization of visual corticostriatal projections in the cat, with observations on visual projections to claustrum and amygdala. *J. Comp. Neurol.* 327, 159–193.
- Urbain, N., Gervasoni, D., Soulière, F., Lobo, L., Rentéro, N., Windels, F., Astier, B., Savasta, M., Fort, P., Renaud, B., et al. (2000). Unrelated course of subthalamic nucleus and globus pallidus neuronal activities across vigilance states in the rat. *Eur. J. Neurosci.* 12, 3361–3374.
- Utter, A.A., and Basso, M.A. (2008). The basal ganglia: An overview of circuits and function. *Neurosci. Biobehav. Rev.* 32, 333–342.
- Vaillancourt, D.E., Schonfeld, D., Kwak, Y., Bohnen, N.I., and Seidler, R. (2013). Dopamine overdose hypothesis: Evidence and clinical implications. *Mov. Disord.* 28, 1920–1929.
- Valadas, J.S., Vos, M., and Verstreken, P. (2014). Therapeutic strategies in Parkinson's disease: what we have learned from animal models. *Ann. N. Y. Acad. Sci.* 1338, 16–37.
- Veazey, C., Aki, S.O.E., Cook, K.F., Lai, E.C., and Kunik, M.E. (2005). Prevalence and treatment of depression in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 17, 310–323.
- Vila, M., Ramonet, D., and Perier, C. (2008). Mitochondrial alterations in Parkinson's disease: new clues. *J. Neurochem.* 107, 317–328.

- Vitay, J., and Hamker, F.H. (2010). A computational model of Basal Ganglia and its role in memory retrieval in rewarded visual memory tasks. *Front. Comput. Neurosci.* 4.
- Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J.L., Obeso, J.A., and Bezaud, E. (2009). Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. *Lancet Neurol.* 8, 1140–1149.
- Voon, V., Mehta, A.R., and Hallett, M. (2011). Impulse control disorders in Parkinson's disease. *Curr. Opin. Neurol.* 24, 324–330.
- Wagle Shukla, A., and Okun, M.S. (2013). Surgical Treatment of Parkinson's Disease: Patients, Targets, Devices, and Approaches. *Neurotherapeutics* 11, 47–59.
- Wall, N.R., De La Parra, M., Callaway, E.M., and Kreitzer, A.C. (2013). Differential Innervation of Direct- and Indirect-Pathway Striatal Projection Neurons. *Neuron* 79, 347–360.
- Wang, A.Y., Miura, K., and Uchida, N. (2013). The dorsomedial striatum encodes net expected return, critical for energizing performance vigor. *Nat. Publ. Group* 16, 639–647.
- Webb, J.T., Ferguson, M.A., Nielsen, J.A., and Anderson, J.S. (2013). BOLD Granger Causality Reflects Vascular Anatomy. *PLoS ONE* 8, e84279.
- Wei, L., Zhang, J., Long, Z., Wu, G.-R., Hu, X., Zhang, Y., and Wang, J. (2014). Reduced Topological Efficiency in Cortical-Basal Ganglia Motor Network of Parkinson's Disease: A Resting State fMRI Study. *PLoS ONE* 9, e108124.
- Weingarten, C.P., Sundman, M.H., and Hickey, P. (2015). Neuroimaging of Parkinson's disease: Expanding views. *Neurosci. Biobehav. Rev.* 59, 16–52.
- Weiskopf, N., Suckling, J., Williams, G., Correia, M.M., Inkster, B., Tait, R., Ooi, C., Bullmore, E.T., and Lutti, A. (2013). Quantitative multi-parameter mapping of R1, PD(*), MT, and R2(*) at 3T: a multi-center validation. *Front. Neurosci.* 7, 95.
- Whitacre, J.M. (2010). Degeneracy: a link between evolvability, robustness and complexity in biological systems. *Theor. Biol. Med. Model.* 7, 6.
- Wichmann, T., and DeLong, M.R. (1996). Functional and pathophysiological models of the basal ganglia. *Curr. Opin. Neurobiol.* 6, 751–758.
- Wichmann, T., and Dostrovsky, J.O. (2011). Pathological basal ganglia activity in movement disorders. *NEUROSCIENCE* 198, 232–244.
- Wickens, A.P. (2001). Ageing and the free radical theory. *Respir. Physiol.* 128, 379–391.
- Wider, C., Ross, O.A., and Wszolek, Z.K. (2010). Genetics of Parkinson disease and essential tremor. *Curr. Opin. Neurol.* 1.

- Wiestler, T., and Diedrichsen, J. (2013). Skill learning strengthens cortical representations of motor sequences. *eLife* 2, e00801–e00801.
- Williams, D.R., and Litvan, I. (2013). Parkinsonian syndromes. *Contin. Minneap.*
- Williams, Z.M., Neimat, J.S., Cosgrove, G.R., and Eskandar, E.N. (2005). Timing and direction selectivity of subthalamic and pallidal neurons in patients with Parkinson disease. *Exp. Brain Res.* 162, 407–416.
- Winklhofer, K.F., and Haass, C. (2010). Mitochondrial dysfunction in Parkinson's disease. *BBA - Mol. Basis Dis.* 1802, 29–44.
- Wolpert, D.M., and Landy, M.S. (2012). Motor control is decision-making. *Curr. Opin. Neurobiol.* 22, 996–1003.
- Wood-Kaczmar, A., Gandhi, S., and Wood, N.W. (2006). Understanding the molecular causes of Parkinson's disease. *Trends Mol. Med.* 12, 521–528.
- Wu, Y., Le, W., and Jankovic, J. (2011). Preclinical biomarkers of Parkinson disease. *Arch. Neurol.* 68, 22–30.
- Wymbs, N.F., Bassett, D.S., Mucha, P.J., Porter, M.A., and Grafton, S.T. (2012). Differential Recruitment of the Sensorimotor Putamen and Frontoparietal Cortex during Motor Chunking in Humans. *Neuron* 74, 936–946.
- Xiong, Q., Znamenskiy, P., and Zador, A.M. (2015). Selective corticostriatal plasticity during acquisition of an auditory discrimination task. *Nature* 521, 348–351.
- Yael, D., Vinner, E., and Bar-Gad, I. (2015). Pathophysiology of tic disorders. *Mov. Disord.* 30, 1171–1178.
- Yarkoni, T., Poldrack, R.A., Nichols, T.E., Van Essen, D.C., and Wager, T.D. (2011). Large-scale automated synthesis of human functional neuroimaging data. *Nat. Methods* 8, 665–670.
- Youdim, M.B.H., Edmondson, D., and Tipton, K.F. (2006). The therapeutic potential of monoamine oxidase inhibitors. *Nat. Publ. Group* 7, 295–309.
- Zecca, L., Youdim, M.B.H., Riederer, P., Connor, J.R., and Crichton, R.R. (2004). Iron, brain ageing and neurodegenerative disorders. *Nat. Publ. Group* 5, 863–873.
- Zhang, H., Schneider, T., Wheeler-Kingshott, C.A., and Alexander, D.C. (2012). NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain. *NeuroImage* 61, 1000–1016.
- Zheng, T., and Wilson, C.J. (2002). Corticostriatal combinatorics: the implications of corticostriatal axonal arborizations. *J. Neurophysiol.* 87, 1007–1017.

Zhuang, X., Mazzoni, P., and Kang, U.J. (2013). The role of neuroplasticity in dopaminergic therapy for Parkinson disease. *Nat. Publ. Group* 9, 248–256.

Zrinzo, L., Zrinzo, L.V., Tisch, S., Limousin, P.D., Yousry, T.A., Afshar, F., and Hariz, M.I. (2008). Stereotactic localization of the human pedunculo-pontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. *Brain* 131, 1588–1598.

van der Zwaag, W., Jorge, J., Buttica, D., and Gruetter, R. (2015). Physiological noise in human cerebellar fMRI. *Magma* N. Y. N.

Harrison, L. and Friston, K.J. (2004). Effective Connectivity. In *Human Brain Function (Second Edition)*, R.S.J. Frackowiak, K.J. Friston, C.D. Frith, R.J. Dolan, C.J. Price, S. Zeki, J.T. Ashburner, and W.D. Penny, eds. (Burlington: Academic Press), pp. 1019–1047.